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The topic and aim of the thesis 
Botanicals and botanical preparations such as herbal teas, herbal medicines and plant food 
supplements (PFS) are widely marketed all over the world. The consumption of botanical products is 
increasingly high. Meantime, the reported cases of adverse events upon consumption of botanicals and 
botanical preparations are also rising globally (Rocha et al., 2016). To adequately guarantee the safe 
use of botanical preparations, it is essential to internationally harmonize the approach and procedures 
for the regulatory safety assessment of those products. In reality, however, the legislation and the risk 
assessment criteria for botanical supplements vary among different countries (Low et al., 2017). While 
some countries classify PFS as a food or health food (CFDA, 2016; JETRO, 2011), others regulate 
PFS as medicines (Health Canada 2016; TGA, 2013). To date, EU, Australia and the US have 
established criteria for the safety evaluation of PFS ingredients (EFSA, 2009) whereas there appears to 
be no such criteria in other countries.  
Botanicals and botanical preparations may contain natural toxins that are of concern for human health. 
One group of such natural toxic compounds that raise a concern is the group of pyrrolizidine alkaloids 
(PAs). PAs are produced by a large number of plants, serving as part of their defence system in 
response to insects (Hartmann, 1999). To date, more than 660 types of PAs and PA N-oxides have 
been identified (Bodi et al., 2014). Previous studies have shown that herbal teas and PFS frequently 
contain PAs (BfR, 2013; Bodi et al., 2014; EFSA, 2016; Mulder et al., 2018; Mulder et al., 2015). 
Especially 1,2-unsaturated PAs are hepatotoxic and may act as genotoxic carcinogens in humans 
(EFSA, 2017). Human intoxication by PAs is documented in a series of case reports and related to 
consumption of PA-containing herbal teas and PFS, while some outbreaks even resulted in deaths 
related to consumption of grain contaminated with PA-producing plants (EFSA, 2017). In 2009, EFSA 
published guidelines for the risk assessment of botanicals and botanical preparations, defining a 2-step 
tiered approach for such a risk assessment. The first level can be based on available knowledge 
including the botanical ingredients history of use. If the available data support the conclusion that a 
known long term exposure to the botanical ingredient under consideration has not resulted in adverse 
effects, the presumption of safety could be applied. However, if such data are lacking, for the second 
level of the risk assessment toxicological studies are required. However, in spite of these suggested 
guidelines, at the current state-of-the-art risk assessment of botanical and botanical preparations is 
generally not required before they can enter the market (Low et al., 2017; van den Berg et al., 2014). 
The aim of this thesis was to contribute to the risk assessment of botanical products containing PAs. 
Considering that risk management can only be based on adequate safety evaluations, the risk 
assessment of intake of PAs from herbal teas, herbal medicines and PFS following realistic exposure 
scenarios was assessed. The currently preferred approach used to assess the risk for compounds that 
are both genotoxic and carcinogenic is the so-called margin of exposure (MOE) approach. The MOE 
values can be calculated by dividing the benchmark dose level associated with 10% extra tumour 
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incidence (BMDL10) by the estimated daily intakes (EDI) (EFSA, 2005). However, in spite of the 
large number of PAs to which the consumer may be exposed, toxicological data on liver toxicity and 
carcinogenicity are available for only a limited number of PAs. Among the 1,2- unsaturated PAs, only 
lasiocarpine and riddelliine have been tested in a two year rodent carcinogenicity bioassay by the 
National Toxicology Program (NTP), and were shown to cause liver tumours (NTP, 1978, 2003). 
Regarding hepatotoxicity, data are only available for lasiocarpine (Dalefield et al., 2016; Jago, 1970; 
Nolan et al., 1966). Given the large number of PAs and the limited number of PAs for which actual in 
vivo toxicity and carcinogenicity data are available, the ultimate aim of the present thesis was to 
contribute to the risk assessment of botanical products containing PAs by applying suitable animal free 
testing strategies. To this end, an alternative method was developed to predict points of departure 
(PoDs) integrating in vitro cytotoxicity or genotoxicity assays with in silico physiologically based 
kinetic (PBK) modelling-facilitated reverse dosimetry. This approach may facilitate read-across from 
the few PAs for which toxicological data are available towards the large number of PAs for which in 
vivo toxicity data are lacking. In the next sections background information on PAs, including their 
physico-chemical characteristics,  exposure characteristics, metabolism, genotoxicity, carcinogenicity, 
hepatotoxicity, risk assessment, and on PBK modelling-based reverse dosimetry is provided. 
Physico-chemical properties of the model PAs used in the present thesis 
Amongst the various PAs, especially the 1,2-unsaturated PAs are of concern because they are 
hepatotoxic, genotoxic and carcinogenic (EFSA, 2017). These PAs are esters of unsaturated necines 
having a 1,2-double bond (Figure 1). This thesis focused on two 1,2-unsaturated PAs, namely 
lasiocarpine and riddelliine. While lasiocarpine is a heliotridine-type PA, riddelliine is retronecine-
type PA. In terms of the basic structure, lasiocarpine and riddelliine have a common bicyclic necine 
base with different stereochemistry at the C7 position; riddelliine possesses an R absolute 
configuration, lasiocarpine has an S stereochemistry (Figure 1). Moreover, lasiocarpine is an open di-
ester and riddelliine a cyclic di-ester. The physico-chemical properties of these two PAs are also 
different. Lasiocarpine appears as a colourless plate or beige crystalline solid. It is soluble in most 
non-polar organic solvents and ethanol, but sparingly soluble in water (0.68%) and light petroleum 
(NTP, 1978). Riddelliine appears as a colourless or off-white crystalline solid, it is soluble in 
chloroform, acetone and ethanol, and sparingly soluble in water (Chan, 1993). In spite of this, 
lasiocarpine and riddelliine share similar metabolic pathways, mode of action (MOA) and biological 
effects (Chen et al., 2010; Fu, 2016; He et al., 2017).  
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Figure 1. The schematic structure of the necine bases of PAs, and the structure of lasiocarpine and riddelliine. 
Exposure of humans to PAs    
Humans may be exposed to PAs through herbal teas, honey, PFS and herbal medicines (BfR, 2013; 
Bodi et al., 2014; EFSA, 2016; Mulder et al., 2018; Mulder et al., 2015). Recently, EFSA published a 
dietary exposure assessment for PAs based on the use of herbal teas, honey, herbal infusions (herbs) 
and PFS, reporting estimates for chronic and acute exposure to PAs via those products (EFSA, 2016). 
In the European population, herbal teas and herbal infusions are thought to be the major contributors 
to the total exposure to PAs. In order to cover the whole range of concentrations of PAs in herbal teas 
and herbal infusions, EFSA considered two scenarios for the estimation of dietary exposure to PAs. In 
the first scenario, the data of herbal tea and herbal infusion samples were obtained from national 
authorities according to the EFSA Article 36 grant. In the adult population (‘Adults’, ‘Elderly’, ‘Very 
elderly’), the highest estimates of mean chronic dietary exposure to PAs ranged from the lower bound 
value of 31.3 ng/kg bw/day to the upper bound value of 41.8 ng/kg bw/day (LB-UB), while the 
maximum 95th percentile exposure to PAs for these populations ranged from 87.7-127.2 ng/kg bw/day 
(LB-UB). In a second scenario, the exposure assessment was based on samples that were collected by 
Tea & Herbal Infusions Europe (THIE). The highest estimates of mean chronic dietary exposure to 
PAs based on these input data ranged from 5.7 to 33.4 ng/kg bw/day in the adult population, while the 
95th percentile exposure estimates amounted to 15.9-78.8 ng/kg bw/day (LB-UB). When estimating the 
acute dietary exposure to PAs, it was assumed that all food categories would contain the highest 
contamination level of PAs. The estimated acute exposure levels ranged from 6 to 170 ng/kg bw/day 
for the average exposure in the adult population, and were 22 to 500 ng/kg bw/day for the 95th 
percentile exposure levels (EFSA, 2016). It was also reported that the estimates of acute exposure to 
PAs via consumption of PFS vary considerably, depending on the type of PFS. Several PFS appeared 
to include PA-producing plants, although also PFS prepared from non-PA producing plants appeared 
to contain PAs. Consumption of such PFS dosed in liquid form was estimated to result in exposure up 
to 890 ng/kg bw/day of PAs in the adult population, whereas consumption of PFS in the form of 
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tablets or capsules could lead to exposure up to 800 or 1800 µg/kg bw/day (EFSA, 2017). The 
estimated long-term exposure via consumption of PFS has only been quantified for pollen-based 
supplements and ranged from 0.7 to 11.5 ng/kg bw/day (EFSA, 2016, 2017). For the other types of 
PFS, such chronic PA exposure estimates have not been provided so far. 
Metabolic fate of PAs  
Metabolic activation is required for the biological effects of PAs. Hepatic cytochrome P450 (CYP) 2B 
and CYP 3A are the main enzymes to metabolize PAs (Fu et al., 2004; Huan et al., 1998; Lin et al., 
2003; Prakash et al., 1999; Reed et al., 1992). After absorption in the intestine, PAs are transported 
into the liver where some PAs are cleaved into necines and necic acids by nonspecific esterases. These 
necines and necic acids are not toxic, and necines can be conjugated and excreted through the kidney 
and urine, representing an important pathway of PA detoxification (Chen et al., 2010; Roeder, 2000). 
Rats have a low esterase activity and therefore are very susceptible to the PAs (Dueker et al., 1992). 
Heliotridine-type PAs like lasiocarpine and retronecine-type PAs like riddelliine can be transformed to 
PA N-oxides through N-oxidation. These PA N-oxides can be further conjugated with polar groups 
and excreted from the body (Williams et al., 1989a; Williams et al., 1989b). Alternatively, the PA N-
oxides can be converted back into their parent PAs (Chou et al., 2003b; Wang et al., 2005c; Yan et al., 
2008). In an alternative pathway of heliotridine- and retronecine-types PA metabolism, the necine 
bases of these PAs are hydroxylated at the C3 and C8 position forming pyrrolic ester metabolites. 
Pyrrolic esters are highly reactive, they may covalently react with DNA and proteins to generate DNA 
adducts, protein adducts and DNA and protein cross-link. In addition, pyrrolic esters can be 
hydrolysed into DHP ((±)-6,7-dihydro-7-hydroxy-1-hydroxymethyl-5H-pyrrolizine), DHP can also 
covalently bind with cellular DNA and proteins to produce DNA-DNA cross-link, DNA-protein cross-
link, and DHP-DNA adducts (Chou et al., 2004; Fu et al., 2001; Fu et al., 2010; Fu et al., 2004; 
Prakash et al., 1999; Wang et al., 2005a; Wang et al., 2005b; Xia et al., 2006; Xia et al., 2013) (Figure 
2). The pyrrolic esters and DHP can react with glutathione to form 7-GS-DHP and 7,9-di-GS-DHP. 
The 7-GS-DHP can also react with DNA to from DNA adducts (Fu et al. 2004; Xia et al., 2015, 2018). 
The DNA adducts are biologically active and can induce liver tumour initiation, while the protein 
adducts may play a role in the liver toxicity of PAs (Chen et al., 2010). The hepatic metabolism of PAs 
to pyrrolic esters and/or DHP is considered the bioactivation pathway (Fu et al., 2004; Prakash et al., 
1999).  
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Figure 2. Heliotridine or retronecine-type PAs metabolism (Chen et al., 2010; Yang et al., 2016; Xia et al., 2015; 
2018). 
PA genotoxicity and carcinogenicity  
PAs have been shown to induce a variety of genotoxic effects, including DNA adduct formation, DNA 
cross-linking, DNA strand breaks, micronuclei and chromosomal aberrations in vivo and in vitro  
(Allemang et al., 2018; Chen et al., 2010; NTP, 2003; Kim et al., 1995; Xia et al., 2003, 2006; Uhl et 
al., 2000). It was shown that all studied 1,2-unsaturated PAs including riddelliine, retrorsine, 
lasiocarpine, monocrotaline, riddelliine N-oxide, senkirkine, heliotrine, clivorine, and lycopsamine 
produced the same 4 types of DHP-derived DNA adducts in vitro and in vivo (Figure 3), and that the 
levels of the DHP-derived DNA adducts correlated closely with tumorigenic potency in rodents fed 
different doses of these PAs (Chou and Fu, 2006; Chou et al., 2004; Wang et al., 2005a; Wang et al., 
2005b; Xia et al., 2006; Xia et al., 2003; Xia et al., 2004; Xia et al., 2008; Xia et al., 2013; Yang et al., 
2001).
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cross-linking, DNA strand breaks, micronuclei and chromosomal aberrations in vivo and in vitro  
(Allemang et al., 2018; Chen et al., 2010; NTP, 2003; Kim et al., 1995; Xia et al., 2003, 2006; Uhl et 
al., 2000). It was shown that all studied 1,2-unsaturated PAs including riddelliine, retrorsine, 
lasiocarpine, monocrotaline, riddelliine N-oxide, senkirkine, heliotrine, clivorine, and lycopsamine 
produced the same 4 types of DHP-derived DNA adducts in vitro and in vivo (Figure 3), and that the 
levels of the DHP-derived DNA adducts correlated closely with tumorigenic potency in rodents fed 
different doses of these PAs (Chou and Fu, 2006; Chou et al., 2004; Wang et al., 2005a; Wang et al., 
2005b; Xia et al., 2006; Xia et al., 2003; Xia et al., 2004; Xia et al., 2008; Xia et al., 2013; Yang et al., 
2001).
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Studies on the DNA-protein cross-linking activity were conducted using cells or isolated nuclei for the 
pyrrolic PA metabolites, dehydrosenecionine, dehydromonocrotaline, dehydroseneciphylline and 
dehydroriddelliine and revealed that all induced DNA-protein crosslinks, and the DNA-protein 
crosslinking potency coincided with their known toxicity potency in animal studies (Hincks et al., 
1991; Kim et al., 1995, 1999). Based on these observations it was concluded that the DNA-protein 
cross-linking may be involved in PA-related toxicity (Coulombe Jr et al., 1999; Kim et al., 1995; Petry 
et al., 1984). In addition, induction of micronuclei was assessed in vitro in HepaRG cells for a series of 
PAs, showing dose-dependent increases in micronuclei (Allemang et al., 2018). Isatidine and 
monocrotaline have been shown to cause DNA strand breaks in human hepatoma cells (HepG2 cells) 
and human glioblastoma cells (Glial cells) using the comet assay, with the treatment causing 
significant dose-dependent increases in cell DNA breaks  (Silva-Neto et al., 2010; Uhl et al., 2000). 
These genotoxic effects may induce gene mutations and have been associated with the induction of 
cancer cells and tumour formation (Chen et al., 2010; Hoeijmakers, 2009). Oral administration of 
lasiocarpine as well as riddelliine for 2 years to rats has been shown to induce liver 
haemangiosarcomas (NTP, 1978, 2003). For lasiocarpine, liver haemangiosarcomas were found at 
frequencies amounting to 5/24, 11/23 and 13/23 at dose levels of 0.35, 0.75 and 1.5 mg/kg bw/day 
(NTP, 1978). For riddelliine, liver haemangiosarcomas were found at frequencies amounting to 3/50 
and 38/50 at dose levels of 0.236 and 0.714 mg/kg bw/day (NTP, 2003). These results demonstrate the 
carcinogenicity of lasiocarpine and riddelliine upon chronic oral exposure. Some other PAs, including 
monocrotaline, clivorine, senkirkine, and symphytine, have also been shown to cause liver tumours in 
rodents, albeit upon different routes of exposure (Hirono et al., 1979; Hirono et al., 1976; Kuhara et al., 
1980; Shumaker et al., 1976). Subcutaneous (s.c.) administration of 0.08 mg/kg bw/day monocrotaline 
to male rats resulted in an increase in a number of tumours, principally liver cell carcinomas and 
pulmonary adenocarcinomas (Shumaker et al., 1976). Clivorine induced liver neoplastic nodules in 
rats when they were exposed to 1.56 mg/kg bw/day clivorine via drinking water (Kuhara et al., 1980). 
Senkirkine and symphytine have been shown to induce liver cell adenomas and liver 
haemangioendothelial sarcomas in rats upon administration via i.p. injection of 1.62 mg/kg bw/day 
senkirkine and 0.92 mg/kg bw/day symphytine, respectively (Hirono et al., 1979). To date, there is no 
direct evidence showing that PA intake can lead to liver tumours in humans. However, considering the 
prevalence of PAs all over the world and the evidence of PA-induced carcinogenicity in rodents, 
human exposure to PAs may raise a concern. The International Agency for Research on Cancer (IARC) 
classified lasiocarpine and riddelliine in Group 2B, defined as being possibly carcinogenic to humans 
(IARC, 1976, 2002). 
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Figure 3. The 4 types of DHP-derived DNA adducts  (Xia et al., 2013). 
PAs hepatotoxicity  
Compared to the lack of data related to the potential carcinogenicity of PAs in humans, PA induced 
acute hepatotoxicity has been reported in several human case studies. This acute liver toxicity was 
generally characterized by several liver diseases, including hemorrhagic necrosis, hepatomegaly, 
ascites. Cases of sub-acute exposure have been reported to result in a blockage of hepatic veins, 
leading to hepatic veno-occlusive disease (HVOD) (EFSA, 2011, 2017). Human poisonings caused by 
intake of PA-containing plants have been reported in several countries (Mohabbat et al., 1976; Prakash 
et al., 1999; Roulet et al., 1988; Sperl et al., 1995; Tandon et al., 1976). In 1989, the International 
Program on Chemical Safety (IPCS) concluded that consumption of contaminated grain or the use of 
PA-containing plants as herbal medicine, beverages, or food by man, or grazing on contaminated 
pastures by animals, may cause acute or chronic toxicity (IPCS, 1988). So far, an acute reference dose 
(ARfD) for PAs has not been established, while a lowest known dose of approximately 2 mg/kg bw 
per day associated with acute/short-term effects has been identified based on two human poisoning 
cases. One of the human cases was a 6-month-old girl who was exposed to a daily dose of 
approximately 0.8-1.7 mg PA/kg bw for 2 weeks and developed HVOD. Another case was a 2-month-
old boy who received an approximate dose of 3 mg/kg bw for 4 days, with a fatal outcome (EFSA, 
2017). With respect to PA induced hepatotoxicity in rodents, data on acute liver toxicity are only 
available for lasiocarpine (Dalefield et al., 2016; Jago, 1970; Nolan et al., 1966). Single oral 
administration 0-80 mg/kg bw/day lasiocarpine to rats resulted in acute zonal hepatic necrosis, 
megalocytosis and subacute or chronic hepatitis (Nolan et al., 1966). Through i.p. injection of 0, 10.28, 
20.56, 41.1, 82.2, 164.4 mg/kg bw/day lasiocarpine to rats, the dose-dependent increased incidence of 
slight periportal nuclear enlargement, periportal megalocytosis, megalocytosis and necrosis has been 
identified (Jago, 1970). Lasiocarpine also has been found to induced alanine amino transferase activity 
when rats were exposed to 0.6, 1.2, 2.5 mg/kg bw/day lasiocarpine for over 28 days (Dalefield et al., 
2016).  
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ascites. Cases of sub-acute exposure have been reported to result in a blockage of hepatic veins, 
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(ARfD) for PAs has not been established, while a lowest known dose of approximately 2 mg/kg bw 
per day associated with acute/short-term effects has been identified based on two human poisoning 
cases. One of the human cases was a 6-month-old girl who was exposed to a daily dose of 
approximately 0.8-1.7 mg PA/kg bw for 2 weeks and developed HVOD. Another case was a 2-month-
old boy who received an approximate dose of 3 mg/kg bw for 4 days, with a fatal outcome (EFSA, 
2017). With respect to PA induced hepatotoxicity in rodents, data on acute liver toxicity are only 
available for lasiocarpine (Dalefield et al., 2016; Jago, 1970; Nolan et al., 1966). Single oral 
administration 0-80 mg/kg bw/day lasiocarpine to rats resulted in acute zonal hepatic necrosis, 
megalocytosis and subacute or chronic hepatitis (Nolan et al., 1966). Through i.p. injection of 0, 10.28, 
20.56, 41.1, 82.2, 164.4 mg/kg bw/day lasiocarpine to rats, the dose-dependent increased incidence of 
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when rats were exposed to 0.6, 1.2, 2.5 mg/kg bw/day lasiocarpine for over 28 days (Dalefield et al., 
2016).  
16 16 
 
Risk assessment of PAs 
PAs are considered genotoxic carcinogens. Data of genotoxic carcinogens in human epidemiological 
studies are rarely available, probably due to the fact that such data are difficult to obtain from the 
human population because effects may be masked by many confounding factors and their detection 
may require extremely large study populations. Thus, to assess the risk of genotoxic carcinogens to 
human health, often data based on animal studies are used. There is no doubt that differences in 
biological responses to genotoxic carcinogens exist between experimental animals and humans, 
meaning that data resulting from animal studies cannot be regarded as fully representative for humans. 
Therefore, uncertainty connected to the extrapolation of animal data to the human situation should be 
considered when assessing the risk of genotoxic carcinogens to human health based on data derived 
from animal experiments. One of the suitable methods for preforming such a risk assessment is the 
MOE approach (EFSA, 2005). The MOE is the dimensionless ratio between a reference point based 
on epidemiologic or experimental data on tumour incidence and the EDI in the relevant human 
population (Barlow et al., 2006; EFSA, 2005). To calculate the reference point, a preferred method is 
the BenchMark Dose (BMD) approach. The BMD can be obtained without extrapolation by fitting the 
mathematical models to the available data (Barlow et al., 2006). The BMDL, defined as the one-sided 
95% lower confidence limit of the BMD, takes statistic uncertainties into account and is thought to be 
the preferred reference point for calculating the MOE (Barlow et al., 2006). BMD and BMDL values 
can be calculated for a pre-defined increased tumour incidence compared to the background, that is the 
BenchMark Response (BMR) including 1%, 5% or 10% extra incidence of tumours (EPA, 1995). In 
general, using the BMDL10 is preferred for calculating the MOE since the use of lower incidences will 
increase the uncertainty as 1% or 5% may be outside the experimentally observed incidences (Barlow 
et al., 2006). To obtain a BMDL10 value for a specific substance, generally a long term animal 
carcinogenicity study using either rats or mice is required, which has to meet three requirements 
including: administration of three different experimental doses, sufficient statistical power requiring at 
least 50 animals per treatment and accomplishment of a two-year experimental period (Edler et al., 
2014). Some studies have experimental durations less than the required span of a two-year (104 weeks) 
period, in which the actual period of the treatment can be even shorter. In this case the dose levels 
should be adjusted according to the following formula: dose × (weeks of treatment/104) × (weeks of 
observation/104) (ECHA, 2008). The adjusted dose levels are then used to derive the BMDL10 value. 
In case that the data cannot meet the requirement for calculation of a BMDL10, EFSA has 
recommended use of the T25 or T10 (the dose level causing 25% or 10% extra tumour incidence) as 
an alternative point of departure (PoD) for MOE calculation. T25 values are calculated by dividing the 
extra risk (% incidence in the dose group minus % incidence in the control group) by the non-affected 
fraction in the control population (100 minus background response in %), and converting the dose 
level causing this tumour incidence to the dose level causing 25% extra tumour incidence by linear
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extrapolation. T10 values are obtained by multiplying T25 values by 10/25. At the current state of the 
art, the T25 with a MOE cut-off value of 25000 and the T10 with a MOE cut-off value of 10000 (also 
applied when using the BMDL10) are used when a BMDL10 is not available. A value of 10000 
incorporates three uncertainty factors including a factor 100 for species differences and human 
variability in kinetics and dynamics, a factor of 10 for the variability in cell cycle control and DNA 
repair within humans, and a factor of 10 because the BMDL10 is not a no observed adverse effect level 
(NOAEL) (EFSA, 2005).  
The MOE is based on the assumption of daily life-time exposure. Thus, the risk assessments for 
exposure to PAs via herbal teas, herbal medicines and PFS that have been done previously were also 
based on the assumption of daily life-time exposure to these products (BfR, 2013; Chen et al., 2017; 
EFSA, 2016, 2017). Such an assumption may not be true as people might rather consume these 
products occasionally or only during certain periods of, for example, illness. At the current state-of-
the-art there is no generally accepted method to correct for this shorter than life-time daily exposure. 
Nevertheless, application of the MOE approach combined with Haber’s rule for risk assessment taking 
into account shorter than life-time realistic exposure scenarios could be considered. According to 
Haber’s rule, the toxic effects are correlated linearly with the timespan of exposure and the 
concentration or dose of a toxic compound (i.e. C × T = k, where C is concentration or dose, T is time 
of exposure, and k is a constant toxic response for the specific substance) (Doull and Rozman, 2000). 
Employing Haber's rule and assuming a lifetime expectancy of 75 years (Felter et al., 2011; van den 
Berg et al., 2014), the EDI values for for example 2 weeks yearly exposure during a lifetime will be 52 
weeks per year/2 weeks = 26 times lower, resulting in 26 times higher MOE values. 
A BMDL10 value is required for the MOE approach. So far, amongst all PAs only for lasiocarpine and 
riddelliine  2-year animal studies are available that provided data suitable to derive BMDL10 values. 
The BMDL10 of 0.07 mg/kg bw/day for lasiocarpine was used in first instance as the PoD value to 
calculate MOEs for exposure to PAs (EFSA, 2011). Recently EFSA defined a reference point of 0.237 
mg/kg/day for riddelliine as the PoD to assess the carcinogenicity risk of PAs based on an updated 
BMD modelling approach. This was done because it was considered that the BMDL10 obtained by 
modelling of the data on liver tumour formation by lasiocarpine were affected by a high degree of 
uncertainty (EFSA, 2017). The EDI values were calculated based on total PA levels in herbal products, 
taking into consideration the combined exposure to different PAs (BfR, 2013; EFSA, 2016, 2017). 
When considering combined exposure, both equal toxic potency or different potency of the different 
PAs could be considered. This implies that the response to the mixtures can be calculated by summing 
up the EDIs of the PAs assuming equal potency, or using their relative potency (REP) to ‘adjust’ the 
individual PA concentrations. Interim REP factors for PAs were proposed by Merz and Schrenk 
(2016), based on available literature data on in vitro cytotoxicity, genotoxicity in Drosophila, and 
acute toxicity in rodents (LD50), and REP factors were defined for the most relevant structural types 
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Risk assessment of PAs 
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of exposure, and k is a constant toxic response for the specific substance) (Doull and Rozman, 2000). 
Employing Haber's rule and assuming a lifetime expectancy of 75 years (Felter et al., 2011; van den 
Berg et al., 2014), the EDI values for for example 2 weeks yearly exposure during a lifetime will be 52 
weeks per year/2 weeks = 26 times lower, resulting in 26 times higher MOE values. 
A BMDL10 value is required for the MOE approach. So far, amongst all PAs only for lasiocarpine and 
riddelliine  2-year animal studies are available that provided data suitable to derive BMDL10 values. 
The BMDL10 of 0.07 mg/kg bw/day for lasiocarpine was used in first instance as the PoD value to 
calculate MOEs for exposure to PAs (EFSA, 2011). Recently EFSA defined a reference point of 0.237 
mg/kg/day for riddelliine as the PoD to assess the carcinogenicity risk of PAs based on an updated 
BMD modelling approach. This was done because it was considered that the BMDL10 obtained by 
modelling of the data on liver tumour formation by lasiocarpine were affected by a high degree of 
uncertainty (EFSA, 2017). The EDI values were calculated based on total PA levels in herbal products, 
taking into consideration the combined exposure to different PAs (BfR, 2013; EFSA, 2016, 2017). 
When considering combined exposure, both equal toxic potency or different potency of the different 
PAs could be considered. This implies that the response to the mixtures can be calculated by summing 
up the EDIs of the PAs assuming equal potency, or using their relative potency (REP) to ‘adjust’ the 
individual PA concentrations. Interim REP factors for PAs were proposed by Merz and Schrenk 
(2016), based on available literature data on in vitro cytotoxicity, genotoxicity in Drosophila, and 
acute toxicity in rodents (LD50), and REP factors were defined for the most relevant structural types 
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of PAs (Merz and Schrenk, 2016). It should be noticed that these interim REP values did not take the 
relative potency of PAs for tumour formation into account, because the lack of carcinogenicity studies 
for PAs hampers such a more detailed (combined) risk assessment.  
PBK modelling-based reverse dosimetry 
Due to the lack of liver toxicity and carcinogenicity data for most PAs, and also considering economic 
and ethical constraints that limit the possibilities to perform toxicity studies for all relevant PAs, 
alternative testing strategies for estimating the toxicity of different PAs are required. However, use of 
alternative testing methods instead of animal studies in quantitative risk assessment, requires 
translation of in vitro concentration-response curves to in vivo dose-response curves. This can be 
achieved using physiologically based kinetic (PBK) modelling-based reverse dosimetry. It has been 
shown that data on in vivo toxicity can be adequately predicted by translation of in vitro 
concentration-response curves to in vivo dose-response curves for toxicity using this in vitro-in silico 
approach (Abdullah et al., 2016; Li et al., 2017; Louisse et al., 2015; Louisse et al., 2010; Strikwold et 
al., 2017; Zhang et al., 2018). In this way in vivo dose effect levels and PoDs have been defined, for 
example for developmental toxicity (Li et al., 2017; Louisse et al., 2015; Louisse et al., 2010; 
Strikwold et al., 2017), kidney toxicity (Abdullah et al., 2016), and estrogenicity (Zhang et al., 2018). 
The present thesis applied the approach for liver toxicity and genotoxicity of lasiocarpine and 
riddelliine, the two PAs for which rodent data on liver toxicity and/or carcinogenicity are available. 
PBK models require different parameters including physiological, physico-chemical and metabolic 
parameters to mathematically describe the absorption, distribution, metabolism and excretion (ADME) 
of the compound of interest in the relevant organ and species (Chiu et al., 2007; Krewski et al., 1994; 
Rietjens et al., 2011). PBK modelling can take time- and dose-dependent changes in metabolism into 
account, and blood and tissue concentrations of a compound and its relevant metabolites can be 
predicted over time (Rietjens et al., 2011). The use of PBK modelling-based reverse dosimetry to 
predict in vivo dose-response curves and PoDs for risk assessment involves several steps: (1) 
establishment of an in vitro concentration-response curve for a selected relevant endpoint using an 
adequate in vitro assay model, (2) development of the PBK model describing in vivo kinetics of the 
parent compound and/or metabolites of interest in the relevant tissue, (3) evaluation of the developed 
PBK model against available literature data on kinetics, (4) translation of the in vitro concentration-
response curves from the in vitro assay into in vivo dose-response curves using PBK modelling-based 
reversed dosimetry taking differences in protein binding of the compound of interest in the in vitro 
model and the in vivo situation into account, (5) BMD analysis on the predicted in vivo dose-response 
curve to obtain a PoD, (6) evaluation of the predicted in vivo dose response curves and/or the 
predicted PoD against available literature data. Development of a PBK model means defining the 
structure of the model including organs and tissues that are considered relevant for the kinetic 
processes and the toxicity of the compound of interest. A PBK model generally includes separate 
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compartments for these tissues relevant for the kinetics and toxicity of the compound, while the 
remaining non-target tissue compartments can be pooled in compartments representing slowly or 
richly perfused tissue. All the compartments are mutually connected through the system circulation 
(Figure. 4). For each compartment, mathematical equations are defined to describe the kinetic 
processes of the compound. For these equations, the relevant physiological, anatomical, physico-
chemical and kinetic values need to be defined. These parameters can be obtained from literature, and 
from in vivo or in vitro assays. Once the mathematic model is established and the relevant parameters 
have been defined, the equations can be solved using specific software in order to predict the 
maximum concentration (Cmax) or the area under the concentration curve (AUC) of the compound in 
plasma or in any tissue of interest. In a next step each concentration (or AUC) that is used in the in 
vitro assay is set equal to Cmax (or AUC) in the blood or in a specific tissue, after correction for 
possible differences in protein binding due to different protein levels in the medium of the in vitro 
assay and the in vivo tissue. Then this Cmax (or AUC) is used as input in the PBK model to calculate 
the oral dose that results in this concentration (or AUC). The AUC values are calculated by 
multiplying the used concentration with the assay time (Daston et al., 2010). The Cmax (or AUC)-
response curves can be translated to the in vivo situation by assessing which oral doses are required to 
reach these Cmax (or AUC) levels in the blood or specific tissue. Use of Cmax or AUC depends on the 
toxicological endpoint studied, with acute toxicity being better reflected by Cmax values while longer 
term toxicity for which the effects accumulate over the time of exposure, such as for example 
genotoxicity or carcinogenicity, might be better predicted using the AUC. Upon translation of the in 
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of PAs (Merz and Schrenk, 2016). It should be noticed that these interim REP values did not take the 
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processes and the toxicity of the compound of interest. A PBK model generally includes separate 
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Objectives and outline of the thesis 
The aim of this thesis was to contribute to the risk assessment for PAs in botanical and botanical 
preparations including herbal teas, herbal medicines and PFS based on life-time exposure and realistic 
exposure scenarios by developing and applying suitable alternative testing strategies. To this end the 
thesis also aimed to investigate whether PBK modelling-based reverse dosimetry could adequately 
convert in vitro concentration-response curves to in vivo dose-response curves to predict liver toxicity 
and genotoxicity induced by lasiocarpine and riddelliine. 
Chapter 1, the introduction chapter, starts with a short background and definition of the aim of the 
present thesis, followed by a description of the physico-chemical properties, exposure characteristics, 
metabolism, genotoxicity, carcinogenicity, hepatotoxicity, and risk assessment of PAs, and of PBK 
modelling-based reverse dosimetry. 
Chapter 2 presents an overview of tumour data available for PAs including, in addition to 
lasiocarpine and riddelliine, monocrotaline, clivorine, senkirkine and symphytine and PoDs derived 
from them. A risk assessment for (combined) exposure to PAs via herbal teas and PFS was performed, 
based on the MOE approach using the BMDL10 for lasiocarpine and mean PA levels corrected by REP 
factors. 
Chapter 3 evaluates the risk of exposure to PAs through consumption of herbal teas, herbal 
medicines and PFS following realistic exposure scenarios. To this end herbal teas were used to 
quantify the effect of comminution on the levels of PAs extracted into hot water and resulting PA 
exposure as compared to use of the intact leaves. The MOE approach was used to evaluate the 
consequences of this difference for the associated risks. Furthermore, considering medicinal use of 
these botanical preparations, the risk under shorter than life-time more realistic exposure scenarios was 
also evaluated. 
Chapter 4 describes the development and evaluation of PBK models for lasiocarpine and riddelliine 
in rat, and use of these models to predict the PoDs for liver toxicity of lasiocarpine and riddelliine. To 
this end in vitro concentration-response curves for cytotoxicity in primary rat hepatocytes were 
converted to in vivo dose-response curves for liver toxicity in rat using PBK modelling-based reverse 
dosimetry. The model performance was evaluated by comparison of the predicted PoDs to in vivo 
available liver toxicity data.  
Chapter 5 extends the PBK model-based reverse dosimetry approach by defining PBK models for 
humans and predicting inter-species and inter-ethnic human differences in liver toxicity of lasiocarpine 
and riddelliine. The concentration-response curves of in vitro cytotoxicity of lasiocarpine and 
riddelliine defined in pooled primary human hepatocytes were translated to in vivo dose-response 
curves by PBK models developed using kinetic data obtained from incubations with pooled tissue
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fractions from Chinese and Caucasian individuals, providing PBK models for the average Chinese and 
average Caucasian, respectively.   
Chapter 6 investigates whether the developed PBK modelling-facilitated reverse dosimetry can 
adequately translate in vitro concentration-response curves for genotoxicity of lasiocarpine and 
riddelliine, to in vivo dose-response curves for genotoxicity induced by lasiocarpine and riddelliine in 
rat. To achieve this aim, the in vitro concentration-responses curves obtained from in vitro 
genotoxicity studies with primary rat hepatocytes using the γH2AX assay were translated into in vivo 
dose-response curves by using PBK modelling-facilitated reverse dosimetry. The predicted PoDs for 
rat were compared to available in vivo rodent data on genotoxicity and carcinogenicity induced by 
lasiocarpine and riddelliine. 
Chapter 7 summarizes the results obtained in the thesis, provides an overall discussion and presents 
the future perspectives that follow from the results obtained.  
21
C
ha
pt
er
 1
20 
 
Objectives and outline of the thesis 
The aim of this thesis was to contribute to the risk assessment for PAs in botanical and botanical 
preparations including herbal teas, herbal medicines and PFS based on life-time exposure and realistic 
exposure scenarios by developing and applying suitable alternative testing strategies. To this end the 
thesis also aimed to investigate whether PBK modelling-based reverse dosimetry could adequately 
convert in vitro concentration-response curves to in vivo dose-response curves to predict liver toxicity 
and genotoxicity induced by lasiocarpine and riddelliine. 
Chapter 1, the introduction chapter, starts with a short background and definition of the aim of the 
present thesis, followed by a description of the physico-chemical properties, exposure characteristics, 
metabolism, genotoxicity, carcinogenicity, hepatotoxicity, and risk assessment of PAs, and of PBK 
modelling-based reverse dosimetry. 
Chapter 2 presents an overview of tumour data available for PAs including, in addition to 
lasiocarpine and riddelliine, monocrotaline, clivorine, senkirkine and symphytine and PoDs derived 
from them. A risk assessment for (combined) exposure to PAs via herbal teas and PFS was performed, 
based on the MOE approach using the BMDL10 for lasiocarpine and mean PA levels corrected by REP 
factors. 
Chapter 3 evaluates the risk of exposure to PAs through consumption of herbal teas, herbal 
medicines and PFS following realistic exposure scenarios. To this end herbal teas were used to 
quantify the effect of comminution on the levels of PAs extracted into hot water and resulting PA 
exposure as compared to use of the intact leaves. The MOE approach was used to evaluate the 
consequences of this difference for the associated risks. Furthermore, considering medicinal use of 
these botanical preparations, the risk under shorter than life-time more realistic exposure scenarios was 
also evaluated. 
Chapter 4 describes the development and evaluation of PBK models for lasiocarpine and riddelliine 
in rat, and use of these models to predict the PoDs for liver toxicity of lasiocarpine and riddelliine. To 
this end in vitro concentration-response curves for cytotoxicity in primary rat hepatocytes were 
converted to in vivo dose-response curves for liver toxicity in rat using PBK modelling-based reverse 
dosimetry. The model performance was evaluated by comparison of the predicted PoDs to in vivo 
available liver toxicity data.  
Chapter 5 extends the PBK model-based reverse dosimetry approach by defining PBK models for 
humans and predicting inter-species and inter-ethnic human differences in liver toxicity of lasiocarpine 
and riddelliine. The concentration-response curves of in vitro cytotoxicity of lasiocarpine and 
riddelliine defined in pooled primary human hepatocytes were translated to in vivo dose-response 
curves by PBK models developed using kinetic data obtained from incubations with pooled tissue
21 
 
fractions from Chinese and Caucasian individuals, providing PBK models for the average Chinese and 
average Caucasian, respectively.   
Chapter 6 investigates whether the developed PBK modelling-facilitated reverse dosimetry can 
adequately translate in vitro concentration-response curves for genotoxicity of lasiocarpine and 
riddelliine, to in vivo dose-response curves for genotoxicity induced by lasiocarpine and riddelliine in 
rat. To achieve this aim, the in vitro concentration-responses curves obtained from in vitro 
genotoxicity studies with primary rat hepatocytes using the γH2AX assay were translated into in vivo 
dose-response curves by using PBK modelling-facilitated reverse dosimetry. The predicted PoDs for 
rat were compared to available in vivo rodent data on genotoxicity and carcinogenicity induced by 
lasiocarpine and riddelliine. 
Chapter 7 summarizes the results obtained in the thesis, provides an overall discussion and presents 
the future perspectives that follow from the results obtained.  
22 22 
 
References 
Abdullah, R., Alhusainy, W., Woutersen, J., Rietjens, I.M., Punt, A., 2016. Predicting points of 
departure for risk assessment based on in vitro  cytotoxicity data and physiologically based 
kinetic (PBK) modeling: the case of kidney toxicity induced by aristolochic acid I. Food and 
Chemical Toxicology 92, 104-116. 
Allemang, A., Mahony, C., Lester, C., Pfuhler, S., 2018. Relative potency of fifteen pyrrolizidine 
alkaloids to induce DNA damage as measured by micronucleus induction in HepaRG human 
liver cells. Food and chemical toxicology 121, 72-81. 
Barlow, S., Renwick, A., Kleiner, J., Bridges, J., Busk, L., Dybing, E., Edler, L., Eisenbrand, G., Fink-
Gremmels, J., Knaap, A., 2006. Risk assessment of substances that are both genotoxic and 
carcinogenic: report of an International Conference organized by EFSA and WHO with support 
of ILSI Europe. Food and chemical toxicology 44, 1636-1650. 
BfR, 2013. Pyrrolizidine alkaloids in herbal teas and teas. BfR Opinion No. 018/2013 of 5 July 2013. 
Pyrrolizidine alkaloids‐in‐herbal‐teas‐and‐teas. 
Bodi, D., Ronczka, S., Gottschalk, C., Behr, N., Skibba, A., Wagner, M., Lahrssen-Wiederholt, M., 
Preiss-Weigert, A., These, A., 2014. Determination of pyrrolizidine alkaloids in tea, herbal 
drugs and honey. Food Additives & Contaminants: Part A 31, 1886-1895. 
CFDA, 2016. “Health food registration and record management approach” (State Food and Drug 
Administration Order No. 22) 
Chan, P., 1993. NTP technical report on the toxicity studies of Riddelliine (CAS No. 23246-96-0) 
Administered by Gavage to F344 Rats and B6C3F1 Mice. Toxicity report series 27, 1-D9. 
Chen, L., Mulder, P.P., Louisse, J., Peijnenburg, A., Wesseling, S., Rietjens, I.M., 2017. Risk 
assessment for pyrrolizidine alkaloids detected in (herbal) teas and plant food supplements. 
Regulatory Toxicology and Pharmacology 86, 292-302. 
Chen, T., Mei, N., Fu, P.P., 2010. Genotoxicity of pyrrolizidine alkaloids. Journal of Applied 
Toxicology: An International Journal 30, 183-196. 
Chiu, W.A., Barton, H.A., DeWoskin, R.S., Schlosser, P., Thompson, C.M., Sonawane, B., Lipscomb, 
J.C., Krishnan, K., 2007. Evaluation of physiologically based pharmacokinetic models for use 
in risk assessment. Journal of Applied Toxicology: An International Journal 27, 218-237. 
Chou, M.W., Fu, P.P., 2006. Formation of DHP-derived DNA adducts in vivo  from dietary 
supplements and Chinese herbal plant extracts containing carcinogenic pyrrolizidine alkaloids. 
Toxicology and industrial health 22, 321-327. 
Chou, M.W., Wang, Y.-P., Yan, J., Yang, Y.-C., Beger, R.D., Williams, L.D., Doerge, D.R., Fu, P.P., 
2003b. Riddelliine N-oxide is a phytochemical and mammalian metabolite with genotoxic 
activity that is comparable to the parent pyrrolizidine alkaloid riddelliine. Toxicology letters 
145, 239-247. 
Chou, M.W., Yan, J., Nichols, J., Xia, Q., Beland, F.A., Chan, P.-C., Fu, P.P., 2004. Correlation of 
DNA adduct formation and riddelliine-induced liver tumorigenesis in F344 rats and B6C3F1 
mice [Cancer Lett. 193 (2003) 119–125]. Cancer letters 207, 119-125. 
Coulombe Jr, R.A., Drew, G.L., Stermitz, F.R., 1999. Pyrrolizidine alkaloids crosslink DNA with 
actin. Toxicology and applied pharmacology 154, 198-202. 
Dalefield, R.R., Gosse, M.A., Mueller, U., 2016. A 28-day oral toxicity study of echimidine and 
lasiocarpine in Wistar rats. Regulatory Toxicology and Pharmacology 81, 146-154. 
Daston, G.P., Chapin, R.E., Scialli, A.R., Piersma, A.H., Carney, E.W., Rogers, J.M., Friedman, J.M., 
2010. A different approach to validating screening assays for developmental toxicity. Birth 
Defects Research Part B: Developmental and Reproductive Toxicology 89, 526-530. 
Doull, J., Rozman, K., 2000. Using Haber's Law to define the margin of exposure. Toxicology 149, 1. 
Dueker, S.R., Lamé, M.W., Morin, D.E.X.T.E.R., Wilson, D.W. and Segall, H.J., 1992. Guinea pig 
and rat hepatic microsomal metabolism of monocrotaline. Drug metabolism and disposition, 
20(2), pp.275-280. 
ECHA, M., 2008. Guidance on information requirements and chemical safety assessment. Chapter R 8. 
23 
 
Edler, L., Hart, A., Greaves, P., Carthew, P., Coulet, M., Boobis, A., Williams, G.M., Smith, B., 2014. 
Selection of appropriate tumour data sets for Benchmark Dose Modelling (BMD) and 
derivation of a Margin of Exposure (MoE) for substances that are genotoxic and carcinogenic: 
Considerations of biological relevance of tumour type, data quality and uncertainty assessment. 
Food and chemical toxicology 70, 264-289. 
EFSA, 2005. Opinion of the Scientific Committee on a request from EFSA related to a harmonised 
approach for risk assessment of substances which are both genotoxic and carcinogenic. EFSA 
Journal 3, 282. 
EFSA, 2009. Guidance on safety assessment of botanicals and botanical preparations intended for use 
as ingredients in food supplements. EFSA Journal 7, 1249. 
EFSA, 2011. Scientific opinion on pyrrolizidine alkaloids in food and feed. EFSA Journal 9, 2406. 
EFSA, 2016. Dietary exposure assessment to pyrrolizidine alkaloids in the European population. 
EFSA Journal 14, e04572. 
EFSA, 2017. Risks for human health related to the presence of pyrrolizidine alkaloids in honey, tea, 
herbal infusions and food supplements. EFSA Journal 15. 
EPA, 1995. The use of the benchmark dose approach in health risk assessment. Risk Assessment 
Forum, US Environmental Protection Agency. 
Felter, S.P., Conolly, R.B., Bercu, J.P., Bolger, P.M., Boobis, A.R., Bos, P.M., Carthew, P., Doerrer, 
N.G., Goodman, J.I., Harrouk, W.A., 2011. A proposed framework for assessing risk from less-
than-lifetime exposures to carcinogens. Critical reviews in toxicology 41, 507-544. 
Fu, P., Chou, M., Xia, Q., Yang, Y.-C., Yan, J., Doerge, D., Chan, P., 2001. Genotoxic pyrrolizidine 
alkaloids and pyrrolizidine alkaloid N-oxides-mechanisms leading to DNA adduct formation 
and tumorigenicity. Journal of Environmental Science and Health, Part C 19, 353-385. 
Fu, P.P., 2016. Pyrrolizidine alkaloids: metabolic activation pathways leading to liver tumor initiation. 
Chemical research in toxicology 30, 81-93. 
Fu, P.P., Chou, M.W., Churchwell, M., Wang, Y., Zhao, Y., Xia, Q., Gamboa da Costa, G.a., Marques, 
M.M., Beland, F.A., Doerge, D.R., 2010. High-performance liquid chromatography 
electrospray ionization tandem mass spectrometry for the detection and quantitation of 
pyrrolizidine alkaloid-derived DNA adducts in vitro  and in vivo . Chemical research in 
toxicology 23, 637-652. 
Fu, P.P., Xia, Q., Lin, G., Chou, M.W., 2004. Pyrrolizidine alkaloids-genotoxicity, metabolism 
enzymes, metabolic activation, and mechanisms. Drug metabolism reviews 36, 1-55. 
Health Canada, 2016. About natural health product regulations in Canada-Health Canada.  
Hartmann, T., 1999. Chemical ecology of pyrrolizidine alkaloids. Planta 207, 483-495. 
He, X., Xia, Q., Fu, P.P., 2017. 7-Glutathione-pyrrole and 7-cysteine-pyrrole are potential 
carcinogenic metabolites of pyrrolizidine alkaloids. Journal of Environmental Science and 
Health, Part C 35, 69-83. 
Hirono, I., Haga, M., Fujii, M., Matsuura, S., Matsubara, N., Nakayama, M., Furuya, T., Hikichi, M., 
Takanashi, H., Uchida, E., 1979. Induction of hepatic tumors in rats by senkirkine and 
symphytine. Journal of the National Cancer Institute 63, 469-472. 
Hirono, I., Mori, H., Culvenor, C.C., 1976. Carcinogenic activity of coltsfoot, Tussilago farfara L. 
GANN Japanese Journal of Cancer Research 67, 125-129. 
Hoeijmakers, J.H., 2009. DNA damage, aging, and cancer. New England Journal of Medicine 361, 
1475-1485. 
Huan, J.-Y., Miranda, C.L., Buhler, D.R., Cheeke, P.R., 1998. The roles of CYP3A and CYP2B 
isoforms in hepatic bioactivation and detoxification of the pyrrolizidine alkaloid senecionine in 
sheep and hamsters. Toxicology and applied pharmacology 151, 229-235. 
Hincks, J.R., Kim, H.Y., Segall, H.J., Molyneux, R.J., Stermitz, F.R. and Coulombe Jr, R.A., 1991. 
DNA cross-linking in mammalian cells by pyrrolizidine alkaloids: structure-activity 
relationships. Toxicology and applied pharmacology, 111(1), pp.90-98. 
IARC, 1976. IARC Monographs on Evaluation of Carcinogenic Risk of chemicals  to Man: Some 
Naturally Occuring Substances. 10.  
IARC, 2002. IARC Monographs on Evaluation of Carcinogenic Risk of Chemicals  to Humans: Some 
Traditional Herbal Medicines, Some Mycotoxins,Naphthalene and Styrene. 82 
23
C
ha
pt
er
 1
22 
 
References 
Abdullah, R., Alhusainy, W., Woutersen, J., Rietjens, I.M., Punt, A., 2016. Predicting points of 
departure for risk assessment based on in vitro  cytotoxicity data and physiologically based 
kinetic (PBK) modeling: the case of kidney toxicity induced by aristolochic acid I. Food and 
Chemical Toxicology 92, 104-116. 
Allemang, A., Mahony, C., Lester, C., Pfuhler, S., 2018. Relative potency of fifteen pyrrolizidine 
alkaloids to induce DNA damage as measured by micronucleus induction in HepaRG human 
liver cells. Food and chemical toxicology 121, 72-81. 
Barlow, S., Renwick, A., Kleiner, J., Bridges, J., Busk, L., Dybing, E., Edler, L., Eisenbrand, G., Fink-
Gremmels, J., Knaap, A., 2006. Risk assessment of substances that are both genotoxic and 
carcinogenic: report of an International Conference organized by EFSA and WHO with support 
of ILSI Europe. Food and chemical toxicology 44, 1636-1650. 
BfR, 2013. Pyrrolizidine alkaloids in herbal teas and teas. BfR Opinion No. 018/2013 of 5 July 2013. 
Pyrrolizidine alkaloids‐in‐herbal‐teas‐and‐teas. 
Bodi, D., Ronczka, S., Gottschalk, C., Behr, N., Skibba, A., Wagner, M., Lahrssen-Wiederholt, M., 
Preiss-Weigert, A., These, A., 2014. Determination of pyrrolizidine alkaloids in tea, herbal 
drugs and honey. Food Additives & Contaminants: Part A 31, 1886-1895. 
CFDA, 2016. “Health food registration and record management approach” (State Food and Drug 
Administration Order No. 22) 
Chan, P., 1993. NTP technical report on the toxicity studies of Riddelliine (CAS No. 23246-96-0) 
Administered by Gavage to F344 Rats and B6C3F1 Mice. Toxicity report series 27, 1-D9. 
Chen, L., Mulder, P.P., Louisse, J., Peijnenburg, A., Wesseling, S., Rietjens, I.M., 2017. Risk 
assessment for pyrrolizidine alkaloids detected in (herbal) teas and plant food supplements. 
Regulatory Toxicology and Pharmacology 86, 292-302. 
Chen, T., Mei, N., Fu, P.P., 2010. Genotoxicity of pyrrolizidine alkaloids. Journal of Applied 
Toxicology: An International Journal 30, 183-196. 
Chiu, W.A., Barton, H.A., DeWoskin, R.S., Schlosser, P., Thompson, C.M., Sonawane, B., Lipscomb, 
J.C., Krishnan, K., 2007. Evaluation of physiologically based pharmacokinetic models for use 
in risk assessment. Journal of Applied Toxicology: An International Journal 27, 218-237. 
Chou, M.W., Fu, P.P., 2006. Formation of DHP-derived DNA adducts in vivo  from dietary 
supplements and Chinese herbal plant extracts containing carcinogenic pyrrolizidine alkaloids. 
Toxicology and industrial health 22, 321-327. 
Chou, M.W., Wang, Y.-P., Yan, J., Yang, Y.-C., Beger, R.D., Williams, L.D., Doerge, D.R., Fu, P.P., 
2003b. Riddelliine N-oxide is a phytochemical and mammalian metabolite with genotoxic 
activity that is comparable to the parent pyrrolizidine alkaloid riddelliine. Toxicology letters 
145, 239-247. 
Chou, M.W., Yan, J., Nichols, J., Xia, Q., Beland, F.A., Chan, P.-C., Fu, P.P., 2004. Correlation of 
DNA adduct formation and riddelliine-induced liver tumorigenesis in F344 rats and B6C3F1 
mice [Cancer Lett. 193 (2003) 119–125]. Cancer letters 207, 119-125. 
Coulombe Jr, R.A., Drew, G.L., Stermitz, F.R., 1999. Pyrrolizidine alkaloids crosslink DNA with 
actin. Toxicology and applied pharmacology 154, 198-202. 
Dalefield, R.R., Gosse, M.A., Mueller, U., 2016. A 28-day oral toxicity study of echimidine and 
lasiocarpine in Wistar rats. Regulatory Toxicology and Pharmacology 81, 146-154. 
Daston, G.P., Chapin, R.E., Scialli, A.R., Piersma, A.H., Carney, E.W., Rogers, J.M., Friedman, J.M., 
2010. A different approach to validating screening assays for developmental toxicity. Birth 
Defects Research Part B: Developmental and Reproductive Toxicology 89, 526-530. 
Doull, J., Rozman, K., 2000. Using Haber's Law to define the margin of exposure. Toxicology 149, 1. 
Dueker, S.R., Lamé, M.W., Morin, D.E.X.T.E.R., Wilson, D.W. and Segall, H.J., 1992. Guinea pig 
and rat hepatic microsomal metabolism of monocrotaline. Drug metabolism and disposition, 
20(2), pp.275-280. 
ECHA, M., 2008. Guidance on information requirements and chemical safety assessment. Chapter R 8. 
23 
 
Edler, L., Hart, A., Greaves, P., Carthew, P., Coulet, M., Boobis, A., Williams, G.M., Smith, B., 2014. 
Selection of appropriate tumour data sets for Benchmark Dose Modelling (BMD) and 
derivation of a Margin of Exposure (MoE) for substances that are genotoxic and carcinogenic: 
Considerations of biological relevance of tumour type, data quality and uncertainty assessment. 
Food and chemical toxicology 70, 264-289. 
EFSA, 2005. Opinion of the Scientific Committee on a request from EFSA related to a harmonised 
approach for risk assessment of substances which are both genotoxic and carcinogenic. EFSA 
Journal 3, 282. 
EFSA, 2009. Guidance on safety assessment of botanicals and botanical preparations intended for use 
as ingredients in food supplements. EFSA Journal 7, 1249. 
EFSA, 2011. Scientific opinion on pyrrolizidine alkaloids in food and feed. EFSA Journal 9, 2406. 
EFSA, 2016. Dietary exposure assessment to pyrrolizidine alkaloids in the European population. 
EFSA Journal 14, e04572. 
EFSA, 2017. Risks for human health related to the presence of pyrrolizidine alkaloids in honey, tea, 
herbal infusions and food supplements. EFSA Journal 15. 
EPA, 1995. The use of the benchmark dose approach in health risk assessment. Risk Assessment 
Forum, US Environmental Protection Agency. 
Felter, S.P., Conolly, R.B., Bercu, J.P., Bolger, P.M., Boobis, A.R., Bos, P.M., Carthew, P., Doerrer, 
N.G., Goodman, J.I., Harrouk, W.A., 2011. A proposed framework for assessing risk from less-
than-lifetime exposures to carcinogens. Critical reviews in toxicology 41, 507-544. 
Fu, P., Chou, M., Xia, Q., Yang, Y.-C., Yan, J., Doerge, D., Chan, P., 2001. Genotoxic pyrrolizidine 
alkaloids and pyrrolizidine alkaloid N-oxides-mechanisms leading to DNA adduct formation 
and tumorigenicity. Journal of Environmental Science and Health, Part C 19, 353-385. 
Fu, P.P., 2016. Pyrrolizidine alkaloids: metabolic activation pathways leading to liver tumor initiation. 
Chemical research in toxicology 30, 81-93. 
Fu, P.P., Chou, M.W., Churchwell, M., Wang, Y., Zhao, Y., Xia, Q., Gamboa da Costa, G.a., Marques, 
M.M., Beland, F.A., Doerge, D.R., 2010. High-performance liquid chromatography 
electrospray ionization tandem mass spectrometry for the detection and quantitation of 
pyrrolizidine alkaloid-derived DNA adducts in vitro  and in vivo . Chemical research in 
toxicology 23, 637-652. 
Fu, P.P., Xia, Q., Lin, G., Chou, M.W., 2004. Pyrrolizidine alkaloids-genotoxicity, metabolism 
enzymes, metabolic activation, and mechanisms. Drug metabolism reviews 36, 1-55. 
Health Canada, 2016. About natural health product regulations in Canada-Health Canada.  
Hartmann, T., 1999. Chemical ecology of pyrrolizidine alkaloids. Planta 207, 483-495. 
He, X., Xia, Q., Fu, P.P., 2017. 7-Glutathione-pyrrole and 7-cysteine-pyrrole are potential 
carcinogenic metabolites of pyrrolizidine alkaloids. Journal of Environmental Science and 
Health, Part C 35, 69-83. 
Hirono, I., Haga, M., Fujii, M., Matsuura, S., Matsubara, N., Nakayama, M., Furuya, T., Hikichi, M., 
Takanashi, H., Uchida, E., 1979. Induction of hepatic tumors in rats by senkirkine and 
symphytine. Journal of the National Cancer Institute 63, 469-472. 
Hirono, I., Mori, H., Culvenor, C.C., 1976. Carcinogenic activity of coltsfoot, Tussilago farfara L. 
GANN Japanese Journal of Cancer Research 67, 125-129. 
Hoeijmakers, J.H., 2009. DNA damage, aging, and cancer. New England Journal of Medicine 361, 
1475-1485. 
Huan, J.-Y., Miranda, C.L., Buhler, D.R., Cheeke, P.R., 1998. The roles of CYP3A and CYP2B 
isoforms in hepatic bioactivation and detoxification of the pyrrolizidine alkaloid senecionine in 
sheep and hamsters. Toxicology and applied pharmacology 151, 229-235. 
Hincks, J.R., Kim, H.Y., Segall, H.J., Molyneux, R.J., Stermitz, F.R. and Coulombe Jr, R.A., 1991. 
DNA cross-linking in mammalian cells by pyrrolizidine alkaloids: structure-activity 
relationships. Toxicology and applied pharmacology, 111(1), pp.90-98. 
IARC, 1976. IARC Monographs on Evaluation of Carcinogenic Risk of chemicals  to Man: Some 
Naturally Occuring Substances. 10.  
IARC, 2002. IARC Monographs on Evaluation of Carcinogenic Risk of Chemicals  to Humans: Some 
Traditional Herbal Medicines, Some Mycotoxins,Naphthalene and Styrene. 82 
24 24 
 
IPCS, 1988. International Programme on Chemical Safety Health and Safety  Environmental Health 
Criteria 80: Pyrrolizidine alkaloids. 
JETRO, 2011. Guidebook for export to Japan (Food Articles) <Health foods and dietary 
supplements>March. 
Jago, M.V., 1970. A method for the assessment of the chronic hepatoxicity of pyrrolizidine alkaloids. 
Australian Journal of Experimental Biology and Medical Science 48, 93-103. 
Kim, H.-Y., Stermitz, F.R., Coulombe Jr, R.A., 1995. Pyrrolizidine alkaloid-induced DNA-protein 
cross-links. Carcinogenesis 16, 2691-2697. 
Kim, H.Y., Stermitz, F.R., Li, J.K. and Coulombe Jr, R.A., 1999. Comparative DNA cross-linking by 
activated pyrrolizidine alkaloids. Food and chemical toxicology, 37(6), pp.619-625. 
Krewski, D., Withey, J.R., Ku, L.-f., Andersen, M.E., 1994. Applications of physiologic 
pharmacokinetic modeling in carcinogenic risk assessment. Environmental Health Perspectives 
102, 37-50. 
Kuhara, K., Takanashi, H., Hirono, I., Furuya, T., Asada, Y., 1980. Carcinogenic activity of clivorine, 
a pyrrolizidine alkaloid isolated from Ligularia dentata. Cancer letters 10, 117-122. 
Li, H., Zhang, M., Vervoort, J., Rietjens, I.M., van Ravenzwaay, B., Louisse, J., 2017. Use of 
physiologically based kinetic modeling-facilitated reverse dosimetry of in vitro  toxicity data 
for prediction of in vivo  developmental toxicity of tebuconazole in rats. Toxicology letters 266, 
85-93. 
Lin, G., Cui, Y.-Y., Liu, X.-Q., 2003. Gender differences in microsomal metabolic activation of 
hepatotoxic clivorine in rat. Chemical research in toxicology 16, 768-774. 
Louisse, J., Bosgra, S., Blaauboer, B.J., Rietjens, I.M., Verwei, M., 2015. Prediction of in vivo  
developmental toxicity of all-trans-retinoic acid based on in vitro  toxicity data and in silico 
physiologically based kinetic modeling. Archives of toxicology 89, 1135-1148. 
Louisse, J., de Jong, E., van de Sandt, J.J., Blaauboer, B.J., Woutersen, R.A., Piersma, A.H., Rietjens, 
I.M., Verwei, M., 2010. The use of in vitro  toxicity data and physiologically based kinetic 
modeling to predict dose-response curves for in vivo  developmental toxicity of glycol ethers in 
rat and man. Toxicological Sciences 118, 470-484. 
Low, T.Y., Wong, K.O., Yap, A.L., De Haan, L.H., Rietjens, I.M., 2017. The regulatory framework 
across international jurisdictions for risks associated with consumption of botanical food 
supplements. Comprehensive Reviews in Food Science and Food Safety 16, 821-834. 
Merz, K.H., Schrenk, D., 2016. Interim relative potency factors for the toxicological risk assessment 
of pyrrolizidine alkaloids in food and herbal medicines. Toxicology letters 263, 44-57. 
Mohabbat, O., Younos, M.S., Merzad, A., Srivastava, R., Sediq, G.G., Aram, G., 1976. An outbreak of 
hepatic veno-occlusive disease in north-western Afghanistan. The Lancet 308, 269-271. 
Mulder, P.P., López, P., Castelari, M., Bodi, D., Ronczka, S., Preiss-Weigert, A., These, A., 2018. 
Occurrence of pyrrolizidine alkaloids in animal-and plant-derived food: results of a survey 
across Europe. Food Additives & Contaminants: Part A 35, 118-133. 
Mulder, P.P., Sánchez, P.L., These, A., Preiss‐Weigert, A., Castellari, M., 2015. Occurrence of 
Pyrrolizidine Alkaloids in food. EFSA Supporting Publications 12, 859E. 
Nolan, J.P., Scheig, R.L., Klatskin, G., 1966. Delayed hepatitis and cirrhosis in weanling rats 
following a single small dose of the senecio alkaloid, lasiocarpine. The American journal of 
pathology 49, 129. 
NTP, 1978. Bioassay of lasiocarpine for possible carcinogenicity. National Cancer Institute 
carcinogenesis technical report series 39, 1. 
NTP, 2003. Toxicology and carcinogenesis studies of riddelliine (CAS No. 23246-96-0) in F344/N 
rats and B6C3F1 mice (gavage studies). National Toxicology Program technical report series, 1. 
Petry, T.W., Bowden, G.T., Huxtable, R.J., Sipes, I.G., 1984. Characterization of hepatic DNA 
damage induced in rats by the pyrrolizidine alkaloid monocrotaline. Cancer research 44, 1505-
1509. 
Prakash, A.S., Pereira, T.N., Reilly, P.E., Seawright, A.A., 1999. Pyrrolizidine alkaloids in human diet. 
Mutation Research/Genetic Toxicology and Environmental Mutagenesis 443, 53-67. 
Reed, R., Miranda, C., Kedzierski, B., Henderson, M., Buhler, D., 1992. Microsomal formation of a 
pyrrolic alcohol glutathione conjugate of the pyrrolizidine alkaloid senecionine. Xenobiotica 22, 
1321-1327.
25 
 
Rietjens, I.M., Louisse, J., Punt, A., 2011. Tutorial on physiologically based kinetic modeling in 
molecular nutrition and food research. Molecular nutrition & food research 55, 941-956. 
Roeder, E., 2000. Medicinal plants in China containing pyrrolizidine alkaloids. Pharmazie 55, 711-726. 
Roulet, M., Laurini, R., Rivier, L., Calame, A., 1988. Hepatic veno-occlusive disease in newborn 
infant of a woman drinking herbal tea. Journal of Pediatrics. 
Rocha, T., Amaral, J.S. and Oliveira, M.B.P., 2016. Adulteration of dietary supplements by the illegal 
addition of synthetic drugs: a review. Comprehensive reviews in food science and food safety, 
15(1), pp.43-62. 
Shumaker, R., Robertson, K., Hsu, I., Allen, J., 1976. Neoplastic transformation in tissues of rats 
exposed to monocrotaline or dehydroretronecine. Journal of the National Cancer Institute 56, 
787-790. 
Silva-Neto, J., Barreto, R., Pitanga, B., Souza, C., Silva, V., Silva, A., Velozo, E.d.S., Cunha, S., 
Batatinha, M., Tardy, M., 2010. Genotoxicity and morphological changes induced by the 
alkaloid monocrotaline, extracted from Crotalaria retusa, in a model of glial cells. Toxicon 55, 
105-117. 
Sperl, W., Stuppner, H., Gassner, I., Judmaier, W., Dietze, O., Vogel, W., 1995. Reversible hepatic 
veno-occlusive disease in an infant after consumption of pyrrolizidine-containing herbal tea. 
European journal of pediatrics 154, 112-116. 
Strikwold, M., Spenkelink, B., de Haan, L.H., Woutersen, R.A., Punt, A., Rietjens, I.M., 2017. 
Integrating in vitro  data and physiologically based kinetic (PBK) modelling to assess the in 
vivo  potential developmental toxicity of a series of phenols. Archives of toxicology 91, 2119-
2133. 
TGA, 2013. Registered complementary medicines | Therapeutic Goods Administration (TGA). 
Tandon, B.N., Tandon, H., Tandon, R., Narndranathan, M., Joshi, Y., 1976. An epidemic of veno-
occlusive disease of liver in central India. The Lancet 308, 271-272. 
Uhl, M., Helma, C., Knasmüller, S., 2000. Evaluation of the single cell gel electrophoresis assay with 
human hepatoma (HepG2) cells. Mutation Research/Genetic Toxicology and Environmental 
Mutagenesis 468, 213-225. 
van den Berg, S.J., Alhusainy, W., Restani, P., Rietjens, I.M., 2014. Chemical analysis of estragole in 
fennel based teas and associated safety assessment using the Margin of Exposure (MOE) 
approach. Food and chemical toxicology 65, 147-154. 
Wang, YP., Fu, P.P., Chou, M.W., 2005a. Metabolic activation of the tumorigenic pyrrolizidine 
alkaloid, retrorsine, leading to DNA adduct formation in vivo . International journal of 
environmental research and public health 2, 74-79. 
Wang, YP., Yan, J., Beger, R.D., Fu, P.P., Chou, M.W., 2005b. Metabolic activation of the 
tumorigenic pyrrolizidine alkaloid, monocrotaline, leading to DNA adduct formation in vivo . 
Cancer letters 226, 27-35. 
Wang, YP., Yan, J., Fu, P.P., Chou, M.W., 2005c. Human liver microsomal reduction of pyrrolizidine 
alkaloid N-oxides to form the corresponding carcinogenic parent alkaloid. Toxicology letters 
155, 411-420. 
Williams, D., Reed, R., Kedzierski, B., Dannan, G., Guengerich, F., Buhler, D., 1989a. Bioactivation 
and detoxication of the pyrrolizidine alkaloid senecionine by cytochrome P-450 enzymes in rat 
liver. Drug metabolism and disposition 17, 387-392. 
Williams, D.E., Reed, R.L., Kedzierski, B., Ziegler, D.M., Buhler, D.R., 1989b. The role of flavin-
containing monooxygenase in the N-oxidation of the pyrrolizidine alkaloid senecionine. Drug 
metabolism and disposition 17, 380-386. 
Xia, Q., Chou, M.W., Edgar, J.A., Doerge, D.R., Fu, P.P., 2006. Formation of DHP-derived DNA 
adducts from metabolic activation of the prototype heliotridine-type pyrrolizidine alkaloid, 
lasiocarpine. Cancer letters 231, 138-145. 
Xia, Q., Chou, M.W., Kadlubar, F.F., Chan, PC., Fu, P.P., 2003. Human liver microsomal metabolism 
and DNA adduct formation of the tumorigenic pyrrolizidine alkaloid, riddelliine. Chemical 
research in toxicology 16, 66-73. 
25
C
ha
pt
er
 1
24 
 
IPCS, 1988. International Programme on Chemical Safety Health and Safety  Environmental Health 
Criteria 80: Pyrrolizidine alkaloids. 
JETRO, 2011. Guidebook for export to Japan (Food Articles) <Health foods and dietary 
supplements>March. 
Jago, M.V., 1970. A method for the assessment of the chronic hepatoxicity of pyrrolizidine alkaloids. 
Australian Journal of Experimental Biology and Medical Science 48, 93-103. 
Kim, H.-Y., Stermitz, F.R., Coulombe Jr, R.A., 1995. Pyrrolizidine alkaloid-induced DNA-protein 
cross-links. Carcinogenesis 16, 2691-2697. 
Kim, H.Y., Stermitz, F.R., Li, J.K. and Coulombe Jr, R.A., 1999. Comparative DNA cross-linking by 
activated pyrrolizidine alkaloids. Food and chemical toxicology, 37(6), pp.619-625. 
Krewski, D., Withey, J.R., Ku, L.-f., Andersen, M.E., 1994. Applications of physiologic 
pharmacokinetic modeling in carcinogenic risk assessment. Environmental Health Perspectives 
102, 37-50. 
Kuhara, K., Takanashi, H., Hirono, I., Furuya, T., Asada, Y., 1980. Carcinogenic activity of clivorine, 
a pyrrolizidine alkaloid isolated from Ligularia dentata. Cancer letters 10, 117-122. 
Li, H., Zhang, M., Vervoort, J., Rietjens, I.M., van Ravenzwaay, B., Louisse, J., 2017. Use of 
physiologically based kinetic modeling-facilitated reverse dosimetry of in vitro  toxicity data 
for prediction of in vivo  developmental toxicity of tebuconazole in rats. Toxicology letters 266, 
85-93. 
Lin, G., Cui, Y.-Y., Liu, X.-Q., 2003. Gender differences in microsomal metabolic activation of 
hepatotoxic clivorine in rat. Chemical research in toxicology 16, 768-774. 
Louisse, J., Bosgra, S., Blaauboer, B.J., Rietjens, I.M., Verwei, M., 2015. Prediction of in vivo  
developmental toxicity of all-trans-retinoic acid based on in vitro  toxicity data and in silico 
physiologically based kinetic modeling. Archives of toxicology 89, 1135-1148. 
Louisse, J., de Jong, E., van de Sandt, J.J., Blaauboer, B.J., Woutersen, R.A., Piersma, A.H., Rietjens, 
I.M., Verwei, M., 2010. The use of in vitro  toxicity data and physiologically based kinetic 
modeling to predict dose-response curves for in vivo  developmental toxicity of glycol ethers in 
rat and man. Toxicological Sciences 118, 470-484. 
Low, T.Y., Wong, K.O., Yap, A.L., De Haan, L.H., Rietjens, I.M., 2017. The regulatory framework 
across international jurisdictions for risks associated with consumption of botanical food 
supplements. Comprehensive Reviews in Food Science and Food Safety 16, 821-834. 
Merz, K.H., Schrenk, D., 2016. Interim relative potency factors for the toxicological risk assessment 
of pyrrolizidine alkaloids in food and herbal medicines. Toxicology letters 263, 44-57. 
Mohabbat, O., Younos, M.S., Merzad, A., Srivastava, R., Sediq, G.G., Aram, G., 1976. An outbreak of 
hepatic veno-occlusive disease in north-western Afghanistan. The Lancet 308, 269-271. 
Mulder, P.P., López, P., Castelari, M., Bodi, D., Ronczka, S., Preiss-Weigert, A., These, A., 2018. 
Occurrence of pyrrolizidine alkaloids in animal-and plant-derived food: results of a survey 
across Europe. Food Additives & Contaminants: Part A 35, 118-133. 
Mulder, P.P., Sánchez, P.L., These, A., Preiss‐Weigert, A., Castellari, M., 2015. Occurrence of 
Pyrrolizidine Alkaloids in food. EFSA Supporting Publications 12, 859E. 
Nolan, J.P., Scheig, R.L., Klatskin, G., 1966. Delayed hepatitis and cirrhosis in weanling rats 
following a single small dose of the senecio alkaloid, lasiocarpine. The American journal of 
pathology 49, 129. 
NTP, 1978. Bioassay of lasiocarpine for possible carcinogenicity. National Cancer Institute 
carcinogenesis technical report series 39, 1. 
NTP, 2003. Toxicology and carcinogenesis studies of riddelliine (CAS No. 23246-96-0) in F344/N 
rats and B6C3F1 mice (gavage studies). National Toxicology Program technical report series, 1. 
Petry, T.W., Bowden, G.T., Huxtable, R.J., Sipes, I.G., 1984. Characterization of hepatic DNA 
damage induced in rats by the pyrrolizidine alkaloid monocrotaline. Cancer research 44, 1505-
1509. 
Prakash, A.S., Pereira, T.N., Reilly, P.E., Seawright, A.A., 1999. Pyrrolizidine alkaloids in human diet. 
Mutation Research/Genetic Toxicology and Environmental Mutagenesis 443, 53-67. 
Reed, R., Miranda, C., Kedzierski, B., Henderson, M., Buhler, D., 1992. Microsomal formation of a 
pyrrolic alcohol glutathione conjugate of the pyrrolizidine alkaloid senecionine. Xenobiotica 22, 
1321-1327.
25 
 
Rietjens, I.M., Louisse, J., Punt, A., 2011. Tutorial on physiologically based kinetic modeling in 
molecular nutrition and food research. Molecular nutrition & food research 55, 941-956. 
Roeder, E., 2000. Medicinal plants in China containing pyrrolizidine alkaloids. Pharmazie 55, 711-726. 
Roulet, M., Laurini, R., Rivier, L., Calame, A., 1988. Hepatic veno-occlusive disease in newborn 
infant of a woman drinking herbal tea. Journal of Pediatrics. 
Rocha, T., Amaral, J.S. and Oliveira, M.B.P., 2016. Adulteration of dietary supplements by the illegal 
addition of synthetic drugs: a review. Comprehensive reviews in food science and food safety, 
15(1), pp.43-62. 
Shumaker, R., Robertson, K., Hsu, I., Allen, J., 1976. Neoplastic transformation in tissues of rats 
exposed to monocrotaline or dehydroretronecine. Journal of the National Cancer Institute 56, 
787-790. 
Silva-Neto, J., Barreto, R., Pitanga, B., Souza, C., Silva, V., Silva, A., Velozo, E.d.S., Cunha, S., 
Batatinha, M., Tardy, M., 2010. Genotoxicity and morphological changes induced by the 
alkaloid monocrotaline, extracted from Crotalaria retusa, in a model of glial cells. Toxicon 55, 
105-117. 
Sperl, W., Stuppner, H., Gassner, I., Judmaier, W., Dietze, O., Vogel, W., 1995. Reversible hepatic 
veno-occlusive disease in an infant after consumption of pyrrolizidine-containing herbal tea. 
European journal of pediatrics 154, 112-116. 
Strikwold, M., Spenkelink, B., de Haan, L.H., Woutersen, R.A., Punt, A., Rietjens, I.M., 2017. 
Integrating in vitro  data and physiologically based kinetic (PBK) modelling to assess the in 
vivo  potential developmental toxicity of a series of phenols. Archives of toxicology 91, 2119-
2133. 
TGA, 2013. Registered complementary medicines | Therapeutic Goods Administration (TGA). 
Tandon, B.N., Tandon, H., Tandon, R., Narndranathan, M., Joshi, Y., 1976. An epidemic of veno-
occlusive disease of liver in central India. The Lancet 308, 271-272. 
Uhl, M., Helma, C., Knasmüller, S., 2000. Evaluation of the single cell gel electrophoresis assay with 
human hepatoma (HepG2) cells. Mutation Research/Genetic Toxicology and Environmental 
Mutagenesis 468, 213-225. 
van den Berg, S.J., Alhusainy, W., Restani, P., Rietjens, I.M., 2014. Chemical analysis of estragole in 
fennel based teas and associated safety assessment using the Margin of Exposure (MOE) 
approach. Food and chemical toxicology 65, 147-154. 
Wang, YP., Fu, P.P., Chou, M.W., 2005a. Metabolic activation of the tumorigenic pyrrolizidine 
alkaloid, retrorsine, leading to DNA adduct formation in vivo . International journal of 
environmental research and public health 2, 74-79. 
Wang, YP., Yan, J., Beger, R.D., Fu, P.P., Chou, M.W., 2005b. Metabolic activation of the 
tumorigenic pyrrolizidine alkaloid, monocrotaline, leading to DNA adduct formation in vivo . 
Cancer letters 226, 27-35. 
Wang, YP., Yan, J., Fu, P.P., Chou, M.W., 2005c. Human liver microsomal reduction of pyrrolizidine 
alkaloid N-oxides to form the corresponding carcinogenic parent alkaloid. Toxicology letters 
155, 411-420. 
Williams, D., Reed, R., Kedzierski, B., Dannan, G., Guengerich, F., Buhler, D., 1989a. Bioactivation 
and detoxication of the pyrrolizidine alkaloid senecionine by cytochrome P-450 enzymes in rat 
liver. Drug metabolism and disposition 17, 387-392. 
Williams, D.E., Reed, R.L., Kedzierski, B., Ziegler, D.M., Buhler, D.R., 1989b. The role of flavin-
containing monooxygenase in the N-oxidation of the pyrrolizidine alkaloid senecionine. Drug 
metabolism and disposition 17, 380-386. 
Xia, Q., Chou, M.W., Edgar, J.A., Doerge, D.R., Fu, P.P., 2006. Formation of DHP-derived DNA 
adducts from metabolic activation of the prototype heliotridine-type pyrrolizidine alkaloid, 
lasiocarpine. Cancer letters 231, 138-145. 
Xia, Q., Chou, M.W., Kadlubar, F.F., Chan, PC., Fu, P.P., 2003. Human liver microsomal metabolism 
and DNA adduct formation of the tumorigenic pyrrolizidine alkaloid, riddelliine. Chemical 
research in toxicology 16, 66-73. 
26 26 
 
Xia, Q., Chou, M.W., Lin, G., Fu, P.P., 2004. Metabolic formation of DHP-derived DNA adducts 
from a representative otonecine type pyrrolizidine alkaloid clivorine and the extract of 
Ligularia hodgsonnii hook. Chemical research in toxicology 17, 702-708. 
Xia, Q., Yan, J., Chou, M.W., Fu, P.P., 2008. Formation of DHP-derived DNA adducts from 
metabolic activation of the prototype heliotridine-type pyrrolizidine alkaloid, heliotrine. 
Toxicology letters 178, 77-82. 
Xia, Q., Zhao, Y., Von Tungeln, L.S., Doerge, D.R., Lin, G., Cai, L., Fu, P.P., 2013. Pyrrolizidine 
alkaloid-derived DNA adducts as a common biological biomarker of pyrrolizidine alkaloid-
induced tumorigenicity. Chemical research in toxicology 26, 1384-1396. 
Xia, Q., He, X., Ma, L., Chen, S. and Fu, P.P., 2018. Pyrrolizidine Alkaloid Secondary Pyrrolic 
Metabolites Construct Multiple Activation Pathways Leading to DNA Adduct Formation and 
Potential Liver Tumor Initiation. Chemical research in toxicology, 31(7), pp.619-628. 
Xia, Q., Ma, L., He, X., Cai, L. and Fu, P.P., 2015. 7-Glutathione pyrrole adduct: a potential DNA 
reactive metabolite of pyrrolizidine alkaloids. Chemical research in toxicology, 28(4), pp.615-
620. 
Yan, J., Xia, Q., Chou, M., Fu, P., 2008. Metabolic activation of retronecine and retronecine N-oxide–
formation of DHP-derived DNA adducts. Toxicology and industrial health 24, 181-188. 
Yang, M., Ruan, J., Fu, P.P., Lin, G., 2016. Cytotoxicity of pyrrolizidine alkaloid in human hepatic 
parenchymal and sinusoidal endothelial cells: Firm evidence for the reactive metabolites 
mediated pyrrolizidine alkaloid-induced hepatotoxicity. Chemico-biological interactions 243, 
119-126. 
Yang, Y.-C., Yan, J., Doerge, D.R., Chan, P.-C., Fu, P.P., Chou, M.W., 2001. Metabolic activation of 
the tumorigenic pyrrolizidine alkaloid, riddelliine, leading to DNA adduct formation in vivo . 
Chemical research in toxicology 14, 101-109. 
Zhang, M., van Ravenzwaay, B., Fabian, E., Rietjens, I.M., Louisse, J., 2018. Towards a generic 
physiologically based kinetic model to predict in vivo  uterotrophic responses in rats by reverse 
dosimetry of in vitro  estrogenicity data. Archives of toxicology 92, 1075-1088. 
27 
 
 
 
Chapter 2 
 
Risk assessment for pyrrolizidine alkaloids detected in (herbal) 
teas and plant food supplements 
 
Lu Chen, Patrick P.J. Mulder, Jochem Louisse, Ad Peijnenburg, Sebas Wesseling, Ivonne M.C.M. 
Rietjens 
 
Published in: Regulatory Toxicology and Pharmacology (2017) 68: 292-302 
26 
 
Xia, Q., Chou, M.W., Lin, G., Fu, P.P., 2004. Metabolic formation of DHP-derived DNA adducts 
from a representative otonecine type pyrrolizidine alkaloid clivorine and the extract of 
Ligularia hodgsonnii hook. Chemical research in toxicology 17, 702-708. 
Xia, Q., Yan, J., Chou, M.W., Fu, P.P., 2008. Formation of DHP-derived DNA adducts from 
metabolic activation of the prototype heliotridine-type pyrrolizidine alkaloid, heliotrine. 
Toxicology letters 178, 77-82. 
Xia, Q., Zhao, Y., Von Tungeln, L.S., Doerge, D.R., Lin, G., Cai, L., Fu, P.P., 2013. Pyrrolizidine 
alkaloid-derived DNA adducts as a common biological biomarker of pyrrolizidine alkaloid-
induced tumorigenicity. Chemical research in toxicology 26, 1384-1396. 
Xia, Q., He, X., Ma, L., Chen, S. and Fu, P.P., 2018. Pyrrolizidine Alkaloid Secondary Pyrrolic 
Metabolites Construct Multiple Activation Pathways Leading to DNA Adduct Formation and 
Potential Liver Tumor Initiation. Chemical research in toxicology, 31(7), pp.619-628. 
Xia, Q., Ma, L., He, X., Cai, L. and Fu, P.P., 2015. 7-Glutathione pyrrole adduct: a potential DNA 
reactive metabolite of pyrrolizidine alkaloids. Chemical research in toxicology, 28(4), pp.615-
620. 
Yan, J., Xia, Q., Chou, M., Fu, P., 2008. Metabolic activation of retronecine and retronecine N-oxide–
formation of DHP-derived DNA adducts. Toxicology and industrial health 24, 181-188. 
Yang, M., Ruan, J., Fu, P.P., Lin, G., 2016. Cytotoxicity of pyrrolizidine alkaloid in human hepatic 
parenchymal and sinusoidal endothelial cells: Firm evidence for the reactive metabolites 
mediated pyrrolizidine alkaloid-induced hepatotoxicity. Chemico-biological interactions 243, 
119-126. 
Yang, Y.-C., Yan, J., Doerge, D.R., Chan, P.-C., Fu, P.P., Chou, M.W., 2001. Metabolic activation of 
the tumorigenic pyrrolizidine alkaloid, riddelliine, leading to DNA adduct formation in vivo . 
Chemical research in toxicology 14, 101-109. 
Zhang, M., van Ravenzwaay, B., Fabian, E., Rietjens, I.M., Louisse, J., 2018. Towards a generic 
physiologically based kinetic model to predict in vivo  uterotrophic responses in rats by reverse 
dosimetry of in vitro  estrogenicity data. Archives of toxicology 92, 1075-1088. 
27 
 
 
 
Chapter 2 
 
Risk assessment for pyrrolizidine alkaloids detected in (herbal) 
teas and plant food supplements 
 
Lu Chen, Patrick P.J. Mulder, Jochem Louisse, Ad Peijnenburg, Sebas Wesseling, Ivonne M.C.M. 
Rietjens 
 
Published in: Regulatory Toxicology and Pharmacology (2017) 68: 292-302 
28 28 
 
Abstract 
Pyrrolizidine alkaloids (PAs) are plant metabolites present in some botanical preparations, with 
especially 1,2-unsaturated PAs being of concern because they are genotoxic carcinogens.  This study 
presents an overview of tumour data on PAs and points of departure (PoDs) derived from them, 
corroborating that the BMDL10 for lasiocarpine represents a conservative PoD for risk assessment. A 
risk assessment using this BMDL10 and mean levels of PAs reported in literature for (herbal) teas, 
indicates that consumption of one cup of tea a day would result in  MOE values lower than 10 000 for 
several types of (herbal) teas, indicating a priority for risk management for these products A refined 
risk assessment using interim relative potency (REP) factors showed that based on the mean PA levels, 
7(54%) of 13 types of (herbal) teas and 1 (14%) of 7 types of plant food supplements (PFS) resulted in 
MOE values lower than 10 000, indicating a priority for risk management also for these products in 
particular. This includes both preparations containing PA-producing and non-PA-producing plants. 
Our study provides insight in the current state-of-the art and limitations in the risk assessment of PA-
containing food products, especially (herbal) teas and PFS, indicating that PAs in food presents a field 
of interest for current and future risk management. 
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Introduction 
Pyrrolizidine alkaloids (PAs) are naturally occurring chemicals which are produced by a large number 
of plants (Griffin et al., 2013; NTP, 1986). To date, more than 660 PAs and PA N-oxides have been 
identified from an estimated 6000 plants (Bodi et al., 2014). Especially 1,2-unsaturated PAs are 
hepatotoxic and considered  as genotoxic carcinogens, thus posing a potential risk to human health 
(Mori et al., 1985). The 1,2-unsaturated PAs can be subdivided by the type of esterification in 
monoesters, open chained diesters and cyclic diesters (Figure 1). In addition, cyclic diester PAs with 
an azacyclooctenone, instead of a 1,2-dehydropyrrolizidine ring system, form a special class (Figure 1).  
Botanical preparations such as (herbal) teas and plant food supplements (PFS) are widely used around 
the world. However, these preparations have recently been shown to frequently contain toxic PAs 
(Bodi et al., 2014; IPCS, 1988; Mulder et al., 2015). Bodi et al. (2014) together with the Federal 
Institute for Risk Assessment (BfR) in Germany who also reported part of the data (BfR, 2013), 
analysed seven types of herbal drugs (41 samples) and 11 types of (herbal) teas (282 samples) all 
supposedly to be derived from non-PA-producing plants. The results showed that (herbal) teas can 
contain significant levels of PAs of up to 5647 g/kg dry material, while in herbal drugs the total PA 
level could reach up to 3099 µg/kg (Bodi et al., 2014). The PAs present in the (herbal) teas and PFS 
were suggested to originate from contamination with PA-containing weeds during harvesting. Mulder 
et al. (2015) analysed four types of PFS (110 samples) which were derived from non-PA-producing 
plants, pollen-based supplements (29 samples) and  two types of PFS (39 samples) which were derived 
from PA-producing plants. These authors also analysed eight types of (herbal) teas (169 samples) 
which were derived from non-PA-producing plants and five types of (herbal) teas (12 samples) 
derived from PA-producing plants. For (herbal) teas and PFS which were derived from non-PA-
producing plants, the level of PAs amounted up to 4805 and 8488 µg/kg in dry material, respectively. 
For (herbal) teas and PFS which were derived from PA-producing plants, the levels of PAs amounted 
up to 31 101 µg/kg in specific teas (as dry material) and to 2 410 275 µg/kg in PFS (Mulder et al., 
2015) (Note: In March 2017 the PA levels reported for 13 herbal tea samples in the study of Mulder et 
al. (2015) have been revised. Consequently, EFSA will publish a revised version of the original 
scientific report on the internet (Patrick P.J. Mulder, patrick.mulder@wur.nl). The revised levels have 
been taken into account in the calculations). These data showed that the highest values were obtained 
for (herbal) teas and PFS produced from PA-producing plants, but that PAs are also present in samples 
produced from non-PA-producing plants. Recently, upon a request form the European Commission, 
the European Food Safety Authority (EFSA) published a dietary exposure assessment reporting 
estimates for chronic and acute exposure to PAs using the PA data collected and available in the EFSA 
Chemical Occurrence database (EFSA, 2016). The data on tea and herbal infusions were submitted by 
several data providers including five national authorities, and consisted of data provided by tea
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producers and traders organised in Tea & Herbal Infusions Europe (THIE), as well as data provided by 
Bodi et al. (2014) and Mulder et al. (2015). EFSA expressed the PA levels per liter of tea infusion as 
consumed dividing the level in µg/kg dry material by 75 assuming 100% extraction of the PAs present 
in 2 g of tea into 150 mL of boiling water. The 95th percentile values amounted up to 773 g/kg for 
individual dry (herbal) tea samples and 55 459 g/kg in PFS, including data from material from PA-
producing plants (EFSA, 2016). 
In the studies reported by Bodi et al. (2014), Mulder et al. (2015) and EFSA (2016), no risk 
assessment was presented for the PA levels detected. Given that 1,2-unsaturated PAs are considered to 
be genotoxic and carcinogenic, the risk assessment can best be done by applying the Margin of 
Exposure (MOE) approach (EFSA, 2011). To calculate the MOE for a particular compound preferably 
a BMDL10 from a carcinogenicity study (benchmark dose lower confidence limit for 10% extra risk on 
tumour formation above background levels) is normally used as a point of departure (PoD). So far, 
suitable experimental data to derive such BMDL10 values have only been reported for two PAs, 
lasiocarpine and riddelliine (NTP, 1978; NTP, 2003). For lasiocarpine EFSA calculated a BMDL10 of 
0.07 mg/kg bw/day based on data for induction of liver haemangiosarcomas in male rats and used this 
as PoD for comparison with the estimated dietary exposure resulting from the presence of PAs in retail 
honey (EFSA, 2011). EFSA indicated that the carcinogenic potency of most PAs present in honey is 
likely to be lower than that of lasiocarpine and that a risk characterisation using the BMDL10 for 
lasiocarpine is considered a conservative approach. This is based on the consideration that lasiocarpine 
is amongst the most toxic of the PAs that have been tested based on the LD50 upon a single 
intraperitoneal (i.p.) dose (COT, 2008), and the fact that toxicity may be associated with the 
carcinogenicity. This assumption is in line with the fact that for riddelliine a BMDL10 of 0.18 mg/kg 
bw/day was calculated based on the incidence of liver haemangiosarcomas in female rats (EFSA, 2011; 
NTP, 2003). In addition to lasiocarpine and riddelliine, other PAs, including monocrotaline, clivorine, 
senkirkine and symphytine, (Figure 1), have been shown to cause tumours in animal bioassays (Hirono 
et al., 1979; Kuhara et al., 1980; Shumaker et al., 1976). Monocrotaline has been classified as a Group 
2B carcinogen (possibly carcinogenic to humans) by the International Agency for Research on Cancer 
(IARC), while senkirkine and symphytine have been classified as Group 3 (not classifiable as to its 
carcinogenicity to humans (IARC, 1976; IARC, 1983; IARC, 2002). For these PAs available tumour 
data are not suitable for dose response modelling and definition of BMDL10 values, but their data 
could still be used to provide a better estimate of  how conservative the use of the BMDL10 of 
lasiocarpine for risk assessment on 1,2-unsaturated PAs would be. PODs for calculating the MOE in 
situations where the data do not facilitate dose-response modelling to obtain a BMDL10 are the T25 
and/or T10 values, representing the dose levels resulting in 25 or 10% tumour incidence above back 
ground levels after lifetime exposure (BfR, 2009; EFSA, 2005). In their opinion on a harmonised 
approach for risk assessment of substances which are both genotoxic and carcinogenic EFSA already
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indicated that in cases where the data would be unsuitable for deriving a BMDL10, use of the T25 is 
recommended (EFSA, 2005). EFSA also indicated that when using the T25 for calculation of the 
MOE a value of 25 000 instead of 10 000 could be used to judge if the MOE indicates a priority for 
risk management (EFSA, 2005). To facilitate comparison to other genotoxic carcinogens BfR derived 
an MOE based risk assessment for glycidol and its esters, using the T10 calculated from the T25 by 
linear extrapolation (multiplying the T25 by 10/25) as an alternative for the BMDL10 for calculating 
MOE values (BfR, 2009).  
In 2013, the BfR presented an initial risk assessment on PAs in (herbal) teas for children and adults 
using several consumption scenarios (BfR, 2013). In their report, BfR considered the toxic potency of 
all the PAs as equal when calculating MOE values. It was concluded that it is improbable that short 
term intake (up to 14 days) poses a health risk for adults and children but that there is a concern for 
people who frequently drink large quantities of the (herbal) teas. This risk assessment was based on 
tea samples from the German market and the BMDL10 for lasiocarpine, using several consumption 
scenarios. BfR indicated that the intake estimates used were likely either overstated or underestimated 
as they included average group PA content values for all types of teas, while tea consumption reported 
by consumers and used for the intake estimates is also likely to include other tea varieties that tend to 
have either lower or higher PA contents. Indeed, it is necessary to consider the fact that some types of 
(herbal) tea infusion may contain large amounts of PAs, as a relevant food safety issue. This also holds 
true for PFS.  
As already indicated above the toxic potency of different PAs may be different. In view of this, Merz 
and Schrenk (2016) recently have proposed interim relative potency (REP) factors for PAs, that 
describe the relative (toxic) potency of each congener compared with the most toxic congener(s) 
(Merz and Schrenk, 2016). Based on available literature data on in vitro cytotoxicity, genotoxicity in 
Drosophila, and acute toxicity in rodents (LD50), REP factors were defined for the most relevant 
structural types of PAs, 1.0 for cyclic di-esters and open-chained di-esters with 7S configuration, 0.3 
for mono-esters with 7S configuration, 0.1 for open-chained diesters with 7R configuration and 0.01 
for mono-esters with 7R configuration (Merz and Schrenk, 2016). It should be noticed that these 
interim REP values do not take the relative potency of PAs for tumour formation into account. 
Furthermore, a risk assessment based on the PA levels in (herbal) teas or PFS, taking the interim REP 
factors into account, has so far not been performed. Given this situation the aims of the present study 
were i) to analyse the literature available on PA induced tumour incidences, to define PODs for PAs 
other than lasiocarpine and to further evaluate the use of the BMDL10 of lasiocarpine for risk 
assessment of 1,2-unsaturated PAs and ii) to present a risk assessment on the use of (herbal) teas and 
PFS containing PAs using the new data presented by Bodi et al. (2014), Mulder et al. (2015) and 
EFSA (2016) taking into account the interim REP factors.   
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Figure 1. Chemical structures of PAs subdivided by the type of esterification: 1,2 dehydropyrrolizidine with A: 
monoester; B: open chained diester; C: cyclic diester. D: azacyclooctenone cyclic diester). 
Materials and Methods  
Literature search 
To obtain the required data on PA-induced tumour incidences, a literature search was performed using 
Google Scholar by combining the search terms: ‘pyrrolizidine alkaloids’, ‘carcinogenic’ and ‘rats’ or 
‘mice’. References that met all the search criteria were collected. From these studies, the essential 
information, such as number of animals, species, gender, dose, tumour data and experimental time, 
was extracted for further evaluation. Based on the carcinogenicity data, potential PoDs were defined as 
described hereafter. 
PoDs definition for risk assessment 
Using the BMD method, the lower confidence limit of the benchmark dose (BMD) giving a 10% extra 
cancer incidence (BMDL10) was determined as a preferred PoD for the MOE approach. BMD 
modelling was performed using all models for dichotomous data of the Environmental Protection 
Agency (EPA)’s Benchmark Dose Software (BMDS) version 2.6 applying default settings. All models 
that  met the requirements for acceptance (P-value > 0.05 and BMD10/BMDL10 <10) were considered 
for the determination of BMDL10 values choosing the lowest BMDL10 value for further assessment. To 
calculate BMDL10 values, data should preferably refer to three experimental doses administrated to 
rats or mice, with at least 50 animals per group and a two-year experimental period (Edler et al., 2014). 
However, in some experiments, the study was terminated before completion of a two-year  (104 weeks) 
period and the actual treatment period was even shorter. For these studies an adjustment of the dose 
level was performed using the formula: dose × (weeks of treatment/104) × (weeks of observation/104) 
(ECHA, 2008), resulting in the dose levels used for deriving the POD. For example for the data on 
clivorine, the experimental dose (5 mg/kg bw/day given for 340 days (= 49 weeks), with experiment 
termination at 480 days (= 69 weeks) was adjusted by multiplying the dose by (49/104) × (69/104), 
giving a dose of 1.56 mg/kg bw/day.  
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In case the data are insufficient for the calculation of a BMDL10, EFSA has recommended the T25 as 
an alternative point for MOE calculation. T25 values are calculated by dividing the extra risk (% 
incidence in the dose group minus % incidence in the control group) by the non-affected fraction in the 
control population (100 minus background response in %), and converting the dose level causing this 
tumour incidence to the dose level causing 25% extra tumour incidence by linear extrapolation. For 
example, if the incidence in the control group was 5/50 (10%) and in the 30 mg/kg bw/day group 
(30/50 (60%)), the extra risk is [(60–10)/(100–10)]/100 = 55.6% and the T25 = 25/55.6 × 30 mg/kg 
bw/day = 13.5 mg/kg bw/day (Benford et al., 2010). T10 values were calculated from the T25 by 
linear extrapolation,  multiplying by 10/25. It is of interest to note that one could argue that statistically 
a T10 would compare to a BMD10 rather than to a BMDL10 but at the current state of the art the T25 
with a MOE cut off value of 25 000 and the T10 with a MOE cut off value of 10 000 (also applied 
when using the BMDL10) are used as PODs when a BMDL10 is not available. 
Estimated Daily Intake (EDI) Calculation  
A number of different data sets were used for estimating exposure including those reported by Bodi et 
al. (2014), Mulder et al. (2015) and EFSA (2016). The mean and maximum values of total PA content 
for different types of (herbal) teas or PFS obtained from Bodi et al. (2014) are summarised in 
Supplementary Table S5 and S9. Instead of maximum PA levels, the EFSA report gives the 95th 
percentile values (EFSA, 2016). These data together with the mean values of total PA contents for 
(herbal) teas and PFS are summarised in Supplementary Table S6 and S10. Only the data reported by 
Mulder et al. (2015) were presented at the level of detail needed for ‘adjustment’ of the PA levels by 
REP factors. The mean and maximum total PA content for different (herbal) teas or PFS obtained 
from Mulder et al. (2015) are summarised in Supplementary Table S7 and S11 and the corresponding 
data adjusted by REP factors and are presented in Supplementary Table S8 and S12. The total PA 
levels that were used in this study were the ones based on the lower bound approach, meaning that 
only quantified levels were taken into account and that non-detected PAs were ignored. To perform 
the risk assessments, the daily PA intake resulting from use of the (herbal) teas was estimated 
assuming daily consumption of the amount of PAs present in 2 g tea, corresponding to one cup of tea, 
as described before (BfR, 2013). Due to the wide range of the recommended daily intake between PFS 
products (COT, 2003), it is difficult to achieve a consensus estimate on the general PFS daily intake. 
In this study, the daily PA intake resulting from use of PFS was estimated by assuming a dose of 200 
mg PFS. This dose reflects the low end of intake of botanical supplements (Van Den Berg et al., 2011). 
The estimated daily intakes (EDIs) were calculated using a default body weight of 70 kg for an adult 
as proposed by EFSA (EFSA, 2012).  
Calculation of the Margin of Exposure 
The MOE was calculated by dividing the selected PoD (BMDL10 or T10 as indicated) by the EDI. To 
evaluate the possible health risk and priority for risk management actions an MOE value of 10 000
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period and the actual treatment period was even shorter. For these studies an adjustment of the dose 
level was performed using the formula: dose × (weeks of treatment/104) × (weeks of observation/104) 
(ECHA, 2008), resulting in the dose levels used for deriving the POD. For example for the data on 
clivorine, the experimental dose (5 mg/kg bw/day given for 340 days (= 49 weeks), with experiment 
termination at 480 days (= 69 weeks) was adjusted by multiplying the dose by (49/104) × (69/104), 
giving a dose of 1.56 mg/kg bw/day.  
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In case the data are insufficient for the calculation of a BMDL10, EFSA has recommended the T25 as 
an alternative point for MOE calculation. T25 values are calculated by dividing the extra risk (% 
incidence in the dose group minus % incidence in the control group) by the non-affected fraction in the 
control population (100 minus background response in %), and converting the dose level causing this 
tumour incidence to the dose level causing 25% extra tumour incidence by linear extrapolation. For 
example, if the incidence in the control group was 5/50 (10%) and in the 30 mg/kg bw/day group 
(30/50 (60%)), the extra risk is [(60–10)/(100–10)]/100 = 55.6% and the T25 = 25/55.6 × 30 mg/kg 
bw/day = 13.5 mg/kg bw/day (Benford et al., 2010). T10 values were calculated from the T25 by 
linear extrapolation,  multiplying by 10/25. It is of interest to note that one could argue that statistically 
a T10 would compare to a BMD10 rather than to a BMDL10 but at the current state of the art the T25 
with a MOE cut off value of 25 000 and the T10 with a MOE cut off value of 10 000 (also applied 
when using the BMDL10) are used as PODs when a BMDL10 is not available. 
Estimated Daily Intake (EDI) Calculation  
A number of different data sets were used for estimating exposure including those reported by Bodi et 
al. (2014), Mulder et al. (2015) and EFSA (2016). The mean and maximum values of total PA content 
for different types of (herbal) teas or PFS obtained from Bodi et al. (2014) are summarised in 
Supplementary Table S5 and S9. Instead of maximum PA levels, the EFSA report gives the 95th 
percentile values (EFSA, 2016). These data together with the mean values of total PA contents for 
(herbal) teas and PFS are summarised in Supplementary Table S6 and S10. Only the data reported by 
Mulder et al. (2015) were presented at the level of detail needed for ‘adjustment’ of the PA levels by 
REP factors. The mean and maximum total PA content for different (herbal) teas or PFS obtained 
from Mulder et al. (2015) are summarised in Supplementary Table S7 and S11 and the corresponding 
data adjusted by REP factors and are presented in Supplementary Table S8 and S12. The total PA 
levels that were used in this study were the ones based on the lower bound approach, meaning that 
only quantified levels were taken into account and that non-detected PAs were ignored. To perform 
the risk assessments, the daily PA intake resulting from use of the (herbal) teas was estimated 
assuming daily consumption of the amount of PAs present in 2 g tea, corresponding to one cup of tea, 
as described before (BfR, 2013). Due to the wide range of the recommended daily intake between PFS 
products (COT, 2003), it is difficult to achieve a consensus estimate on the general PFS daily intake. 
In this study, the daily PA intake resulting from use of PFS was estimated by assuming a dose of 200 
mg PFS. This dose reflects the low end of intake of botanical supplements (Van Den Berg et al., 2011). 
The estimated daily intakes (EDIs) were calculated using a default body weight of 70 kg for an adult 
as proposed by EFSA (EFSA, 2012).  
Calculation of the Margin of Exposure 
The MOE was calculated by dividing the selected PoD (BMDL10 or T10 as indicated) by the EDI. To 
evaluate the possible health risk and priority for risk management actions an MOE value of 10 000
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was applied. This value of 10 000 includes a factor of 100, consisting of a factor of 10 for possible 
inter-species differences, and a factor of 10 for differences between human individuals. Furthermore it 
includes an additional factor of 10 to account for inter-individual human variability in cell cycle 
control and DNA repair and a factor 10 because the MOE is based on the BMDL10 which is not a no 
effect level (EFSA, 2005). An MOE value of 10 000 or higher, based on animal cancer bioassay data, 
is considered to be a low concern from a public health standpoint, while a value lower than 10 000 
might raise a potential concern for human health (EFSA, 2005). When using the T25 for calculation of 
the MOE a value of 25 000 instead of 10 000 should be used to judge if the MOE indicates a safety 
concern (EFSA, 2005). As proposed by the BfR a value of 10 000 could be considered when using a 
T10 to facilitate comparison to the BMDL10 (BfR, 2009). 
Results 
Carcinogenicity data and PoDs for PAs 
Table 1 provides an overview of the carcinogenicity data of PAs as present in the literature, describing 
the incidence of liver haemangiosarcomas for lasiocarpine and riddelliine, pulmonary 
adenocarcinomas for monocrotaline, liver neoplastic nodules for clivorine, liver cell adenomas for 
senkirkine and hemangioendothelial sarcoma of the liver for symphytine, in all cases observed in rats. 
Only the data for lasiocarpine, and riddelliine appeared suitable for BMD modelling, as was also 
concluded by EFSA (EFSA, 2011). The results of a BMD analysis of these data confirmed the 
BMDL10 values previously reported by EFSA, of 0.07 and 0.18 mg/kg bw/day for lasiocarpine and 
riddelliine, respectively, based on the data for induction of liver haemangiosarcoma in male and 
female rats (Table 2). Based on the experimental doses, the duration of the studies and tumour 
incidences, T25 and T10 values for induction of the different tumour types were calculated for 
monocrotaline, clivorine, senkirkine and symphytine (Supplementary Tables S1-S4). Table 2 presents 
an overview of these values listing the lowest BMDL10 and T10 values for the tumour types that can 
be used as a preferred PoD for the further assessment. For monocrotaline, the T10 value was 1.5 
mg/kg bw/day based on a study using subcutaneous (s.c.) administration of monocrotaline inducing 
pulmonary adenocarcinoma in male rats (Shumaker et al., 1976). The T10 value for clivorine was 0.31 
mg/kg bw/day based on a rat study in which clivorine was administered in drinking water, inducing an 
increased incidence of liver neoplastic nodules in the liver in male and female rats (Kuhara et al., 
1980). The T10 values were 2.4 mg/kg bw/day for senkirkine and 4.0 mg/kg bw/day for symphytine, 
based on the incidence of liver cell adenomas and liver haemangioendothelial sarcoma, respectively, in 
male rats exposed via i.p. injection (Hirono et al., 1979). T10 values derived for lasiocarpine and 
riddelliine amounted to 0.16 and 0.09 mg/kg bw/day and were thus somewhat different from the 
BMDL10 values derived from the same data. Based on comparison of the BMDL10 and T10 values 
shown in Table 2, it can be concluded that the BMDL10 of 0.07 mg/kg bw/day for lasiocarpine, 
appears to be the lowest PoD of all values obtained. This value is 3 to 60-fold lower than the PoDs
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obtained for related 1, 2-unsaturated PAs (Table 2). This indicates that lasiocarpine is the most toxic 
PA compared to those for which tumour data are available and that therefore a risk characterisation 
based on the BMDL10 for lasiocarpine can indeed be considered a conservative approach (EFSA, 
2011). However, given the fact that for several PAs the PoD seems to be more than ten-fold higher 
than the BMDL10 for lasiocarpine, it should be kept in mind that, depending on the nature of the PAs 
actually present, use of the BMDL10 for lasiocarpine may result in MOE values that may be too low. 
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Estimated Daily Intakes (EDIs) and risk assessment of PAs from consumption of (herbal) 
teas  
Based on the mean and maximum PA levels reported by Bodi et al. (2014) (Supplementary Table S5), 
the EDI and MOE values for a total of 11 types of (herbal) teas (with at least 9 samples per type of tea) 
were calculated assuming daily consumption of one cup of tea (using 2 g dry tea). Figure 2 presents 
the resulting MOE values for the different types of (herbal) teas based on the BMDL10 for lasiocarpine. 
The MOE values ranged from 430 to around 47 500 upon consumption of one cup of (herbal) tea per 
day. Overall, the MOE values vary significantly among the different types of (herbal) teas. Depending 
on the use of mean or maximum PA levels, the types of tea with MOE values below 10 000, amount to 
four (36%) and nine (82%) of the 11 types of (herbal) teas, respectively. More specifically, based on 
the mean PA level, MOE values lower than 10 000 were found for chamomile, black, rooibos and 
melissa teas (Figure 2A). In addition to those teas, the MOE values of mixed herbal, peppermint, green, 
fennel and nettle teas were below 10 000 when taking the maximum PA levels into account (Figure 
2B). It is of interest to note that all (herbal) teas were derived from non-PA-producing plants.  
 
Figure 2. The MOE values for 11 different types of herbal teas obtained for daily consumption of one cup of tea 
per day using A) mean, B) maximum PA levels reported by Bodi et al. (2014). The number of teas analysed in 
each category is given in brackets. # PA content <  LOQ. The BMDL10 for lasiocarpine is used as PoD. 
Figure 3 presents MOE values calculated by using the mean and 95th percentile of total PA values 
based on the type of (herbal) teas that were reported by EFSA (2016), including the data reported by 
Bodi et al. (2014) and Mulder et al. (2015). The EDI and MOE values were calculated by assuming 
consumption of one cup of tea per day (2 g dry weight) and are presented in the Supplementary Table 
S6. Based on the mean PA levels, most types of teas have MOE values higher than 10 000 except 
peppermint and rooibos tea (Figure 3A). When considering the 95th percentile PA levels, in addition 
to peppermint and rooibos tea, another four types of tea, including tea and herbs, black, green and
39 
 
chamomile teas, were found to result in MOE values below 10 000 (Figure 3B). Again, all of these are 
from non-PA- producing plants.  
 
Figure 3. The MOE values  for 10 different types of herbal teas obtained for daily consumption of one cup of tea 
per day using A) mean, B) 95th percentile PA levels reported by EFSA (2016). The number of teas analysed in 
each category is given in brackets. * Data are not available in EFSA (2016). The BMDL10 for lasiocarpine is 
used as PoD. 
Estimated Daily Intakes (EDIs) and risk assessment of PAs from consumption of (herbal) 
teas, taking relative potencies into account 
The data reported by Mulder et al. (2015) (see note above on the recent revision of the report) also 
include information on the individual PAs detected, which is essential when taking the different 
potencies of the PAs into account by applying REP factors. The individual PA levels reported by 
Mulder et al. (2015) were recalculated using the interim REP factors, reported by Merz and Schrenk 
(Merz and Schrenk, 2016), to adjust the mean and maximum total PA levels and to calculate the EDI 
values for 13 types of (herbal) teas in relative potency assuming consumption of one cup of tea. These 
data without and with taking the REP factors into account are presented in the Supplementary Table 
S7 and S8, respectively. The MOE values thus obtained, either with or without taking the REP factors 
into account, are presented in Figure 4. After REP factor correction, the MOE values ranged from 460 
to around 445 000 upon consumption of one cup of (herbal) tea per day. Based on the mean and 
maximum PA levels and with taking the REP factors into account, the types of teas with MOE values 
below 10 000, amounted to 7 (54%) and 8 (62%) out of a total of 13 types of (herbal) teas, 
respectively. More specifically, based on the mean PA levels and REP correction, MOE values less 
than 10 000 were found for peppermint, rooibos, black, green, mixed herbal, borago and coltsfoot tea 
(Figure 4A). When considering maximum PA levels, also camomile flower resulted in MOE values
39
C
ha
pt
er
 2
38 
 
Estimated Daily Intakes (EDIs) and risk assessment of PAs from consumption of (herbal) 
teas  
Based on the mean and maximum PA levels reported by Bodi et al. (2014) (Supplementary Table S5), 
the EDI and MOE values for a total of 11 types of (herbal) teas (with at least 9 samples per type of tea) 
were calculated assuming daily consumption of one cup of tea (using 2 g dry tea). Figure 2 presents 
the resulting MOE values for the different types of (herbal) teas based on the BMDL10 for lasiocarpine. 
The MOE values ranged from 430 to around 47 500 upon consumption of one cup of (herbal) tea per 
day. Overall, the MOE values vary significantly among the different types of (herbal) teas. Depending 
on the use of mean or maximum PA levels, the types of tea with MOE values below 10 000, amount to 
four (36%) and nine (82%) of the 11 types of (herbal) teas, respectively. More specifically, based on 
the mean PA level, MOE values lower than 10 000 were found for chamomile, black, rooibos and 
melissa teas (Figure 2A). In addition to those teas, the MOE values of mixed herbal, peppermint, green, 
fennel and nettle teas were below 10 000 when taking the maximum PA levels into account (Figure 
2B). It is of interest to note that all (herbal) teas were derived from non-PA-producing plants.  
 
Figure 2. The MOE values for 11 different types of herbal teas obtained for daily consumption of one cup of tea 
per day using A) mean, B) maximum PA levels reported by Bodi et al. (2014). The number of teas analysed in 
each category is given in brackets. # PA content <  LOQ. The BMDL10 for lasiocarpine is used as PoD. 
Figure 3 presents MOE values calculated by using the mean and 95th percentile of total PA values 
based on the type of (herbal) teas that were reported by EFSA (2016), including the data reported by 
Bodi et al. (2014) and Mulder et al. (2015). The EDI and MOE values were calculated by assuming 
consumption of one cup of tea per day (2 g dry weight) and are presented in the Supplementary Table 
S6. Based on the mean PA levels, most types of teas have MOE values higher than 10 000 except 
peppermint and rooibos tea (Figure 3A). When considering the 95th percentile PA levels, in addition 
to peppermint and rooibos tea, another four types of tea, including tea and herbs, black, green and
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chamomile teas, were found to result in MOE values below 10 000 (Figure 3B). Again, all of these are 
from non-PA- producing plants.  
 
Figure 3. The MOE values  for 10 different types of herbal teas obtained for daily consumption of one cup of tea 
per day using A) mean, B) 95th percentile PA levels reported by EFSA (2016). The number of teas analysed in 
each category is given in brackets. * Data are not available in EFSA (2016). The BMDL10 for lasiocarpine is 
used as PoD. 
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into account, are presented in Figure 4. After REP factor correction, the MOE values ranged from 460 
to around 445 000 upon consumption of one cup of (herbal) tea per day. Based on the mean and 
maximum PA levels and with taking the REP factors into account, the types of teas with MOE values 
below 10 000, amounted to 7 (54%) and 8 (62%) out of a total of 13 types of (herbal) teas, 
respectively. More specifically, based on the mean PA levels and REP correction, MOE values less 
than 10 000 were found for peppermint, rooibos, black, green, mixed herbal, borago and coltsfoot tea 
(Figure 4A). When considering maximum PA levels, also camomile flower resulted in MOE values
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below 10 000 (Figure 4B). Of these teas, chamomile flowers, peppermint, rooibos, black, green and 
mixed herbs are derived from non-PA-producing plants, whereas borago and coltsfoot are derived 
from PA-producing plants. It is of interest to note that the MOE values for chamomile flowers, 
peppermint, rooibos, black, green and mixed herbs increase by only about 1 to 2 fold after applying 
REP factors. This limited effect is due to the fact that the major PAs in these teas were senecionine, 
retrorsine and seneciphylline (Mulder et al., 2015) for which the interim REP factors are 1.0. In 
contrast, for teas derived from PA containing plants such as borago, gromwell, eupatorium and 
lungwort, the MOE values increased by 30 to 100 fold after applying REP factors (Figure 4), due to 
the fact that the major PAs in these preparations were intermedine and lycopsamine, for which the 
proposed  REP factors are 0.01 (Merz and Schrenk, 2016).  
 
Figure 4 . The MOE values of 13 different types of herbal teas obtained for daily consumption of one cup of tea 
per day using A) mean, B) maximum PA levels, reported by Mulder et al. (2015). The number of teas analysed 
in each category is given in brackets. The area above the black solid line inside each bar represents the increment 
of MOE values after the REP factor correction of the individual PA levels. The bars filled inside with black lines 
are corresponding to the samples that were derived from non-PA-producing plants and the ones with red lines are 
corresponding to the samples that were derived from PA-producing plants. # PA content < LOQ. & No mean 
values calculated, as only one sample was measured. These results were treated as maximum values. The 
BMDL10 for lasiocarpine is used as PoD. 
Estimated Daily Intakes (EDIs) and risk assessment of PAs from consumption of plant 
food supplements  
The EDI and MOE values for seven types of PFS for which PA levels were reported by Bodi et al. 
(2014) are presented in the Supplementary Table S9. The different types of PFS with MOE values 
lower or higher than 10 000 upon daily consumption of 200 mg PFS per day are presented in Figure 5.
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Overall, the MOE values vary considerably among the types of PFS, ranging from 7900 to around 17 
500 000. Based on the mean or maximum PA levels reported, none and one (14%) of a total of seven 
types of PFS resulted in an MOE value below 10 000, respectively (Figure 5). Based on the maximum 
PA levels, the MOE values of PFS containing anise that were derived from non-PA-producing plants 
were lower than 10 000 (Figure 5B).  
Figure 6 presents MOE values calculated by using mean and the 95th percentile of total PA levels of 
PFS that were reported by EFSA (2016). The EDI and MOE values were calculated by assuming 
consumption of 200 mg PFS per day and presented in the Supplementary Table S10. According to 
either the mean or the 95th percentile PA values, the plant extract formula supplements resulted in an 
MOE value below 10 000 (Figure 6).  
 
Figure 5. The MOE values of 7 different types of PFS obtained for daily consumption of 200 mg of PFS per day  
using A) mean, B) maximum PA levels reported by Bodi et al. (2014). The number of PFS analysed in each 
category is given in brackets.  # PA content <  LOQ. The BMDL10 for lasiocarpine is used as PoD. 
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Figure 6. The MOE values for 5 different types of PFS obtained for daily consumption of 200 mg dry weight per 
day using A) mean, B) 95th percentile PA levels reported by EFSA (2016). The number of PFS analysed in each 
category is given in brackets. * Data is are not available in EFSA (2016). The BMDL10 for lasiocarpine is used 
as PoD. 
Estimated Daily Intakes (EDIs) and safety assessment of PAs from consumption of plant 
food supplements taking relative potencies into account 
The EDI and MOE values, without and with REP factor correction for seven types of PFS reported by 
Mulder et al. (2015) are presented in the Supplementary Table S11 and S12. The MOE values upon 
daily consumption of 200 mg PFS per day are presented in Figure 7. Overall, and taking the relative 
potencies into account, the MOE values vary substantially among the types of PFS, ranging from 1000 
to around 983 000. Based on the mean and maximum PA levels, when taking the relative potencies 
into account, only the supplements prepared from PA-plant extract formula resulted in an MOE value 
below 10 000, accounting for one (14%) of the seven types of PFS investigated (Figure 7). It is of 
interest to note that only a small proportion of the PFS analysed contained lasciocarpine: two PA-plant 
extract formulas out of 18 (11%), three out of 75 samples (4%) of non-PA-producing plants extract 
formulas and none of the 29 pollen-based PFS. Supplements containing special fatty acids, derived 
from PA-producing plants did not contain measurable amounts of PAs due to the fact that in the 
production process the PAs are effectively removed by refinement of the oil. These products therefore 
comply with legislation in the Netherlands that states that preparations made from PA-containing
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plants shall not contain more than 1 µg/kg PAs (Warenwetbesluit kruidenpreparaten 2001) 
(Supplementary materials Table S11 and S12). Notably, the MOE values of pollen-based supplements, 
plant extract formula made of non-PA-producing plant material, valerian, St John’s wort or PA-
producing plant extract material increased after applying REP factors by about 6-, 4-, 1-, 10- and 65-
fold, respectively. This can be ascribed to the fact that the major PAs present in these PFS were 
lycopsamine, intermedine and echimidine (Mulder et al., 2015), which were reported to have REP 
factors of 0.01, 0.01 and 0.1, respectively (Merz and Schrenk, 2016). 
 
Figure 7. The MOE values for 7 different types of PFS obtained for daily consumption of 200 mg of dry weight 
per day using A) mean, B) maximum PA levels, reported by  Mulder et al. (2015). The number of PFS analysed 
in each category is given in brackets. The area above the black solid line inside each bar represents the increment 
of MOE values after the REP factor correction of the individual PA levels. The bars filled inside with black lines 
are corresponding to the samples that are derived from non-PA-producing plants and the ones with red lines are 
corresponding to the samples that are derived from PA-producing plants. #PA content <LOQ. The BMDL10 for 
lasiocarpine is used as PoD. 
Discussion 
In the present study, first a literature review on tumour data on PAs was performed to obtain a better 
insight in PoDs available for risk assessment of PAs and the extent to which the BMDL10 of 
lasiocarpine currently used presents a  worst case PoD. Data on lasiocarpine and riddelliine were
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insight in PoDs available for risk assessment of PAs and the extent to which the BMDL10 of 
lasiocarpine currently used presents a  worst case PoD. Data on lasiocarpine and riddelliine were
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available and suitable for dose-response modelling, providing the BMDL10 values reported previously 
by EFSA of 0.07 and 0.18 mg/kg bw/day, respectively (EFSA, 2011). In addition, tumour data for 
monocrotaline, clivorine, senkirkine and symphytine were retrieved that were unsuitable for a BMD 
modelling but allowed derivation of a T25 and T10. In a carcinogenicity study of monocrotaline in 
male rats, there were treatment-related increases in a number of tumours, principally liver cell 
carcinomas and pulmonary adenocarcinomas (Shumaker et al., 1976). The T10 value for liver cell 
carcinomas of 3.0 mg/kg bw/day was higher than the T10 for pulmonary adenocarcinomas (1.5 mg/kg 
bw/day). The latter was thus selected as the preferred PoD for monocrotaline. Clivorine induced an 
increased incidence of haemangioendothelial sarcomas and neoplastic nodules in the liver of rats 
(Kuhara et al., 1980). Although the T10 value of liver hemangioendothelial sarcoma was higher than 
that derived for liver neoplastic nodules (0.96 vs 0.31 mg/kg bw/day), liver neoplastic nodules, being 
non-malignant tumours, may be less suitable for the risk assessment thus leaving the T10 of 0.96 
mg/kg bw/day as the PoD for clivorine. Senkirkine increased the incidence of liver cell adenomas with 
a T10 of 2.4 mg/kg bw/day and symphytine induced liver haemangioendothelial sarcoma, a type of 
malignant tumour, with a lower T10 value than that for liver cell adenomas (4.0 mg/kg bw/day vs 12 
mg/kg bw/day). All these tumour data appeared inadequate for dose response modelling, because only 
one level of dosing was included in the studies. The T25 has been suggested by EFSA as an alternative 
PoD in case a BMDL10 cannot be calculated (EFSA, 2005) and was recently used for glycidol and its 
esters (EFSA, 2016). For these same compounds BfR used the T10 as an alternative to make an MOE 
based risk assessment, because it better allows a comparison to the BMDL10 than the T25 (BfR, 2009). 
Our results showed that the T10 values of monocrotaline, clivorine, senkirkine and symphytine were 
21-, 4-, 34- and 60- fold higher, respectively, than the BMDL10 value of 0.07 mg/kg bw/day for 
lasiocarpine (Table 2). For comparison, T10 values for lasiocarpine and riddelliine were also 
calculated by using the data presented in Table 1. The T10 values amounted to 0.16 and 0.09 mg/kg 
bw/day, respectively, and were thus somewhat different from the BMDL10 values derived from the 
same data (Table 2). However these values are still in line with the conclusion that the BMDL10 for 
lasiocarpine of 0.07 mg/kg bw/day is the lowest PoD and thus seems a conservative estimate when 
applied for other PAs. Given the consideration that ultimately most 1,2-unsaturated PAs lead to the 
same type of tumour, namely angiosarcomas, and produce the same type of reactive metabolite, a 6,7-
dihydro-7-hydroxy-1-hydroxymethyl-5H-pyrrolizine (DHP) analogue, the Committee on 
Carcinogenicity of Chemicals in Food, Consumer Products and the Environment (COT) agreed that 
the BMDL10 of lasiocarpine, the most potent PA, would be an appropriate basis for the MOE approach 
for risk assessment of PAs (COT, 2008). Also EFSA considered lasiocarpine to be the most toxic of 
the PAs that have been investigated (EFSA, 2011) and BfR as well used the BMDL10 of lasiocarpine 
in their risk assessment of PAs in teas (BfR, 2013). The literature overview presented here strongly 
indicates that this approach using the BMDL10 of 0.07 mg/kg bw/day for risk assessment of combined 
exposure to 1,2-unsturated PAs is a conservative approach since tumour data available for other PAs
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so far point at PoDs that are higher. It is important to notethat some of these PoDs were derived from 
studies where the route of administration was not oral but subcutaneous (s.c.) or intraperitoneal (i.p.) 
(Table 1). Given that bioavailability by these other routes may be different and perhaps higher than by 
the oral route, this could provide another reason why the use of the BMDL10 for lasiocarpine for these 
other PAs might be a conservative approach. It should be noted, that the cancer studies used were 
carried out in different laboratories, using different species strains, genders, duration and other 
circumstances. This should be kept in  mind when comparing and using the different PoDs’ 
(MacGregor et al., 2015).  
Based on PA levels reported by Bodi et al. (2014), when calculating MOE values based on mean and 
maximum level of PAs, most types of (herbal) teas resulted in MOE values below 10 000. These 
results indicate a potential risk for human health, even for (herbal) teas derived from non-PA-
containing botanicals. The presence of  PAs detected in teas made from non-PA-producing plants has 
been suggested to be due to (unintentional) contamination with PA-containing weeds during 
harvesting, processing or blending of the teas (Bodi et al., 2014; Shimshoni et al., 2015). Better 
production and manufacture practices will likely result in a reduction of the PA contamination in the 
end products. For PFS, based on the mean PA level, only one (14%) of in total seven types of PFS 
would result in EDI values that give rise to an MOE value below 10 000.  
To provide a more refined estimate for PA risk assessment, mean and maximum PA levels as reported 
by Mulder et al. (2015) were used to investigate the effect of applying recently proposed interim REP 
factors to obtain refined EDI and MOE estimates. The MOE values obtained without REP factor 
correction were generally lower than those with REP factor correction, especially for the PFS because 
they  contained as major PAs congeners with REP values of 0.01 and 0.1, while in the teas the major 
PAs were those with REP values of 1.0, resulting only in a limited effect.    
It is important to stress that the risk assessment presented here is a conservative estimate in various 
aspects. First of all, the method of preparing the hot water extracts of (herbal) teas and PFS to 
determine the PA levels in the procedure applied by Mulder et al. (2015) is stated to be in accordance 
with the real situation to make a cup of tea, but it should be noted that the method included grinding 
the (herbal) teas and (part of the) herbal food supplements with dry ice before extraction. Grinding the 
tea and PFS material with dry ice and to a small particle size (≤ 500 µm) can be expected to facilitate 
extraction as compared to using the intact samples as such, with the latter being more representative of 
daily practice. Extraction without the grinding step could result in lower extraction efficiency and thus, 
lower EDI and higher MOE values, reducing the concern. Previous studies on the risks of exposure to 
alkenylbenzenes from consumption of fennel based teas by van den Berg et al. (2014) and Raffo et al. 
(2011) reported that hot water extraction of compounds of concern from comminuted fennel fruits is 
indeed more efficient than from the whole fruits (Raffo et al., 2011; van den Berg et al., 2014). The 
effect of this processing and extraction process on the actual risk of the (herbal) tea and PFS samples
45
C
ha
pt
er
 2
44 
 
available and suitable for dose-response modelling, providing the BMDL10 values reported previously 
by EFSA of 0.07 and 0.18 mg/kg bw/day, respectively (EFSA, 2011). In addition, tumour data for 
monocrotaline, clivorine, senkirkine and symphytine were retrieved that were unsuitable for a BMD 
modelling but allowed derivation of a T25 and T10. In a carcinogenicity study of monocrotaline in 
male rats, there were treatment-related increases in a number of tumours, principally liver cell 
carcinomas and pulmonary adenocarcinomas (Shumaker et al., 1976). The T10 value for liver cell 
carcinomas of 3.0 mg/kg bw/day was higher than the T10 for pulmonary adenocarcinomas (1.5 mg/kg 
bw/day). The latter was thus selected as the preferred PoD for monocrotaline. Clivorine induced an 
increased incidence of haemangioendothelial sarcomas and neoplastic nodules in the liver of rats 
(Kuhara et al., 1980). Although the T10 value of liver hemangioendothelial sarcoma was higher than 
that derived for liver neoplastic nodules (0.96 vs 0.31 mg/kg bw/day), liver neoplastic nodules, being 
non-malignant tumours, may be less suitable for the risk assessment thus leaving the T10 of 0.96 
mg/kg bw/day as the PoD for clivorine. Senkirkine increased the incidence of liver cell adenomas with 
a T10 of 2.4 mg/kg bw/day and symphytine induced liver haemangioendothelial sarcoma, a type of 
malignant tumour, with a lower T10 value than that for liver cell adenomas (4.0 mg/kg bw/day vs 12 
mg/kg bw/day). All these tumour data appeared inadequate for dose response modelling, because only 
one level of dosing was included in the studies. The T25 has been suggested by EFSA as an alternative 
PoD in case a BMDL10 cannot be calculated (EFSA, 2005) and was recently used for glycidol and its 
esters (EFSA, 2016). For these same compounds BfR used the T10 as an alternative to make an MOE 
based risk assessment, because it better allows a comparison to the BMDL10 than the T25 (BfR, 2009). 
Our results showed that the T10 values of monocrotaline, clivorine, senkirkine and symphytine were 
21-, 4-, 34- and 60- fold higher, respectively, than the BMDL10 value of 0.07 mg/kg bw/day for 
lasiocarpine (Table 2). For comparison, T10 values for lasiocarpine and riddelliine were also 
calculated by using the data presented in Table 1. The T10 values amounted to 0.16 and 0.09 mg/kg 
bw/day, respectively, and were thus somewhat different from the BMDL10 values derived from the 
same data (Table 2). However these values are still in line with the conclusion that the BMDL10 for 
lasiocarpine of 0.07 mg/kg bw/day is the lowest PoD and thus seems a conservative estimate when 
applied for other PAs. Given the consideration that ultimately most 1,2-unsaturated PAs lead to the 
same type of tumour, namely angiosarcomas, and produce the same type of reactive metabolite, a 6,7-
dihydro-7-hydroxy-1-hydroxymethyl-5H-pyrrolizine (DHP) analogue, the Committee on 
Carcinogenicity of Chemicals in Food, Consumer Products and the Environment (COT) agreed that 
the BMDL10 of lasiocarpine, the most potent PA, would be an appropriate basis for the MOE approach 
for risk assessment of PAs (COT, 2008). Also EFSA considered lasiocarpine to be the most toxic of 
the PAs that have been investigated (EFSA, 2011) and BfR as well used the BMDL10 of lasiocarpine 
in their risk assessment of PAs in teas (BfR, 2013). The literature overview presented here strongly 
indicates that this approach using the BMDL10 of 0.07 mg/kg bw/day for risk assessment of combined 
exposure to 1,2-unsturated PAs is a conservative approach since tumour data available for other PAs
45 
 
so far point at PoDs that are higher. It is important to notethat some of these PoDs were derived from 
studies where the route of administration was not oral but subcutaneous (s.c.) or intraperitoneal (i.p.) 
(Table 1). Given that bioavailability by these other routes may be different and perhaps higher than by 
the oral route, this could provide another reason why the use of the BMDL10 for lasiocarpine for these 
other PAs might be a conservative approach. It should be noted, that the cancer studies used were 
carried out in different laboratories, using different species strains, genders, duration and other 
circumstances. This should be kept in  mind when comparing and using the different PoDs’ 
(MacGregor et al., 2015).  
Based on PA levels reported by Bodi et al. (2014), when calculating MOE values based on mean and 
maximum level of PAs, most types of (herbal) teas resulted in MOE values below 10 000. These 
results indicate a potential risk for human health, even for (herbal) teas derived from non-PA-
containing botanicals. The presence of  PAs detected in teas made from non-PA-producing plants has 
been suggested to be due to (unintentional) contamination with PA-containing weeds during 
harvesting, processing or blending of the teas (Bodi et al., 2014; Shimshoni et al., 2015). Better 
production and manufacture practices will likely result in a reduction of the PA contamination in the 
end products. For PFS, based on the mean PA level, only one (14%) of in total seven types of PFS 
would result in EDI values that give rise to an MOE value below 10 000.  
To provide a more refined estimate for PA risk assessment, mean and maximum PA levels as reported 
by Mulder et al. (2015) were used to investigate the effect of applying recently proposed interim REP 
factors to obtain refined EDI and MOE estimates. The MOE values obtained without REP factor 
correction were generally lower than those with REP factor correction, especially for the PFS because 
they  contained as major PAs congeners with REP values of 0.01 and 0.1, while in the teas the major 
PAs were those with REP values of 1.0, resulting only in a limited effect.    
It is important to stress that the risk assessment presented here is a conservative estimate in various 
aspects. First of all, the method of preparing the hot water extracts of (herbal) teas and PFS to 
determine the PA levels in the procedure applied by Mulder et al. (2015) is stated to be in accordance 
with the real situation to make a cup of tea, but it should be noted that the method included grinding 
the (herbal) teas and (part of the) herbal food supplements with dry ice before extraction. Grinding the 
tea and PFS material with dry ice and to a small particle size (≤ 500 µm) can be expected to facilitate 
extraction as compared to using the intact samples as such, with the latter being more representative of 
daily practice. Extraction without the grinding step could result in lower extraction efficiency and thus, 
lower EDI and higher MOE values, reducing the concern. Previous studies on the risks of exposure to 
alkenylbenzenes from consumption of fennel based teas by van den Berg et al. (2014) and Raffo et al. 
(2011) reported that hot water extraction of compounds of concern from comminuted fennel fruits is 
indeed more efficient than from the whole fruits (Raffo et al., 2011; van den Berg et al., 2014). The 
effect of this processing and extraction process on the actual risk of the (herbal) tea and PFS samples
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should be investigated in more detail. In addition, the PA levels presented, and thus the calculated 
MOE values, are based on adding up the levels of all 1,2-unsaturated PAs and using the BMDL10 
value of lasiocarpine. This might also contribute to an overestimation of the risk. The results of the 
present study show that PoD values for other PAs are 3 to 60-fold higher than the BMDL10 of 
lasiocarpine. For this reason, calculated MOEs might overestimate the potential risk for human health. 
Close analysis of the type of PAs present in the different herbal teas and PFS revealed that in most 
cases lasiocarpine is not a major PA and in the majority of samples it is even absent. However, for the 
major PAs present in the samples, PoDs were absent hampering a further refinement of the MOE 
calculation. Whether the BMDL10 for lasiocarpine is really the most appropriate or rather a too 
conservative PoD for risk assessment remains to be established. Use of REP factors to take the relative 
potencies into account may be a way forward to. It is of interest to note that the interim REP factors 
defined by Merz and Schrenk (Merz and Schrenk, 2016) were based on data from in vitro cytotoxicity, 
genotoxicity in Drosophila, and acute toxicity in rodents (LD50), and did not take into account in vivo 
potencies for tumour formation. Comparison of the T10 values presented in the current study to the 
BMDL10 of lasiocarpine, provided REP factors for the relative potency in tumour formation of 
riddelline, monocrotaline, clivorine, senkirkine and symphytine of0.39, 0.05, 0.23, 0.03, and 0.02 
respectively, suggesting there is room for further refinement of the interim REP factors now available. 
This would likely further increase the MOE values.  
Another factor to take into account is that the MOE calculations assume daily use of the teas and PFS 
during a whole lifetime. Calculation of the MOEs using the EDI values over a lifetime might 
overestimate the potential risk for human health and may therefore not be realistic. It could be 
considered that use of the (herbal) teas and PFS for only a few weeks instead of during a whole 
lifetime may decrease EDI values and increase MOE values by 2 to 3 orders of magnitude indicating 
their use would no longer be of concern. On the other hand some consumers may take more than one 
cup of tea a day and use the respective label for longer periods of time. Moreover, although as much as 
28 PAs were monitored in the studies of Bodi et al. (2014), Mulder et al. (2015) and EFSA (2016), 
more PAs could be present in herbal teas and PFS that have eluded detection due to the lack of 
reference standards, resulting in underestimation of the PA content and consequently overestimation 
of the MOE values. 
Yet another factor of importance to note is that the MOE will vary between different age groups. The 
present MOE values were calculated for adults while consumption of one cup of tea or 200 mg of PFS 
by children with a 2-3 fold lower body weight will increase the EDI and decrease MOE values 
accordingly implying higher instead of lower concerns. The Committee On Toxicology (COT) already 
concluded that the age group with the highest PA exposure on a body weight basis would be infants 
(COT, 2008). In addition, the BfR concluded that there was a risk of health impairment, particularly in 
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children (BfR, 2013).  
With respect to the MOE values obtained for the PFS it is important to note that current EDI and 
resulting MOE values were based on an assumed daily intake of 200 mg of supplement material per 
person per day. This amount is at the low end of intake estimates often recommended for botanical 
supplements on the respective labels (Van Den Berg et al., 2011). Intake of larger amounts would 
result in proportional increases of the EDI values and decreases of the MOE values resulting in values 
below 10 000 if intake is much larger than 200 mg a day for some of these PFS. 
Finally, it should be considered that honey may be used by some consumers as a sweetener in their tea. 
Because honey is a food commodity that may also contain PAs (EFSA, 2011) this may further 
increase PA exposure upon tea consumption. The average level of contamination of retail honey was 
calculated for the sum of 8 PAs as 16 μg/kg for the lower bound and 26 μg/kg for the upper bound 
situation (EFSA, 2011). Data on what percentage of the tea drinkers would actually use honey as a 
sweetener are not available. One could estimate that using one spoon of 10 gram of honey per cup of 
tea on average would add between 0.16 and 0.26 μg PAs to a cup of tea, amounting to between 
0.00229 and 0.00371 μg PAs/kg bw for a 70 kg person. Using the BMDL10 of lasiocarpine of 0.07 
mg/kg bw/day this would result in an MOE between 18 900 and 30 600 and not be of concern as such, 
but in combination with (herbal) tea consumption this could in some cases result in MOEs lower than 
10 000. In conclusion, use and also further refinement of REP factors defining the relative potency of 
PAs for tumour induction seems crucial for a refined MOE based risk assessment of products 
containing PAs. For (herbal) teas, the PA levels and resulting EDI and MOE values for chamomile 
flowers, peppermint, rooibos, black, green and mixed herbs, which are tea types derived from non-PA-
producing plants, and for borago and coltsfoot teas which are derived from PA-producing plants, 
confirm the importance of risk management actions especially for consumers with regular daily use. 
For PFS, plant extract formula which were derived from PA- producing plants might pose a potential 
risk for human health. Our study provides additional insight in the current state-of-the art and 
limitations in risk assessment on PA-containing botanical food products, especially on (herbal) teas 
and PFS, indicating that PAs in food may present an important field of interest for current and future 
risk management.  
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calculation. Whether the BMDL10 for lasiocarpine is really the most appropriate or rather a too 
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respectively, suggesting there is room for further refinement of the interim REP factors now available. 
This would likely further increase the MOE values.  
Another factor to take into account is that the MOE calculations assume daily use of the teas and PFS 
during a whole lifetime. Calculation of the MOEs using the EDI values over a lifetime might 
overestimate the potential risk for human health and may therefore not be realistic. It could be 
considered that use of the (herbal) teas and PFS for only a few weeks instead of during a whole 
lifetime may decrease EDI values and increase MOE values by 2 to 3 orders of magnitude indicating 
their use would no longer be of concern. On the other hand some consumers may take more than one 
cup of tea a day and use the respective label for longer periods of time. Moreover, although as much as 
28 PAs were monitored in the studies of Bodi et al. (2014), Mulder et al. (2015) and EFSA (2016), 
more PAs could be present in herbal teas and PFS that have eluded detection due to the lack of 
reference standards, resulting in underestimation of the PA content and consequently overestimation 
of the MOE values. 
Yet another factor of importance to note is that the MOE will vary between different age groups. The 
present MOE values were calculated for adults while consumption of one cup of tea or 200 mg of PFS 
by children with a 2-3 fold lower body weight will increase the EDI and decrease MOE values 
accordingly implying higher instead of lower concerns. The Committee On Toxicology (COT) already 
concluded that the age group with the highest PA exposure on a body weight basis would be infants 
(COT, 2008). In addition, the BfR concluded that there was a risk of health impairment, particularly in 
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children (BfR, 2013).  
With respect to the MOE values obtained for the PFS it is important to note that current EDI and 
resulting MOE values were based on an assumed daily intake of 200 mg of supplement material per 
person per day. This amount is at the low end of intake estimates often recommended for botanical 
supplements on the respective labels (Van Den Berg et al., 2011). Intake of larger amounts would 
result in proportional increases of the EDI values and decreases of the MOE values resulting in values 
below 10 000 if intake is much larger than 200 mg a day for some of these PFS. 
Finally, it should be considered that honey may be used by some consumers as a sweetener in their tea. 
Because honey is a food commodity that may also contain PAs (EFSA, 2011) this may further 
increase PA exposure upon tea consumption. The average level of contamination of retail honey was 
calculated for the sum of 8 PAs as 16 μg/kg for the lower bound and 26 μg/kg for the upper bound 
situation (EFSA, 2011). Data on what percentage of the tea drinkers would actually use honey as a 
sweetener are not available. One could estimate that using one spoon of 10 gram of honey per cup of 
tea on average would add between 0.16 and 0.26 μg PAs to a cup of tea, amounting to between 
0.00229 and 0.00371 μg PAs/kg bw for a 70 kg person. Using the BMDL10 of lasiocarpine of 0.07 
mg/kg bw/day this would result in an MOE between 18 900 and 30 600 and not be of concern as such, 
but in combination with (herbal) tea consumption this could in some cases result in MOEs lower than 
10 000. In conclusion, use and also further refinement of REP factors defining the relative potency of 
PAs for tumour induction seems crucial for a refined MOE based risk assessment of products 
containing PAs. For (herbal) teas, the PA levels and resulting EDI and MOE values for chamomile 
flowers, peppermint, rooibos, black, green and mixed herbs, which are tea types derived from non-PA-
producing plants, and for borago and coltsfoot teas which are derived from PA-producing plants, 
confirm the importance of risk management actions especially for consumers with regular daily use. 
For PFS, plant extract formula which were derived from PA- producing plants might pose a potential 
risk for human health. Our study provides additional insight in the current state-of-the art and 
limitations in risk assessment on PA-containing botanical food products, especially on (herbal) teas 
and PFS, indicating that PAs in food may present an important field of interest for current and future 
risk management.  
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Abstract 
In this study five types of herbal teas were used to quantify the effect of comminution of the leaves on 
resulting PA exposure. Results show that PA levels extracted from intact leaves were consistently 
lower than from comminuted tea leaves. The Margin of Exposure (MOE) approach was applied to 
evaluate the consequences of this difference for the associated risks in the scenario of lifetime 
exposure. Furthermore, we considered medicinal use of these teas for shorter-than-lifetime exposure 
scenarios, and also analysed the risks of shorter-than-lifetime use of eight herbal medicines and 19 
previously analysed plant food supplements. This analysis revealed that shorter-than-lifetime use 
resulted in MOE values < 10,000 upon use for 40 to 3450 weeks during a lifetime, with for only a 
limited number of herbal teas and medicines use of two weeks a year (150 weeks during a 75 year 
lifetime) would still raise a concern. It is concluded that taking more realistic conditions into account 
markedly reduces the concerns raised for these herbal preparations. These results also illustrate the 
need for development of a generally accepted method for taking short term exposure into account in 
risk assessment of compounds that are genotoxic and carcinogenic. 
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Introduction 
Botanicals and botanical preparations, such as herbal teas and herbal medicines, have been marketed 
for several decades. Due to (misleading) advertisement and/or overstatement of the benefits arising 
from consumption of these products and also because many customers equate ‘natural’ with ‘safe’, 
botanical preparations are widely used around the world (Rietjens et al., 2008). In addition to the fact 
that benefits of these preparations are often not scientifically proven and/or due to illegal adulteration 
with pharmaceutical ingredients (Ancuceanu et al., 2013; Carvalho et al., 2012; Reeuwijk et al., 2014), 
botanical preparations may even contain ingredients of concern. For example, herbal teas and plant 
food supplements (PFS) have been shown to frequently contain toxic pyrrolizidine alkaloids (PAs) 
(Bodi et al., 2014; EFSA, 2016; Mulder et al., 2018; Mulder et al., 2015). Especially 1,2-unsaturated 
PAs have been shown to be hepatotoxic, genotoxic and carcinogenic in rats and other experimental 
rodents (Hirono et al., 1979; Hirono et al., 1976; Kuhara et al., 1980; NTP, 1978, 2003; Schoental, 
1970; Shumaker et al., 1976). These results also raise a concern for human health when levels of 
intake would be too high. A number of cases of intoxication and even death caused by PAs through 
consumption of herbal teas and herbal medicines have been reported (Lin et al., 2011; Margalith et al., 
1985; Mohabbat et al., 1976; Ruan et al., 2015; Tandon et al., 1976; Weston et al., 1987). Intake of 
herbal teas and medicines has proven to be a major route for human exposure to PA-containing plants 
(Bodi et al., 2014; Edgar et al., 1992; Roeder, 2000).  
In light of the health relevance of PAs derived from herbal teas, recently a number of studies have 
performed a risk assessment for PAs in herbal teas (BfR, 2013; Chen et al., 2017; EFSA, 2016). Given 
that 1,2-unsaturated PAs are genotoxic and carcinogenic, this risk assessment was based on the Margin 
of Exposure (MOE) approach. An MOE cut-off value of 10,000 is generally applied, which 
incorporates factors including possible inter-species and intra-species differences in toxicokinetics and 
toxicodynamics, inter-individual human variability in cell cycle control and DNA repair, and the fact 
that the BMDL10 (the lower confidence limit of the dose level that results in 10% extra cancer 
incidence above background level), is not a no effect level (EFSA, 2005). MOE values below 10,000 
indicate that there might be a potential concern for human health (EFSA, 2005). The risk assessments 
suggested that long-term consumption of certain herbal teas may pose a potential risk for human 
health, especially when considering lifetime exposure (BfR, 2013; Chen et al., 2017; EFSA, 2016). 
These studies evaluated the MOE values for lifelong daily use of herbal teas based on occurrence data 
obtained from extraction of finely ground, comminuted leaves. Considering the fact that consumption 
of teas usually occurs by hot water extraction of partially intact or coarsely ground leaves, extraction 
of comminuted leaves may represent a worst case, and not reflect a real life scenario. This is especially 
of importance given that previous studies demonstrated that hot water extraction of alkenylbenzenes 
from comminuted fennel fruits is more efficient than that from the whole fruits (Raffo et al., 2011; van 
den Berg et al., 2014). It is conceivable that also for PAs use of comminuted leaves may facilitate their
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extraction from the teas. This may influence the actual exposure and corresponding risk assessment. 
Therefore, the aim of the present study was to compare the extraction of PAs from comminuted leaves 
and intact leaves of herbal teas, and quantify the consequences of possible differences for the MOE 
based risk assessment. Furthermore, when considering realistic exposure scenario’s it should also be 
taken into account that herbal teas are frequently used for medicinal purposes, a practice being quite 
popular in many developing and developed countries (Fu et al., 2002; Prakash et al., 1999; Roeder, 
2000; Stegelmeier et al., 1999). Thus, people might consume herbal teas as a medicine only during 
certain periods of for example illness. This shorter-than-lifetime use also holds true for herbal 
medicinal supplements, while evaluation by the MOE approach generally assumes lifelong everyday 
use. According to a survey of usage of herbal preparations by European adults, the majority of all 
respondents indicated to take these botanicals only during a specified time period or when they had a 
worsened condition (Garcia-Alvarez et al., 2014). In addition shorter-than-lifetime use of these herbal 
preparations is in line with the EMA (European Medicines Agency) who indicates for example that 
bitter fennel preparations should not be taken for periods exceeding two weeks (EMA, 2008). The 
limit of two weeks was established by EMA considering the lack of available safety data on long term 
exposure and the traditional short term use of such herbal products in self-medication (EMA, 2007). 
The German and Netherlands regulations indicate that the use of PA containing preparations should be 
limited to short time (defined as 6 weeks) use at dose levels of 1 g/day (Bundesgesundheitsamt, 1992; 
WKB, 2001). It is thus of significance to analyse the presence of PAs in extracts of comminuted and 
whole leaf teas and herbal medicines and perform a risk assessment taking shorter exposure duration 
into consideration. In our previous study, we used the data from Bodi et al. (2014), Mulder et al. (2015) 
and EFSA (2016) to perform a risk assessment for herbal teas and PFS based on daily consumption of 
one cup of tea or 200 mg of PFS per day during a lifetime, mainly because lifetime exposure is the 
default assumption in the MOE approach (Chen et al., 2017). This evaluation confirmed that 
consumption of certain herbal teas and PFS may raise a health concern when consumed regularly 
during a lifespan (Chen et al., 2017). The aim of the present study was to assess the risk of exposure to 
PAs from herbal teas, herbal medicines and PFS using the MOE approach considering shorter and 
more realistic exposure scenarios, also taking the potentially lower extraction efficiency from whole 
herbal tea leaves versus comminuted samples into account. 
Materials and Methods 
Standards and reagents 
Formic acid (analytical grade) and ammonium carbonate (analytical grade) were obtained from Sigma-
Aldrich, Zwijndrecht, the Netherlands). Acetonitrile (LC-MS grade) and methanol (LC-MS grade) 
were obtained from Actu-all, Oss, the Netherlands). Fifty-four PA analytical standards were sourced 
from Phytoplan (Heidelberg, Germany), except for: heliotrine and trichodesmine from Latoxan 
(Valence, France); usaramine from BOC Sciences (Shirley, NY, USA), florosenine from PRISNA
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(Leiden, the Netherlands), echimidine, indicine, indicine N-oxide, intermedine, intermedine N-oxide, 
lycopsamine, lycopsamine N-oxide, monocrotaline, monocrotaline N-oxide and otosenine from 
Phytolab (Vestenbergsgreuth, Germany). Usaramine N-oxide, trichodesmine N-oxide were in-house 
synthesized by the method of (Chou et al., 2003). See Supplementary Data 1 for a full list of PA 
standards used in this study.  
Stock solutions of the 54 available PAs were prepared in methanol (100 µg/mL). A mixed solution (1 
µg/mL in methanol) containing all PA standards was prepared from the stock solutions. This mixed 
standard solution was used to spike the herbal teas and medicine samples as described below. 
Herbal teas and PA extraction 
Five types of herbal teas derived from PA-producing plants were used to investigate the difference of 
PAs extraction efficiency between intact leaves and comminuted leaves, including coltsfoot (Tussilago 
farfara), comfrey (Symphytum officinale), borage (Borago officinalis), climbing groundsel (Senecio 
scandens) and sunn hemp (Crotalaria juncea) teas. These herbal teas were selected, because they are 
available on the market as intact leaves. Table 1 presents an overview of the herbal teas used in the 
present study, their country and year of origin, and also the presumptive health effects of the 
respective teas as derived from the literatures. 
The intact leaves of each tea were randomly selected and ground to produce the comminuted leaves 
using a grinder (HR2056, Philips, the Netherlands). The intact leaves as well as the comminuted 
leaves of these teas were used for hot water extraction and subsequent PA analysis. For PA extraction, 
2 g of the sample were positioned in a 250 mL glass beaker and 150 mL of boiling water was poured 
onto the tea. The infusion was stirred 3 times in 10 minutes. This procedure was selected as a worst 
case scenario for extraction of bioactive ingredients upon hot water extraction based on literature 
(Molan et al., 2009; McKAY et al., 1995; Raffo et al., 2011). Then, the infusion passed through a 
paper filter. The extraction was performed in triplicate.  
From each of the filtered infusions four aliquots were taken and transferred to autosampler vials. Of 
tea 1 (coltsfoot) aliquots of 400 µL; of tea 3 (borage) aliquots of 20 µL; of tea 2 (comfrey) and tea 4 
(climbing groundsel) aliquots of 100 µL and of tea 5 (sunn hemp) aliquots of 200 µL were taken. For 
each infusion one of the aliquots was spiked with 25 ng/mL (25 µl of 1 µg/mL PA mix) and one was 
spiked with 100 ng/mL (100 µL of 1 µg/mL PA mix). The total volumes were made up to 1 mL with 
water.
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extraction from the teas. This may influence the actual exposure and corresponding risk assessment. 
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taken into account that herbal teas are frequently used for medicinal purposes, a practice being quite 
popular in many developing and developed countries (Fu et al., 2002; Prakash et al., 1999; Roeder, 
2000; Stegelmeier et al., 1999). Thus, people might consume herbal teas as a medicine only during 
certain periods of for example illness. This shorter-than-lifetime use also holds true for herbal 
medicinal supplements, while evaluation by the MOE approach generally assumes lifelong everyday 
use. According to a survey of usage of herbal preparations by European adults, the majority of all 
respondents indicated to take these botanicals only during a specified time period or when they had a 
worsened condition (Garcia-Alvarez et al., 2014). In addition shorter-than-lifetime use of these herbal 
preparations is in line with the EMA (European Medicines Agency) who indicates for example that 
bitter fennel preparations should not be taken for periods exceeding two weeks (EMA, 2008). The 
limit of two weeks was established by EMA considering the lack of available safety data on long term 
exposure and the traditional short term use of such herbal products in self-medication (EMA, 2007). 
The German and Netherlands regulations indicate that the use of PA containing preparations should be 
limited to short time (defined as 6 weeks) use at dose levels of 1 g/day (Bundesgesundheitsamt, 1992; 
WKB, 2001). It is thus of significance to analyse the presence of PAs in extracts of comminuted and 
whole leaf teas and herbal medicines and perform a risk assessment taking shorter exposure duration 
into consideration. In our previous study, we used the data from Bodi et al. (2014), Mulder et al. (2015) 
and EFSA (2016) to perform a risk assessment for herbal teas and PFS based on daily consumption of 
one cup of tea or 200 mg of PFS per day during a lifetime, mainly because lifetime exposure is the 
default assumption in the MOE approach (Chen et al., 2017). This evaluation confirmed that 
consumption of certain herbal teas and PFS may raise a health concern when consumed regularly 
during a lifespan (Chen et al., 2017). The aim of the present study was to assess the risk of exposure to 
PAs from herbal teas, herbal medicines and PFS using the MOE approach considering shorter and 
more realistic exposure scenarios, also taking the potentially lower extraction efficiency from whole 
herbal tea leaves versus comminuted samples into account. 
Materials and Methods 
Standards and reagents 
Formic acid (analytical grade) and ammonium carbonate (analytical grade) were obtained from Sigma-
Aldrich, Zwijndrecht, the Netherlands). Acetonitrile (LC-MS grade) and methanol (LC-MS grade) 
were obtained from Actu-all, Oss, the Netherlands). Fifty-four PA analytical standards were sourced 
from Phytoplan (Heidelberg, Germany), except for: heliotrine and trichodesmine from Latoxan 
(Valence, France); usaramine from BOC Sciences (Shirley, NY, USA), florosenine from PRISNA
65 
 
(Leiden, the Netherlands), echimidine, indicine, indicine N-oxide, intermedine, intermedine N-oxide, 
lycopsamine, lycopsamine N-oxide, monocrotaline, monocrotaline N-oxide and otosenine from 
Phytolab (Vestenbergsgreuth, Germany). Usaramine N-oxide, trichodesmine N-oxide were in-house 
synthesized by the method of (Chou et al., 2003). See Supplementary Data 1 for a full list of PA 
standards used in this study.  
Stock solutions of the 54 available PAs were prepared in methanol (100 µg/mL). A mixed solution (1 
µg/mL in methanol) containing all PA standards was prepared from the stock solutions. This mixed 
standard solution was used to spike the herbal teas and medicine samples as described below. 
Herbal teas and PA extraction 
Five types of herbal teas derived from PA-producing plants were used to investigate the difference of 
PAs extraction efficiency between intact leaves and comminuted leaves, including coltsfoot (Tussilago 
farfara), comfrey (Symphytum officinale), borage (Borago officinalis), climbing groundsel (Senecio 
scandens) and sunn hemp (Crotalaria juncea) teas. These herbal teas were selected, because they are 
available on the market as intact leaves. Table 1 presents an overview of the herbal teas used in the 
present study, their country and year of origin, and also the presumptive health effects of the 
respective teas as derived from the literatures. 
The intact leaves of each tea were randomly selected and ground to produce the comminuted leaves 
using a grinder (HR2056, Philips, the Netherlands). The intact leaves as well as the comminuted 
leaves of these teas were used for hot water extraction and subsequent PA analysis. For PA extraction, 
2 g of the sample were positioned in a 250 mL glass beaker and 150 mL of boiling water was poured 
onto the tea. The infusion was stirred 3 times in 10 minutes. This procedure was selected as a worst 
case scenario for extraction of bioactive ingredients upon hot water extraction based on literature 
(Molan et al., 2009; McKAY et al., 1995; Raffo et al., 2011). Then, the infusion passed through a 
paper filter. The extraction was performed in triplicate.  
From each of the filtered infusions four aliquots were taken and transferred to autosampler vials. Of 
tea 1 (coltsfoot) aliquots of 400 µL; of tea 3 (borage) aliquots of 20 µL; of tea 2 (comfrey) and tea 4 
(climbing groundsel) aliquots of 100 µL and of tea 5 (sunn hemp) aliquots of 200 µL were taken. For 
each infusion one of the aliquots was spiked with 25 ng/mL (25 µl of 1 µg/mL PA mix) and one was 
spiked with 100 ng/mL (100 µL of 1 µg/mL PA mix). The total volumes were made up to 1 mL with 
water.
66
6
6 
 Ta
bl
e 
1:
 T
he
 fi
ve
 ty
pe
s o
f h
er
ba
l t
ea
s u
se
d 
an
d 
th
ei
r c
ha
ra
ct
er
is
tic
s.
 
H
er
ba
l 
te
a 
sa
m
pl
e 
Ty
pe
 o
f h
er
ba
l t
ea
 
 (P
in
 Y
in
 n
am
e)
  
La
tin
 n
am
e 
 
H
ea
lth
 c
la
im
 fr
om
 st
ud
ie
s 
R
ef
er
en
ce
 
O
rig
in
 
Y
ea
r 
Te
a 
1 
C
ol
ts
fo
ot
  
(K
ua
n 
D
on
g)
 
Tu
ss
ila
go
 fa
rfa
ra
  
El
im
in
at
es
 
irr
ita
tio
n 
an
d 
in
fla
m
m
at
io
n 
of
 
th
e 
re
sp
ira
to
ry
 
sy
st
em
 a
nd
 p
er
si
st
en
t c
ou
gh
s 
 
(L
ap
en
na
 
et
 
al
., 
20
15
)  
N
et
he
rla
nd
s 
20
15
 
Te
a 
2 
C
om
fr
ey
  
(J
u 
H
e 
C
ao
)  
Sy
m
ph
yt
um
 o
ffi
ci
na
le
 T
re
at
m
en
t 
of
 
rh
eu
m
at
oi
d 
ar
th
rit
is
, 
br
on
ch
iti
s, 
va
rio
us
 a
lle
rg
ie
s 
an
d 
fo
r 
di
ar
rh
oe
a 
(S
tic
ke
l 
an
d 
Se
itz
, 
20
00
)  
C
hi
na
 
20
16
 
Te
a 
3 
B
or
ag
e 
 
(L
iu
 L
i J
u)
 
Bo
ra
go
 o
ffi
ci
na
lis
  
Su
pp
re
ss
io
n 
of
 
in
fla
m
m
at
io
n,
 
tre
at
m
en
t o
f d
ia
be
tic
 n
eu
ro
pa
th
y 
 
(O
om
ah
 a
nd
 M
az
za
, 
19
99
) 
Sp
ai
n 
20
15
 
Te
a 
4 
C
lim
bi
ng
 g
ro
un
ds
el
 (
Q
ia
n 
Li
 
G
ua
ng
)  
  
Se
ne
ci
o 
sc
an
de
ns
 
In
du
ce
s d
iu
re
si
s, 
an
th
el
m
in
tic
  
(L
in
g,
 2
00
8)
 
C
hi
na
 
20
16
 
Te
a 
5 
Su
nn
 h
em
p 
 
(T
ai
 Y
an
g 
M
a)
   
  
Cr
ot
al
ar
ia
 ju
nc
ea
  
A
nt
ia
rth
rit
ic
  
(A
sh
ok
 e
t a
l.,
 2
00
6)
 
C
hi
na
 
20
16
 
 
67 
 
Herbal medicines and PA extraction 
A total of eight herbal medicines were purchased from the Chinese market. The products were in the 
form of capsules, pills or tablets, four of them containing PA-producing plants and four containing 
non-PA-producing plants. Table 2 presents an overview of the collected herbal medicine samples and 
their characteristics.  
For PA analysis from each sample three test portions of 1.0 gram were extracted with 20 mL of 1.0% 
formic acid solution by agitation for 30 minutes. Before extraction one of the test portions was 
fortified with the mixed PA standard solution at 500 µg/kg (500 µL of 1 µg/mL PA mix). After 
centrifugation 5 mL of supernatant was transferred to a new tube and brought to pH 6-7 with 1 M 
ammonium carbonate solution, pH 9. The extracts were further purified by SPE over a StrataX 200 mg, 
6 cc cartridge. Cartridges were conditioned with 6 mL methanol, followed by 6 mL water. After the 
extract was passed through the cartridge, this was washed with 6 mL 1% formic acid, followed by 6 
mL water and dried under vacuum using a vacuum manifold for 10 min. PAs were eluted with 6 mL of 
methanol and the eluates were dried under a stream of nitrogen at 50oC using a TurboVap. The 
extracts were reconstituted in 500 µL of 10% methanol and filtered using 0.45 µm PTFE filtervials 
(UniPrep, Whatman, Maidstone, UK). 
Medicines 5 and 8 contained senkirkine at concentrations exceeding the spiked concentration of 500 
µg/kg. Senkirkine was quantified in these samples by spiking aliquots (1 mL) of the herbal extracts 
with senkirkine at 50 µg/mL (5 µL of a 10 µg/mL solution of senkirkine in methanol and at 250 
ng/mL (25 µL of a 10 µg/mL solution of senkirkine). The fortifications correspond to 1000 and 5000 
µg/kg in the herbal medicine, respectively.  
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LOD, LOQ, recovery, and precision data  
In-house validated methods for 54 PAs in herbal tea infusions and in PFS were used. For PAs in 
herbal infusions the LOQs obtained were at 0.05 µg/L and in herbal supplements at 4-5 µg/kg. LODs 
were estimated at 0.01-0.02 µg/L in herbal infusions and at 1-2 µg/kg in PFS. For PFS recoveries 
(level: 100 µg/kg) varied from 73-107%. Repeatability (n = 5) ranged between 8.1 and 24% at 10 
µg/kg, between 3.1 and 8.5% at 100 µg/kg and between 3.1 and 10.9% at 250 µg/kg. Linearity of the 
LC-MS/MS system was checked by analysis of 8-point calibration curves prepared in blank tea extract 
and in blank PFS extract over the range of 0 to 250 ng/mL. 
LC-MS/MS analysis 
Analysis of PAs was performed in positive electrospray mode on an LC-MS/MS system consisting of 
a Waters Acquity UPLC coupled to a Xevo TQ-S tandem mass spectrometer (Waters, Milford, MA, 
USA). At least two MRM transitions were measured per analyte. Besides the 54 PAs for which an 
analytical standard was available, the samples were screened for another 35 1,2-unsaturated PAs for 
which no standards were available. These PAs could be included in the analytical method because 
mass spectrometric data were available from the analysis of extracts of authentic Borago, Symphytum, 
Crotalaria, Senecio, Petasites and Tussilago plant samples. See Supplementary Data 1 for an 
overview of the MS/MS transitions used for the complete set of PAs. Chromatographic separation was 
obtained on a 150 × 2.1 mm, 1.7 μm particle size, UPLC BEH C18 analytical column (Waters, 
Milford, MA, USA). Eluent A consisted of water containing 10 mM ammonium carbonate pH 9 and 
acetonitrile was used as eluent B. A gradient elution was performed as follows: 0.0 min 100% A/0% B, 
0.1 min 95% A/5% B, 3.0 min 90% A/10% B, 7.0 min 76% A/24% B, 9.0 min 70% A/30% B, 12.0 
min 30% A/70% B, 12.1-15.0 min 100% A/0% B. The column was kept at 50ºC and a flow rate of 400 
μL/min was applied; 2 μL sample extract was injected. For some PA isomers, e.g. lycopsamine and 
intermedine and their N-oxide and 7-acetyl analogues no or only partial separation could be obtained 
under the chromatographic conditions used. For verification of the identity of the isomers, tea samples 
2 (Comfrey) and 3 (Borage) were reanalysed using acidic chromatography, which allows the 
separation of lycopsamine and intermedine isomers (Bodi et al., 2014). Comfrey tea contained 
intermedine and lycosamine isomers in equal amounts, while borage tea contained only the 
lycopsamine isomer (data not shown). 
Quantification of PAs in herbal tea infusions and in PFS 
Quantification of the PAs in the herbal infusions was based on one-point standard addition of PAs to 
the infusion. Depending on the concentration found in the extract, either the standard addition at 25 
ng/mL was used or the one at 100 ng/mL. 
The PAs in the herbal medicines were quantified based on one-point standard addition of 500 µg/kg to 
the herbal product. Medicines 5 and 8 contained senkirkine at higher concentrations and these were 
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separation of lycopsamine and intermedine isomers (Bodi et al., 2014). Comfrey tea contained 
intermedine and lycosamine isomers in equal amounts, while borage tea contained only the 
lycopsamine isomer (data not shown). 
Quantification of PAs in herbal tea infusions and in PFS 
Quantification of the PAs in the herbal infusions was based on one-point standard addition of PAs to 
the infusion. Depending on the concentration found in the extract, either the standard addition at 25 
ng/mL was used or the one at 100 ng/mL. 
The PAs in the herbal medicines were quantified based on one-point standard addition of 500 µg/kg to 
the herbal product. Medicines 5 and 8 contained senkirkine at higher concentrations and these were 
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quantified by spiking the herbal extracts with senkirkine at 50 and 250 ng/mL (corresponding to 1000 
and 5000 µg/kg in the herbal medicine, respectively).  
PAs for which no PA reference standard was available were semi-quantified by taking a structurally 
related PA reference standard, as indicated in the Supplementary Data 1.  
Estimation of daily intakes of PAs resulting from the consumption of herbal teas and 
herbal medicines 
To perform a risk assessment, the daily PA intake resulting from use of the herbal teas was estimated 
assuming daily consumption of the amount of PAs extracted by hot water extraction from 2 g tea, 
corresponding to one cup of tea, as described before (BfR, 2013). For estimation of the PA exposure 
resulting from herbal medicines, the concentration of the PAs quantified in the extracts was multiplied 
by the daily use of the herbal medicines as recommended by the supplier (Table 2). The estimated 
daily intake (EDI) values were calculated using a default body weight of 70 kg for an adult as 
proposed by EFSA (EFSA, 2012). 
𝐸𝐸𝐸𝐸𝐸𝐸 =
𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 𝑃𝑃𝑃𝑃 𝑐𝑐𝑡𝑡𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑡𝑡𝑐𝑐𝑡𝑡𝑡𝑡𝑐𝑐𝑡𝑡𝑐𝑐 ∗ 𝑑𝑑𝑡𝑡𝑐𝑐𝑡𝑡𝑑𝑑 𝑢𝑢𝑢𝑢𝑐𝑐
𝑏𝑏𝑏𝑏 (70 𝑘𝑘𝑘𝑘)
 
Calculation of the Margin of Exposure (MOE) 
Risk assessment was performed using the MOE approach. EFSA has recently set a reference point of 
237 μg/kg bw/day for riddelliine as the point of departure (PoD) to assess the carcinogenicity risk of 
PAs (EFSA, 2017), based on an updated benchmark dose (BMD) modelling approach. This was done 
because it was considered that the BMDL10 of 70 μg/kg/day obtained previously for lasiocarpine 
(EFSA, 2011) was affected by a high degree of uncertainty. In this study the MOE values were 
calculated by dividing the BMDL10 of 237 μg/kg bw/day for riddelliine by the EDIs. 
Real life exposure scenario 
MOE values for the chronic lifetime exposure to herbal teas and herbal medicines were calculated 
based on daily exposure during a lifetime. We applied Haber’s rule to correct the EDI values for this 
short term exposure (Doull and Rozman, 2000). According to Haber’s rule, the toxic effect varies 
linearly with the time of exposure and the concentration or dose (i.e. C × T = k, where C is 
concentration or dose, T is time of exposure, and k is a constant toxic response for the specific 
substance) (Doull and Rozman, 2000). Using Haber's rule and a lifetime expectancy of 75 years 
(Felter et al., 2011; van den Berg et al., 2014), the EDI values for two weeks yearly exposure during a 
lifetime will be 52 weeks per year/2 weeks = 26 times lower than for daily lifelong exposure. EDI 
values for 6 weeks exposure a year, defined by the German and Netherlands regulations as short term 
exposure, would be 8.67 times lower. Another consideration to take into account when considering 
real life exposure scenario’s for the use of herbal teas, is that these teas may not be ground before 
making the hot water extract. Using comminuted leaves is expected to facilitate diffusion of PAs into 
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the hot water, and thus may result in a higher concentration of PAs in tea infusion then when using 
intact leaves. This will further influence the EDI and the MOE values. In the present study, five types 
of herbal teas were employed to compare the PA levels between comminuted leaves and intact leaves, 
as well as their resulting MOE values. 
The possibility was considered that herbal teas or herbal medicines may be used for longer periods 
than 2 weeks or 6 weeks a year during a lifetime. For those herbal products, assuming a 75-year 
lifetime, the maximum number of weeks was calculated during which the product could be consumed 
to result in an MOE value of 10,000 given a BMDL10 of 237 µg/kg bw per day: 
𝐸𝐸𝐸𝐸𝐸𝐸 =
BMDL10
10,000
=
𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 𝑃𝑃𝑃𝑃 𝑐𝑐𝑡𝑡𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑡𝑡𝑐𝑐𝑡𝑡𝑡𝑡𝑐𝑐𝑡𝑡𝑐𝑐 ∗ 𝑑𝑑𝑡𝑡𝑐𝑐𝑡𝑡𝑑𝑑 𝑢𝑢𝑢𝑢𝑐𝑐
𝑏𝑏𝑏𝑏 (70 𝑘𝑘𝑘𝑘)
: (
75 𝑑𝑑𝑐𝑐𝑡𝑡𝑐𝑐𝑢𝑢 ∗ 52 𝑏𝑏𝑐𝑐𝑐𝑐𝑘𝑘𝑢𝑢
𝑐𝑐 𝑏𝑏𝑐𝑐𝑐𝑐𝑘𝑘𝑢𝑢
) 
This calculation was also applied for the 34 types of herbal teas and 19 PFS, based on the data that 
have been previously reported by Bodi et al. (2014), EFSA (2016) and Mulder et al. (2015). In all 
calculations it has been assumed that the concentrations reported are representative for the specific tea 
or PFS and that exposure to PAs is only due to that tea or PFS. 
Results 
PA concentrations in herbal teas and the effect of hot water extraction of comminuted 
and intact leaves  
Five types of herbal teas were used to compare the total amount of PAs that were extracted either from 
the intact or the comminuted leaves. The amounts of PAs extracted from the intact leaves of each tea 
were consistently lower compared to the levels extracted from the comminuted leaves (Fig. 1). The 
total PA concentrations varied from 30.7 to 845.4 µg/L for the intact leaves and from 61.3 to 1120.0 
µg/L for the comminuted leaves. Overall, the PA levels extracted from intact leaves were 1.1- to 4.1-
fold lower than from the corresponding comminuted leaves. The PA levels were significantly different 
between intact leaves and comminuted leaves in borage, comfrey and climbing groundsel teas. The 
highest PA concentration was found in borage tea and lycopsamine N-oxide was the PA found in the 
highest concentration. In general, the same PAs and also similar profiles were found in intact and 
comminuted leaves of the teas (Table 3 and Supplementary Data 2). The tested herbal teas contained 
between 3 and 11 different PAs (Table 3 and Supplementary Data 2), the lowest number of PAs was 
detected in coltsfoot tea, the highest number in comfrey and sunn hemp tea. Interestingly, in sunn 
hemp tea trichodesmine N-oxide was the most abundant PA extracted from the intact leaves, whereas 
monocrotaline N-oxide was highest when extracted from comminuted leaves. This suggests that the 
size of the leaves may also have an impact on the relative extraction efficiency of PAs in the leaves.  
We were interested whether the PAs present in the teas could be correlated with the botanical plant 
name listed on the label. Coltsfoot (T. farfara) is known to contain senkirkine as the dominant PA and 
varying but smaller amounts of senecionine (Roeder, 1995). In our sample senkirkine was indeed 
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quantified by spiking the herbal extracts with senkirkine at 50 and 250 ng/mL (corresponding to 1000 
and 5000 µg/kg in the herbal medicine, respectively).  
PAs for which no PA reference standard was available were semi-quantified by taking a structurally 
related PA reference standard, as indicated in the Supplementary Data 1.  
Estimation of daily intakes of PAs resulting from the consumption of herbal teas and 
herbal medicines 
To perform a risk assessment, the daily PA intake resulting from use of the herbal teas was estimated 
assuming daily consumption of the amount of PAs extracted by hot water extraction from 2 g tea, 
corresponding to one cup of tea, as described before (BfR, 2013). For estimation of the PA exposure 
resulting from herbal medicines, the concentration of the PAs quantified in the extracts was multiplied 
by the daily use of the herbal medicines as recommended by the supplier (Table 2). The estimated 
daily intake (EDI) values were calculated using a default body weight of 70 kg for an adult as 
proposed by EFSA (EFSA, 2012). 
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short term exposure (Doull and Rozman, 2000). According to Haber’s rule, the toxic effect varies 
linearly with the time of exposure and the concentration or dose (i.e. C × T = k, where C is 
concentration or dose, T is time of exposure, and k is a constant toxic response for the specific 
substance) (Doull and Rozman, 2000). Using Haber's rule and a lifetime expectancy of 75 years 
(Felter et al., 2011; van den Berg et al., 2014), the EDI values for two weeks yearly exposure during a 
lifetime will be 52 weeks per year/2 weeks = 26 times lower than for daily lifelong exposure. EDI 
values for 6 weeks exposure a year, defined by the German and Netherlands regulations as short term 
exposure, would be 8.67 times lower. Another consideration to take into account when considering 
real life exposure scenario’s for the use of herbal teas, is that these teas may not be ground before 
making the hot water extract. Using comminuted leaves is expected to facilitate diffusion of PAs into 
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the hot water, and thus may result in a higher concentration of PAs in tea infusion then when using 
intact leaves. This will further influence the EDI and the MOE values. In the present study, five types 
of herbal teas were employed to compare the PA levels between comminuted leaves and intact leaves, 
as well as their resulting MOE values. 
The possibility was considered that herbal teas or herbal medicines may be used for longer periods 
than 2 weeks or 6 weeks a year during a lifetime. For those herbal products, assuming a 75-year 
lifetime, the maximum number of weeks was calculated during which the product could be consumed 
to result in an MOE value of 10,000 given a BMDL10 of 237 µg/kg bw per day: 
𝐸𝐸𝐸𝐸𝐸𝐸 =
BMDL10
10,000
=
𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 𝑃𝑃𝑃𝑃 𝑐𝑐𝑡𝑡𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑡𝑡𝑐𝑐𝑡𝑡𝑡𝑡𝑐𝑐𝑡𝑡𝑐𝑐 ∗ 𝑑𝑑𝑡𝑡𝑐𝑐𝑡𝑡𝑑𝑑 𝑢𝑢𝑢𝑢𝑐𝑐
𝑏𝑏𝑏𝑏 (70 𝑘𝑘𝑘𝑘)
: (
75 𝑑𝑑𝑐𝑐𝑡𝑡𝑐𝑐𝑢𝑢 ∗ 52 𝑏𝑏𝑐𝑐𝑐𝑐𝑘𝑘𝑢𝑢
𝑐𝑐 𝑏𝑏𝑐𝑐𝑐𝑐𝑘𝑘𝑢𝑢
) 
This calculation was also applied for the 34 types of herbal teas and 19 PFS, based on the data that 
have been previously reported by Bodi et al. (2014), EFSA (2016) and Mulder et al. (2015). In all 
calculations it has been assumed that the concentrations reported are representative for the specific tea 
or PFS and that exposure to PAs is only due to that tea or PFS. 
Results 
PA concentrations in herbal teas and the effect of hot water extraction of comminuted 
and intact leaves  
Five types of herbal teas were used to compare the total amount of PAs that were extracted either from 
the intact or the comminuted leaves. The amounts of PAs extracted from the intact leaves of each tea 
were consistently lower compared to the levels extracted from the comminuted leaves (Fig. 1). The 
total PA concentrations varied from 30.7 to 845.4 µg/L for the intact leaves and from 61.3 to 1120.0 
µg/L for the comminuted leaves. Overall, the PA levels extracted from intact leaves were 1.1- to 4.1-
fold lower than from the corresponding comminuted leaves. The PA levels were significantly different 
between intact leaves and comminuted leaves in borage, comfrey and climbing groundsel teas. The 
highest PA concentration was found in borage tea and lycopsamine N-oxide was the PA found in the 
highest concentration. In general, the same PAs and also similar profiles were found in intact and 
comminuted leaves of the teas (Table 3 and Supplementary Data 2). The tested herbal teas contained 
between 3 and 11 different PAs (Table 3 and Supplementary Data 2), the lowest number of PAs was 
detected in coltsfoot tea, the highest number in comfrey and sunn hemp tea. Interestingly, in sunn 
hemp tea trichodesmine N-oxide was the most abundant PA extracted from the intact leaves, whereas 
monocrotaline N-oxide was highest when extracted from comminuted leaves. This suggests that the 
size of the leaves may also have an impact on the relative extraction efficiency of PAs in the leaves.  
We were interested whether the PAs present in the teas could be correlated with the botanical plant 
name listed on the label. Coltsfoot (T. farfara) is known to contain senkirkine as the dominant PA and 
varying but smaller amounts of senecionine (Roeder, 1995). In our sample senkirkine was indeed 
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present but senecionine was not detected. Borago (B. officinalis) typically contains the monoesters 
lycopsamine and intermedine as well as their 7-acetyl derivatives (El-Shazly and Wink, 2014; Roeder, 
1995). In the sample tested only lycopsamine and its 7-acetyl derivative were found. Comfrey (S. 
officinale) can contain a range of mono and diester compounds, including lycopsamine, intermedine, 
echinatine, echimidine, and heliosupine (El-Shazly and Wink, 2014). Lycopsamine, intermedine, 
echimidine and heliosupine were present in the tested sample, as well as leptanthine (a hydroxy 
analogue of lycopsamine) and an acetyl derivative of echimidine. Climbing groundsel (Senecio 
scandens) is reported to contain senecionine, seneciphylline (Roeder, 2000), although in another report 
adonifoline was identified as the main PA (Xiong et al., 2012). None of these PAs were detected in the 
tested sample. Based on the PA profile present in the extracts primarily senkirkine and lower levels of 
petasitenine and dehydrosenkirkine it is more likely to be a Petasitis (butterbur) species, e.g. P. 
japonicus (Hartmann and Witte, 1995). Sunn hemp (C. juncea) reportedly can contain trichodesmine, 
junceine, senecionine, integerrimine and seneciphylline (Roeder and Wiedenfeld, 2013). In the tested 
sample trichodesmine and integerrimine were indeed found, but senecionine, seneciphylline and 
junceine were not. Instead, monocrotaline and low levels of incanine and fulvine were detected. It is 
therefore possible that another or a mixture of Crotalaria species was used (Roeder and Wiedenfeld, 
2013). 
In several preparations trace levels PAs were found that could not be directly attributed to the 
botanical species reported on the label. These PAs can come from impurities present in the herbal teas, 
due to co-harvesting or processing of unrelated PA-containing plants.  
 
Fig.1 The total PA concentrations of five herbal teas extracted either from intact leaves (bars filled with black 
dots) or from the corresponding comminuted leaves (bars filled with black lines). Average of three extractions. 
Data are expressed as mean ± SD and analyzed using t-test. * p< 0.05. 
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Table 3. Total number of PAs, total PA concentration and the top three PAs in the tested herbal teas. See 
Supplementary Data 2 for a complete data overview. 
Herbal tea Form Number of PAs >LOD 
Total PA 
concentration 
(µg/L) 
EDI (µg/kg 
bw/day) 
Top three PAs and their concentration 
(µg/L) 
Coltsfoot 
Comminuted 5 61.3 0.1 
Senkirkine (58.2);  
Neosenkirkine (2.6); 
Echinatine N-oxide (0.27) 
Intact 3 30.7 0.07 
Senkirkine (29.7);  
Neosenkirkine (0.94); 
Echinatine N-oxide (0.02) 
Borage 
Comminuted 4 1120.0 2.4 
Lycopsamine N-oxide (889.3);  
Lycopsamine (209.5);  
7-Acetyllycopsamine N-oxide (15.7) 
Intact 4 845.4 1.8 
Lycopsamine N-oxide (679.7);  
Lycopsamine (149.2);  
7-Acetyllycopsamine N-oxide (13.0) 
Comfrey 
Comminuted 10 415.0 0.9 
Echimidine N-oxide (321.5);  
Echimidine (29.1); 
Leptanthine (22.7)  
Intact 11 101.1 0.2 
Echimidine N-oxide (75.9);  
Echimidine (16.2); 
Leptanthine N-oxide (4.0) 
Climbing 
groundsel 
Comminuted 7 293.1 0.6 
Senkirkine (248.2);  
Dehydrosenkirkine (22.8); 
Petasitenine (19.7) 
Intact 6 85.2 0.2 
Senkirkine (74.3);  
Petasitenine (5.0); 
Dehydrosenkirkine (4.6) 
Sunn hemp 
Comminuted 11 192.8 0.4 
Monocrotaline N-oxide (82.0);  
Monocrotaline (60.1);  
Integerrimine N-oxide (29.2) 
Intact 9 170.0 0.4 
Trichodesmine N-oxide (61.8);  
Monocrotaline N-oxide (50.0);   
Integerrimine N-oxide (18.7) 
 
Risk assessment for the herbal teas based on lifetime and shorter duration exposure 
The MOE values based on the total PA levels that were extracted from either comminuted leaves or 
intact leaves of the five types of herbal teas assuming daily use during a whole lifetime are depicted in 
Fig. 2A. It is assumed that the PA concentration is representative for the specific tea. For the 
comminuted leaves, the MOE values ranged from 100 to 1,800, and from 130 to 3,600 for the intact 
leaves. The MOE values were, regardless of the state and size of the leaves, all below 10,000 for these 
five types of herbal teas, the lowest MOE value was found for the borage tea. 
Fig. 2B shows the MOE values for herbal teas in the form of comminuted leaves and intact leaves 
assuming consumption for two or six weeks/year during a lifetime. In particular consumption of 
borage tea still resulted in MOE values below 10,000, independent of the form of the leaves. Short 
term two weeks exposure to the extracts of comminuted leaves of comfrey and climbing groundsel 
teas resulted in MOE values just below 10,000, but for the intact leaves above 10,000. For coltsfoot 
and sunn hemp teas MOE values above 10,000 were obtained, irrespective of the form of the leaves.
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Table 3. Total number of PAs, total PA concentration and the top three PAs in the tested herbal teas. See 
Supplementary Data 2 for a complete data overview. 
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The MOE values based on the total PA levels that were extracted from either comminuted leaves or 
intact leaves of the five types of herbal teas assuming daily use during a whole lifetime are depicted in 
Fig. 2A. It is assumed that the PA concentration is representative for the specific tea. For the 
comminuted leaves, the MOE values ranged from 100 to 1,800, and from 130 to 3,600 for the intact 
leaves. The MOE values were, regardless of the state and size of the leaves, all below 10,000 for these 
five types of herbal teas, the lowest MOE value was found for the borage tea. 
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assuming consumption for two or six weeks/year during a lifetime. In particular consumption of 
borage tea still resulted in MOE values below 10,000, independent of the form of the leaves. Short 
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teas resulted in MOE values just below 10,000, but for the intact leaves above 10,000. For coltsfoot 
and sunn hemp teas MOE values above 10,000 were obtained, irrespective of the form of the leaves.
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Assuming six weeks exposure/year during a lifetime, to mimic the definition of short term exposure in 
existing regulations, reduces the MOE values 3-fold resulting in a value < 10,000 for borage, comfrey 
and sunn hemp teas, independent of the form of the leaves. These results show that the size of the 
leaves and the duration of the short term exposure may influence the corresponding risk assessment.  
 
Fig.2 The MOE values of five types of herbal teas obtained when assuming daily consumption of one cup of tea 
per day for a lifetime (A) and for 2 weeks (left Y axis) and 6 weeks (right Y axis) every year during a lifetime (B) 
using the total PA levels extracted from either comminuted leaves (bars filled with black dots) or intact leaves 
(bars filled with black lines). The red dashed line (-----) and black dotted line (·····) represent the MOE values of 
10,000 for 2 weeks and 6 weeks a year, respectively. 
PA concentrations in herbal medicines  
Table 4 and Supplementary data 3 show the total PA concentrations found in eight herbal medicines, 
including four products (M5-8) that contain PA-producing plants such as coltsfoot or climbing 
groundsel as one of the ingredients. The other four herbal medicines (M1-4) were supposed to contain 
no PA-producing plants. In M1 and M2 the total PA levels were indeed below LOQ. A small amount 
of senkirkine (4.2 µg/kg) was found in M3 and traces of lycopsamine/intemedine (4.0 µg/kg) were 
detected in M4. In the medicines that contain a PA-producing plant ingredient, the measured total PA 
concentration ranged from 404 to 7883 µg/kg. Medicine 6 contained the highest total PA 
concentration as well as the highest number of different PAs. In this sample adonifoline was the 
dominant PA, accounting for approximately 98% of the total PA concentration. M5 and M8 contained 
coltsfoot (T. farfara) as one of the ingredients and in accordance with this, senkirkine, its isomer 
neosenkirkine, senecionine and its isomer integerrimine, were found as the main PAs (Roeder, 1995; 
Roeder, 2000). The results for M6 and M7, both containing climbing groundsel (S. scandens) as an 
ingredient, were more diverse. The total PA concentration in M7 was only 5% of that of M6, what 
could be due to different inclusion levels of climbing groundsel in the products. However, also the PA 
profile in both medicines was quite different. M6 contained, besides the high concentration of 
adonifoline mentioned above, also lower levels of senecionine, seneciphylline and the monoesters 
lycopsamine, intermedine, echinatine and rinderine. The first three compounds have been reported for 
climbing groundsel (Roeder, 2000; Xiong et al., 2012). The monoesters are probably due to a 
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contamination of the product (or an undeclared ingredient) with an Eupatorium or Boraginaceae 
species. The same monoesters were also found in M7, indicating a similar contamination, but for the 
rest this sample contained only senkirkine and lower levels of adonifoline. 
Table 4. Total number of PAs, total PA concentration and the top three PAs in the tested herbal medicines. See 
Supplementary Data 3 for a complete data overview. 
Herbal 
medicine 
Number of PAs 
detected  
 Total PA concentration 
(µg/kg)  
EDI (µg/kg 
bw/day) 
Top three PAs and their 
concentration (µg/kg) 
M1 0 <LOQ ˗ ˗ 
M2 0 <LOQ ˗ ˗ 
M3 1 4.2 0.0003 Senkirkine (4.2) 
M4 1 4.0 0.001 Lycopsamine/intermedine (4.0) 
M5 6 6344.3 2.18 Senkirkine (5369.3); Neosenkirkine (868.9); Senecionine (79.7) 
M6 8 7883.2 0.59 
Adonifoline (7734.3); 
Seneciphylline (67.4); Senecionine 
(39.9) 
M7 7 403.9 0.02 
Senkirkine (292.1);  
Adonifoline (49.7);  
Echinatine (41.4) 
M8 4 1430.5 0.45 Senkirkine (1215.1); Neosenkirkine (199.2); Senecionine (10.8) 
˗: Cannot be calculated because PA levels were < LOQ. 
Risk assessment for the tested herbal medicines based on chronic exposure and short 
term exposure scenarios  
The MOE values for the eight types of medicines were evaluated according to three exposure 
scenario’s including consumption at the recommended daily intake of that medicine daily throughout 
the whole lifespan (Fig. 3A), or shorter-than-lifetime during two or six weeks/year for 75 years, 
assuming a representative PA concentration and assuming exclusive exposure (Fig. 3B). Since M3 and 
M4 each only contained one PA at low concentrations, use of these two herbal medicines resulted in 
MOE values far above 10,000 irrespective of the duration of the exposure. However, of the four PA-
producing plant containing herbal medicines, three samples resulted in low MOE values of between 
110 and 530 when assuming lifelong daily consumption. For medicine 5 even short term consumption 
of two weeks/year resulted in an MOE value of 2800, well below 10,000, indicating that this medicine 
may pose a potential risk for human health. Considering shorter-than-lifetime exposure for 6 
weeks/year resulted in MOE values < 10,000 for three medicines containing PA plant material. 
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Assuming six weeks exposure/year during a lifetime, to mimic the definition of short term exposure in 
existing regulations, reduces the MOE values 3-fold resulting in a value < 10,000 for borage, comfrey 
and sunn hemp teas, independent of the form of the leaves. These results show that the size of the 
leaves and the duration of the short term exposure may influence the corresponding risk assessment.  
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Fig. 3 The MOE values of eight different types of herbal medicines assuming lifelong daily consumption (A), 
and for 2 weeks (left Y axis) and 6 weeks (right Y axis) every year during a lifetime (B). The red dashed line (---
--) and black dotted line (·····) represents the MOE values of 10,000 for 2 weeks and 6 weeks a year, 
respectively.  # implies PA content < LOQ, no MOE values obtained. 
Risk assessment for the herbal teas, herbal medicine and previously analysed teas and 
PFS based on shorter-than-lifetime use 
In addition to the herbal teas and herbal medicines analysed in the present study also a risk assessment 
for shorter-than-lifetime exposure was made for the 34 types of (herbal) teas and 19 PFS for which PA 
levels were previously reported by Bodi et al. (2014), EFSA (2016) and Mulder et al. (2015). Given 
that the number of weeks a year selected for this shorter-than-life time exposure influences the MOE 
values and final conclusion, in this analysis the number of weeks during a lifetime that would result in 
an MOE of 10,000 was evaluated. The five types of herbal teas and eight types of herbal medicines 
analysed in the present study were also included in this evaluation. 
Fig. 4 presents the maximum number of weeks during a 75-year lifetime that a herbal tea from the 
present study (Fig. 4A), a herbal medicine from the present study (Fig. 4B), a herbal tea analysed in 
previous studies (Fig. 4C) or a PFS sample analysed before (Fig. 4D) could be consumed to result in 
an MOE value of 10,000. From these data it follows for example that consumption of coltsfoot tea 
prepared from comminuted leaves, containing the PA concentration as determined in this study, for up 
to 700 weeks during a lifetime (corresponding to 9.3 weeks/year during 75 years) would be of little 
concern, whereas use of intact leaves to prepare the tea would increase this to 1400 weeks during a 
lifetime (18 weeks/year) (Fig. 4A). Similarly, use of intact borage, comfrey, climbing groundsel and 
sunn hemp tea leaves would raise no concern for, respectively, 50, 425, 500 and 250 weeks during a 
life time (corresponding to 0.6, 5.6, 6.7 and 3.3 weeks/year, respectively). However, use of 
comminuted borage, comfrey, climbing groundsel and sunn hemp tea, would result in an acceptable
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exposure for, respectively, 40, 100, 150 and 225 weeks during a lifetime (corresponding to 0.5, 1.3, 
2.0 and 3.0 weeks/year) (Fig. 4A).  
Consumption of herbal medicines that contain a PA-producing plant as ingredient, would not raise a 
concern for medicines 5, 6 and 8 when consumption is less than approximately 40, 150 and 200 weeks 
during a lifetime (0.5, 2.0 and 2.7 weeks/year). The other herbal medicines could be consumed on a 
daily basis, provided the medicine is the only source of PA exposure (Fig. 4B). 
For the herbal teas for which PA levels were reported by Bodi et al. (2014), EFSA. (2016) and Mulder 
et al. (2015), 29 out of in total of 34 types of herbal teas displayed a maximum number of weeks 
exceeding a lifetime of 3900 weeks, assuming a daily consumption of one cup of tea (Fig 4C). Of the 
regular (herbal) tea types, only rooibos tea appeared to be contaminated with PA levels that would 
require them to be consumed shorter-than-life-time, for not more than 1750 weeks (23.3 weeks a year) 
to be of low concern. Regarding the 5 types of herbal teas, derived from PA-producing plants, the 
acceptable exposures ranged from 110 weeks (1.5 weeks a year) for borage tea to more than lifetime 
consumption for Eupatorium tea (Fig. 4C). The exposures calculated for borage tea and coltsfoot tea 
(900 weeks or 12 weeks/year) were in the same range as calculated for the samples of the same type in 
this study. 
With respect to the PFS, 17 of 19 PFS showed that a daily use of 200 mg during a lifetime would not 
raise a concern, and only for two samples, a plant extract formula reported by EFSA. (2016) and a 
plant extract formula (PA-plant) reported by Mulder et al. (2015), the consumption should be 
substantially shorter than lifetime, 690 weeks (9.2 weeks/year), and 160 weeks (2.1 week/year), 
respectively (Fig. 4D). 
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Fig. 4 The maximum number of weeks during a 75-year lifetime that a tea analysed in the present study (A), a 
medicine analysed in present study (B), a type of tea reported in the literature (C) or a type of PFS reported in the 
literature (D) could be consumed to result in an MOE of 10,000, assuming consumption of one cup of tea (150 
mL) or 200 mg PFS. Bars filled with black dots represent the herbal teas prepared from comminuted leaves, bars 
filled with black slanted lines represent the herbal teas from intact leaves. The red bars represent the samples 
derived from PA-producing plants. The black dashed line represents daily intake during a 75 year lifetime (equal 
to 3900 weeks). # indicates that data are not quantifiable due to a PA content < LOQ. 
Discussion 
In the present study, we investigated the extraction of PAs in hot water from intact leaves and the 
corresponding finely ground leaves of five herbal PA containing teas and also examined the presence 
of PAs in eight samples of commercially available herbal medicines. For preparation of the infusion, 
the tea sample was steeped in the water for 10 minutes and the infusion was stirred 3 times. This 
procedure was selected as a worst case scenario for extraction of bioactive ingredients upon hot water 
extraction. For instance, Molan et al. (2009) investigated the effects of infusion time and stirring on 
the total phenolic levels extracted from green teas. The results showed that the total phenolic contents 
increased from 52.76±2.19 to 102.83±2.33 mg/g (95%) by increasing the infusion time of 3 minutes to 
10 minutes at 100 °C (P < 0.0001). The extraction was not further improved upon increasing the 
infusion time from 10 minutes to 30 minutes, at which time point the total phenolic levels was 
106.8±3.29 mg/g. In addition, infusion with stirring resulted in an increased total phenolic level of 
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96.12±2.67 mg/g, which is increased by 37% compared to a total phenolic level of 70.39±0.27 mg/g 
resulted from infusion without stirring (P ≤ 0.0110-0.0001) (Molan et al., 2009). Similarly, McKAY 
et al. (1995) found that stirring during tea infusion resulted in a marked increase on oxalate 
concentrations in black teas (McKAY et al., 1995). EFSA also pointed out that the infusion time and 
stirring may have an influence on the extraction of PAs during consumer preparation (EFSA, 2016). 
Raffo et al. (2011) suggested that stirring 3 times could reflect best the scenario of preparing tea 
infusions by the consumer in general (Raffo et al., 2011).  
In order to minimize the risk to miss relevant PAs, the samples were analysed for a comprehensive set 
of 89 1,2-unsaturated PAs. The previous studies on exposure and risk assessment for herbal teas and 
supplements were based on a set of 28 PAs (Bodi et al. (2014), EFSA (2016), Mulder et al. (2015)). 
The herbal teas and medicines investigated in this study, contained several PAs, that had not been 
included in previous studies, such as adonifoline, trichodesmine N-oxide, petasitenine, isomers of 
senkirkine and isomers of intermedine and lycopsamine. Herbal medicine M6 contained adonifoline in 
substantial amounts. When analysed with the set of 28 PAs, for this sample a relatively low amount of 
131 µg/kg would have been found, instead of 7883 µg/kg with this method (Supplementary Data 3). In 
the other PA-containing medicines, the set of 28 PAs accounted for 74% to 86% of the total content 
found using the comprehensive set. With respect to the five herbal teas, the difference in total PA 
concentration was relatively small, except for sunn hemp tea. For this tea the 28 PAs accounted for 42% 
(intact leaves) to 75% (comminuted leaves), while for the other preparations it ranged from 85% to 98% 
(Supplementary Data 2). It may be concluded that the set of 28 PAs is not always sufficient to get a 
reliable impression of the PAs present in these herbal teas and medicines.  
The herbal teas selected in this study are available for the consumer in the form of intact leaves. 
Comparing total PA levels in hot water extracts of the intact and comminuted leaves from five PA-
plant containing herbal teas, we found that, overall, the PA concentrations extracted from the 
comminuted leaves were 1.1 to 4.1 times higher compared to concentrations extracted from the intact 
leaves. It is of interest that, not only higher levels of PAs were extracted from the comminuted leaves 
but sometimes also different PAs were found in the hot water extracts from the comminuted leaves. 
This indicates that PA extraction efficiency can be influenced by the particle size of the botanical 
sample. In line with this, previous studies have demonstrated that using comminuted fruits increased 
the extraction efficiency of alkenylbenzenes as compared to the whole fruits (Raffo et al., 2011; van 
den Berg et al., 2014). The results of the current study suggest that the use of comminuted tea 
materials to prepare hot water extracts, as routinely done in studies on PAs in herbal teas (Bodi et al., 
2014; EFSA, 2016; Mulder et al., 2015) may overestimate the levels and thus, also the corresponding 
exposure and risk. It was noted that hot water extraction from intact leaves resulted in a larger 
variation in the PA levels than observed for comminuted leaves. This may be due to the fact that PA 
levels can vary between the individual intact leaves, which are likely to originate from different plants. 
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The leaves may also originate from different batches of teas, from different locations, which were 
mixed during processing and packaging. Therefore, it is conceivable that the PA levels of intact leaves 
derived from a single bag of tea are variable. Grinding the leaves and homogenizing the ground 
product will strongly reduce differences in the samples. 
It is of interest to note that the form of the leaves also may have an effect on the type of PAs extracted. 
For example trichodesmine N-oxide was the PA present at the highest concentrations in sunn hemp 
teas extracted from the intact leaves, whereas monocrotaline N-oxide was the most abundant PA in the 
extract from the comminuted leaves. In hot water extracts from intact and comminuted leaves the 
amount of PA N-oxides dominated over that of PA free bases, which is in line with other studies 
However, in the herbal medicines the PAs were present solely in the free-base form. In line with this, 
Griffin et al. (2014) reported that only 6 samples out of a total of 54 herbal medicines contained PA N-
oxides (Griffin et al., 2014).  
Using the total PA levels, we performed a risk assessment for these herbal products taking the use of 
intact tea leaves as well as shorter-than-lifetime exposure scenario’s into account. In addition, we 
analysed the consequences of shorter-than-lifetime use for the risk assessment of herbal teas and PFS 
reported by Bodi et al. (2014), EFSA (2016), and Mulder et al. (2015). 
We previously found that whole lifetime exposure to PA-plant containing herbal teas, including 
borage and coltsfoot teas with consumption of one cup of those teas per day would result in the MOE 
values below 10,000 (Chen et al., 2017). However, results of the present study indicate that when 
considering shorter-than-lifetime exposure the outcome of the risk assessment may be different. When 
use of the herbal teas analysed in the present study was assumed to be limited to 2 weeks a year during 
a lifetime, coltsfoot tea was shown to result in an MOE value higher than 10,000. Considering use 
during 2 (or 6) weeks a year for a lifetime increased the MOE values 26- (or 8.67-) fold, while using 
the BMDL10 for riddelliine of 237 µg/kg bw per day instead of that for lasiocarpine of 70 µg/kg bw 
per day in our previous study, additionally increased the MOE values by a factor of 3.4 (EFSA, 2017).  
We also estimated the number of weeks one could consume the different types of teas and PFS that 
have been analysed before by Bodi et al. (2014), EFSA (2016) and Mulder et al. (2015) during a 75-
year lifetime. The results showed that the regular consumption of herbal teas derived from PA-
producing plants except for eupatorium tea would not raise a concern when consumed for periods 
varying from 40 to 3450 weeks during a lifetime, which is equivalent to 0.5 to 46 weeks/year for 75 
years. Obviously, the outcome strongly depends on the average PA content in these teas and the 
amount of tea consumed. Similarly, the weeks of regular consumption of PFS that would not raise a 
concern varied from 160 to 690 weeks during a life time, equivalent to 2.1 to 9.2 weeks a year during 
75 years.  
It is of interest to note that the values from 2.1 to 9.2 weeks a year obtained for safe consumption of 
PA containing PFS, are all covered by the limit of two weeks established by EMA for the short term 
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exposure and risk. It was noted that hot water extraction from intact leaves resulted in a larger 
variation in the PA levels than observed for comminuted leaves. This may be due to the fact that PA 
levels can vary between the individual intact leaves, which are likely to originate from different plants. 
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The leaves may also originate from different batches of teas, from different locations, which were 
mixed during processing and packaging. Therefore, it is conceivable that the PA levels of intact leaves 
derived from a single bag of tea are variable. Grinding the leaves and homogenizing the ground 
product will strongly reduce differences in the samples. 
It is of interest to note that the form of the leaves also may have an effect on the type of PAs extracted. 
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However, in the herbal medicines the PAs were present solely in the free-base form. In line with this, 
Griffin et al. (2014) reported that only 6 samples out of a total of 54 herbal medicines contained PA N-
oxides (Griffin et al., 2014).  
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intact tea leaves as well as shorter-than-lifetime exposure scenario’s into account. In addition, we 
analysed the consequences of shorter-than-lifetime use for the risk assessment of herbal teas and PFS 
reported by Bodi et al. (2014), EFSA (2016), and Mulder et al. (2015). 
We previously found that whole lifetime exposure to PA-plant containing herbal teas, including 
borage and coltsfoot teas with consumption of one cup of those teas per day would result in the MOE 
values below 10,000 (Chen et al., 2017). However, results of the present study indicate that when 
considering shorter-than-lifetime exposure the outcome of the risk assessment may be different. When 
use of the herbal teas analysed in the present study was assumed to be limited to 2 weeks a year during 
a lifetime, coltsfoot tea was shown to result in an MOE value higher than 10,000. Considering use 
during 2 (or 6) weeks a year for a lifetime increased the MOE values 26- (or 8.67-) fold, while using 
the BMDL10 for riddelliine of 237 µg/kg bw per day instead of that for lasiocarpine of 70 µg/kg bw 
per day in our previous study, additionally increased the MOE values by a factor of 3.4 (EFSA, 2017).  
We also estimated the number of weeks one could consume the different types of teas and PFS that 
have been analysed before by Bodi et al. (2014), EFSA (2016) and Mulder et al. (2015) during a 75-
year lifetime. The results showed that the regular consumption of herbal teas derived from PA-
producing plants except for eupatorium tea would not raise a concern when consumed for periods 
varying from 40 to 3450 weeks during a lifetime, which is equivalent to 0.5 to 46 weeks/year for 75 
years. Obviously, the outcome strongly depends on the average PA content in these teas and the 
amount of tea consumed. Similarly, the weeks of regular consumption of PFS that would not raise a 
concern varied from 160 to 690 weeks during a life time, equivalent to 2.1 to 9.2 weeks a year during 
75 years.  
It is of interest to note that the values from 2.1 to 9.2 weeks a year obtained for safe consumption of 
PA containing PFS, are all covered by the limit of two weeks established by EMA for the short term 
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use of such herbal products in self-medication (EMA, 2007), but not fully covered by the 6 weeks 
defined as short term exposure in the German and Netherlands regulation (Bundesgesundheitsamt, 
1992; WKB, 2001). This regulation however also defines a maximum daily use of 1 g/day. This 
means that a yearly 6-weeks intake of 1 g/day by a 70 kg person would result in an MOE of about 
144,000, and thus not raise a concern. In fact, an intake of 1 g/day during a lifetime by a 70 kg 
person would result in an MOE of 16,600, which is still a sufficient safety margin. It is of interest to 
note that the PA content in the herbal products evaluated in the present study can result in intakes far 
beyond the levels specified in regulations for PAs in botanicals and botanical preparations. As outlined 
above this includes the regulations in Germany and the Netherlands, where the government has 
established maximum limits for daily intake of 1 µg/day (for short term use up to 6 weeks) and 0.1 
µg/day (for long term use) and a maximum PA content for herbal supplements of 1 µg/kg or 1 µg/L 
(Bundesgesundheitsamt, 1992; WKB, 2001). In Austria and Belgium, this regulation is even more 
strict, with a “zero tolerance” approach towards PAs (Bundesgesetzblatt, 1994; Koninklijk besluit, 
1997). So far there are no maximum limits established in the EU for daily PA intake (other than what 
is specified for specific medicinal herbal products). The EU is currently considering maximum limits 
(ML) for PAs in teas and supplements in general. These maximum limits will likely be based on the 
evaluation made by EFSA regarding the occurrence of PAs in herbal teas and PFS, and the 
consumption of these products by different age and population groups (EFSA, 2016; EFSA, 2017). 
Depending on the level of safety that is pursued and the evaluation on what is reasonably achievable in 
lowering the contamination levels in these products, it is not unlikely that the maximum limits will be 
set in the range of 100 to 500 µg/kg, with the possibility that different MLs may be set for different 
(types of) products. On the other hand, in other countries such as China, there are no specific 
regulations for the maximum limits of daily PA intake (CP, 2010). This situation may raise a possible 
concern for human health especially when these preparations would be used for longer periods of time.  
In the current study we focused primarily on the individual MOEs for a set of herbal teas and 
medicines, assuming that there is no additional exposure to PAs from any other source. One could 
argue that our approach for herbal teas and PFS could be prone to underestimate the risks in terms of 
the amounts of PAs consumed, since individuals may drink different types of herbal teas at the same 
time with addition of honey, a product which contains PAs (EFSA, 2011). Importantly, according to 
the EFSA risk assessment report, there are consumer groups that have a relatively high exposure to 
PAs due to consumption of contaminated teas and honey (EFSA, 2017). It is conceivable that these 
consumers may be at greater risk in case that they would also use the PA-containing herbal products 
such as PFS. A more complex scenario could be developed that considers short exposure to 
combinations of herbal teas, PFS, or other herbal products which are derived from PA-producing 
plants. More detailed information on consumption habits of herbal teas by the average population and 
by the 95th percentile population (heavy consumers) should be collected to further evaluate the 
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influence of shorter-than-lifetime exposure scenario’s. However, at the moment data regarding 
combined consumption of different types of herbal preparations are mostly lacking, which makes the 
related risk assessment difficult to perform. Such data await to be collected and will contribute to risk 
assessment for the current exposure to PAs. 
Taken together the results of the present study illustrate the need for development of a generally 
accepted method for taking shorter-than-lifetime exposure into account when analysing the risks of 
botanicals and botanical preparations containing compounds that can be genotoxic and carcinogenic. 
Using Haber’s rule to correct for shorter periods of use may prevent from an overestimation of the 
actual risk to human health. The application of Haber’s rule is based on the assumption that the tumour 
incidence and carcinogenic processes induced by carcinogens have a linear relationship with the 
cumulative dose (Crump et al., 1976). At present there is only limited data available that supports such 
a linear dose-response relationship for tumour formation. Currently, there is no valid method on how 
to take a shorter-than-lifetime exposure into account in an MOE based risk assessment. Nevertheless 
using Haber’s rule gives a reasonable first approach to assess the risks related to shorter-than-lifetime 
exposure. It is obvious that future developments in risk assessment should consider how to further 
advance this issue of taking shorter-than-lifetime exposure into account when applying the MOE 
approach in risk assessment of compounds that are both genotoxic and carcinogenic. 
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Abstract 
Lasiocarpine and riddelliine are pyrrolizidine alkaloids (PAs) present in food and able to cause liver 
toxicity. The aim of this study was to investigate whether physiologically based kinetic (PBK) 
modelling-facilitated reverse dosimetry can adequately translate in vitro concentration-response curves 
for toxicity of lasiocarpine and riddelliine to in vivo liver toxicity data for the rat. To this purpose, 
PBK models were developed for lasiocarpine and riddelliine, and predicted blood concentrations were 
compared to available literature data to evaluate the models. Concentration-response curves obtained 
from in vitro cytotoxicity assays in primary rat hepatocytes were converted to in vivo dose-response 
curves from which points of departure (PoDs) were derived and that were compared to available 
literature data on in vivo liver toxicity. The results showed that the predicted PoDs fall well within the 
range of PoDs derived from available in vivo toxicity data. To conclude, this study shows the proof-
of-principle for a method to predict in vivo liver toxicity for PAs by an alternative testing strategy 
integrating in vitro cytotoxicity assays with in silico PBK modelling-facilitated reverse dosimetry. The 
approach may facilitate prediction of acute liver toxicity for the large number of PAs for which in vivo 
toxicity data are lacking.  
111 
 
Introduction 
Pyrrolizidine alkaloids (PAs) are plant secondary metabolites (Fu et al., 2004; Mattocks, 1986) 
naturally occurring in several food items (EFSA, 2013; Wiedenfeld, 2011). To date, more than 660 
PAs and PA N-oxides have been identified from more than 6 000 plants (Wiedenfeld, 2013; 
Wiedenfeld and Edgar, 2011). PAs are a class of heterocyclic chemicals, and most PAs are derived 
from esters of basic alcohols, known as the necine bases. Especially the PAs with an 1,2-unsaturated 
necine base tend to be toxic (Mori et al., 1985). Of the four common necine bases encountered in PAs, 
including platynecine, retronecine, heliotridine and otonecine, especially the later three give rise to 
1,2-unsaturated PAs that have been shown to be hepatotoxic, genotoxic and carcinogenic in rats and 
other experimental rodents (Chan, 1993; Chan et al., 2003; Hirono et al., 1979; Hirono et al., 1976; 
Hirono et al., 1977; Kuhara et al., 1980; NTP, 1978; Schoental, 1970; Shumaker et al., 1976). Human 
poisonings caused by intake of PA-containing plants have been reported in several countries (Kumana 
et al., 1985; Mohabbat et al., 1976; Prakash et al., 1999; Roulet et al., 1988; Sperl et al., 1995; Tandon 
et al., 1976). Due to the carcinogenicity of PAs, the International Agency for Research on Cancer 
(IARC) classified lasiocarpine and riddelliine in Group 2B, possibly carcinogenic to humans (IARC, 
1976, 2002). In addition, the European Food Safety Authority (EFSA) recently stated that 1,2-
unsaturated PAs may act as carcinogens in humans based on the actual knowledge of metabolism, 
activation, DNA adduct-formation, genotoxicity and carcinogenicity (EFSA, 2011). 
PAs need metabolic activation to form pyrrolic metabolites to exhibit their hepatotoxicity and 
genotoxicity (Chan et al., 2003; Chou et al., 2003; Fu et al., 2002, 2004; Lin et al., 2000; Mattocks, 
1986; Miranda et al., 1991; Stegelmeier et al., 1999; Yan et al., 2002). In general, there are three 
principal metabolic pathways for the metabolism of 1,2-unsaturated PAs such as lasiocarpine (Figure 
1). In the first pathway, the necine base is formed by hydrolysis of the ester group. For the second 
pathway, the necine base is N-oxidised to generate pyrrolizidine alkaloid N-oxide. In addition, the 
necine base can also be oxidised to form the corresponding reactive pyrrolic ester metabolite (Fu, 2016; 
Li et al., 2011). The generated pyrrolic ester can immediately bind to DNA and proteins in the liver 
resulting in DNA cross-links, DNA-protein cross-links, protein adducts and DNA adducts, that may 
induce hepatotoxicity and liver cancer (Bovee et al., 2015; Lin et al., 1998, 2000; Lin et al., 2011; 
White, 1976; Yan and Huxtable, 1995a, b). 
In spite of the large number of PAs known at present, toxicity data on only a limited number of PAs 
are available. Among the 1,2-unsaturated PAs, lasiocarpine and riddelliine have been tested in two 
year rodent carcinogenicity bioassays by the National Toxicology Program (NTP), and were shown to 
cause liver carcinogenicity (NTP, 1978, 2003). However, of all these PAs, data on liver toxicity are 
only available for lasiocarpine (Dalefield et al., 2016; Jago, 1970; Nolan et al., 1966).  
Given the large number of PAs and the limited number of PAs for which actual in vivo data on liver
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toxicity and carcinogenicity are available, it is of importance to investigate whether information on 
relative potency for hepatotoxicity of the different PAs can be obtained from alternative testing 
strategies reducing the need for a large number of animal experiments. In our previous work, we have 
shown that data on in vivo toxicity can be adequately predicted by translation of in vitro 
concentration-response curves for toxicity to in vivo dose-response curves for toxicity using so-called 
physiologically based kinetic (PBK) modelling-facilitated reverse dosimetry (Abdullah et al., 2016; Li 
et al., 2017; Louisse et al., 2015; Louisse et al., 2010; Strikwold et al., 2017). In this way in vivo dose-
response curves for developmental toxicity and kidney toxicity were defined (Abdullah et al., 2016; Li 
et al., 2017; Louisse et al., 2015; Louisse et al., 2010; Strikwold et al., 2017). The aim of the present 
study was to investigate whether PBK modelling-facilitated reverse dosimetry can adequately translate 
in vitro concentration-response curves for toxicity of PAs, to in vivo dose-response curves for liver 
toxicity for the rat. Riddelliine and lasiocarpine were used as model PAs because for these two PAs in 
vivo data on kinetics (Williams et al., 2002) and liver toxicity (Dalefield et al., 2016; Jago, 1970; 
Nolan et al., 1966), respectively, are available enabling evaluation of the PBK models and the toxicity 
predictions made. 
To achieve the aim of this study, rat PBK models were developed for lasiocarpine and riddelliine, and 
concentration-response curves obtained from in vitro cytotoxicity studies with rat hepatocytes were 
translated into in vivo dose-response curves by using PBK modelling-facilitated reverse dosimetry 
from which PoDs for evaluation liver toxicity induced by lasiocarpine and riddelliine could be derived. 
For evaluating the performance of the PBK models, PBK model-predicted blood concentrations were 
compared with in vivo kinetic data. Because of the lack of any in vivo kinetic data of lasiocarpine, we 
also developed a PBK model for riddelliine in rat and mouse to enable examination of model 
performance based on available blood concentration values in the literature for this related PA. To 
evaluate the prediction of liver toxicity, PoDs derived from predicted liver toxicity induced by 
lasiocarpine were compared with available in vivo liver toxicity data of this PA. 
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Fig. 1 The proposed pathways for metabolism of lasiocarpine, also relevant for riddelliine (Derived from Bovee 
et al., 2015; Fu, 2016; Li et al., 2011; Lin et al., 2011). 
Materials and Methods 
Chemicals 
Lasiocarpine (> 97 %) was purchased from PhytoLab (PhytoLab GmbH & Co. KG, Germany), and 
riddelliine (90 %) was kindly provided by RIKILT Wageningen University & Research (Wageningen, 
The Netherlands). The cryopreserved rat (Sprague-Dawley) hepatocytes, the thawing/plating 
supplement pack, the cell maintenance supplement pack, fetal bovine serum and Williams E Medium 
(WEM, A1217601) were purchased from ThermoFisher (Naarden, The Netherlands). Trypsin-EDTA 
was purchased from Gibco (Paisley, Scotland, UK). Dimethyl sulfoxide (DMSO) was obtained from 
Acros Organics (Geel, Belgium). Acetonitrile (UPLC/MS grade) was obtained from Biosolve 
(Valkenswaard, The Netherlands). Potassium hydrogen phosphate (K2HPO4) and trifluoroacetic acid 
(TFA) was purchased from Merck (Darmstadt, Germany). The reduced form of nicotinamide adenine 
dinucleotide phosphate (NADPH) was obtained from Sigma-Aldrich (Zwijndrecht, The Netherlands). 
Pooled liver microsomes from male Sprague-Dawley rats were obtained from Corning (Amsterdam, 
The Netherlands) and pooled liver microsomes from male CD-1 mice were purchased from Sigma 
Aldrich (Zwijndrecht, The Netherlands). Pooled intestinal microsomes from male Sprague-Dawley  
rats and male CD-1 mice were purchased from Xenotech (Lenexa, USA). 
General outline for PBK modelling-facilitated reverse dosimetry approach 
The combined in vitro PBK modelling approach to predict in vivo dose-response curves and a PoD for 
risk assessment using in vitro cytotoxicity data consisted of the following steps: (1) establishment 
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of in vitro concentration-response curves for the toxicity of lasiocarpine and riddelliine in rat 
hepatocytes, (2) development of PBK models describing in vivo kinetics of lasiocarpine and 
riddelliine, using kinetic parameters defined based on in vitro assays using tissue fractions of rat and 
mouse, (3) evaluation of the PBK models against available literature data on blood levels and liver 
toxicity upon oral dosing of the PAs, (4) translation of the in vitro concentration-response curves for 
acute liver toxicity into in vivo dose-response curves for acute liver toxicity in rat using the PBK 
models, (5) BMD analysis on the predicted in vivo dose-response data to obtain a PoD for risk 
assessment, and (6) evaluation of the predicted PoD against available literature data. 
In vitro liver toxicity 
Rat hepatocytes were used to define the in vitro concentration-response curves for cytotoxicity. To this 
end rat hepatocytes were seeded at concentrations of 5×105 cells/ml into 96-well plates according to 
the supplier’s protocol, and cultured in plating medium for 4-6 h. After incubation, medium was 
replaced by exposure medium (serum free), containing different concentrations of lasiocarpine or 
riddelliine ranging from 0 to 300 µM (final concentrations), added from 200 times concentrated stock 
solutions in DMSO. After 23 hours treatment, 10 µl MTT (5 mg/mL) was added and cells were 
incubated for an additional 1h. Cells were lysed and the MTT formazan crystals formed were 
dissolved by addition of 100 µl DMSO, and the absorbance was measured at 562 nm and 620 nm 
using a microplate reader (SpectraMax M2, USA). Relative cell viability (%) was calculated as (mean 
absorbance of sample/mean absorbance of vehicle control) × 100 %.  Each concentration was tested in 
three replicates, and three independent experiments with 3 different batches of hepatocytes were 
carried out. 
Determination of fraction unbound (fub) of lasiocarpine and riddelliine in rat serum 
Since it is assumed that the toxicity is caused by the fraction unbound (fub) of the chemical and since 
the fub in vitro and in vivo differ, a correction for the differences in fub needs to be made. The fub of 
lasiocarpine and riddelliine in rat serum were determined by using rapid equilibrium dialysis (RED) 
(Waters et al., 2008). The RED device insert has two chambers, a blood and a buffer chamber. Briefly, 
a sample of 300 μl of spiked rat serum containing 5 μM of lasiocarpine or 50 μM of riddelliine (final 
concentration, 0.5 % DMSO) were added to the blood chamber, while 500 μl PBS (containing 100 
mM sodium phosphate and 150 mM sodium chloride) were added to the buffer chamber. The device 
was sealed with tape and incubated at 37 °C on a shaker at 250 rpm. After incubation for 5 hours the 
system reaches equilibrium (van Liempd et al., 2011) and 25 µL of post-dialysis samples were 
collected from the blood and buffer chambers in separate tubes. Simultaneously, 25 µL of 
corresponding buffer was added to the sample taken from the blood chamber and the same volume of 
corresponding rat serum was added to the sample taken from the buffer chamber. Then, 300 µL cold 
precipitation buffer (90/10 acetonitrile/water) was added to both samples to precipitate the proteins
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and release the compound. The samples were put on ice for 30 min and subsequently centrifuged for 
15 min at 15 000 g. Then, the supernatants were collected for UPLC analysis. By determining the 
compound concentration in each chamber, the fub can be calculated with the following equation: fub = 
(concentration in buffer chamber) / (concentration in blood chamber) (van Liempd et al., 2011; Waters 
et al., 2008). Then the effect concentration of lasiocarpine (LC) or riddelliine (RD) in rat serum 
(CLC/RD, rat serum) used for reverse dosimetry was corrected by the following equation: CLC/RD, rat serum = 
Cub, in vitro / fub, rat serum , where Cub, in vitro is the unbound concentration of lasiocarpine or riddelliine in 
the in vitro culture medium. Since the exposure medium for the rat hepatocytes was serum free, the 
concentration of lasiocarpine or riddelliine in the in vitro cytotoxicity assay was considered to be equal 
to the unbound concentration in rat serum. 
In vitro incubations of lasiocarpine or riddelliine to derive the kinetic parameters for the 
PBK model 
Microsomal incubations were performed with rat tissue fractions to determine kinetic parameter values 
for lasiocarpine and riddelliine clearance, using a substrate depletion approach. The incubation 
mixtures for lasiocarpine contained, in a final volume of 100 µl (final concentrations): 0.1 M K2HPO4  
(pH 7.4), pooled rat liver or intestinal microsomes (0.04 mg protein/ml), and lasiocarpine ranging from 
0 to 200 µM (added from 100 times concentrated stock solutions in DMSO). Under these conditions 
PA conversion was linear with time and the amount of protein added (data not shown). For riddelliine, 
the incubation mixtures contained in a final volume of 100 µl (final concentrations): 0.1 M K2HPO4  
(pH 7.4), pooled rat liver or intestinal microsomes (0.5 mg protein/ml), and riddelliine ranging from 0 
to 400 µM (added from 100 times concentrated stock solutions in DMSO). Under these conditions PA 
conversion was linear with time and the amount of protein added (data not shown). After 5 min of pre-
incubation in a shaking water bath at 37 ºC, the reactions were started by the addition of 2 mM 
NADPH. The reactions were carried out for 30 min with liver microsomes and 2 h with intestinal 
microsomes. Control incubations were performed without NADPH. The incubations were terminated 
by the addition of 25 µl ice-cold acetonitrile followed by centrifugation at 16 000 g for 5 min before 
analyse of the supernatant by UPLC (Waters Acquity). The incubation conditions for metabolism of 
riddelliine by pooled mouse liver and intestinal microsomes were performed in a similar way. The 
clearance of lasiocarpine and riddelline in lung or kidney was determined using either lung or kidney 
microsomes of rat or mouse, by following the same incubation procedure for intestinal microsomes 
using final microsomal concentrations of 0.04 mg/mL for rat and 0.5 mg/mL for mouse.  
From each incubation, 3.5 µl of supernatant were injected into the UPLC (Waters Acquity) equipped 
with a Waters BEH C18 1.7 mm column, 2.1×50 mm (Waters, Ireland). A gradient was made with 
ultra-pure water containing 0.1% (v/v) TFA as solvent A and 100 % acetonitrile as solvent B. The 
flow rate was set to 0.6 ml/min. The starting condition was 100:0 (A:B), changing to 50:50 from 0 to 2 
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of in vitro concentration-response curves for the toxicity of lasiocarpine and riddelliine in rat 
hepatocytes, (2) development of PBK models describing in vivo kinetics of lasiocarpine and 
riddelliine, using kinetic parameters defined based on in vitro assays using tissue fractions of rat and 
mouse, (3) evaluation of the PBK models against available literature data on blood levels and liver 
toxicity upon oral dosing of the PAs, (4) translation of the in vitro concentration-response curves for 
acute liver toxicity into in vivo dose-response curves for acute liver toxicity in rat using the PBK 
models, (5) BMD analysis on the predicted in vivo dose-response data to obtain a PoD for risk 
assessment, and (6) evaluation of the predicted PoD against available literature data. 
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absorbance of sample/mean absorbance of vehicle control) × 100 %.  Each concentration was tested in 
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carried out. 
Determination of fraction unbound (fub) of lasiocarpine and riddelliine in rat serum 
Since it is assumed that the toxicity is caused by the fraction unbound (fub) of the chemical and since 
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mM sodium phosphate and 150 mM sodium chloride) were added to the buffer chamber. The device 
was sealed with tape and incubated at 37 °C on a shaker at 250 rpm. After incubation for 5 hours the 
system reaches equilibrium (van Liempd et al., 2011) and 25 µL of post-dialysis samples were 
collected from the blood and buffer chambers in separate tubes. Simultaneously, 25 µL of 
corresponding buffer was added to the sample taken from the blood chamber and the same volume of 
corresponding rat serum was added to the sample taken from the buffer chamber. Then, 300 µL cold 
precipitation buffer (90/10 acetonitrile/water) was added to both samples to precipitate the proteins
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(pH 7.4), pooled rat liver or intestinal microsomes (0.04 mg protein/ml), and lasiocarpine ranging from 
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flow rate was set to 0.6 ml/min. The starting condition was 100:0 (A:B), changing to 50:50 from 0 to 2 
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min, then to 0:100 from 2 to 5 min, then to 100:0 from 5 to 8 min. Detection was carried out with a 
photodiode array detector (Waters, Milford, MA, USA) at a wavelength of 220 nm. The amount of 
substrate depletion of lasiocarpine or riddelliine was quantified as the amount detected in the control 
incubations performed without the respective cofactor NADPH minus the amount detected in the 
incubations with NADPH using a calibration curve made with available reference compounds. The 
data for the rate of depletion of lasiocarpine and riddelliine with increasing lasiocarpine or riddelliine 
concentrations were fitted to the standard Michaelis-Menten equation:  
𝑉𝑉 = 𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉 ∗ [𝑆𝑆]/(𝐾𝐾𝑉𝑉 + [𝑆𝑆]) 
with [S] being the substrate concentration, Vmax being the apparent maximum velocity, and Km being 
the apparent Michaelis-Menten constant. This was done with GraphPad Prism, 5.0 software (San 
Diego, CA, USA). 
PBK models for rat and mouse 
A schematic diagram of the structure of the PBK models developed for rat and mouse is shown in Fig. 
2. The models include separate compartments for liver and intestine (as metabolizing compartments), 
fat, arterial blood, venous blood, rapidly perfused and slowly perfused tissue. Lasiocarpine and 
riddelliine were assumed to be taken up from the gastrointestinal tract following first order kinetics 
and absorbed directly by the intestine. No absorption rate constants (Ka) are available for lasiocarpine 
and riddelliine, but for the PA adonifoline, a Ka of 0.6/h has been reported (Wang et al., 2011). The 
Ka of lasiocarpine and riddelliine was estimated based on two approaches. In the first approach, the 
Ka was estimated by relating the Ka values of the PAs to the permeability coefficients (Papp values) of 
the PAs as predicted by Qikprop (Schrödinger, trial version, Germany). The Papp values of adonifoline, 
lasciocarpine and riddelliine as derived from Qikprop amount to 241, 542 and 107 nm/s for 
adonifoline, lasiocarpine and riddelliine, respectively. The Ka values for lasioicarpine and riddelliine 
were calculated relative to adonifoline as the standard compound (Papp LC/RD  / Ka LC/RD  = Papp  adonifoline / 
0.6 ). Based on the Papp for lasicoarpine and riddelliine of 542 nm/s and 107 nm/s, Ka values for 
lasiocarpine and riddelliine were calculated to amount to 1.35/h and 0.27/h, respectively. Ka values for 
lasiocarpjne and riddelliine were also estimated based on Papp values obtained from the correlation 
between Caco-2 permeation and molecular properties described by Hou et al. (Hou et al., 2004) 
reflected by the equation log Papp = -5.469 + 0.236 log P. The log P values for lasiocarpine, riddelliine 
and adonifoline were obtained using the ChemBio 3D 2010 software (CambrigeSoft, USA) and 
amounted to 0.48, -0.26 and -1.49, respectively. Based on these log P values, the corresponding log 
Papp values were calculated to be -5.35 for lasiocarpine, -5.53 for riddelliine and -5.82 for adonifoline. 
Then, the relative Ka values for lasiocarpine or riddelliine were calculated relative to adonifoline as 
the standard compound as described above (log Papp  LC/RD / Ka LC/RD  = log Papp adonifoline / 0.6). 
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The Ka values thus obtained for lasiocarpine and riddelliine were 1.75/h and 1.17/h, respectively. In 
this study, we calculated the average Ka values for lasiocarpine and riddelliine from those two 
methods, which amounted to 1.55/h and 0.72/h, respectively. Physiological parameter values for the 
model, such as for tissue volumes and blood flows, were obtained from literature (Brown et al., 1997). 
The tissue/blood partition coefficients applied in the rat model were calculated based on the method 
reported by DeJongh et al. (DeJongh et al., 1997). All physiological parameters and partition 
coefficients used in the rat PBK models are presented in Table 1. For evaluation of the generic PBK 
models developed in the present study, we also developed a mouse PBK model for riddelliine, because 
for riddelliine also kinetic data in mice were available for model evaluation (Williams et al., 2002). 
The physiological parameters for the mouse PBK model were taken from literature (Brown et al., 1997) 
and the tissue/blood partition coefficients were assumed to be the same as in rat. These values used in 
this mouse PBK model are also presented in Table 1. On the basis of data obtained in the in vitro 
incubations with liver and intestinal fractions with lasiocarpine and riddelline, the conversion of 
lasiocarpine and riddelliine were described in the liver and intestine. The Vmax values for conversion of 
lasiocarpine or riddelliine by rat or mouse liver and intestinal microsomal fractions were scaled 
accordingly using an estimated microsomal protein yield of 35 mg/g liver (Medinsky et al., 1994) and 
20.6 mg/g small intestine (Cubitt et al., 2009), respectively as scaling factors. The in vivo Km values 
were assumed to equal the in vitro Km values.  
In the present study it was assumed that clearance of the PAs fully depends on their metabolic 
conversion and that excretion of the parent compound in its unmodified form does not add 
significantly to the systemic clearance. This assumption is supported by data reported by Bull et al. 
(1968) who delivered lasiocarpine to rats through ip injection, after which only 1-1.5 % of total 
lasiocarpine was found in unmodified form in the urine (Bull et al., 1968), so excretion of the parent 
compound was not included in the current PBK model. The set of differential equations describing the 
mass balance equations can be found in the supplementary data. The PBK model equations were 
coded and numerically integrated in Berkeley Madonna (version 8.3.18, UC Berkeley, CA, USA) 
using Rosenbrock's algorithms for solving stiff systems. 
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A schematic diagram of the structure of the PBK models developed for rat and mouse is shown in Fig. 
2. The models include separate compartments for liver and intestine (as metabolizing compartments), 
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amounted to 0.48, -0.26 and -1.49, respectively. Based on these log P values, the corresponding log 
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Then, the relative Ka values for lasiocarpine or riddelliine were calculated relative to adonifoline as 
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The tissue/blood partition coefficients applied in the rat model were calculated based on the method 
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this mouse PBK model are also presented in Table 1. On the basis of data obtained in the in vitro 
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Fig. 2 Schematic diagram of the generic PBK model for lasiocarpine and riddelliine in rat and mouse. 
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Table 1 Parameters used in the rat or mouse PBK models for lasiocarpine and riddelliine. 
Parameters                Values 
 Rat                         Mouse 
Physiological parametersa  
  Body weight (kg) 0.25                        0.0025 
Tissue volumes (% body weight)  
  Liver 3.4                          5.5 
  Fat 7.0                          10 
  Small intestine 1.4                          2.5 
  Richly perfused tissue 4.2                          1 
  Slowly perfused tissue 75                           72 
  Blood 7.4                          4.9 
  Cardiac output ( L · h-1 · kg bw-0.74) 15.0                        15.0 
Blood flow to tissue (% cardiac output)  
  Liver 13.2                        6.7 
  Fat 7                             9 
  Small intestine 11.8                        18.3 
  Richly perfused tissue 51                           51 
  Slowly perfused tissue 17                           15 
Physicochemical parametersb  
Tissue/blood partition coefficients  
  Lasiocarpine  
    Liver 88           88 
    Fat 244                         244 
    Small intestine 88                           88 
    Richly perfused tissue 88                           88 
    Slowly perfused tissue 48                           48 
  Riddelliine  
    Liver 77                          77 
    Fat 44                          44 
    Small intestine 77                          77 
    Richly perfused tissue 77                          77 
    Slowly perfused tissue 43                          43 
a (Brown et al., 1997) 
b Derived using the approach described by DeJongh et al. (1997) 
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PBK model evaluation  
Normalized sensitivity coefficients (SC) were determined to identify parameters that largely influence 
the prediction of the maximal blood concentrations (Cmax) in liver blood by the PBK model, using the 
equation: 
 SC = ((C′ − C)/(𝑃𝑃′ − 𝑃𝑃)) ∗ (𝑃𝑃/𝐶𝐶) 
where P and Pʹ are the initial and modified parameter values respectively, and C and Cʹ are the initial 
and modified values of the model output resulting from an increase in parameter value, respectively 
(Evans and Andersen, 2000). A 5% increase in parameter value was chosen to analyse the effect of a 
change in a parameter. The sensitivity analysis was conducted at an oral dose of 0.008 and 0.144 
µg/kg bw/day PAs representing the lowest and the highest daily intake previously estimated to 
originate from use of herbal teas (BfR, 2013). Each parameter was analysed individually, keeping the 
other parameters to their initial values.  
Because of the lack of available in vivo kinetic data for lasiocarpine, to evaluate the performance of 
the PBK model developed in the present study, the predicted riddelliine blood concentrations obtained 
with the rat and mouse models were compared with blood concentrations from in vivo kinetic studies 
in rat and mouse reported in the literature (Williams et al., 2002).  
Translation of the in vitro concentration-response curves to in vivo dose-response curves 
Based on the reverse dosimetry approach, the in vitro effect concentrations of lasiocarpine and 
riddelliine inducing cytotoxicity were considered as surrogate in vivo (free) concentrations in blood 
that could result in adverse effect on the liver. In the present study, each concentration used in the 
cytotoxicity assay, corrected by fub (determined as described above), was set equal to the maximum 
concentration (Cmax) of lasiocarpine or riddelliine in the liver blood and the developed PBK models 
were used to determine the oral dose required that results in this concentration. 
BMD analysis of in vitro concentration-response data and of predicted in vivo dose-
response data 
The continue model in PROAST programme (version 38.9, The Dutch National Institute for Public 
Health and the Environment, The Netherlands) was used to analyse the predicted in vivo dose-
response data and to obtain the BMDL5-BMDU5  (lower/upper limit of the 90 % confidence interval of 
the benchmark dose that gives a 5 % response) values for liver toxicity. The aim of the use of continue 
model was to determine BMDU5 value. The goodness of fit application of the models was used to 
judge if the model can be accepted, using the P value with P > 0.05. Only the models which met the 
requirements for acceptance of the model fit were considered for the determination of BMDL5-
BMDU5  values. The same analysis was performed to predict in vivo dose-response curves derived 
upon extrapolation of the concentration-response curves for in vitro cytotoxicity derived from the 
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literature (Hayes et al., 1984). 
Evaluation of the combined in vitro-PBK modelling approach 
To support the validity and use of the in vitro-in silico approach to obtain a PoD for risk assessment, 
the predicted BMDL5-BMDU5 values of lasiocarpine for rat were compared with PoDs derived from in 
vivo rat acute liver toxicity data from the literature (Dalefield et al., 2016; Jago, 1970; Nolan et al., 
1966). For comparison of the predicted in vivo toxicity data to the available in vivo toxicity data form 
the literature it was assumed that the BMDL5-BMDU5 from such work, could be a reasonable 
approximation of an in vivo NOAEL-LOAEL (No/Lowest observed adverse effect level) value.  
Results 
In vitro cytotoxicity 
Figure 3 shows the concentration-response curves for the cytotoxicity of lasiocarpine or riddelliine in 
incubations with rat hepatocytes. The IC50 of lasiocarpine and riddelliine derived from these curves 
amounted to 10.9 µM and 6.3 µM, respectively as shown in Table 2. The in vitro concentration-
response curve of lasiocarpine in the present study was comparable with in vitro concentration-
response curves previously reported by Hayes et al. (Hayes et al., 1984) (Figure 3). Table 2 shows the 
IC50 values obtained from the concentration-response curves in Figure 3.  
 
 
Fig. 3 Concentration-response curves for primary rat hepatocytes treated with increasing concentrations of 
lasiocarpine (red circles) and riddelliine (black squares) for 24 hours (mean ± SD) and as reported by Hayes et al. 
(1984) for lasiocarpine. 
121
C
ha
pt
er
 4
120 
 
PBK model evaluation  
Normalized sensitivity coefficients (SC) were determined to identify parameters that largely influence 
the prediction of the maximal blood concentrations (Cmax) in liver blood by the PBK model, using the 
equation: 
 SC = ((C′ − C)/(𝑃𝑃′ − 𝑃𝑃)) ∗ (𝑃𝑃/𝐶𝐶) 
where P and Pʹ are the initial and modified parameter values respectively, and C and Cʹ are the initial 
and modified values of the model output resulting from an increase in parameter value, respectively 
(Evans and Andersen, 2000). A 5% increase in parameter value was chosen to analyse the effect of a 
change in a parameter. The sensitivity analysis was conducted at an oral dose of 0.008 and 0.144 
µg/kg bw/day PAs representing the lowest and the highest daily intake previously estimated to 
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literature (Hayes et al., 1984). 
Evaluation of the combined in vitro-PBK modelling approach 
To support the validity and use of the in vitro-in silico approach to obtain a PoD for risk assessment, 
the predicted BMDL5-BMDU5 values of lasiocarpine for rat were compared with PoDs derived from in 
vivo rat acute liver toxicity data from the literature (Dalefield et al., 2016; Jago, 1970; Nolan et al., 
1966). For comparison of the predicted in vivo toxicity data to the available in vivo toxicity data form 
the literature it was assumed that the BMDL5-BMDU5 from such work, could be a reasonable 
approximation of an in vivo NOAEL-LOAEL (No/Lowest observed adverse effect level) value.  
Results 
In vitro cytotoxicity 
Figure 3 shows the concentration-response curves for the cytotoxicity of lasiocarpine or riddelliine in 
incubations with rat hepatocytes. The IC50 of lasiocarpine and riddelliine derived from these curves 
amounted to 10.9 µM and 6.3 µM, respectively as shown in Table 2. The in vitro concentration-
response curve of lasiocarpine in the present study was comparable with in vitro concentration-
response curves previously reported by Hayes et al. (Hayes et al., 1984) (Figure 3). Table 2 shows the 
IC50 values obtained from the concentration-response curves in Figure 3.  
 
 
Fig. 3 Concentration-response curves for primary rat hepatocytes treated with increasing concentrations of 
lasiocarpine (red circles) and riddelliine (black squares) for 24 hours (mean ± SD) and as reported by Hayes et al. 
(1984) for lasiocarpine. 
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Table 2 IC50 values derived from the concentration-response curves presented in Figure 3. 
Compound IC50 ± SD (µM) Studies 
Lasiocarpine 
10.9 ± 1.6 Present study 
19.5 ± 4.6 (Hayes et al., 1984) 
  
Riddelliine 6.3 ± 0.9 Present study 
 
In vitro kinetic data 
Figure 4a and b shows the rate of depletion of the PAs in incubations with liver and intestinal 
microsomes with increasing concentrations of lasiocarpine or riddelliine. The results reveal that 
lasiocarpine and riddelliine are converted in a concentration-dependent manner. For each reaction, 
metabolism followed Michaelis-Menten kinetics. The apparent Vmax  and Km values and the (scaled) 
catalytic efficiency (Vmax/Km) for the depletion of lasiocarpine and riddelliine derived from these 
curves are presented in Table 3. The scaled in vivo catalytic efficiency (calculated as Vmax/Km) of liver 
for conversion of lasiocarpine and riddelliine by rat was 6.3 times and 107.8 times higher than the 
catalytic efficiency for conversion by intestine, respectively. The total scaled in vivo catalytic 
efficiency (sum of liver and intestine) for depletion of lasiocarpine was 11 times higher than that for 
riddelliine. The results reveal that in rat, lasiocarpine and riddelliine are especially converted in the 
liver, and that intestinal conversion contributes only to a minor extent.  
The rate of depletion of riddelliine in incubations with mouse tissue samples and increasing 
concentrations of riddelliine is shown in Figure 4c. The (scaled) catalytic efficiencies (Vmax/Km) for the 
depletion of riddelliine in mouse tissue are also shown in Table 3. For mouse tissues, the scaled 
catalytic efficiency of the liver for conversion of riddelliine was 9.6 times higher than that of the 
intestine. The total catalytic efficiency for metabolic conversion of riddelliine by rat and mouse liver 
and intestine was comparable, being only 1.8 times higher in rat than in mouse. Incubations with lung 
and kidney rat and mouse tissue samples did not result in detectable conversion (data not shown). 
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Fig. 4 Concentration-dependent rate of lasiocarpine (a) and riddelliine (b and c) depletion in incubations with rat 
liver (filled circle) and intestinal (filled square) microsomes (a and b) and mouse liver (filled circle) and 
intestinal (filled square) microsomes (c). Results represent data of three independent experiments. 
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Table 3 Kinetic parameters for lasiocarpine and riddelliine depletion by pooled rat tissue fractions, and for 
riddelliine depletion by pooled mouse tissue fractions. 
Species 
Organ 
 
Vmax  
(nmol/min/mg 
microsomal 
protein) 
Km(µM) Catalytic 
efficiency b 
(mL/min/mg 
microsomal 
protein) 
Scaled Vmaxa  
(nmol/min/g 
tissue) 
Scaled catalytic 
efficiencyb 
(mL/min/g 
tissue) 
Rat      
Lasiocarpine      
Liver 5.3 ± 0.6 19.5 ± 7.7 0.27 185.5 9.5 
Intestine 1.7 ± 0.1 23.4 ± 6.3 0.07 35 1.5 
Riddelliine      
Liver 2.1 ± 0.07 75.7 ± 7.4 0.03 73.5 0.97 
Intestine 0.1 ± 0.02 221.0 ± 71.2 0.0005 2.06 0.009 
Mouse       
Riddelliine      
Liver 1.4 ± 0.3 101.3 ± 49.9 0.01 49 0.48 
Intestine 1.6 ± 0.5 695.8 ± 342.7 0.002 33 0.05 
a Scaled Vmax calculated from the in vitro Vmax based on a microsome protein yield of 35 mg/(g liver) or 20.6 
mg/(g small intestine) 
b Catalytic efficiency expressed as mL/min/(g liver) or mL/min/(g intestine) is the ratio of scaled Vmax and Km 
PBK model evaluation 
Due to unavailability of in vivo kinetic data for lasiocarpine, to evaluate the performance of the PBK 
models, the blood concentration-time curves of riddelliine as predicted by the developed PBK models 
were compared with the in vivo kinetic data from the literature on the blood concentration of 
riddelliine in rat and mouse exposed to riddelliine. Williams et al. reported riddelliine blood 
concentrations in rat and mouse that were orally exposed to 10 mg/kg bw of riddelliine, and from 
which blood samples were collected from 0.5-24 hours (Williams et al., 2002). Figure 5a shows that 
for the mouse model there is only 2 to 6.5 (average 4.6 ± 2.2) fold difference at time points of 0.5, 2, 3, 
4, 8, 24 hours between the predicted blood concentrations using the developed PBK model and the 
observed blood concentration of riddelliine upon a dose of 10 mg/kg bw in mouse (Williams et al., 
2002). When comparing the predicted blood concentrations with in vivo blood concentrations of 
riddelliine upon a dose of 10 mg/kg bw in rat, the results showed that the predicted values are 0.9 to 
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23.7 (average 14.5 ± 9.1) fold higher at time points of 0.5, 1, 2, 3, 4, 8, 24 hours than the observed 
blood concentrations. Further, the differences between the predicted and observed Cmax of riddelliine at 
a dose of 10 mg/kg bw, were 2-fold for mouse and 9.7-fold for rat (Figure 5). The predicted blood 
concentration-time curves of riddelliine in mouse using the two individual Ka values are shown in the 
Supplementary data (Figure S1). As shown in Figure S1, the two Ka values for riddelliine result in 
different predicted blood concentration-time curves and in Cmax values that are 3.2- fold different.   
In addition, the predicted AUC values were also calculated. The observed AUC were 516 ng h/ mL for 
rat and 1307 ng h/ mL for mouse (Williams et al., 2002), while the predicted AUC values were 5323 
ng h/ mL for rat and 6113 ng h/mL for mouse, respectively. Thus, the predicted AUC for rat was 10.3-
fold higher than the observed AUC, while the predicted AUC for mouse was 4.7-fold higher than the 
observed AUC. 
 
Fig. 5 PBK modelling-predicted time-dependent blood concentrations (black line) and reported time-dependent 
blood concentrations (filled square) for riddelliine in mouse (a) or (filled circle) in rat (b) upon a dose of 10 
mg/kg bw.  
Sensitivity analysis 
To further evaluate the performance of the developed models, a sensitivity analysis was performed to 
assess the parameters that affect the prediction of the Cmax of lasiocarpine and riddelliine in liver blood. 
The sensitivity analysis was performed at an oral dose of 0.008 and 0.144 µg/kg bw/day. These PA 
dose levels represent the reported lowest and the highest daily intake originating from use of herbal 
teas (BfR, 2013). Only the parameters that result in a normalized sensitivity coefficient higher than 0.1 
(in absolute value) are shown in Figure 6. The results obtained reveal that the fraction of liver volume, 
partition coefficient of liver, the uptake rate constant, the liver microsomal protein yield, the kinetic 
parameters (Vmax and Km) for depletion of lasiocarpine and riddelliine in the liver were the most 
sensitive parameters in the rat PBK models for lasiocarpine and riddelliine. Compared to the rat PBK
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for riddelliine, the parameters related to the intestine are more influential in the rat PBK model for 
lasiocarpine (Figure 6A). Comparison of the sensitivity analysis performed at 0.008 and 0.144 µg/kg 
bw/day reveals that the influence of all parameters was not dose-dependent in the rat PBK model for 
lasiocarpine and riddelliine (Figure 6). 
 
Fig. 6 Normalized sensitivity coefficients for the parameters of the rat PBK model for lasiocarpine (A) and 
riddelliine (B) on predicted Cmax in liver blood values at a single oral dose of 0.008 µg/kg bw/day (white bars) 
and 0.144 µg/kg bw/day (grey bars) PAs. VLc = fraction of liver volume, VSi = fraction of small intestine 
volume, QSi = blood flow to small intestine, PLL= liver/blood partition coefficient, PSL = slowly perfused 
tissue/blood partition coefficient, Ka = uptake rate constant, MPL and MPSi = liver and small intestinal 
microsomal protein yield, VmaxL and KmL = the maximum rate of depletion and the Michaelis-Menten constant 
for depletion of lasiocarpine or riddelliine in liver, VmaxSi and KmSi = the maximum rate of depletion and the 
Michaelis-Menten constant for depletion of lasiocarpine or riddelliine in small intestine. 
Translation of the in vitro concentration-response curves to in vivo dose-response curves, 
and application of PROAST modelling on predicted dose-response data to derive PoDs 
Figure 7 shows the predicted in vivo dose-response curves for liver toxicity of lasiocarpine and 
riddelliine in rat using PBK modelling-facilitated reverse dosimetry. The two predicted dose-response 
curves were derived from the in vitro cytotoxicity concentration-response curves obtained with rat 
hepatocytes (Figure 3) based on the Cmax assuming the in vitro concentration to be equal to the Cmax 
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of unbound PA in liver blood. The fub of lasiocarpine and riddelliine in rat serum was estimated to be 
0.64 and 0.66, respectively. Table 4 displays the range of BMDL5-BMDU5 values derived from these 
predicted dose-response curves. The predicted BMDL5-BMDU5 values for lasiocarpine and riddelliine 
in rats were 23-34.4 and 4.9-8.4 mg/kg bw/day, respectively. When converting the concentration-
response curves from Hayes et al. (1984) for rat hepatocytes depicted in Figure 3 and using the same 
PBK model, the predicted BMDL5-BMDU5 values for lasiocarpine were 34.5-72.1 mg/kg bw/day 
(Table 4). When using the individual Ka for prediction of the BMDL5-BMDU5 values, the predicted 
BMDL5-BMDU5 values for riddelliine in rat result in the ranges of 3.3-14.6 and 1.0-2.2 mg/kg bw/day, 
respectively.  
 
Fig. 7 Predicted in vivo dose-response curves for acute liver toxicity of lasiocarpine and riddelliine in rat. The 
solid line represents the predicted in vivo dose-response curves for lasiocarpine and the dashed line represents 
the predicted dose-response curve for riddelliine. 
Table 4 Predicted BMDL5-BMDU5 values derived from the dose-response curves predicted using PBK 
modelling-facilitated reverse dosimetry to convert the in vitro concentration-response curves as obtained in the 
present study and obtained from the literature (Figure 3) to in vivo dose-response curves. 
Compound  Cell model Predicted BMDL5-BMDU5  
(mg/kg bw/day)  
Source in vitro 
concentration-response 
curve 
Lasiocarpine Rat hepatocytes 23.0-34.4 Present study 
Riddelliine Rat hepatocytes 4.9-8.4 Present study 
Lasiocarpine Rat hepatocytes 34.5-72.1 (Hayes et al., 1984) 
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Evaluation of the predicted PoDS for in vivo liver toxicity  
Due to the absence of in vivo acute liver toxicity data reported in the literature for riddelliine, the 
predicted PoDs for in vivo liver toxicity could only be evaluated for lasiocarpine. To this end, the 
BMDL5-BMDU5 values presented in Table 4 were compared with in vivo reported data for acute liver 
toxicity of lasiocarpine as available in the literature (Dalefield et al., 2016; Jago, 1970; Nolan et al., 
1966). Table 5 presents an overview of literature data on acute liver toxicity of lasiocarpine in rat, 
measuring endpoints including megalocytosis, the mitotic index value, or the alanine amino 
transferase concentration in serum as a measure of acute liver toxicity. The data from these studies 
were not suitable for BMD analysis due to the limited number of data points and insufficient 
distribution of the data points over the dose-response curves. Therefore, the NOAEL values and/or the 
range of estimated NOAEL to LOAEL values that could be derived from these studies were taken as 
the PoDs (Table 5). When only the LOAEL was available, the NOAEL was calculated using the 
LOAEL divided by a factor of 10 (Barnes et al., 1988).  
Figure 8 shows a comparison of the predicted range of BMDL5-BMDU5 values for in vivo liver 
toxicity of lasiocarpine and the PoDs derived from in vivo literature rat data for liver toxicity of 
lasiocarpine. The literature values for single oral exposure are the ones that can best be compared to 
the values predicted in the present study. Values for IP or oral repeated exposure appear to be 
somewhat lower probably because of these different dose regimes. The predicted BMDL5-BMDU5 
values derived from the present study appear to fall well within the range of PoDs obtained from the 
available oral single dose in vivo studies. The BMDL5, a possible PoD for evaluation of acute toxicity 
of PAs, determined from predicted concentration-response curves was 1.9- to 2.9-fold higher than the 
NOAELs derived as corresponding PoD from the experimental data. The BMDU5 predicted in the 
present study was 2.3- to 3.5-fold lower compared to the LOAELs derived as corresponding PoD from 
the in vivo studies. The results indicate that the data and range of PoD values derived using our 
combined in vitro-PBK modelling approach are a good approximation to the in vivo acute liver 
toxicity of lasiocarpine.  
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Evaluation of the predicted PoDS for in vivo liver toxicity  
Due to the absence of in vivo acute liver toxicity data reported in the literature for riddelliine, the 
predicted PoDs for in vivo liver toxicity could only be evaluated for lasiocarpine. To this end, the 
BMDL5-BMDU5 values presented in Table 4 were compared with in vivo reported data for acute liver 
toxicity of lasiocarpine as available in the literature (Dalefield et al., 2016; Jago, 1970; Nolan et al., 
1966). Table 5 presents an overview of literature data on acute liver toxicity of lasiocarpine in rat, 
measuring endpoints including megalocytosis, the mitotic index value, or the alanine amino 
transferase concentration in serum as a measure of acute liver toxicity. The data from these studies 
were not suitable for BMD analysis due to the limited number of data points and insufficient 
distribution of the data points over the dose-response curves. Therefore, the NOAEL values and/or the 
range of estimated NOAEL to LOAEL values that could be derived from these studies were taken as 
the PoDs (Table 5). When only the LOAEL was available, the NOAEL was calculated using the 
LOAEL divided by a factor of 10 (Barnes et al., 1988).  
Figure 8 shows a comparison of the predicted range of BMDL5-BMDU5 values for in vivo liver 
toxicity of lasiocarpine and the PoDs derived from in vivo literature rat data for liver toxicity of 
lasiocarpine. The literature values for single oral exposure are the ones that can best be compared to 
the values predicted in the present study. Values for IP or oral repeated exposure appear to be 
somewhat lower probably because of these different dose regimes. The predicted BMDL5-BMDU5 
values derived from the present study appear to fall well within the range of PoDs obtained from the 
available oral single dose in vivo studies. The BMDL5, a possible PoD for evaluation of acute toxicity 
of PAs, determined from predicted concentration-response curves was 1.9- to 2.9-fold higher than the 
NOAELs derived as corresponding PoD from the experimental data. The BMDU5 predicted in the 
present study was 2.3- to 3.5-fold lower compared to the LOAELs derived as corresponding PoD from 
the in vivo studies. The results indicate that the data and range of PoD values derived using our 
combined in vitro-PBK modelling approach are a good approximation to the in vivo acute liver 
toxicity of lasiocarpine.  
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Fig.8 BMDL5-BMDU5 values for acute liver toxicity of lasiocarpine in rat predicted by the PBK modelling-
facilitated reverse dosimetry approach using data for rat hepatocytes from the present study and literature data 
for rat hepatocytes (rectangle bars filled with grid) as compared to comparable PoDs (rectangle bars filled with 
horizontal lines) derived from in vivo liver toxicity studies as shown in Tabls 5 upon oral or IP exposure. Range 
of estimated PoD from in vivo data = estimated NOAEL to LOAEL. 
Discussion 
The aim of present study was to assess whether a physiologically based kinetic (PBK) modelling-
facilitated reverse dosimetry approach could adequately predict in vivo dose-response curves for 
hepatotoxicity of PAs in rats. Especially 1,2-unsaturated PAs are of concern because of their 
hepatotoxicity and carcinogenicity. However, of the large group of 1,2-unsaturated PAs in vivo data 
for liver toxicity are only available for lasiocarpine (Dalefield et al., 2016; Jago, 1970; Nolan et al., 
1966). A method to estimate liver toxicity for related PAs using read-across from lasiocarpine based 
on quantitative insight into the relative level of their bioactivation and detoxification would enable 
priority setting in the further evaluation of the toxicity of PAs for which no toxicity data are availabe. 
To facilitate this approach the aim of the present study was to develop a PBK model for PAs and use 
this model to generate a proof of principle that liver toxicty of the model PA lasiocarpine can be 
adequately predicted by this comined in silico-in vitro alternative tetsing strategy. 
In the present study, the in vitro concentration-response curves of lasiocarpine and riddelliine in 
primary rat hepatocytes were used as the in vitro toxicity data. Riddelliine and lasiocarpine were 
selected as the model PAs, because for riddelliine data on dose- and time-dependent blood levels in 
mouse and rats were available enabling evaluation of the PBK models, while for lasiocarpine in vivo 
data for liver toxicity were available, enabling valuation of the final prediction of the in vivo liver
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toxicity. Primary rat liver hepatocytes were selected as the in vitro model because they are expected to 
best reflect the intrinsic sensitivity and metabolism of liver cells in vivo. Furthermore, hepatocytes 
were used before to characterise in vitro liver toxicity of lasiocarpine (Hayes et al., 1984; Moore et al., 
1989). The results for the in vitro cytotoxicity of lasiocarpine in rat primary hepatocytes obtained in 
the present study were comparable to the literature data (Hayes et al., 1984).  
The PBK models developed could be evaluated based on in vivo kinetic data available for riddelliine 
(Williams et al., 2002). The predicted riddelliine blood concentrations by the PBK model for mouse 
were 2 to 6.5 (average 4.6 ± 2.2) fold different from those reported by Williams et al. (2002) and for 
the rat PBK model the predicted blood concentrations were 0.9 to 23.7 (average 14.5 ± 9.1) fold 
different from those reported by Williams et al. (2002). In a subsequent step, the PBK models were 
used to convert the in vitro cytotoxicity data for lasiocarpine and riddelliine to in vivo dose-response 
curves for liver toxicity, enabling to assess the validity and use of the PBK model for reverse 
dosimetry, by comparison of the predicted toxicity data to available in vivo toxicity data for 
lasiocarpine. The predicted BMDL5-BMDU5 values derived from the present study appeared to fall 
well within the range of PoDs obtained from the available oral single dose in vivo studies. The results 
indicate that the data and range of PoD values derived using our combined in vitro-in silico PBK 
modelling approach are a good approximation of the in vivo acute liver toxicity of lasiocarpine.  
In addition, the BMDL5-BMDU5 values predicted for riddelliine were 2.7 to 7.0 times lower than 
those values predicted for lasiocarpine. This indicates that in vivo riddelliine is predcited to induce 
liver toxicity at lower dose levels than lasiocarpine. In line with this, the in vitro cytotoxicity of 
riddelliine was also higher than that of lasiocarpine. The higher in vivo toxicity of ridelliine may in 
part be due to the fact that there are differences in kinetics which revealed a slower clearance of 
riddelliine compared to lasiocarpine. Given all the results above, it is concluded that the developed 
PBK modeling-facilitated reverse dosimetry approach provides a promising method to predict acute 
liver toxicity in vivo for lasiocarpine, and related PAs. Based on the results of the sensitivity analysis 
(Figure 6), the model preditions are highly influenced by the kinetic constant Ka for uptake of the PAs 
in the small intestine. In current study, the predicted BMDL5-BMDU5 values derived when using the 
average Ka value fall within the ranges of predicted BMDL5-BMDU5 values using the individual Ka 
values. Nevertheless the method used to determine the Papp value and resulting Ka for intestinal uptake 
of PAs may need further refinement.   
In addition it is also of interest to compare the PoDs predicted for acute oral toxicity in rats, to what 
can be derived from reported cases on actue toxicity in humans. This includes for example cases in 
Afghanistan in 1976 (Mohabbat et al., 1976), in Jamaica in 1954 (Bras et al., 1954), and in India in 
1975 (Tandon et al., 1976). In fact, these reports reveal that during the past century, a lot of acute PAs 
poisoning cases took place in central Asia, while other cases have been reported for other countries
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with poorly developed agricultural systems (Dharmananda, 2001). Culvenor estimated the dose and 
duration of exposure to the toxic PAs that may lead to liver toxicity in humans (Culvenor, 1983) and 
concluded that an intake of 0.7-1.5 mg/kg bw/day for riddelliine for 2 weeks can induce hepatotoxicity. 
The predicted BMDL5-BMDU5 value for acute liver toxicity of riddelliine in rats reported in the 
present study amounted to 4.9-8.4 mg/kg bw/day. Comparison of these values suggests that humans 
might be more sensitive than rats, although it should be kept in mind that the human study was based 
on more than a single exposure and that estimation of dose levels in human case studies is generally 
not acurate. In a next step, the PBK modelling based approach developed in the present study will be 
modified to predict human liver toxicity using human hepatocytes and the PBK model modified to 
describe human kinetics.  
In conclusion, we showed that PBK modelling-facilitated reverse dosimetry can translate in vitro 
concentration-response curves to in vivo dose-response curves for acute liver toxicity of lasiocarpine 
and riddelliine. BMDL5-BMDU5 values could be derived that were in line with available in vivo data. 
This study provides another proof-of-principle for integrating in vitro toxicity data and PBK 
modelling-facilitated reverse dosimetry to obtain a promising alternative testing strategy in risk and 
safety evaluation of chemicals. 
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with poorly developed agricultural systems (Dharmananda, 2001). Culvenor estimated the dose and 
duration of exposure to the toxic PAs that may lead to liver toxicity in humans (Culvenor, 1983) and 
concluded that an intake of 0.7-1.5 mg/kg bw/day for riddelliine for 2 weeks can induce hepatotoxicity. 
The predicted BMDL5-BMDU5 value for acute liver toxicity of riddelliine in rats reported in the 
present study amounted to 4.9-8.4 mg/kg bw/day. Comparison of these values suggests that humans 
might be more sensitive than rats, although it should be kept in mind that the human study was based 
on more than a single exposure and that estimation of dose levels in human case studies is generally 
not acurate. In a next step, the PBK modelling based approach developed in the present study will be 
modified to predict human liver toxicity using human hepatocytes and the PBK model modified to 
describe human kinetics.  
In conclusion, we showed that PBK modelling-facilitated reverse dosimetry can translate in vitro 
concentration-response curves to in vivo dose-response curves for acute liver toxicity of lasiocarpine 
and riddelliine. BMDL5-BMDU5 values could be derived that were in line with available in vivo data. 
This study provides another proof-of-principle for integrating in vitro toxicity data and PBK 
modelling-facilitated reverse dosimetry to obtain a promising alternative testing strategy in risk and 
safety evaluation of chemicals. 
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Figure S1 Reported time-dependent blood concentrations (filled square) for riddelliine in mouse and PBK 
modelling-predicted time-dependent blood concentrations when using Ka value of 0.27/h (black line) (a) or 
using Ka value of 1.17/h (dotted line) upon a dose of 10 mg/kg bw. 
 
 
Supplementary Material 2 
PBK Model for lasiocarpine, built with in vitro and in silico data; Species: Rat 
;======================================================================== 
;Physiological parameters 
;======================================================================== 
;Tissue volumes 
BW = 0.250 {Kg}  ; body weight rat (Brown, p)  
VFc = 0.07   ; fraction of fat tissue 
VLc = 0.034   ; fraction of liver 
VSic = 0.014   ; fraction of small intestine 
VAc = 0.0185   ; fraction of arterial blood: 0.074*1/4  
VVc = 0.0555   ; fraction of venous blood: 0.074*3/4 
VBc = 0.074 
VRc = 0.09-VLc-VSic  ; fraction of richly perfused tissue 
VSc = 0.82-VFc                ; Fraction of blood flow to slowly perfused tissue 
VF = VFc*BW                              {L or Kg}        ; volume of fat tissue 
VL = VLc*BW   ; Liver volume 
VSi = VSic*BW 
VR = VRc*BW     
VS = VSc*BW  
VA = VAc*BW
139 
 
VV = VVc*BW 
VB = VBc*BW 
;----------------------------------------------------------------------------------------------------------------------------- ----------  
;Blood flow rates 
QC = 15*BW^0.74 {L/hr}  ; Info: QC=15*BW^0.74 Reference: Brown, p and Krishnan, p 
QFc = 0.07   ; Fraction of blood flow to fat 
QLc = 0.25 -QSic               ; Fraction of blood flow to liver  
QSic = 0.76*0.014/0.09               ; Fraction of blood flow to small intestine 
QRc = 0.76-QLc-QSic  ; Fraction of blood flow to richly perfused tissue  
  QSc = 0.24-QFc                 ; Fraction of blood flow to slowly perfused tissue 
  QF = QFc*QC {L/hr} 
  QL = QLc*QC 
  QSi = QSic*QC 
  QR = QRc*QC    
  QS = QSc*QC  
 ;============================================================================== 
;Partition Coefficients 
;=============================================================================== 
lasiocarpine 
PLL = 0.88   ; liver/blood partition coefficient  
PFL = 2.44   ; fat/blood partition coefficient 
PRL = 0.88   ; richly perfused tissues/blood partition coefficient 
PSL = 0.48   ; slowly perfused tissues/blood partition coefficient 
PIL = 0.88                                         ; intestine/blood partition coefficient 
;=============================================================================== 
;Biochemical parameters  
;===============================================================================
Linear uptake rate (hr-1) 
Ka = 1.55  ; 
;-------------------------------------------------------------------------------------------------------------------------------------- - 
;----------------------------------------------------------------------------------------------------------------------------- ----------
;Metabolism liver 
;Scaling factors 
MPL=35                            ;Liver microsomal protein yield (mg/gram liver) Atio et al. 1976 
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;Partition Coefficients 
;=============================================================================== 
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;Biochemical parameters  
;===============================================================================
Linear uptake rate (hr-1) 
Ka = 1.55  ; 
;-------------------------------------------------------------------------------------------------------------------------------------- - 
;----------------------------------------------------------------------------------------------------------------------------- ----------
;Metabolism liver 
;Scaling factors 
MPL=35                            ;Liver microsomal protein yield (mg/gram liver) Atio et al. 1976 
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L=VLC*1000                            ;Liver = 34 (gram/kg BW)   
;metabolites of lasiocarpine, unscaled maximum rate of metabolism (nmol min-1 (mg protein)-1) 
VmaxLM1c = 5.267              ; based on substrate depletion in rat liver microsome  
;metabolites of  lasiocarpine, scaled maximum rate of metabolism (umol hr-1) 
VMaxLM1 = VMaxLM1c/1000*60*MPL*L*BW 
;metabolites of  lasiocarpine, affinity constants (umol/L) 
KmLM1 = 19.54     ; based on substrate depletion in rat liver microsome  
;------------------------------------------------------------------------------------------------------- -------------------------------
 ;Metabolism small intestine 
 ;Scaling factors 
  MPSi=20.6           ;Small intestine microsomal fraction yield (uL/gram small intestine) , rung, 2017  
  SI =VSiC*1000   
;metabolites of  lasiocarpine, unscaled maximum rate of metabolism (nmol min-1 (mg)-1) 
VmaxSiM2c = 1.736     ;based on adding all the metabolites in the rat intestine microsome  
;metabolites of  lasiocarpine, scaled maximum rate of metabolism (umol hr-1) 
VMaxSiM2 = VMaxSiM2c/1000*60*MPSi*SI*BW 
;metabolites of  lasiocarpine, affinity constants (umol/L) 
KmSiM2 = 23.42         ;based on adding all the metabolites in the rat intestine microsome  
;=============================================================================== 
;Run settings 
;===============================================================================;
Molecular weight  
MWL =411.2                                    ;Molecular weight lasiocarpine  
;Given dose (mg/ kg bw) and oral dose umol/ kg bw}  
GDOSE = 10   {mg/ kg bw}                    ; GDOSE = given dose 
ODOSE = GDOSE*1E-3/MWL*1E6  {umol/ kg bw}     ; ODOSE = given dose recalculated to umol/kg bw 
DOSE=ODOSE*BW;        ; DOSE = umol 
;Time 
Starttime = 0                                     ;in hrs 
Stoptime = 24                                     ;in hrs 
;===============================================================================  
;Dynamics 
;===============================================================================; 
slowly perfused tissue compartment 
141 
 
;AS = Amount lasiocarpine in slowly perfused tissue, umol 
       AS' = QS*(CB-CVS)  
       Init AS = 0 
       CS = AS/VS 
       CVS = CS/PSL 
;----------------------------------------------------------------------------------------------------------------------------- ----------
 ;richly perfused tissue compartment 
 ;AR = Amount lasiocarpine in richly perfused tissue, umol 
       AR' = QR*(CB-CVR)  
       Init AR = 0 
       CR = AR/VR 
       CVR = CR/PRL 
;----------------------------------------------------------------------------------------------------------------------------- ----------
 ;fat compartment 
 ;AF = Amount lasiocarpine in fat tissue, umol 
       AF' = QF*(CB-CVF)  
       Init AF = 0 
       CF = AF/VF 
       CVF = CF/PFL 
;------------------------------------------------------------------------------------------------- --------------------------------------
 ;uptake lasiocarpine from GI tract 
;AGI = Amount  lasiocarpine remaining in GI tract (umol) 
      AGI' =-ka*AGI 
      Init AGI = dose 
;---------------------------------------------------------------------------------------------------------------------------------------
 ;liver compartment 
 ;AL = Amount  lasiocarpine in liver tissue, umol 
      AL' = QL*CB +QSi*CVSi - (QL+QSi) *CVL - AMLM1'  
       Init AL = 0 
       CL = AL/VL 
       CVL = CL/PLL 
;AMLM1=Amount  lasiocarpine metabolized in liver to metabolite 1, umol 
       AMLM1' = VmaxLM1*CVL/(KmLM1 + CVL)  
       Init AMLM1 = 0 
;----------------------------------------------------------------------------------------------------------------------------- ---------- 
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 ;fat compartment 
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       Init AF = 0 
       CF = AF/VF 
       CVF = CF/PFL 
;------------------------------------------------------------------------------------------------- --------------------------------------
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;AGI = Amount  lasiocarpine remaining in GI tract (umol) 
      AGI' =-ka*AGI 
      Init AGI = dose 
;---------------------------------------------------------------------------------------------------------------------------------------
 ;liver compartment 
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;----------------------------------------------------------------------------------------------------------------------------- ---------- 
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;small intestine compartment 
;ASi = Amount  lasiocarpine in small intestine tissue, 
      ASi' = QSi*(CB -CVSi) + ka*AGI - AMSiM2'  
       Init ASi = 0 
       CSi = ASi/VSi 
       CVSi = CSi/PIL 
;AMSiM2=Amount lasiocarpine metabolized in small intestine to metabolites2, umol 
      AMSiM2'= VmaxSiM2*CVSi/(KmSiM2 + CVSi)  
      Init AMSiM2 = 0 
;----------------------------------------------------------------------------------------------------------------------------- ----------
 ; arterial blood compartment       
;CA = Concentration arterial blood  lasiocarpine 
;CA =  CV 
;----------------------------------------------------------------------------------------------------------------------------- ----------
;venous blood compartment      
;CB = Concentration venous blood  lasiocarpine (umol/L) 
      AB' = (QF*CVF + (QL+QSi)*CVL + QR*CVR + QS*CVS - QC*CB) 
      Init AB = 0             
      CB = AB/VB 
     AUC' = CB 
      init AUC = 0 
;===============================================================================;
Mass balance calculations 
{Mass Balance} 
Total = DOSE 
Calculated = AF + AS + AR + AL +  AB  + AGI + ASI + AMLM1+AMSiM2 
ERROR=((Total-Calculated)/Total+1E-30)*100 
MASSBBAL=Total-Calculated + 1 
;===============================================================================; 
;blood concentration in ng/ml 
CBngmL = CB*MWL 
;=============================================================================== 
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PBK Model for riddelliine, built with in vitro and in silico data; Species: Rat 
;============================================================================= 
 
;Physiological parameters 
 
;============================================================================= 
;Tissue volumes 
 BW = 0.250 {Kg}  ; body weight rat (Brown, p)  
 VFc = 0.07   ; fraction of fat tissue 
 VLc = 0.034   ; fraction of liver 
 VSic = 0.014   ; fraction of small intestine 
 VAc = 0.0185   ; fraction of arterial blood: 0.074*1/4  
 VVc = 0.0555   ; fraction of venous blood: 0.074*3/4 
 VBc = 0.074 
 VRc = 0.09-VLc-VSic  ; fraction of richly perfused tissue 
 VSc = 0.82-VFc                 ; Fraction of blood flow to slowly perfused tissue 
     
 VF = VFc*BW  {L or Kg} 
 VL = VLc*BW   ; Liver volume 
 VSi = VSic*BW 
 VR = VRc*BW     
 VS = VSc*BW  
 VA = VAc*BW 
 VV = VVc*BW 
 VB = VBc*BW 
;---------------------------------------------------------------------------------------------------------------------------------------   
;Blood flow rates 
QC = 15*BW^0.74 {L/hr}  ; Info: QC=15*BW^0.74 Reference: Brown, p and Krishnan, p 
QFc = 0.07   ; Fraction of blood flow to fat 
QLc = 0.25 -QSic               ; Fraction of blood flow to liver  
QSic = 0.76*0.014/0.09               ; Fraction of blood flow to small intestine 
QRc = 0.76-QLc-QSic  ; Fraction of blood flow to richly perfused tissue  
QSc = 0.24-QFc                 ; Fraction of blood flow to slowly perfused tissue 
     
QF = QFc*QC {L/hr} 
QL = QLc*QC 
QSi = QSic*QC 
QR = QRc*QC    
QS = QSc*QC   
;=============================================================================== 
;Partition Coefficients 
;=============================================================================== 
;Riddelliine 
143
C
ha
pt
er
 4
142 
 
;small intestine compartment 
;ASi = Amount  lasiocarpine in small intestine tissue, 
      ASi' = QSi*(CB -CVSi) + ka*AGI - AMSiM2'  
       Init ASi = 0 
       CSi = ASi/VSi 
       CVSi = CSi/PIL 
;AMSiM2=Amount lasiocarpine metabolized in small intestine to metabolites2, umol 
      AMSiM2'= VmaxSiM2*CVSi/(KmSiM2 + CVSi)  
      Init AMSiM2 = 0 
;----------------------------------------------------------------------------------------------------------------------------- ----------
 ; arterial blood compartment       
;CA = Concentration arterial blood  lasiocarpine 
;CA =  CV 
;----------------------------------------------------------------------------------------------------------------------------- ----------
;venous blood compartment      
;CB = Concentration venous blood  lasiocarpine (umol/L) 
      AB' = (QF*CVF + (QL+QSi)*CVL + QR*CVR + QS*CVS - QC*CB) 
      Init AB = 0             
      CB = AB/VB 
     AUC' = CB 
      init AUC = 0 
;===============================================================================;
Mass balance calculations 
{Mass Balance} 
Total = DOSE 
Calculated = AF + AS + AR + AL +  AB  + AGI + ASI + AMLM1+AMSiM2 
ERROR=((Total-Calculated)/Total+1E-30)*100 
MASSBBAL=Total-Calculated + 1 
;===============================================================================; 
;blood concentration in ng/ml 
CBngmL = CB*MWL 
;=============================================================================== 
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PBK Model for riddelliine, built with in vitro and in silico data; Species: Rat 
;============================================================================= 
 
;Physiological parameters 
 
;============================================================================= 
;Tissue volumes 
 BW = 0.250 {Kg}  ; body weight rat (Brown, p)  
 VFc = 0.07   ; fraction of fat tissue 
 VLc = 0.034   ; fraction of liver 
 VSic = 0.014   ; fraction of small intestine 
 VAc = 0.0185   ; fraction of arterial blood: 0.074*1/4  
 VVc = 0.0555   ; fraction of venous blood: 0.074*3/4 
 VBc = 0.074 
 VRc = 0.09-VLc-VSic  ; fraction of richly perfused tissue 
 VSc = 0.82-VFc                 ; Fraction of blood flow to slowly perfused tissue 
     
 VF = VFc*BW  {L or Kg} 
 VL = VLc*BW   ; Liver volume 
 VSi = VSic*BW 
 VR = VRc*BW     
 VS = VSc*BW  
 VA = VAc*BW 
 VV = VVc*BW 
 VB = VBc*BW 
;---------------------------------------------------------------------------------------------------------------------------------------   
;Blood flow rates 
QC = 15*BW^0.74 {L/hr}  ; Info: QC=15*BW^0.74 Reference: Brown, p and Krishnan, p 
QFc = 0.07   ; Fraction of blood flow to fat 
QLc = 0.25 -QSic               ; Fraction of blood flow to liver  
QSic = 0.76*0.014/0.09               ; Fraction of blood flow to small intestine 
QRc = 0.76-QLc-QSic  ; Fraction of blood flow to richly perfused tissue  
QSc = 0.24-QFc                 ; Fraction of blood flow to slowly perfused tissue 
     
QF = QFc*QC {L/hr} 
QL = QLc*QC 
QSi = QSic*QC 
QR = QRc*QC    
QS = QSc*QC   
;=============================================================================== 
;Partition Coefficients 
;=============================================================================== 
;Riddelliine 
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PLL = 0.77   ;liver/blood partition coefficient  
PFL = 0.44   ; fat/blood partition coefficient 
PRL = 0.77   ; richly perfused tissues/blood partition coefficient 
PSL = 0.43   ; slowly perfused tissues/blood partition coefficient 
PIL = 0.77                                        ; intestine/blood partition coefficien 
;=============================================================================== 
;Biochemical parameters  
;=============================================================================== 
;Linear uptake rate (hr-1) 
Ka = 0.72  ; 
;----------------------------------------------------------------------------------------------------------------------------- ----------  
;Metabolism liver 
;Scaling factors 
MPL=35                             ;Liver microsomal protein yield (mg/gram liver) Atio et al. 1976 
L=VLC*1000                             ;Liver = 34 (gram/kg BW)   
;metabolites of riddelliine, unscaled maximum rate of metabolism (nmol min-1 (mg protein)-1) 
VmaxLM1c = 2.093               ;based on substrate depletion in rat liver microsome  
;metabolites of  riddelliine, scaled maximum rate of metabolism (umol hr-1) 
VMaxLM1 = VMaxLM1c/1000*60*MPL*L*BW 
;metabolites of  riddelliine, affinity constants (umol/L) 
KmLM1 = 75.69                              ;based on substrate depletion in rat liver microsome  
;----------------------------------------------------------------------------------------------------------------------------- ----------  
;Metabolism small intestine 
;Scaling factor 
MPSi=20.6                             ;Small intestine microsome fraction yield (mg/g small intestine) , Rung 2017 
Si =VSiC*1000   
;metabolites of  riddelliine, unscaled maximum rate of metabolism (nmol min-1 (mg)-1) 
VmaxSiM2c = 0.1182              ;based on the substrate depletion  intestine microsome 
;metabolites of  riddelliine, scaled maximum rate of metabolism (umol hr-1) 
VMaxSiM2 = VMaxSiM2c/1000*60*MPSi*SI*BW 
;metabolites of  riddelliine, affinity constants (umol/L) 
KmSiM2 = 221  ;  based on the substrate depletion on intestine microsome    
;=============================================================================== 
;Run settings 
;=============================================================================== 
;Molecular weight 
MWL =349.38;                                              ;Molecular weight riddelliine  
;Given dose (mg/ kg bw) and oral dose umol/ kg bw}  
GDOSE = 10 {mg/ kg bw}    ;GDOSE = given dose 
ODOSE = GDOSE*1E-3/MWL*1E6  {umol/ kg bw}  ;ODOSE = given dose recalculated to umol/kg bw 
DOSE=ODOSE*BW     ; DOSE = umol 
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;Time 
Starttime = 0                                              ;in hrs 
Stoptime = 24                                              ;in hrs 
;=============================================================================== 
;Dynamics 
;=============================================================================== 
;slowly perfused tissue compartment 
;AS = Amount riddelliine in slowly perfused tissue, umol 
       AS' = QS*(CB-CVS)  
       Init AS = 0 
       CS = AS/VS 
       CVS = CS/PSL 
;----------------------------------------------------------------------------------------------------------------------------- ----------  
;richly perfused tissue compartment 
;AR = Amount riddelliine in richly perfused tissue, umol 
      AR' = QR*(CB-CVR)  
       Init AR = 0 
       CR = AR/VR 
       CVR = CR/PRL 
;----------------------------------------------------------------------------------------------------------------------------- ----------  
;fat compartment 
;AF = Amount riddelliine in fat tissue, umol 
       AF' = QF*(CB-CVF)  
       Init AF = 0 
       CF = AF/VF 
       CVF = CF/PFL 
;--------------------------------------------------------------------------------------------------------------- ------------------------  
;uptake riddelliine from GI tract 
;AGI = Amount  riddelliine remaining in GI tract (umol) 
     AGI' =-ka*AGI 
      Init AGI = dose 
;-------------------------------------------------------------------------------------------------- -----------------------------------
;liver compartment 
;AL = Amount  riddelliine in liver tissue, umol 
      AL' = QL*CB +QSi*CVSi - (QL+QSi) *CVL - AMLM1'  
       Init AL = 0 
       CL = AL/VL 
       CVL = CL/PLL 
;AMLM1=Amount  riddelliine metabolized in liver to metabolite 1, umol 
       AMLM1' = VmaxLM1*CVL/(KmLM1 + CVL)  
       Init AMLM1 = 0 
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PLL = 0.77   ;liver/blood partition coefficient  
PFL = 0.44   ; fat/blood partition coefficient 
PRL = 0.77   ; richly perfused tissues/blood partition coefficient 
PSL = 0.43   ; slowly perfused tissues/blood partition coefficient 
PIL = 0.77                                        ; intestine/blood partition coefficien 
;=============================================================================== 
;Biochemical parameters  
;=============================================================================== 
;Linear uptake rate (hr-1) 
Ka = 0.72  ; 
;----------------------------------------------------------------------------------------------------------------------------- ----------  
;Metabolism liver 
;Scaling factors 
MPL=35                             ;Liver microsomal protein yield (mg/gram liver) Atio et al. 1976 
L=VLC*1000                             ;Liver = 34 (gram/kg BW)   
;metabolites of riddelliine, unscaled maximum rate of metabolism (nmol min-1 (mg protein)-1) 
VmaxLM1c = 2.093               ;based on substrate depletion in rat liver microsome  
;metabolites of  riddelliine, scaled maximum rate of metabolism (umol hr-1) 
VMaxLM1 = VMaxLM1c/1000*60*MPL*L*BW 
;metabolites of  riddelliine, affinity constants (umol/L) 
KmLM1 = 75.69                              ;based on substrate depletion in rat liver microsome  
;----------------------------------------------------------------------------------------------------------------------------- ----------  
;Metabolism small intestine 
;Scaling factor 
MPSi=20.6                             ;Small intestine microsome fraction yield (mg/g small intestine) , Rung 2017 
Si =VSiC*1000   
;metabolites of  riddelliine, unscaled maximum rate of metabolism (nmol min-1 (mg)-1) 
VmaxSiM2c = 0.1182              ;based on the substrate depletion  intestine microsome 
;metabolites of  riddelliine, scaled maximum rate of metabolism (umol hr-1) 
VMaxSiM2 = VMaxSiM2c/1000*60*MPSi*SI*BW 
;metabolites of  riddelliine, affinity constants (umol/L) 
KmSiM2 = 221  ;  based on the substrate depletion on intestine microsome    
;=============================================================================== 
;Run settings 
;=============================================================================== 
;Molecular weight 
MWL =349.38;                                              ;Molecular weight riddelliine  
;Given dose (mg/ kg bw) and oral dose umol/ kg bw}  
GDOSE = 10 {mg/ kg bw}    ;GDOSE = given dose 
ODOSE = GDOSE*1E-3/MWL*1E6  {umol/ kg bw}  ;ODOSE = given dose recalculated to umol/kg bw 
DOSE=ODOSE*BW     ; DOSE = umol 
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;Time 
Starttime = 0                                              ;in hrs 
Stoptime = 24                                              ;in hrs 
;=============================================================================== 
;Dynamics 
;=============================================================================== 
;slowly perfused tissue compartment 
;AS = Amount riddelliine in slowly perfused tissue, umol 
       AS' = QS*(CB-CVS)  
       Init AS = 0 
       CS = AS/VS 
       CVS = CS/PSL 
;----------------------------------------------------------------------------------------------------------------------------- ----------  
;richly perfused tissue compartment 
;AR = Amount riddelliine in richly perfused tissue, umol 
      AR' = QR*(CB-CVR)  
       Init AR = 0 
       CR = AR/VR 
       CVR = CR/PRL 
;----------------------------------------------------------------------------------------------------------------------------- ----------  
;fat compartment 
;AF = Amount riddelliine in fat tissue, umol 
       AF' = QF*(CB-CVF)  
       Init AF = 0 
       CF = AF/VF 
       CVF = CF/PFL 
;--------------------------------------------------------------------------------------------------------------- ------------------------  
;uptake riddelliine from GI tract 
;AGI = Amount  riddelliine remaining in GI tract (umol) 
     AGI' =-ka*AGI 
      Init AGI = dose 
;-------------------------------------------------------------------------------------------------- -----------------------------------
;liver compartment 
;AL = Amount  riddelliine in liver tissue, umol 
      AL' = QL*CB +QSi*CVSi - (QL+QSi) *CVL - AMLM1'  
       Init AL = 0 
       CL = AL/VL 
       CVL = CL/PLL 
;AMLM1=Amount  riddelliine metabolized in liver to metabolite 1, umol 
       AMLM1' = VmaxLM1*CVL/(KmLM1 + CVL)  
       Init AMLM1 = 0 
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;------------------------------------------------------------------------------------------------------- -------------------------------  
;small intestine compartment 
;ASi = Amount  riddelliine in small intestine tissue, umol 
      ASi' = QSi*(CB -CVSi) + ka*AGI - AMSiM2'  
       Init ASi = 0 
       CSi = ASi/VSi 
       CVSi = CSi/PIL 
;AMSiM2=Amount riddelliine metabolized in small intestine to metabolites2, umol 
      AMSiM2'= VmaxSiM2*CVSi/(KmSiM2 + CVSi)  
      Init AMSiM2 = 0 
;----------------------------------------------------------------------------------------------------------------------------- ----------  
; arterial blood compartment       
;CA = Concentration arterial blood  riddelliine 
;CA =  CV 
;----------------------------------------------------------------------------------------------------------------------------- ----------  
; venous blood compartment      
 
;CB = Concentration venous blood  riddelliine (umol/L) 
      AB' = (QF*CVF + (QL+QSi)*CVL + QR*CVR + QS*CVS - QC*CB) 
      Init AB = 0             
      CB = AB/VB 
     AUC' = CB 
      init AUC = 0 
;=============================================================================== 
;Mass balance calculations 
{Mass Balance} 
Total = DOSE 
Calculated = AF + AS + AR + AL +  AB  + AGI + ASI + AMLM1+AMSiM2 
ERROR=((Total-Calculated)/Total+1E-30)*100 
MASSBBAL=Total-Calculated + 1  
;=============================================================================== 
; blood concentration in ng/ml 
CBngmL = CB*MWL 
;=============================================================================== 
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PBK Model for riddelliine, built with in vitro and in silico data; Species: Mouse 
;============================================================================= 
;Physiological parameters 
;============================================================================= 
;Tissue volumes 
BW = 0.0250 {Kg}  ; body weight rat (Brown, p)  
VFc = 0.1   ; fraction of fat tissue 
VLc = 0.055   ; fraction of liver 
VSic = 0.025   ; fraction of small intestine 
VAc = 0.0185   ; fraction of arterial blood: 0.074*1/4  
VVc = 0.0555   ; fraction of venous blood: 0.074*3/4 
VBc = 0.049 
VRc = 0.09-VLc-VSic  ; fraction of richly perfused tissue 
VSc = 0.82-VFc                ; Fraction of blood flow to slowly perfused tissue 
 
VF = VFc*BW  {L or Kg} 
VL = VLc*BW   ; Liver volume 
VSi = VSic*BW 
VR = VRc*BW     
VS = VSc*BW  
;VA = VAc*BW 
;VV = VVc*BW 
VB = VBc*BW 
;---------------------------------------------------------------------------------------------------------------------------------------  
;Blood flow rates 
QC = 15*BW^0.74 {L/hr}  ; Info: QC=15*BW^0.74 Reference: Brown, p and Krishnan, p 
  QFc = 0.09   ; Fraction of blood flow to fat 
  QLc = 0.25 -QSic  ; Fraction of blood flow to liver  
  QSic = 0.183                              ; Fraction of blood flow to small intestine 
  QRc = 0.76-QLc-QSic  ; Fraction of blood flow to richly perfused tissue  
  QSc = 0.24-QFc                ; Fraction of blood flow to slowly perfused tissue 
       
 QF = QFc*QC {L/hr} 
 QL = QLc*QC 
 QSi = QSic*QC 
 QR = QRc*QC    
 QS = QSc*QC  
;=============================================================================== 
;Partition Coefficients 
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;------------------------------------------------------------------------------------------------------- -------------------------------  
;small intestine compartment 
;ASi = Amount  riddelliine in small intestine tissue, umol 
      ASi' = QSi*(CB -CVSi) + ka*AGI - AMSiM2'  
       Init ASi = 0 
       CSi = ASi/VSi 
       CVSi = CSi/PIL 
;AMSiM2=Amount riddelliine metabolized in small intestine to metabolites2, umol 
      AMSiM2'= VmaxSiM2*CVSi/(KmSiM2 + CVSi)  
      Init AMSiM2 = 0 
;----------------------------------------------------------------------------------------------------------------------------- ----------  
; arterial blood compartment       
;CA = Concentration arterial blood  riddelliine 
;CA =  CV 
;----------------------------------------------------------------------------------------------------------------------------- ----------  
; venous blood compartment      
 
;CB = Concentration venous blood  riddelliine (umol/L) 
      AB' = (QF*CVF + (QL+QSi)*CVL + QR*CVR + QS*CVS - QC*CB) 
      Init AB = 0             
      CB = AB/VB 
     AUC' = CB 
      init AUC = 0 
;=============================================================================== 
;Mass balance calculations 
{Mass Balance} 
Total = DOSE 
Calculated = AF + AS + AR + AL +  AB  + AGI + ASI + AMLM1+AMSiM2 
ERROR=((Total-Calculated)/Total+1E-30)*100 
MASSBBAL=Total-Calculated + 1  
;=============================================================================== 
; blood concentration in ng/ml 
CBngmL = CB*MWL 
;=============================================================================== 
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PBK Model for riddelliine, built with in vitro and in silico data; Species: Mouse 
;============================================================================= 
;Physiological parameters 
;============================================================================= 
;Tissue volumes 
BW = 0.0250 {Kg}  ; body weight rat (Brown, p)  
VFc = 0.1   ; fraction of fat tissue 
VLc = 0.055   ; fraction of liver 
VSic = 0.025   ; fraction of small intestine 
VAc = 0.0185   ; fraction of arterial blood: 0.074*1/4  
VVc = 0.0555   ; fraction of venous blood: 0.074*3/4 
VBc = 0.049 
VRc = 0.09-VLc-VSic  ; fraction of richly perfused tissue 
VSc = 0.82-VFc                ; Fraction of blood flow to slowly perfused tissue 
 
VF = VFc*BW  {L or Kg} 
VL = VLc*BW   ; Liver volume 
VSi = VSic*BW 
VR = VRc*BW     
VS = VSc*BW  
;VA = VAc*BW 
;VV = VVc*BW 
VB = VBc*BW 
;---------------------------------------------------------------------------------------------------------------------------------------  
;Blood flow rates 
QC = 15*BW^0.74 {L/hr}  ; Info: QC=15*BW^0.74 Reference: Brown, p and Krishnan, p 
  QFc = 0.09   ; Fraction of blood flow to fat 
  QLc = 0.25 -QSic  ; Fraction of blood flow to liver  
  QSic = 0.183                              ; Fraction of blood flow to small intestine 
  QRc = 0.76-QLc-QSic  ; Fraction of blood flow to richly perfused tissue  
  QSc = 0.24-QFc                ; Fraction of blood flow to slowly perfused tissue 
       
 QF = QFc*QC {L/hr} 
 QL = QLc*QC 
 QSi = QSic*QC 
 QR = QRc*QC    
 QS = QSc*QC  
;=============================================================================== 
;Partition Coefficients 
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;Riddelliine 
PLL = 0.77   ; liver/blood partition coefficient  
PFL = 0.44   ; fat/blood partition coefficient 
PRL = 0.77   ; richly perfused tissues/blood partition coefficient 
PSL = 0.43   ; slowly perfused tissues/blood partition coefficient 
PIL = 0.77                                         ; intestine/blood partition coefficient 
;============================================================================== 
;Biochemical parameters  
;=============================================================================== 
;Linear uptake rate (hr-1) 
Ka = 0.72; 
;----------------------------------------------------------------------------------------------------------------------------- ----------
;Metabolism liver 
;Scaling factors 
MPL=35                              ;Liver microsomal protein yield (mg/gram liver) Atio et al. 1976 
L=VLC*1000                              ;Liver = 34 (gram/kg BW)   
;metabolites of riddelliine, unscaled maximum rate of metabolism (nmol min-1 (mg protein)-1) 
VmaxLM1c = 1.427  ;based on substrate depletion in rat liver microsome  
;metabolites of  riddelliine, scaled maximum rate of metabolism (umol hr-1) 
VMaxLM1 = VMaxLM1c/1000*60*MPL*L*BW 
;metabolites of riddelliine, affinity constants (umol/L) 
KmLM1 = 101.3                             ; based on substrate depletion in rat liver microsome  
;----------------------------------------------------------------------------------------------------------------------------- ----------
  ;Metabolism small intestine 
  ;Scaling factor 
   MPSi=20.6                          ;Small intestine microsome fraction yield (mg/g small intestine) , Rung 2017 
   Si =VSiC*1000   
;metabolites of  riddelliine, unscaled maximum rate of metabolism (nmol min-1 (mg)-1) 
VmaxSiM2c = 1.619  ;based on the substrate depletion  intestine microsome 
;metabolites of  riddelliine, scaled maximum rate of metabolism (umol hr-1) 
VMaxSiM2 = VMaxSiM2c/1000*60*MPSi*SI*BW 
;metabolites of  riddelliine, affinity constants (umol/L) 
KmSiM2 = 695.8  ;  based on the substrate depletion on intestine microsome    
;=============================================================================== 
;Run settings 
;=============================================================================== 
;Molecular weight 
MWL =349.38   ;Molecular weight riddelliine 
;Given dose (mg/ kg bw) and oral dose umol/ kg bw}  
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GDOSE = 10 {mg/ kg bw}    ; GDOSE = given dose 
ODOSE = GDOSE*1E-3/MWL*1E6  {umol/ kg bw}               ; ODOSE = given dose recalculated to umol/kg 
bw 
DOSE=ODOSE*BW;     ; DOSE = umol 
;Time 
Starttime = 0;                                              ;in hrs 
Stoptime = 24;                                              ;in hrs 
;=============================================================================== 
;Dynamics 
;=============================================================================== 
;slowly perfused tissue compartment 
;AS = Amount riddelliine in slowly perfused tissue, umol 
       AS' = QS*(CB-CVS)  
       Init AS = 0 
       CS = AS/VS 
       CVS = CS/PSL 
;----------------------------------------------------------------------------------------------- ----------------------------------------  
;richly perfused tissue compartment 
;AR = Amount riddelliine in richly perfused tissue, umol 
       AR' = QR*(CB-CVR)  
       Init AR = 0 
       CR = AR/VR 
       CVR = CR/PRL 
;---------------------------------------------------------------------------------------------------------------------------------------
;fat compartment 
;AF = Amount riddelliine in fat tissue, umol 
       AF' = QF*(CB-CVF)  
       Init AF = 0 
       CF = AF/VF 
       CVF = CF/PFL 
;---------------------------------------------------------------------------------------------------------------------------------------   
;uptake riddelliine from GI tract 
;AGI = Amount  riddelliine remaining in GI tract (umol) 
      AGI' =-ka*AGI 
      Init AGI = dose 
;----------------------------------------------------------------------------------------------------------------------------- ----------  
;liver compartment 
;AL = Amount  riddelliine in liver tissue, umol 
      AL' = QL*CB +QSi*CVSi - (QL+QSi) *CVL - AMLM1'  
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;Riddelliine 
PLL = 0.77   ; liver/blood partition coefficient  
PFL = 0.44   ; fat/blood partition coefficient 
PRL = 0.77   ; richly perfused tissues/blood partition coefficient 
PSL = 0.43   ; slowly perfused tissues/blood partition coefficient 
PIL = 0.77                                         ; intestine/blood partition coefficient 
;============================================================================== 
;Biochemical parameters  
;=============================================================================== 
;Linear uptake rate (hr-1) 
Ka = 0.72; 
;----------------------------------------------------------------------------------------------------------------------------- ----------
;Metabolism liver 
;Scaling factors 
MPL=35                              ;Liver microsomal protein yield (mg/gram liver) Atio et al. 1976 
L=VLC*1000                              ;Liver = 34 (gram/kg BW)   
;metabolites of riddelliine, unscaled maximum rate of metabolism (nmol min-1 (mg protein)-1) 
VmaxLM1c = 1.427  ;based on substrate depletion in rat liver microsome  
;metabolites of  riddelliine, scaled maximum rate of metabolism (umol hr-1) 
VMaxLM1 = VMaxLM1c/1000*60*MPL*L*BW 
;metabolites of riddelliine, affinity constants (umol/L) 
KmLM1 = 101.3                             ; based on substrate depletion in rat liver microsome  
;----------------------------------------------------------------------------------------------------------------------------- ----------
  ;Metabolism small intestine 
  ;Scaling factor 
   MPSi=20.6                          ;Small intestine microsome fraction yield (mg/g small intestine) , Rung 2017 
   Si =VSiC*1000   
;metabolites of  riddelliine, unscaled maximum rate of metabolism (nmol min-1 (mg)-1) 
VmaxSiM2c = 1.619  ;based on the substrate depletion  intestine microsome 
;metabolites of  riddelliine, scaled maximum rate of metabolism (umol hr-1) 
VMaxSiM2 = VMaxSiM2c/1000*60*MPSi*SI*BW 
;metabolites of  riddelliine, affinity constants (umol/L) 
KmSiM2 = 695.8  ;  based on the substrate depletion on intestine microsome    
;=============================================================================== 
;Run settings 
;=============================================================================== 
;Molecular weight 
MWL =349.38   ;Molecular weight riddelliine 
;Given dose (mg/ kg bw) and oral dose umol/ kg bw}  
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GDOSE = 10 {mg/ kg bw}    ; GDOSE = given dose 
ODOSE = GDOSE*1E-3/MWL*1E6  {umol/ kg bw}               ; ODOSE = given dose recalculated to umol/kg 
bw 
DOSE=ODOSE*BW;     ; DOSE = umol 
;Time 
Starttime = 0;                                              ;in hrs 
Stoptime = 24;                                              ;in hrs 
;=============================================================================== 
;Dynamics 
;=============================================================================== 
;slowly perfused tissue compartment 
;AS = Amount riddelliine in slowly perfused tissue, umol 
       AS' = QS*(CB-CVS)  
       Init AS = 0 
       CS = AS/VS 
       CVS = CS/PSL 
;----------------------------------------------------------------------------------------------- ----------------------------------------  
;richly perfused tissue compartment 
;AR = Amount riddelliine in richly perfused tissue, umol 
       AR' = QR*(CB-CVR)  
       Init AR = 0 
       CR = AR/VR 
       CVR = CR/PRL 
;---------------------------------------------------------------------------------------------------------------------------------------
;fat compartment 
;AF = Amount riddelliine in fat tissue, umol 
       AF' = QF*(CB-CVF)  
       Init AF = 0 
       CF = AF/VF 
       CVF = CF/PFL 
;---------------------------------------------------------------------------------------------------------------------------------------   
;uptake riddelliine from GI tract 
;AGI = Amount  riddelliine remaining in GI tract (umol) 
      AGI' =-ka*AGI 
      Init AGI = dose 
;----------------------------------------------------------------------------------------------------------------------------- ----------  
;liver compartment 
;AL = Amount  riddelliine in liver tissue, umol 
      AL' = QL*CB +QSi*CVSi - (QL+QSi) *CVL - AMLM1'  
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       Init AL = 0 
       CL = AL/VL 
CVL = CL/PLL 
;AMLM1=Amount  riddelliine metabolized in liver to metabolite 1, umol 
       AMLM1' = VmaxLM1*CVL/(KmLM1 + CVL)  
       Init AMLM1 = 0 
;---------------------------------------------------------------------------------------------------------------------------------------  
;small intestine compartment 
;ASi = Amount  riddelliine in small intestine tissue, umol 
      ASi' = QSi*(CB -CVSi) + ka*AGI - AMSiM2'  
       Init ASi = 0 
       CSi = ASi/VSi 
       CVSi = CSi/PIL 
;AMSiM2=Amount riddelliine metabolized in small intestine to metabolites2, umol 
      AMSiM2'= VmaxSiM2*CVSi/(KmSiM2 + CVSi)  
      Init AMSiM2 = 0 
;-------------------------------------------------------------------------------------------- -------------------------------------------  
; arterial blood compartment       
;CA = Concentration arterial blood  riddelliine 
;CA =  CV 
;--------------------------------------------------------------------------------------------------------------------- ------------------  
; venous blood compartment      
;CB = Concentration venous blood  riddelliine (umol/L) 
      AB' = (QF*CVF + (QL+QSi)*CVL + QR*CVR + QS*CVS - QC*CB) 
      Init AB = 0             
      CB = AB/VB 
     AUC' = CB 
      init AUC = 0 
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;=============================================================================== 
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Abstract 
Lasiocarpine and riddelliine are pyrrolizidine alkaloids (PAs) known to cause liver toxicity. The aim 
of this study was to predict the inter-species and inter-ethnic human differences in acute liver toxicity 
of lasiocarpine and riddelliine using physiologically based kinetic (PBK) modelling based reverse 
dosimetry of in vitro toxicity data. The concentration-response curves of in vitro cytotoxicity of 
lasiocarpine and riddelliine defined in pooled human hepatocytes were translated to in vivo dose-
response curves by PBK models developed using kinetic data obtained from incubations with pooled 
tissue fractions from Chinese and Caucasian individuals, providing PBK models for the average 
Chinese and average Caucasian, respectively. From the predicted in vivo dose-response curves, the 
benchmark dose lower and upper confidence limits for 5 % effect (BMDL5 and BMDU5) were derived 
and subsequently compared to those previously obtained in rat to evaluate inter-species differences. 
The inter-species differences amounted to 2.0-fold for lasiocarpine and 8.2-fold for riddelliine with 
humans being more sensitive than rats. The inter-ethnic human differences varied 2.0-fold for 
lasiocarpine and 5.0-fold for riddelliine with the average Caucasian being more sensitive than the 
average Chinese. In conclusion, the present study provides the proof-of-principle to predict inter-
species and inter-ethnic differences in in vivo liver toxicity for PAs by an alternative testing strategy 
integrating in vitro cytotoxicity data with PBK modelling-based reverse dosimetry.  
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Introduction 
Lasiocarpine and riddelliine (Figure 1) are chemicals belonging to the group of pyrrolizidine alkaloids 
(PAs) which are important secondary metabolites of approximately 6000 plant species distributed 
around the world (Smith and Culvenor, 1981). Lasiocarpine is widely distributed in the Heliotropium 
and Symphytum genus (Boraginaceae species), and riddelliine is present in the genus Senecio 
(Asteraceae species) (Adams et al., 1942; Smith and Culvenor, 1981). PA-containing plants can be 
toxic to livestock, wildlife and humans (Stegelmeier et al., 1999). Human exposure to lasiocarpine and 
riddelliine may result from the consumption of contaminated food staples, plant food supplements, 
herbal medicines, herbal teas, honey and milk (EFSA, 2011, 2017). Exposure to lasiocarpine, as well 
as riddelliine has been shown to cause fatal liver veno-occlusive disease in animals and humans (Bane 
et al., 2012; Mohabbat et al., 1976; Tandon et al., 1978). A 2-year National Toxicology Program (NTP) 
study testing the genotoxicity and carcinogenicity of lasiocarpine and riddelliine showed that these 
PAs are also carcinogenic and genotoxic compounds (Chan et al., 2003; NTP, 1978, 2003). Liver 
angiosarcomas were observed in 11 of 23 male rats and 7 of 24 female rats following dietary 
administration of 0.75 mg/kg bw/day of lasiocarpine. Riddelliine induced a high incidence of liver 
hemangiosarcoma in both male (43 out of 50 rats) and female rats (38 out of 50 rats) at 0.7 mg/kg 
bw/day (Chan et al., 2003; NTP, 1978, 2003). The International Agency for Research on Cancer 
(IARC) classified these alkaloids in Group 2B, potentially carcinogenic to humans  (IARC, 2017). 
Following absorption in the gastrointestinal tract, PAs are distributed to the liver where the main 
metabolism occurs (Fu et al., 2004). In general, three metabolic pathways have been identified for 
lasiocarpine (heliotridine-type PA) and riddelliine (retronecine-type PA) (Figure 1) (EFSA, 2011; Fu 
et al., 2004). The bioactivation pathway is the conversion of lasiocarpine or riddelliine into a toxic 
intermediate, known as a dehydropyrrolizidine alkaloid, in a reaction mainly catalysed by cytochrome 
P450 3A4 (Fu et al., 2004). Dehydropyrrolizidine alkaloids react with cellular proteins and DNA 
leading to liver toxicity, genotoxicity and carcinogenicity (Fu et al., 2004). Other metabolic pathways 
include hydrolysis and N-oxidation, leading to the formation of necine bases and PA N-oxides, 
respectively (Figure 1). These latter two metabolic pathways are considered to lead to detoxification 
(EFSA, 2011). 
Significant variations between species regarding the toxicity of PAs have been observed. Recently, 
Fashe et al. (2015) conducted a comparative study on the metabolism of lasiocarpine by human and rat 
liver microsomes and found that humans might be more susceptible to lasiocarpine-induced toxicity, 
because the overall metabolic fingerprint detected upon incubation with human liver microsomes 
differed from that obtained with rat liver microsomes in the following two major aspects: 1) the 
amount of detoxified metabolites was lower in incubations with human liver microsomes than with rat 
liver microsomes, and 2) higher levels of GSH-reactive metabolites were formed in incubations with
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the human liver microsomes than with the rat liver microsomes. These species differences may be 
mediated by interspecies differences in biotransformation capacities including CYP 3A4 catalysed 
bioactivation, carboxylesterase-mediated hydrolysis and the level of cellular GSH (Fashe et al., 2015). 
In addition to these possible species differences in biotransformation capacities, other studies reported 
ethnic differences in P450 dependent metabolism and these may potentially result in inter-ethnic 
differences in PA bioactivation and detoxification. Yang et al. (2012) reported significant differences 
in phenacetin O‐deethylation, diclofenac 4′‐hydroxylation, (S)‐mephenytoin 4′‐hydroxylation and 
chlorzoxazone 6‐hydroxylation reactions, mediated by CYP 1A2, CYP 2C9, CYP 2C19 and CYP 2E1, 
respectively between Chinese and Caucasian liver microsomal preparations. Previously, we also 
reported differences between Chinese and Caucasians regarding the metabolic bioactivation and 
detoxification of the food-borne genotoxic carcinogen estragole, resulting in a predicted 4.5-fold lower 
formation of the ultimate carcinogenic metabolite of estragole with similar rates of detoxification in 
Chinese as compared to the Caucasians, and thus a possible lower risk of estragole exposure for the 
average Chinese at similar levels of exposure (Ning et al., 2017).  
Thus, inter-species and inter-ethnic human differences in metabolism might occur and may in theory 
also affect the sensitivity towards PA toxicity. The aim of this study was to predict the inter-species 
and inter-ethnic human differences in acute liver toxicity of lasiocarpine and riddelliine using 
physiologically based kinetic (PBK) modelling-based reverse dosimetry of in vitro toxicity data. 
Previously, we developed a PBK modelling-based approach to predict acute liver toxicity of 
lasiocarpine and riddelliine in rats (Chen et al., 2018). The predicted BMDL5-BMDU5 values for in 
vivo liver toxicity of lasiocarpine and riddelliine in rats amounted to 23.0-34.4 and 4.9-8.4 mg/kg 
bw/day, respectively (Chen et al., 2018). That study already showed that the PBK modelling-based 
approach was able to define inter-compound differences in acute liver toxicity of PAs. The study of 
Culvenor (1983) estimated that a dose of 0.7-3 mg/kg bw/day of riddelliine may lead to acute liver 
toxicity in humans, indicating that humans might be more sensitive than rats towards liver toxicity of 
PAs. In the present study we developed PBK models for lasiocarpine and riddelliine in different ethnic 
populations (Chinese and Caucasian) and used these models to convert in vitro toxicity data obtained 
in pooled human hepatocytes to predict in vivo dose-response data and BMDL5-BMDU5 values for 
acute liver toxicity of lasiocarpine and riddelliine in humans. Subsequently, these points of departure 
(PoDs) were compared to PoDs derived previously for rats by the same methodology (Chen et al., 
2018) to evaluate the occurrence of species differences in the metabolism and toxicity of lasiocarpine 
and riddelliine while the PoDs obtained for the average Chinese and average Caucasian provided 
insight in inter-ethnic differences. 
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Fig. 1 Schematic presentation of the major metabolic pathways of lasiocarpine (heliotridine-type PA) and 
riddelliine (retronecine-type PA), the latter shown in brackets. FMO = flavin-containing monooxygenase, CYP 
450 = cytochromes P450. 
Materials and Methods 
Chemicals and biological materials  
Lasiocarpine (purity > 97 %) was purchased from Phytolab (Vestenbergsgreuth, Germany). 
Riddelliine (purity > 90 %) was a gift from RIKILT (Wageningen, The Netherlands) and from the 
National Institute for Environmental Health Sciences (NIEHS) (Durham, USA). The HepaRG cell line 
was obtained from Biopredic International (Saint-Grégoire, France). Cryopreserved pooled human 
hepatocytes (5 mixed gender donors), cryopreserved hepatocyte plating medium (CHPM) (CM 9000) 
and cryopreserved hepatocyte recovery medium (CHRM) (CM 7000) were purchased from Invitrogen 
(Cheshire, UK). Willliams medium E (without glutamine), penicillin/streptomycine-solution, L-
glutamine, phosphate buffered saline (PBS), and trypsin-EDTA were purchased from Gibco (Paisley, 
Scotland, UK). Fetal bovine serum was purchased from the American Type Culture Collection (ATCC) 
(Manassas, USA). Dimethylsulfoxide (DMSO), human insulin and hydrocortisone-21-hemisuccinate 
were purchased from Sigma-Aldrich (Steinheim, Germany). Potassium dihydrogen phosphate, 
dipotassium hydrogen phosphate trihydrate, sodium phosphate, sodium chloride and trifluoroacetic 
acid (TFA) were purchased from VWR International (Darmstadt, Germany). Reduced nicotinamide 
adenine dinucleotide phosphate (NADPH) was obtained from Roche Diagnostics (Mannheim, 
Germany). Acetonitrile (UPLC/MS grade) was obtained from Biosolve BV (Valkenswaard, 
Netherlands). Human plasma and rapid equilibrium dialysis (RED) materials, including RED inserts, 
RED base plate and sealing tape were obtained from Thermo Fisher Scientific (Bleiswijk, the the 
Netherlands). Pooled Caucasian liver microsomes (33 donors) were purchased from Corning 
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the human liver microsomes than with the rat liver microsomes. These species differences may be 
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bioactivation, carboxylesterase-mediated hydrolysis and the level of cellular GSH (Fashe et al., 2015). 
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(Woburn, MA, USA). Pooled Caucasian intestinal microsomes (15 donors) were obtained from 
Xenotech (Lenexa, USA). Pooled Caucasian human lung and kidney microsomes were purchased 
from Biopredic International (Rennes, France). Pooled Chinese liver microsomes (40 donors) were 
purchased from PrimeTox (Wuhan, China). 
Outline of the PBK modelling-based reverse dosimetry approach in human 
The PBK modelling-based reverse dosimetry approach to predict the in vivo dose-response curves for 
risk assessment from in vitro cytotoxicity concentration-response data included the following steps: 1) 
establishment of in vitro cytotoxicity concentration-response curves for lasiocarpine and riddelliine in 
HepaRG cells and in cryopreserved pooled human hepatocytes from Caucasian donors and correcting 
for toxicity expected in hepatocytes from the Chinese population as described below, development of 
PBK models for lasiocarpine and riddelliine in human using the kinetic parameters defined in the 
present study using both Chinese and Caucasian human liver subcellular factions, 3) translation of in 
vitro concentration-response curves to the in vivo dose-response curves using the PBK models, 4) 
BMD analysis based on the predicted in vivo dose-response curves to obtain the BMDL5 and BMDU5 
values as points of departure (PoDs), 5) comparison of the predicted PoDs in human (Chinese and 
Caucasian) to one another and to the previously predicted PoDs in rats (Chen et al., 2018) to assess for 
inter-ethnic and inter-species differences in acute liver toxicity.  
In vitro liver toxicity data 
Two types of cells were used to determine the in vitro concentration-response curves for acute 
cytotoxicity in human liver including cells from the HepaRG cell line and human hepatocytes. The 
HepaRG cell line is a human hepatoma cell line, which can differentiate into hepatocyte-like 
morphology by treatment with DMSO (Kanebratt and Andersson, 2008). HepaRG cells were seeded at 
a density of 9000 cells/well in 96-well plates in growth medium consisting of Williams’ medium E, 
supplemented with 10 % fetal bovine serum (FCS), 100 IU/ml penicillin, 100 μg/ml streptomycin, 1 % 
(v/v) L-glutamine, 5 μg/ml human insulin and 50 μM hydrocortisone-21-hemisuccinate. The medium 
was renewed every two to three days. After two weeks, the cells were nearly confluent and were 
cultured in the differentiation medium supplemented with 1.7 % (v/v) DMSO. The medium was 
refreshed every two to three days. After two weeks differentiation treatment, HepaRG cells were fully 
differentiated and were used for experiments within four weeks with refreshing the medium every two 
to three days according to the protocol provided by Biopredic International.  
Cryopreserved mixed gender primary human hepatocytes from five Caucasian donors were also used 
to perform the cytotoxicity experiments and define in vitro concentration-response curves. 
Cryopreserved human hepatocytes were thawed according to the protocol provided by Invitrogen. 
Briefly, human hepatocytes were thawed in a 37 °C water bath and transferred to 50 ml thawing  
medium (CM 7000). The cells were centrifuged at room temperature at 100 g for 10 min and re-
suspended in the plating were seeded in 96-well plates at a density of 50,000 cells/well and incubated 
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in a 5 % CO2 : 95 % air- humidified incubator for 6 h, after which the cells were ready to be exposed 
to the compounds. Only batches with a cell viability > 90 % were used for experiments. 
Cytotoxicity was determined with the MTT assay by assessing the activity of mitochondrial 
dehydrogenase enzymes according to the method of Field et al. (2015). In brief, the fully differentiated 
HepaRG cells and human hepatocytes were exposed to serum free medium containing different 
concentrations of lasiocarpine and riddelliine ranging from 4 to 300 μM (final concentrations), added 
from 200 times concentrated stock solutions in DMSO. Each concentration was measured in triplicate 
and three independent experiments were performed. A solvent control was included in each 
independent experiment. After 24 hours exposure, MTT (0.45 mg/ml final concentration) was added 
and cells were incubated for another 2 hours in the incubator. The formed MTT formazan crystals 
were dissolved in DMSO and the absorbance was measured at a microplate reader at 562 nm 
(SpectraMax M2, USA). All the data are presented as mean values ± SD. The half maximal inhibitory 
concentration (IC50) values used to assess the in vitro acute liver toxicity of lasiocarpine and riddelliine 
were obtained using GraphPad Prism 5.04 (GraphPad software, San Diego California U.S.A.) using a 
non-linear regression model for curve fitting Y=Bottom + (Top-Bottom)/(1+10^((X-LogIC50))). The 
in vitro concentration-response curve for liver toxicity for Chinese hepatocytes was obtained as 
described below. 
In vitro microsomal incubations 
The in vitro incubation for the conversion of lasiocarpine with Chinese and Caucasian liver 
microsomes were performed as described by Fashe et al. (2015). Briefly, mixed gender human liver 
microsomes were incubated with lasiocarpine in the presence of NADPH. The incubation mixtures 
contained (final concentrations) 2 mM NADPH and 0.04 mg/ml microsomal protein in 0.1 M 
potassium phosphate (pH 7.4). After pre-incubation for 5 min, the reaction was started by adding 
NADPH. Incubations were performed for 30 min at substrate concentrations ranging from 3 to 200 
μM (final concentrations) (added from 100 times concentrated stock solutions in DMSO), after which 
the reaction was terminated by adding ice-cold acetonitrile (20 % v/v). Under these conditions 
conversion of lasiocarpine was linear in time (1-30 min) and with the amount of microsomal protein 
(0.01-0.04 mg/ml) (data not shown). Blank incubations were performed in the absence of the cofactor 
NADPH. 
The incubation conditions for metabolism of riddelliine with human liver microsomes contained (final 
concentrations) 2 mM NADPH, 0.5 mg/ml microsomal protein for Chinese and Caucasian samples in 
0.1 M potassium phosphate (pH 7.4) and 3 to 400 μM (final concentrations) riddelliine added from 
100 times concentrated stock solutions in DMSO. After 5 min pre-incubation at 37 °C, the reactions 
were started by adding NADPH. Incubations were carried out for 30 min and the reaction was 
terminated by adding ice-cold acetonitrile (20 % v/v). Under these conditions conversion 
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inter-ethnic and inter-species differences in acute liver toxicity.  
In vitro liver toxicity data 
Two types of cells were used to determine the in vitro concentration-response curves for acute 
cytotoxicity in human liver including cells from the HepaRG cell line and human hepatocytes. The 
HepaRG cell line is a human hepatoma cell line, which can differentiate into hepatocyte-like 
morphology by treatment with DMSO (Kanebratt and Andersson, 2008). HepaRG cells were seeded at 
a density of 9000 cells/well in 96-well plates in growth medium consisting of Williams’ medium E, 
supplemented with 10 % fetal bovine serum (FCS), 100 IU/ml penicillin, 100 μg/ml streptomycin, 1 % 
(v/v) L-glutamine, 5 μg/ml human insulin and 50 μM hydrocortisone-21-hemisuccinate. The medium 
was renewed every two to three days. After two weeks, the cells were nearly confluent and were 
cultured in the differentiation medium supplemented with 1.7 % (v/v) DMSO. The medium was 
refreshed every two to three days. After two weeks differentiation treatment, HepaRG cells were fully 
differentiated and were used for experiments within four weeks with refreshing the medium every two 
to three days according to the protocol provided by Biopredic International.  
Cryopreserved mixed gender primary human hepatocytes from five Caucasian donors were also used 
to perform the cytotoxicity experiments and define in vitro concentration-response curves. 
Cryopreserved human hepatocytes were thawed according to the protocol provided by Invitrogen. 
Briefly, human hepatocytes were thawed in a 37 °C water bath and transferred to 50 ml thawing  
medium (CM 7000). The cells were centrifuged at room temperature at 100 g for 10 min and re-
suspended in the plating were seeded in 96-well plates at a density of 50,000 cells/well and incubated 
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in a 5 % CO2 : 95 % air- humidified incubator for 6 h, after which the cells were ready to be exposed 
to the compounds. Only batches with a cell viability > 90 % were used for experiments. 
Cytotoxicity was determined with the MTT assay by assessing the activity of mitochondrial 
dehydrogenase enzymes according to the method of Field et al. (2015). In brief, the fully differentiated 
HepaRG cells and human hepatocytes were exposed to serum free medium containing different 
concentrations of lasiocarpine and riddelliine ranging from 4 to 300 μM (final concentrations), added 
from 200 times concentrated stock solutions in DMSO. Each concentration was measured in triplicate 
and three independent experiments were performed. A solvent control was included in each 
independent experiment. After 24 hours exposure, MTT (0.45 mg/ml final concentration) was added 
and cells were incubated for another 2 hours in the incubator. The formed MTT formazan crystals 
were dissolved in DMSO and the absorbance was measured at a microplate reader at 562 nm 
(SpectraMax M2, USA). All the data are presented as mean values ± SD. The half maximal inhibitory 
concentration (IC50) values used to assess the in vitro acute liver toxicity of lasiocarpine and riddelliine 
were obtained using GraphPad Prism 5.04 (GraphPad software, San Diego California U.S.A.) using a 
non-linear regression model for curve fitting Y=Bottom + (Top-Bottom)/(1+10^((X-LogIC50))). The 
in vitro concentration-response curve for liver toxicity for Chinese hepatocytes was obtained as 
described below. 
In vitro microsomal incubations 
The in vitro incubation for the conversion of lasiocarpine with Chinese and Caucasian liver 
microsomes were performed as described by Fashe et al. (2015). Briefly, mixed gender human liver 
microsomes were incubated with lasiocarpine in the presence of NADPH. The incubation mixtures 
contained (final concentrations) 2 mM NADPH and 0.04 mg/ml microsomal protein in 0.1 M 
potassium phosphate (pH 7.4). After pre-incubation for 5 min, the reaction was started by adding 
NADPH. Incubations were performed for 30 min at substrate concentrations ranging from 3 to 200 
μM (final concentrations) (added from 100 times concentrated stock solutions in DMSO), after which 
the reaction was terminated by adding ice-cold acetonitrile (20 % v/v). Under these conditions 
conversion of lasiocarpine was linear in time (1-30 min) and with the amount of microsomal protein 
(0.01-0.04 mg/ml) (data not shown). Blank incubations were performed in the absence of the cofactor 
NADPH. 
The incubation conditions for metabolism of riddelliine with human liver microsomes contained (final 
concentrations) 2 mM NADPH, 0.5 mg/ml microsomal protein for Chinese and Caucasian samples in 
0.1 M potassium phosphate (pH 7.4) and 3 to 400 μM (final concentrations) riddelliine added from 
100 times concentrated stock solutions in DMSO. After 5 min pre-incubation at 37 °C, the reactions 
were started by adding NADPH. Incubations were carried out for 30 min and the reaction was 
terminated by adding ice-cold acetonitrile (20 % v/v). Under these conditions conversion 
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of riddelliine was linear in time (1-30 min) and with the amount of microsomal protein (0.04-0.5 
mg/ml) (data not shown). Blank incubations were performed in the absence of the cofactor NADPH. 
To compare the inter-ethnic differences in metabolic activation of lasiocarpine and riddelliine, 
incubations with Chinese and Caucasian liver microsomes were performed as described above in the 
presence of 4 mM glutathione (GSH) to scavenge dehydropyrrolizidine alkaloids metabolites. The 
level of GSH in the incubations was optimized to obtain the maximum scavenging of 
dehydropyrrolizidine alkaloids metabolites as major glutathione conjugate, namely 7-GS-DHP (Tamta 
et al., 2012), which was analyzed by LC-MS/MS analysis as described below.  
The kinetic constants for conversion of lasiocarpine and riddelliine by Caucasian intestinal, lung and 
kidney microsomal preparations were determined as described above for liver microsomes but 
increasing the incubation time to 2 h. Under these conditions conversion of lasiocarpine and riddelliine 
was linear with time (1-120 minutes) and with the amount of microsomal protein added (0.01-0.04 
mg/ml for lasiocarpine, 0.04-0.5 mg/ml for riddelliine) for the intestine, whereas negligible conversion 
was observed for lung and kidney (data not shown). Before Ultra Performance Liquid 
Chromatography photodiode array analysis (UPLC-PDA) or LC-MS/MS analysis, all samples were 
centrifuged for 5 min at 15,000 g to precipitate microsomal proteins. Intestine, lung and kidney 
microsomes from the Chinese population are not available. However, the kinetic parameters obtained 
using pooled intestinal microsomal preparations from Caucasian individuals were used for the Chinese 
PBK model, because the results of the sensitivity analysis revealed that the parameters related to the 
intestinal metabolism of lasiocarpine and riddelliine do not have a large influence on the predicted 
maximum concentration in the liver blood (Cmax). Because conversion by kidney and lung microsomes 
was negligible (see result section), no further kinetic data for these organs were required. 
The substrate depletion approach was used to obtain the kinetic parameters. The amount of substrate 
depletion of lasiocarpine and riddelliine was determined as the amount detected in the blank 
incubations in the absence of the cofactor NADPH minus the amount detected in the incubations with 
NADPH. The amounts of 7-GS-DHP formed were corrected for the amounts detected in the blank 
incubations performed without cofactor NADPH. The data for the rate of conversion of lasiocarpine 
and riddelliine with increasing substrate concentration [S] were fitted to the standard Michaelis-
Menten equation (1): 
(1) max mv V / (1 K /[S])   
The apparent maximum velocity (Vmax) and the apparent Michaelis-Menten constant (Km) were 
determined by fitting the data to this equation using GraphPad Prism version 5.04 (GraphPad software, 
San Diego California U.S.A.). Vmax values expressed as nmol/min/(mg microsomal protein) were 
scaled to the Vmax expressed as mol/h/kg bw using microsomal protein yields of 35 mg/g liver
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(Medinsky et al. 1994) and 20.6 mg/g small intestine (Cubitt et al. 2009). The Km values determined in 
vitro were assumed to be equal to in vivo Km values. 
Protein binding correction 
To correct for protein binding in the in vivo situation in human liver blood, while the in vitro toxicity 
was determined in serum free medium, the fraction of unbound lasiocarpine and riddelliine under the 
in vivo conditions (fub) was determined. To this end the fub for both compounds in human blood was 
determined using the RED (rapid equilibrium dialysis) device. According to the protocol described by 
Waters et al. (2008), 300 μl of spiked human plasma containing 5 μM lasiocarpine and 5 or 50 μM 
riddelliine (final concentration, 1 % v/v DMSO) were added to the plasma chambers of the RED 
device insert, while 500 μl dialysis buffer (PBS containing 100 mM sodium phosphate and 150 mM 
sodium chloride) were added to the buffer chamber. The device was sealed with tape and incubated at 
37 °C on a shaker at 250 rpm for 5 h. After the system reached equilibrium, 50 μl of post-dialysis 
samples were collected from the plasma and buffer chambers into separate tubes. Subsequently, 50 μl 
of human plasma was added to the buffer samples and the same volume of dialysis buffer was added 
to the plasma samples,  after which protein was precipitated by addition of ice-cold acetonitrile (75 % 
v/v). After incubation on ice for 30 min, the mixtures were centrifuged at 15,000 g for 15 min at 4 °C, 
and the supernatants were analyzed by UPLC-PDA. The measurements were performed in three 
independent experiments. 
The fraction of unbound lasiocarpine and riddelliine in human blood (fub) was assumed to be the same 
as in human plasma in the present study and was defined as the ratio of the concentration of the test 
compound in the buffer chamber and the concentration in the plasma chamber (van Liempd et al., 
2011; Waters et al., 2008). The fub thus obtained was used to correct for the difference in protein 
binding in the in vitro assay and the in vivo situation when performing the PBK modelling-based 
reverse dosimetry. To this end the effect concentration of lasiocarpine and  riddelliine in human liver 
blood (CLc/Rd, human blood) used for reverse dosimetry was corrected by the following equation (2):  
(2) Lc/Rd, human blood ub, in vitro ubC C / f  
Where fub is the fraction of the unbound lasiocarpine and riddelliine in human blood and Cub, in vitro is 
the unbound concentration of lasiocarpine and riddelliine in the in vitro culture medium. Since the 
exposure medium for the HepaRG and human hepatocyte cell lines was serum free, the concentrations 
of lasiocarpine and riddelliine in the in vitro cytotoxicity assay were considered to be the unbound 
concentration. This correction implies that the unbound fraction in vitro is set equal to the unbound 
fraction in vivo. 
UPLC and LC-MS/MS analysis  
The supernatant of each sample was analyzed on UPLC using a BEH C18 (1.7 μm 2.1×50 mm)
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of riddelliine was linear in time (1-30 min) and with the amount of microsomal protein (0.04-0.5 
mg/ml) (data not shown). Blank incubations were performed in the absence of the cofactor NADPH. 
To compare the inter-ethnic differences in metabolic activation of lasiocarpine and riddelliine, 
incubations with Chinese and Caucasian liver microsomes were performed as described above in the 
presence of 4 mM glutathione (GSH) to scavenge dehydropyrrolizidine alkaloids metabolites. The 
level of GSH in the incubations was optimized to obtain the maximum scavenging of 
dehydropyrrolizidine alkaloids metabolites as major glutathione conjugate, namely 7-GS-DHP (Tamta 
et al., 2012), which was analyzed by LC-MS/MS analysis as described below.  
The kinetic constants for conversion of lasiocarpine and riddelliine by Caucasian intestinal, lung and 
kidney microsomal preparations were determined as described above for liver microsomes but 
increasing the incubation time to 2 h. Under these conditions conversion of lasiocarpine and riddelliine 
was linear with time (1-120 minutes) and with the amount of microsomal protein added (0.01-0.04 
mg/ml for lasiocarpine, 0.04-0.5 mg/ml for riddelliine) for the intestine, whereas negligible conversion 
was observed for lung and kidney (data not shown). Before Ultra Performance Liquid 
Chromatography photodiode array analysis (UPLC-PDA) or LC-MS/MS analysis, all samples were 
centrifuged for 5 min at 15,000 g to precipitate microsomal proteins. Intestine, lung and kidney 
microsomes from the Chinese population are not available. However, the kinetic parameters obtained 
using pooled intestinal microsomal preparations from Caucasian individuals were used for the Chinese 
PBK model, because the results of the sensitivity analysis revealed that the parameters related to the 
intestinal metabolism of lasiocarpine and riddelliine do not have a large influence on the predicted 
maximum concentration in the liver blood (Cmax). Because conversion by kidney and lung microsomes 
was negligible (see result section), no further kinetic data for these organs were required. 
The substrate depletion approach was used to obtain the kinetic parameters. The amount of substrate 
depletion of lasiocarpine and riddelliine was determined as the amount detected in the blank 
incubations in the absence of the cofactor NADPH minus the amount detected in the incubations with 
NADPH. The amounts of 7-GS-DHP formed were corrected for the amounts detected in the blank 
incubations performed without cofactor NADPH. The data for the rate of conversion of lasiocarpine 
and riddelliine with increasing substrate concentration [S] were fitted to the standard Michaelis-
Menten equation (1): 
(1) max mv V / (1 K /[S])   
The apparent maximum velocity (Vmax) and the apparent Michaelis-Menten constant (Km) were 
determined by fitting the data to this equation using GraphPad Prism version 5.04 (GraphPad software, 
San Diego California U.S.A.). Vmax values expressed as nmol/min/(mg microsomal protein) were 
scaled to the Vmax expressed as mol/h/kg bw using microsomal protein yields of 35 mg/g liver
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(Medinsky et al. 1994) and 20.6 mg/g small intestine (Cubitt et al. 2009). The Km values determined in 
vitro were assumed to be equal to in vivo Km values. 
Protein binding correction 
To correct for protein binding in the in vivo situation in human liver blood, while the in vitro toxicity 
was determined in serum free medium, the fraction of unbound lasiocarpine and riddelliine under the 
in vivo conditions (fub) was determined. To this end the fub for both compounds in human blood was 
determined using the RED (rapid equilibrium dialysis) device. According to the protocol described by 
Waters et al. (2008), 300 μl of spiked human plasma containing 5 μM lasiocarpine and 5 or 50 μM 
riddelliine (final concentration, 1 % v/v DMSO) were added to the plasma chambers of the RED 
device insert, while 500 μl dialysis buffer (PBS containing 100 mM sodium phosphate and 150 mM 
sodium chloride) were added to the buffer chamber. The device was sealed with tape and incubated at 
37 °C on a shaker at 250 rpm for 5 h. After the system reached equilibrium, 50 μl of post-dialysis 
samples were collected from the plasma and buffer chambers into separate tubes. Subsequently, 50 μl 
of human plasma was added to the buffer samples and the same volume of dialysis buffer was added 
to the plasma samples,  after which protein was precipitated by addition of ice-cold acetonitrile (75 % 
v/v). After incubation on ice for 30 min, the mixtures were centrifuged at 15,000 g for 15 min at 4 °C, 
and the supernatants were analyzed by UPLC-PDA. The measurements were performed in three 
independent experiments. 
The fraction of unbound lasiocarpine and riddelliine in human blood (fub) was assumed to be the same 
as in human plasma in the present study and was defined as the ratio of the concentration of the test 
compound in the buffer chamber and the concentration in the plasma chamber (van Liempd et al., 
2011; Waters et al., 2008). The fub thus obtained was used to correct for the difference in protein 
binding in the in vitro assay and the in vivo situation when performing the PBK modelling-based 
reverse dosimetry. To this end the effect concentration of lasiocarpine and  riddelliine in human liver 
blood (CLc/Rd, human blood) used for reverse dosimetry was corrected by the following equation (2):  
(2) Lc/Rd, human blood ub, in vitro ubC C / f  
Where fub is the fraction of the unbound lasiocarpine and riddelliine in human blood and Cub, in vitro is 
the unbound concentration of lasiocarpine and riddelliine in the in vitro culture medium. Since the 
exposure medium for the HepaRG and human hepatocyte cell lines was serum free, the concentrations 
of lasiocarpine and riddelliine in the in vitro cytotoxicity assay were considered to be the unbound 
concentration. This correction implies that the unbound fraction in vitro is set equal to the unbound 
fraction in vivo. 
UPLC and LC-MS/MS analysis  
The supernatant of each sample was analyzed on UPLC using a BEH C18 (1.7 μm 2.1×50 mm)
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column with a guard column and a photodiode array detector (PDA) (Acquity, Waters). The flow rate 
was 0.6 ml/min and the mobile phase consisted of ultrapure water with 0.1 % (v/v) TFA and 
acetonitrile. For the analysis of lasiocarpine, a gradient was applied from 0 to 50 % acetonitrile in 
ultrapure water in 2 min, after which the percentage of acetonitrile was increased to 100 % in 3 min 
and kept at this level for 2 min longer, after which the column was set back to the starting conditions. 
Under these conditions, lasiocarpine had a retention time of 1.9 min. For detection of riddelliine, a 
linear gradient from 0 to 50 % acetonitrile in ultrapure water during 4 min was applied, followed by an 
increase to 100 % acetonitrile in 1 min. This percentage was kept for 1 min to wash the column, after 
which the column was set back to the starting conditions. Under these conditions, riddelliine eluted at 
1.8 min. Identification of lasiocarpine and riddelliine was achieved by comparison of the UV spectra 
and retention times of these compounds to those of reference compounds. Quantification of 
lasiocarpine and riddelliine was done by comparing the peak areas of these compounds at a 
wavelength of 220 nm to the calibration curve of the corresponding standard compounds.  
The major glutathione conjugate of lasiocarpine and riddelliine, 7-GS-DHP was analyzed and 
quantified by LC-MS/MS. LC-MS/MS analysis was performed on a Shimadzu Nexera XR LC-20AD 
SR UPLC system coupled with a Shimadzu LCMS-8040 mass spectrometer (Kyoto, Japan). The 
samples (1 μl) were loaded onto a reverse phase C18 column (1.7 μm 2.1×50 mm) with a flow rate of 
0.3 ml/min. The column temperature was set to 40 °C. The mobile phase consisted of ultrapure water 
with 0.1 % (v/v) formic acid and acetonitrile containing 0.1 % (v/v) formic acid. The gradient began 
with 0 % acetonitrile for one minute to wash away unwanted salts, followed by a linear gradient from 
0 to 5 % in 8 min and a further increase to 100 % in 6 min. This percentage was kept for 0.5 min, after 
which the column was set back to the starting conditions. A Shimadzu LCMS-8040 triple quadrupole 
with electrospray ionization (ESI) interface was used to perform the MS-MS analysis. The instrument 
was operated in positive mode in the multiple reaction monitoring (MRM) mode with a spray voltage 
of 4.5 KV. The 7-GS-DHP was monitored at the [M+H]+ of precursor to product 443.2 → 
425.15(CE=-7kV), 443.2 → 118.1 (CE=-24kV) and 443.2 → 247.2 (CE=-15kV) m/z. Some of these 
MRMs were also used in study of Tamta et al. (2012). Under these conditions, 7-GS-DHP eluted at 
8.97 min and the chromatogram of 7-GS-DHP is presented in the supplementary materials 1. The peak 
area of total ion chromatogram (TIC) of 7-GS-DHP was acquired using Postrun analysis in the 
software LabSolution (Shimadzu). The ratio of the peak areas of 7-GS-DHP formed in incubations 
with  Chinese and Caucasian liver microsomes at each substrate concentration, was assumed to reflect 
the inter-ethnic differences in metabolic activation of lasiocarpine and riddelliine. Thus these ratios 
were  used to convert the concentration-response curve for in vitro toxicity obtained with human 
hepatocytes derived from Caucasian donors to a curve for Chinese donors. To this end the percentage 
of cytotoxicity at each concentration was multiplied by the amount of 7-GS-DHP formed in incubation 
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with Caucasian liver samples divided by the amount formed in similar incubations with Chinese liver 
microsomes. This provided an estimated concentration-response curve for cytotoxicity towards 
Chinese liver hepatocytes. 
Development of a PBK model for lasiocarpine and riddelliine in human  
PBK models for lasiocapine and riddelliine for the average Chinese and average Caucasian were 
developed based on the PBK models previously defined and evaluated by Chen et al. (2018) for 
lasiocarpine and riddelliine in rats. The structure of the model for lasiocarpine and riddelliine is 
presented in Figure 2. The model has 7 compartments including blood, fat, rapidly perfused tissue, 
slowly perfused tissue, liver and intestine that are mutually connected through the systemic circulation 
which is represented by a blood compartment. The intestine and liver compartments are included in 
the model, since the conversion of lasiocarpine and riddelliine occurs in these organs. The 
physiological parameters for the average Chinese and average Caucasian were derived from the 
literature (Brown et al., 1997; NHFPC, 2007, 2014) and are presented in Table S2 in the 
supplementary materials 2. Several reports from the literature indicate that Chinese have significantly 
smaller livers than Caucasians (Chan et al., 2006; Shi et al., 2009; Yuan et al., 2008). The 
physiological parameters provided by National Health Commission of the People’s Republic of China 
(NHFPC) also show that the Chinese liver volume is 1.3-fold lower than the Caucasian liver volume. 
The tissue:blood partition coefficients were estimated from log Kow according to the method described 
by DeJongh et al. (1997). The log Kow values for lasiocarpine and riddelliine were estimated by 
ChemBio 3D 2010 software (CambrigeSoft, USA).  
Lasiocarpine and riddelliine were assumed to enter the body from the gastrointestinal tract lumen 
following first order uptake. The in vivo oral absorption rate constant (Ka) of lasiocarpine and 
riddelliine in human were assumed to be the same as previously determined (Chen et al. 2018). The 
Ka obtained for lasiocarpine was 1.55/h and for riddelliine the value amounted to 0.72/h. Model 
equations were coded (supplementary materials 3) and numerically integrated in Berkeley Madonna 
8.0.1 (Macey and Oster, UC Berkeley, CA, USA) using the Rosenbrock's algorithm for stiff systems.
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column with a guard column and a photodiode array detector (PDA) (Acquity, Waters). The flow rate 
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ultrapure water in 2 min, after which the percentage of acetonitrile was increased to 100 % in 3 min 
and kept at this level for 2 min longer, after which the column was set back to the starting conditions. 
Under these conditions, lasiocarpine had a retention time of 1.9 min. For detection of riddelliine, a 
linear gradient from 0 to 50 % acetonitrile in ultrapure water during 4 min was applied, followed by an 
increase to 100 % acetonitrile in 1 min. This percentage was kept for 1 min to wash the column, after 
which the column was set back to the starting conditions. Under these conditions, riddelliine eluted at 
1.8 min. Identification of lasiocarpine and riddelliine was achieved by comparison of the UV spectra 
and retention times of these compounds to those of reference compounds. Quantification of 
lasiocarpine and riddelliine was done by comparing the peak areas of these compounds at a 
wavelength of 220 nm to the calibration curve of the corresponding standard compounds.  
The major glutathione conjugate of lasiocarpine and riddelliine, 7-GS-DHP was analyzed and 
quantified by LC-MS/MS. LC-MS/MS analysis was performed on a Shimadzu Nexera XR LC-20AD 
SR UPLC system coupled with a Shimadzu LCMS-8040 mass spectrometer (Kyoto, Japan). The 
samples (1 μl) were loaded onto a reverse phase C18 column (1.7 μm 2.1×50 mm) with a flow rate of 
0.3 ml/min. The column temperature was set to 40 °C. The mobile phase consisted of ultrapure water 
with 0.1 % (v/v) formic acid and acetonitrile containing 0.1 % (v/v) formic acid. The gradient began 
with 0 % acetonitrile for one minute to wash away unwanted salts, followed by a linear gradient from 
0 to 5 % in 8 min and a further increase to 100 % in 6 min. This percentage was kept for 0.5 min, after 
which the column was set back to the starting conditions. A Shimadzu LCMS-8040 triple quadrupole 
with electrospray ionization (ESI) interface was used to perform the MS-MS analysis. The instrument 
was operated in positive mode in the multiple reaction monitoring (MRM) mode with a spray voltage 
of 4.5 KV. The 7-GS-DHP was monitored at the [M+H]+ of precursor to product 443.2 → 
425.15(CE=-7kV), 443.2 → 118.1 (CE=-24kV) and 443.2 → 247.2 (CE=-15kV) m/z. Some of these 
MRMs were also used in study of Tamta et al. (2012). Under these conditions, 7-GS-DHP eluted at 
8.97 min and the chromatogram of 7-GS-DHP is presented in the supplementary materials 1. The peak 
area of total ion chromatogram (TIC) of 7-GS-DHP was acquired using Postrun analysis in the 
software LabSolution (Shimadzu). The ratio of the peak areas of 7-GS-DHP formed in incubations 
with  Chinese and Caucasian liver microsomes at each substrate concentration, was assumed to reflect 
the inter-ethnic differences in metabolic activation of lasiocarpine and riddelliine. Thus these ratios 
were  used to convert the concentration-response curve for in vitro toxicity obtained with human 
hepatocytes derived from Caucasian donors to a curve for Chinese donors. To this end the percentage 
of cytotoxicity at each concentration was multiplied by the amount of 7-GS-DHP formed in incubation 
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Chinese liver hepatocytes. 
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PBK models for lasiocapine and riddelliine for the average Chinese and average Caucasian were 
developed based on the PBK models previously defined and evaluated by Chen et al. (2018) for 
lasiocarpine and riddelliine in rats. The structure of the model for lasiocarpine and riddelliine is 
presented in Figure 2. The model has 7 compartments including blood, fat, rapidly perfused tissue, 
slowly perfused tissue, liver and intestine that are mutually connected through the systemic circulation 
which is represented by a blood compartment. The intestine and liver compartments are included in 
the model, since the conversion of lasiocarpine and riddelliine occurs in these organs. The 
physiological parameters for the average Chinese and average Caucasian were derived from the 
literature (Brown et al., 1997; NHFPC, 2007, 2014) and are presented in Table S2 in the 
supplementary materials 2. Several reports from the literature indicate that Chinese have significantly 
smaller livers than Caucasians (Chan et al., 2006; Shi et al., 2009; Yuan et al., 2008). The 
physiological parameters provided by National Health Commission of the People’s Republic of China 
(NHFPC) also show that the Chinese liver volume is 1.3-fold lower than the Caucasian liver volume. 
The tissue:blood partition coefficients were estimated from log Kow according to the method described 
by DeJongh et al. (1997). The log Kow values for lasiocarpine and riddelliine were estimated by 
ChemBio 3D 2010 software (CambrigeSoft, USA).  
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Fig. 2 Schematic diagram of the PBK models for lasiocarpine and riddelliine in human. 
Sensitivity analysis  
A sensitivity analysis was performed to identify which parameters have the largest influence on the 
model predictions. Normalized sensitivity coefficients (SC) were determined using the following 
equation (3) for the prediction of maximum liver blood concentration (Cmax) of lasiocarpine and 
riddelliine: 
(3) ' 'SC (C C) / (P P) (P / C)     
Where C is the initial value of the model output (Cmax in liver blood); C' is the modified model output 
resulting from a 5 % increase of the parameter value; P is the initial parameter value; P' is the modified 
parameter value (Evans and Andersen, 2000). A 5 % increase in parameter values was chosen to 
analyze the effect of a change in parameter values on Cmax of lasiocarpine and riddelliine at a dose of 8 
ng/kg bw/day and 3 mg/kg bw/day for 24 hours exposure, representing respectively an average daily 
intake of PAs via consumption of herbal tea (Bfr, 2013) and a dose level known to cause liver toxicity 
in humans (Culvenor, 1983). Each parameter was analyzed individually while other parameters were 
kept at their initial value. 
Translation of the in vitro concentration-response curves to in vivo dose-response curves 
The in vitro concentration-response curves on acute cytotoxicity were translated to in vivo dose-
response curves on hepatotoxicity of lasiocarpine and riddelliine by PBK modelling-based reverse 
dosimetry. For this translation, each concentration applied in the cytotoxicity experiments was
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converted to a corresponding CLc/Rd, human blood which was then assumed to be the Cmax (the maximum 
concentration) of lasiocarpine and riddelliine in the liver blood and used as input in the PBK model to 
determine the corresponding oral dose which would result in acute hepatotoxicity. By performing this 
exercise for each concentration used in the in vitro cytotoxicity assay, the concentration-response 
curve was translated to an in vivo dose-response curve.  
The in vitro concentration-response curve on cytotoxicity of lasiocarpine and riddelliine for the 
average Chinese was obtained based on in vitro concentration-response curves on cytotoxicity derived 
from mixed gender human (Caucasian) liver hepatocytes, correcting the curve for the differences in 
bioactivation between Chinese and Caucasians as explained above. This was done because mixed 
gender Chinese liver hepatocytes were not available. To this end each concentration in the cytotoxicity 
experiment was first multiplied by the fold difference in the peak area of the major glutathione 
conjugate, 7-GS-DHP formed in liver microsomal incubations in the presence of GSH for Chinese and 
Caucasian samples. Subsequently, the corrected in vitro concentration-response curves for Chinese 
was translated to the in vivo dose-response curves based on the same approach as described above for 
Caucasians using the PBK model for the average Chinese.  
BMD analysis of predicted in vivo dose-response data 
BMD modelling was applied on the predicted in vivo dose-response curves to derive the BMDL5-
BMDU5 (lower-upper 90 % confidence interval of the benchmark dose that gives a 5 % response) for 
hepatotoxicity by the PROAST software version 38.9 developed by RIVM (the Dutch National 
Institute for Public Health and the Environment) (Slob, 2002). This BMD modelling was performed 
using Exponential and Hill models for continuous data. Models were selected if they passed the 
goodness-of-fit test at P = 0.05 and the ratio of the BMD5 and BMDL5 was not more than 3-fold (EPA, 
2017). 
Resultes 
In vitro cytotoxicity 
Figure 3 shows the concentration-response curves for the cytotoxicity of lasiocarpine and riddelliine in 
HepaRG cells and human pooled hepatocytes from Caucasian donors. Table 1 shows the IC50 values 
derived from these concentration-response curves. The IC50 for the cytotoxicity of lasiocarpine and 
riddelliine towards rat hepatocytes reported in the previous study of Chen et al. (2018) are also shown 
in Table 1 for comparison (Chen et al., 2018). The results show that rat hepatocytes are more sensitive 
to lasiocarpine and riddelliine than the HepaRG and human hepatocytes, with the IC50 of lasiocarpine 
in rat hepatocytes being 20- and 2-fold lower than the IC50 in HepaRG and human hepatocytes, 
respectively and the IC50 of riddelliine in rat hepatocytes being 22- and 7-fold lower than the IC50 for 
riddelliine in HepaRG and human hepatocytes, respectively. Therefore, the sensitivity towards the 
toxicity of lasiocarpine and riddelliine decreases in the order: rat hepatocytes > human hepatocytes >
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Fig. 2 Schematic diagram of the PBK models for lasiocarpine and riddelliine in human. 
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(3) ' 'SC (C C) / (P P) (P / C)     
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resulting from a 5 % increase of the parameter value; P is the initial parameter value; P' is the modified 
parameter value (Evans and Andersen, 2000). A 5 % increase in parameter values was chosen to 
analyze the effect of a change in parameter values on Cmax of lasiocarpine and riddelliine at a dose of 8 
ng/kg bw/day and 3 mg/kg bw/day for 24 hours exposure, representing respectively an average daily 
intake of PAs via consumption of herbal tea (Bfr, 2013) and a dose level known to cause liver toxicity 
in humans (Culvenor, 1983). Each parameter was analyzed individually while other parameters were 
kept at their initial value. 
Translation of the in vitro concentration-response curves to in vivo dose-response curves 
The in vitro concentration-response curves on acute cytotoxicity were translated to in vivo dose-
response curves on hepatotoxicity of lasiocarpine and riddelliine by PBK modelling-based reverse 
dosimetry. For this translation, each concentration applied in the cytotoxicity experiments was
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> HepaRG cells. In the different cell models the cytotoxicity of lasiocarpine and riddelliine is 
comparable. For HepaRG cells the IC50 of lasiocarpine is 1.7-fold higher than that of riddelliine while 
for human hepatocytes, the IC50 of lasiocarpine is 2.1-fold lower than that of riddelliine. Chen et al. 
(2018) already reported that the IC50 of lasiocarpine was 1.8-fold higher than that of riddelliine in rat 
hepatocytes (Chen et al., 2018).  
Given that Chinese human liver hepatocytes are not available, the cytotoxicity of lasiocarpine and 
riddelliine towards Chinese liver hepatocytes was modelled based on the concentration-response 
curves obtained with mixed gender Caucasian liver hepatocytes, making a correction for the relative 
difference in bioactivation as determined in in vitro incubations. Figure 3 also shows the in vitro 
concentration-response curves of lasiocarpine and riddelliine for the Chinese population obtained in 
this way. From figure 3, the IC50 of lasiocarpine and riddelliine were derived for the average Chinese 
amounting to 126 ± 39 µM and 380 ± 67 µM, respectively. Comparing these IC50 values to the values 
obtained for the average Caucasian (Table 1), reveals that the IC50 values of lasiocarpine and 
riddelliine for the Chinese is estimated to be 6.0-fold and 8.6-fold higher, respectively. The 
cytotoxicity data are presented in the supplementary materials 4. 
Table 1 IC50 values for the cytotoxicity of lasiocarpine and riddelliine in different cell models 
Cell line IC50 (µM) ± SD Studies  
Lasiocarpine    
HepaRG cells 215 ± 47 Present study  
Human (Caucasian) hepatocytes  21 ± 7 Present study 
Corrected human (Chinese) hepatocytes 126 ± 39 Present study 
Rat hepatocytes  11 ± 2 Chen et al. (2018) 
Riddelliine    
HepaRG cells 130 ± 30 Present study  
Human (Caucasian) hepatocytes  44 ± 9 Present study 
Corrected human (Chinese) hepatocytes 380 ± 67 Present study 
Rat hepatocytes  6 ± 1 Chen et al. (2018) 
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Fig. 3 Concentration-response curves for the cytotoxicity of lasiocarpine (black line) and riddelliine (grey line) 
in  HepaRG cells (squares), human (Caucasian) hepatocytes (triangles) and corrected human (Chinese) 
hepatocytes (circles) upon 24 hours exposure (mean values ± SD). 
Microsomal conversion of lasiocarpine and riddelliine by Chinese and Caucasian tissue 
fractions 
Upon incubation of increasing concentrations of lasiocarpine and riddelliine with Chinese and 
Caucasian tissue fractions and NADPH, the extent of substrate depletion was quantified by UPLC-
PDA analysis. Table 2 displays the apparent Vmax and Km values obtained from the plots as shown in 
Figure 4 and the catalytic efficiency, calculated as Vmax/Km. Conversion of lasiocarpine and riddelliine 
was detected in incubations with liver and intestinal microsomes. Incubations of lasiocarpine and 
riddelliine with lung and kidney microsomes of Caucasians did not result in detectable metabolic 
conversion. Lung and kidney microsomes from Chinese individuals were not available, but it was 
assumed that they would also not cause metabolic conversion of lasiocarpine and riddelliine. Liver 
was the major organ for lasiocarpine and riddelliine metabolism, as reflected by the fact that the 
catalytic efficiency for the depletion of lasiocarpine or riddelliine in incubations with pooled liver 
microsomes from Caucasian individuals is around 15-fold higher than the catalytic efficiency derived 
from incubations with intestinal microsomes. Comparison of the kinetic constants for lasiocarpine and 
riddelliine reveals that for depletion of lasiocarpine by Chinese liver fractions, the Vmax is 15.3-fold 
higher and the Km is 3.7-fold lower than for riddelliine, resulting in a 54.8-fold higher catalytic 
efficiency for lasiocarpine metabolism. For Caucasian liver samples, the Vmax and Km for depletion of 
lasiocarpine are 2.6-fold higher and 10.5-fold lower, respectively, than those of riddelliine, resulting in 
a 27.1-fold higher catalytic efficiency for depletion of lasiocarpine. In the case of the intestine, the 
apparent Vmax and Km for the depletion of lasiocarpine in incubations with small intestinal microsomes 
from Caucasians are 5.0-fold higher and 5.3-fold lower, respectively, than those of riddelliine. The 
catalytic efficiency for depletion of lasiocarpine in these intestinal incubations is 25-fold higher than 
for depletion of riddelliine. 
Comparison of the kinetic data for the depletion of lasiocarpine and riddelliine by liver fractions from
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the Chinese and Caucasians reveals that the catalytic efficiency for both compounds by the Chinese 
liver samples is 2.3 to 4.6-fold lower, which is mainly due to a 2.0-fold higher Km for depletion of 
lasiocarpine and 6.7-fold lower Vmax for depletion of riddelliine in Chinese liver. Comparison of the 
kinetic data for formation of 7-GS-DHP of both compounds by Chinese and Caucasian liver fractions, 
reveals that over the substrate concentration range used in incubations with Chinese liver microsomes 
bioactivation of lasiocarpine and riddelliine is 7.5-fold and 8.1-fold lower, respectively. Vmax values in 
these incubations were not quantified because for correction of the in vitro curves only the relative 
ratio in bioactivation were required. The curves of the concentration-dependent rate of formation of 7-
GS-DHP of both compounds, expressed in peak area/min/mg liver protein and the ratio of the peak 
areas of 7-GS-DHP formed in incubations with Chinese and Caucasian liver microsomes at each 
substrate concentrationare presented in the supplementary materials 5. Since the 7-GS-DHP metabolite 
formed from lasiocarpine and riddelliine is the same, also bioactivation of the two compounds can be 
compared based on peak areas. 
Table 2 Kinetic constants for depletion of lasiocarpine and riddelliine by Chinese and Caucasian tissue fractions 
 Chinese  Caucasian  
Organ Vmax a 
(nmol/min/mg 
microsomal 
protein) 
Km a 
(M) 
Catalytic 
efficiency b 
L/min/mg 
microsomal 
protein) 
Vmax a 
(nmol/min/mg 
microsomal 
protein)  
Km a 
(M)  
Catalytic 
efficiency b 
L/min/mg 
microsomal 
protein) 
Lasiocarpine        
Liver 4.6 ± 0.9 52.5 ± 23.2 87.8 5.1 ± 0.9 25.8 ± 13.0 197.7 
Intestine n.a. c n.a. c - 0.9 ± 0.2 72.1 ± 37.9 12.5 
Lung n.a. c n.a. c - n.d. d n.d. d - 
Kidney n.a. c n.a. c - n.d. d n.d.d - 
Riddelliine        
Liver 0.3 ± 0.05 195.5  ± 61.0 1.6 2.0 ± 0.5 274.1 ± 150.7 7.3 
Intestine n.a. c n.a. c - 0.2 ± 0.1 380.4 ± 285.3 0.5 
Lung n.a. c n.a. c - n.d. d n.d. d - 
Kidney n.a. c n.a. c - n.d. d n.d. d - 
a Average ± SD of three independent experiments 
b Vmax/Km × 1000 
c Not available 
d Not detected
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Fig. 4 Concentration-dependent rate of depletion of lasiocarpine and riddelliine in incubations with Chinese 
(dotted line) and Caucasian (solid line) liver microsomes (a) and Caucasian intestinal microsomes (b) in the 
presence of the cofactor NADPH. Data points represent mean values ± SD of three individual experiments. 
Comparison of the scaled kinetic constants for lasiocarpine and riddelliine by human 
and rat tissue fractions 
In a subsequent step the kinetic constants presented in table 2 were scaled to human tissues. To this 
end, the in vitro Vmax values expressed as nmol/min/mg microsomal protein (Table 2) were scaled to 
mol/h/kg bw using the microsomal protein yields of 35 mg/(g liver) or 20.6 mg/(g small intestine) as 
scaling factors as described previously (Cubitt et al., 2009; Medinsky et al., 1994), and bodyweight 
and tissue fractions of human (Chinese and Caucasian) and rat (Chen et al., 2018). This scaling allows 
the comparison of the kinetic constants obtained from tissue fractions of different species and from 
different organs. Table 3 presents a summary of the kinetic parameters for lasiocarpine and riddelliine 
by human (Chinese and Caucasian) tissue fractions thus obtained and the comparable kinetic 
parameter values previously reported for rat tissue fractions (Chen et al., 2018). 
Comparison of the kinetic constants between human (Chinese and Caucasians) and rat shows that liver 
is the major organ for lasiocarpine and riddelliine metabolism. Compared to the human (Caucasian), 
the contribution of intestinal metabolism for both compounds is higher in the rat. The catalytic 
efficiency for the depletion of lasiocarpine is generally 3.2-fold lower in human liver (Chinese and 
Caucasian) and 6-fold lower in human intestine (Caucasian) than in rat. The overall catalytic
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the Chinese and Caucasians reveals that the catalytic efficiency for both compounds by the Chinese 
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efficiency for depletion of lasiocarpine in human (Caucasian) is 1.9-fold lower than in rat. The 
catalytic efficiency for the depletion of riddelliine is generally 16.8-fold lower in human liver (Chinese 
and Caucasian) and 1.2-fold lower in small intestine (Caucasian) compared to those values in rat 
tissues. The overall catalytic efficiency for depletion of riddelliine in human (Caucasian) is 5.0-fold 
lower. Those generally lower values of catalytic efficiency for depletion of lasiocarpine and riddelliine 
in human liver and small intestine compared to the rat were mainly due to relatively higher Km values 
for depletion of both compounds in human. 
Table 3 Scaled kinetic constants for depletion of lasiocarpine and riddelliine by human (Chinese and Caucasian) 
and rat tissue fractions 
 Human (Chinese/Caucasian)  Rat  
 
Organ 
Scaled Vmax a 
(mol/h/kg bw) 
Km 
(M) 
Scaled catalytic 
efficiency b 
L/h/kg bw) 
Scaled Vmax a,c 
(mol/h/kg bw)  
Km a, c 
(M)  
Scaled catalytic 
efficiency b,c 
L/h/kg bw) 
Lasiocarpine       
Liver 222.2 e/278.2 f 52.5 e/25.8 f 4.2 e/10.8 f 377.4 19.5 19.4 
Intestine n.a d,e/9.9 f n.a d,e/72.1 f n.a d,e/0.2 f 29.4  23.4 1.3 
Riddelliine        
Liver 14.5 e/109.2 f 195.5 e/274.1 f  0.07 e/0.4 f 149.6 75.7 2.0 
Intestine n.a d,e/1.8 f n.a d,e/380.4 f  n.a d, e/0.005 f 1.4 221.0 0.006 
a Scaled Vmax calculated from the in vitro Vmax using the scaling factor of microsome protein yields of 35 mg/(g 
liver) or 20.6 mg/(g small intestine), bodyweight and tissue fractions of human (Chinese and Caucasian) and rat  
b Scaled catalytic efficiency (scaled Vmax/Km) 
c Chen et al. 2018 
d Not available 
e Scaled kinetic constants by Chinese tissue fractions 
f Scaled kinetic constants by Caucasian tissue fractions 
Unbound fraction in human blood as determined in the RED assay 
The unbound fraction for lasiocarpine in human plasma was determined to be 0.43. For as yet 
unknown reasons, and in contrast to lasiocarpine, the unbound faction (fub) of riddelliine could not be 
detected after incubation in the RED device, even not when the concentration was increased from 5 to 
50 M. Previously, Chen et al. (2018) defined fub values for lasiocarpine and riddelliine by rat serum 
using the same method as provided in above, and reported that the fub values of lasiocarpine and 
riddelliine in rat plasma were comparable, amounting to 0.64 for lasiocarpine and to 0.66 for 
riddelliine. Therefore, in the present study the fub of riddelliine in human plasma was assumed to be 
the same as the fub value of lasiocarpine in human plasma amounting to 0.43. 
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PBK model prediction and evaluation   
To evaluate the performance of the human PBK models, ideally the model outcomes should be 
compared to available human data. Since such human in vivo data on the kinetics of lasiocarpine and 
riddelliine are not available, model evaluation is mainly based on evaluation of the same model in our 
previous study where we developed and evaluated the model for riddellliine and lasiocarpine in rat and 
mouse (Chen et al., 2018). Chen et al. (2018) described the performance of the rat and mouse PBK 
model of riddelliine by comparing the predicted Cmax of riddelliine in rat and mouse blood to the 
observed in vivo data reported in the literature (Chen et al., 2018). Data revealed that the predicted 
levels of Cmax of riddelliine in rat and mouse blood and the Cmax values observed in these species in the 
in vivo studies matched adequately (Chen et al., 2018). An additional evaluation of the model emerged 
from comparison of the PBK modelling-based predicted BMDL5-BMDU5 values derived from the 
predicted in vivo dose-response curve for liver toxicity of lasiocarpine in rats. The results fell well 
within the range of PoDs obtained from actual in vivo studies on acute liver toxicity of lasiocarpine in 
rats, indicating that the PoDs derived from the combined in vitro and in silico PBK modelling 
approach provided a good approximation of in vivo acute liver toxicity of lasiocarpine (Chen et al., 
2018). Based on these results for the rat model, the developed PBK model for lasiocarpine or 
riddelliine are considered an adequate first approximation to describe the in vivo situation for human. 
An additional approach to describe the performance of the human PBK model for lasiocarpine and 
riddelliine for the human populations, especially for the difference between the Chinese and the 
Caucasian populations, was done based on the approach described previously (Ning et al., 2017). In 
this approach a comparison is made between the predicted inter-ethnic differences for the dose-
dependent concentration of lasiocarpine and riddelliine in the liver blood and the observed inter-ethnic 
differences in hepatic metabolising enzymes that mainly catalyse the depletion of lasiocarpine or 
riddelliine. CYP 3A4 predominately catalyses the depletion of lasiocarpine and riddelliine in human 
liver (Fu et al., 2004; Miranda et al., 1991; Wiedenfeld and Edgar, 2011). Figure 5 shows that at 
similar dose levels the predicted Cmax of lasiocarpine and riddelliine in the liver blood from average 
Chinese subjects is generally 2- to 3-fold higher than in the liver from average Caucasian subjects. 
This is mainly due to the fact that the catalytic efficiency for depletion of lasiocarpine and riddelliine 
by Chinese liver microsomes is 2- to 4-fold lower compared to Caucasian liver mirosomes. The 
prediction of higher Cmax values for lasiocarpine and riddelliine for Chinese subjects is in line with the 
reported data for the Cmax and AUC of alprazolam, the substrate for CYP 3A4/5, for which the Cmax 
and AUC for Asian subjects (ten Chinese, three Filipino, and one Japanese) were 1.2- and 1.3-fold, 
respectively, higher than for Caucasian subjects (n=14) (Lin et al., 1988). Furthermore, in a meta-
analysis Barter et al. (2013) showed that the plasma clearance of the CYP 3A4/5 substrate midazolam 
following an oral dosing was 2.4-fold higher in Caucasian than in Chinese subjects. 
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efficiency for depletion of lasiocarpine in human (Caucasian) is 1.9-fold lower than in rat. The 
catalytic efficiency for the depletion of riddelliine is generally 16.8-fold lower in human liver (Chinese 
and Caucasian) and 1.2-fold lower in small intestine (Caucasian) compared to those values in rat 
tissues. The overall catalytic efficiency for depletion of riddelliine in human (Caucasian) is 5.0-fold 
lower. Those generally lower values of catalytic efficiency for depletion of lasiocarpine and riddelliine 
in human liver and small intestine compared to the rat were mainly due to relatively higher Km values 
for depletion of both compounds in human. 
Table 3 Scaled kinetic constants for depletion of lasiocarpine and riddelliine by human (Chinese and Caucasian) 
and rat tissue fractions 
 Human (Chinese/Caucasian)  Rat  
 
Organ 
Scaled Vmax a 
(mol/h/kg bw) 
Km 
(M) 
Scaled catalytic 
efficiency b 
L/h/kg bw) 
Scaled Vmax a,c 
(mol/h/kg bw)  
Km a, c 
(M)  
Scaled catalytic 
efficiency b,c 
L/h/kg bw) 
Lasiocarpine       
Liver 222.2 e/278.2 f 52.5 e/25.8 f 4.2 e/10.8 f 377.4 19.5 19.4 
Intestine n.a d,e/9.9 f n.a d,e/72.1 f n.a d,e/0.2 f 29.4  23.4 1.3 
Riddelliine        
Liver 14.5 e/109.2 f 195.5 e/274.1 f  0.07 e/0.4 f 149.6 75.7 2.0 
Intestine n.a d,e/1.8 f n.a d,e/380.4 f  n.a d, e/0.005 f 1.4 221.0 0.006 
a Scaled Vmax calculated from the in vitro Vmax using the scaling factor of microsome protein yields of 35 mg/(g 
liver) or 20.6 mg/(g small intestine), bodyweight and tissue fractions of human (Chinese and Caucasian) and rat  
b Scaled catalytic efficiency (scaled Vmax/Km) 
c Chen et al. 2018 
d Not available 
e Scaled kinetic constants by Chinese tissue fractions 
f Scaled kinetic constants by Caucasian tissue fractions 
Unbound fraction in human blood as determined in the RED assay 
The unbound fraction for lasiocarpine in human plasma was determined to be 0.43. For as yet 
unknown reasons, and in contrast to lasiocarpine, the unbound faction (fub) of riddelliine could not be 
detected after incubation in the RED device, even not when the concentration was increased from 5 to 
50 M. Previously, Chen et al. (2018) defined fub values for lasiocarpine and riddelliine by rat serum 
using the same method as provided in above, and reported that the fub values of lasiocarpine and 
riddelliine in rat plasma were comparable, amounting to 0.64 for lasiocarpine and to 0.66 for 
riddelliine. Therefore, in the present study the fub of riddelliine in human plasma was assumed to be 
the same as the fub value of lasiocarpine in human plasma amounting to 0.43. 
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PBK model prediction and evaluation   
To evaluate the performance of the human PBK models, ideally the model outcomes should be 
compared to available human data. Since such human in vivo data on the kinetics of lasiocarpine and 
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mouse (Chen et al., 2018). Chen et al. (2018) described the performance of the rat and mouse PBK 
model of riddelliine by comparing the predicted Cmax of riddelliine in rat and mouse blood to the 
observed in vivo data reported in the literature (Chen et al., 2018). Data revealed that the predicted 
levels of Cmax of riddelliine in rat and mouse blood and the Cmax values observed in these species in the 
in vivo studies matched adequately (Chen et al., 2018). An additional evaluation of the model emerged 
from comparison of the PBK modelling-based predicted BMDL5-BMDU5 values derived from the 
predicted in vivo dose-response curve for liver toxicity of lasiocarpine in rats. The results fell well 
within the range of PoDs obtained from actual in vivo studies on acute liver toxicity of lasiocarpine in 
rats, indicating that the PoDs derived from the combined in vitro and in silico PBK modelling 
approach provided a good approximation of in vivo acute liver toxicity of lasiocarpine (Chen et al., 
2018). Based on these results for the rat model, the developed PBK model for lasiocarpine or 
riddelliine are considered an adequate first approximation to describe the in vivo situation for human. 
An additional approach to describe the performance of the human PBK model for lasiocarpine and 
riddelliine for the human populations, especially for the difference between the Chinese and the 
Caucasian populations, was done based on the approach described previously (Ning et al., 2017). In 
this approach a comparison is made between the predicted inter-ethnic differences for the dose-
dependent concentration of lasiocarpine and riddelliine in the liver blood and the observed inter-ethnic 
differences in hepatic metabolising enzymes that mainly catalyse the depletion of lasiocarpine or 
riddelliine. CYP 3A4 predominately catalyses the depletion of lasiocarpine and riddelliine in human 
liver (Fu et al., 2004; Miranda et al., 1991; Wiedenfeld and Edgar, 2011). Figure 5 shows that at 
similar dose levels the predicted Cmax of lasiocarpine and riddelliine in the liver blood from average 
Chinese subjects is generally 2- to 3-fold higher than in the liver from average Caucasian subjects. 
This is mainly due to the fact that the catalytic efficiency for depletion of lasiocarpine and riddelliine 
by Chinese liver microsomes is 2- to 4-fold lower compared to Caucasian liver mirosomes. The 
prediction of higher Cmax values for lasiocarpine and riddelliine for Chinese subjects is in line with the 
reported data for the Cmax and AUC of alprazolam, the substrate for CYP 3A4/5, for which the Cmax 
and AUC for Asian subjects (ten Chinese, three Filipino, and one Japanese) were 1.2- and 1.3-fold, 
respectively, higher than for Caucasian subjects (n=14) (Lin et al., 1988). Furthermore, in a meta-
analysis Barter et al. (2013) showed that the plasma clearance of the CYP 3A4/5 substrate midazolam 
following an oral dosing was 2.4-fold higher in Caucasian than in Chinese subjects. 
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For the inter-species comparison, the predicted Cmax of lasiocarpine and riddelliine in the human 
(Chinese and Caucasian) liver blood is generally 2- to 5-fold higher than those in the rat liver blood as 
shown in figure 5. This is because the catalytic efficiency for depletion of both compounds in human 
(Caucasian) is 2- to 5-fold lower compared to rat. Altogether, the PBK models obtained in the present 
study were considered adequate for further prediction of the inter-species and inter-ethnic differences 
in hepatotoxicity of lasiocarpine and riddelliine. 
 
Fig. 5 PBK modelling-based predictions for the dose-dependent Cmax of lasiocarpine and riddelliine in liver 
blood in Chinese (black dotted line), Caucasian (black solid line) and rat (grey line). 
Sensitivity analysis 
The normalized sensitivity coefficients of the model parameters for prediction of the Cmax of 
lasiocarpine and riddelliine in liver blood of Chinese and Caucasian was analyzed. The sensitivity 
coefficients were calculated at a dose of 8 ng/kg bw and 3 mg/kg bw lasiocarpine and riddelliine and 
all model parameters with sensitivity coefficients higher than |0.1| are shown in the supplementary 
materials 6. The results obtained reveal that for both Chinese and Caucasian subjects at a dose of 8 
ng/kg bw lasiocarpine the predicted Cmax in liver blood in the PBK model is most sensitive to liver 
related parameters and the absorption rate constant (Ka) for uptake from the GI tract. At 3 mg/kg bw 
lasiocarpine, the results of the sensitivity analysis of both ethnic groups are similar to the situation at 8 
ng/kg bw lasiocarpine. The results for the sensitivity analysis of the PBK models for riddelliine shown 
in Figure S6 reveal similar results showing that Ka and liver related parameters have the highest 
influence on the predicted Cmax of riddelliine in the liver blood in both ethnic groups. At 8 ng/kg bw 
riddelliine the results of the sensitivity analysis of both ethnic groups are similar to the analysis at 3 
mg/kg bw. For both compounds, Ka and liver related parameters have less influence on the predicted 
Cmax in the liver blood in average Chinese compared to average Caucasian.  
Predicted inter-ethnic differences in hepatotoxicity of lasiocarpine and riddelliine 
Figure 6 shows the predicted in vivo dose-response curves for liver toxicity of lasiocarpine and 
riddelliine in Chinese and Caucasian subjects obtained by translation of the in vitro concentration-
response curves obtained from human hepatocytes (Figure 3) by reverse dosimetry using the 
respective PBK models. The response % indicated at the y-axis of the in vivo dose-response curve was
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calculated based on the equation (4): response % = 100 %  (solvent control) - cell viability % in the in 
vitro concentration response curve.  
Table 4 presents the BMDL5-BMDU5 values derived from the predicted dose-response curves as 
shown in figure 6 for Chinese and Caucasian subjects. The values of the BMD5 (benchmark dose 
corresponding to 5% extra risk) were also presented to enable calculation of the ratio between the 
BMD5 and BMDL5/BMDU5 showing they are  generally lower than 3, which was one of the criteria 
for acceptance of the model fit. Detailed information on the BMD analysis can be found in the 
supplementary materials 7.  
Interestingly, the PBK modelling-based predictions for in vivo human toxicity of riddelliine could be 
evaluated using available human data, supporting further evaluation of the PBK models and the PBK 
modelling-based reverse dosimetry approach. The study of Culvenor (1983) estimated that in human 
subjects a dose of 1.4-3 mg/kg bw/day and 0.7-1.5 mg/kg bw/day of riddelliine may lead to liver 
necrosis (exposure of a boy for shorter than 2 weeks) and liver cirrhosis (exposure of a girl for 2 
weeks), respectively (Culvenor, 1983). The BMD5 values for Caucasian and Chinese subjects 
predicted in the present study are comparable since they amount to 0.5 and 2.6 mg/kg bw/day, 
respectively. For the inter-ethnic comparison, the predicted BMDL5 of lasiocarpine was observed to be 
2.0-fold higher for Chinese than for Caucasian subjects and for riddelliine the predicted BMDL5 value 
was 5.0-fold higher for Chinese than for Caucasian subjects, indicating Chinese may be less sensitive 
to the liver toxicity of these PAs than the Caucasian population. This difference can be mainly 
ascribed to the lower relative level of bioactivation resulting in lower toxicity at similar dose levels in 
spite of the slower metabolic clearance.  
Table 4 Predicted BMD5 and BMDL5-BMDU5 values derived from dose-response curves predicted using PBK 
modelling-based reverse dosimetry of in vitro cytotoxicity data with human hepatocytes 
Compounds 
Predicted BMDL5-BMDU5 (BMD5) (mg/kg bw/day) 
Chinese Caucasian 
Lasiocarpine  14.7-41.2 (26.0) 7.4-23.7 (14.1) 
Riddelliine  1.0-5.9 (2.6) 0.2-1.2 (0.5) 
 
171
C
ha
pt
er
 5
170 
 
For the inter-species comparison, the predicted Cmax of lasiocarpine and riddelliine in the human 
(Chinese and Caucasian) liver blood is generally 2- to 5-fold higher than those in the rat liver blood as 
shown in figure 5. This is because the catalytic efficiency for depletion of both compounds in human 
(Caucasian) is 2- to 5-fold lower compared to rat. Altogether, the PBK models obtained in the present 
study were considered adequate for further prediction of the inter-species and inter-ethnic differences 
in hepatotoxicity of lasiocarpine and riddelliine. 
 
Fig. 5 PBK modelling-based predictions for the dose-dependent Cmax of lasiocarpine and riddelliine in liver 
blood in Chinese (black dotted line), Caucasian (black solid line) and rat (grey line). 
Sensitivity analysis 
The normalized sensitivity coefficients of the model parameters for prediction of the Cmax of 
lasiocarpine and riddelliine in liver blood of Chinese and Caucasian was analyzed. The sensitivity 
coefficients were calculated at a dose of 8 ng/kg bw and 3 mg/kg bw lasiocarpine and riddelliine and 
all model parameters with sensitivity coefficients higher than |0.1| are shown in the supplementary 
materials 6. The results obtained reveal that for both Chinese and Caucasian subjects at a dose of 8 
ng/kg bw lasiocarpine the predicted Cmax in liver blood in the PBK model is most sensitive to liver 
related parameters and the absorption rate constant (Ka) for uptake from the GI tract. At 3 mg/kg bw 
lasiocarpine, the results of the sensitivity analysis of both ethnic groups are similar to the situation at 8 
ng/kg bw lasiocarpine. The results for the sensitivity analysis of the PBK models for riddelliine shown 
in Figure S6 reveal similar results showing that Ka and liver related parameters have the highest 
influence on the predicted Cmax of riddelliine in the liver blood in both ethnic groups. At 8 ng/kg bw 
riddelliine the results of the sensitivity analysis of both ethnic groups are similar to the analysis at 3 
mg/kg bw. For both compounds, Ka and liver related parameters have less influence on the predicted 
Cmax in the liver blood in average Chinese compared to average Caucasian.  
Predicted inter-ethnic differences in hepatotoxicity of lasiocarpine and riddelliine 
Figure 6 shows the predicted in vivo dose-response curves for liver toxicity of lasiocarpine and 
riddelliine in Chinese and Caucasian subjects obtained by translation of the in vitro concentration-
response curves obtained from human hepatocytes (Figure 3) by reverse dosimetry using the 
respective PBK models. The response % indicated at the y-axis of the in vivo dose-response curve was
171 
 
calculated based on the equation (4): response % = 100 %  (solvent control) - cell viability % in the in 
vitro concentration response curve.  
Table 4 presents the BMDL5-BMDU5 values derived from the predicted dose-response curves as 
shown in figure 6 for Chinese and Caucasian subjects. The values of the BMD5 (benchmark dose 
corresponding to 5% extra risk) were also presented to enable calculation of the ratio between the 
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for acceptance of the model fit. Detailed information on the BMD analysis can be found in the 
supplementary materials 7.  
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necrosis (exposure of a boy for shorter than 2 weeks) and liver cirrhosis (exposure of a girl for 2 
weeks), respectively (Culvenor, 1983). The BMD5 values for Caucasian and Chinese subjects 
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was 5.0-fold higher for Chinese than for Caucasian subjects, indicating Chinese may be less sensitive 
to the liver toxicity of these PAs than the Caucasian population. This difference can be mainly 
ascribed to the lower relative level of bioactivation resulting in lower toxicity at similar dose levels in 
spite of the slower metabolic clearance.  
Table 4 Predicted BMD5 and BMDL5-BMDU5 values derived from dose-response curves predicted using PBK 
modelling-based reverse dosimetry of in vitro cytotoxicity data with human hepatocytes 
Compounds 
Predicted BMDL5-BMDU5 (BMD5) (mg/kg bw/day) 
Chinese Caucasian 
Lasiocarpine  14.7-41.2 (26.0) 7.4-23.7 (14.1) 
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Fig. 6 Predicted dose-response curves for acute liver toxicity of lasiocarpine and riddelliine in average Chinese 
(black dotted line) and average Caucasians (black solid line) as obtained by translation of cytotoxicity 
concentration-response data obtained with human hepatocytes using PBK modelling-based reverse dosimetry 
Predicted species differences in hepatotoxicity of lasiocarpine and riddelliine 
To obtain insight in possible species differences in sensitivity toward liver toxicity of the PAs, the 
BMDL5-BMDU5 values of lasiocarpine and riddelliine for acute liver toxicity for humans (Chinese 
and Caucasians) (Table 4) defined in the present study were compared to the same PoDs defined 
previously for rats using in vitro toxicity data in rat hepatocytes and PBK models for rats (Chen et al. 
2018) (see Figure 7). The BMDL5-BMDU5 values derived from the predicted dose-response curves for 
lasiocarpine for humans amounting to 11.1-32.3 mg/kg bw (average PoDs of Chinese and Caucasians) 
are up to 2.0-fold lower than the predicted BMDL5-BMDU5 values of Chen et al. (2018) for 
lasiocarpine for rat which amounted to 23.0-34.4 mg/kg bw/day. For riddelliine, the predicted 
BMDL5-BMDU5 values for humans amounting to 0.6-3.6 mg/kg bw (average PoDs of Chinese and 
Caucasians) are up to 8.2-fold lower than the BMDL5-BMDU5 for rat amounting to 4.9-8.4 mg/kg 
bw/day. Thus humans seem to be somewhat more sensitive to liver toxicity of these PAs than rats.
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Fig. 7 Predicted BMDL5-BMDU5 values for acute liver toxicity of lasiocarpine (above the dashed line) and 
riddelliine (below the dashed line) in humans (Caucasians and Chinese) (bars containing horizontal lines) 
predicted by the PBK modelling-based reversed dosimetry approach using data for human hepatocytes from the 
present study as compared to the predicted BMDL5-BMDU5 values for acute liver toxicity of lasiocarpine (above 
the dashed line) and riddelliine (below the dashed line) in rat (bars containing vertical lines) derived from our 
previous study using data for rat hepatocytes and a rat PBK model (Chen et al., 2018). 
Discussion  
The aim of the present study was to use PBK modelling-based reverse dosimetry to translate human 
cytotoxicity data of lasiocarpine and riddelliine to in vivo dose-response data in humans (Chinese and 
Caucasians) and study ethnic human differences. Comparison of the results to a similar study 
previously performed for rats (Chen et al., 2018) would provide insight in species differences in 
sensitivity to these two PAs.  
The PBK model developed in the present study describes the kinetics of lasiocarpine and riddelliine 
and not of their metabolites, since we assume that the acute liver toxicity of lasiocarpine and 
riddelliine can be modelled based on cytotoxicity data of the parent compound provided that the in 
vitro model used contains the adequate enzymes required for their bioactivation to hepatotoxic 
metabolites. Especially the dehydropyrrolizidine alkaloids metabolites of PAs are reactive with 
proteins and DNA, thereby causing toxic effects (Fu et al., 2004). The in vitro cytotoxicity experiment 
using HepaRG cells and human hepatocytes can be expected to take this bioactivation into account. 
The HepaRG cell line is a human hepatoma cellular model consisting of a mixture of both hepatocyte-
like and biliary-like cells (Lambert et al., 2009). After the treatment with DMSO, HepaRG cells 
differentiate into hepatocyte-like morphology. Kanebratt and Andersson (2008) reported that the 
expression of P450 in HepaRG cells was generally lower compared with human hepatocytes, except 
for a higher expression of CYP 3A4 and CYP 7A1. However, the CYP 3A4 activity was still about1.5-
fold higher in human hepatocytes in 2 out of 3 individuals compared to DMSO treated HepaRG cells
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as determined by measuring the clearance of the CYP 3A4 probe substrate midazolam (Kanebratt and 
Andersson, 2008). Other studies also showed that P450 activities such as CYP 1A2, CYP 2B6, CYP 
2C8, CYP 2C9, CYP 2C19 and CYP 2D6 were generally lower in HepaRG cells than in human 
hepatocytes, expect for CYP 3A4 showing a generally 1.5-fold higher activity in HepaRG cells (Kvist 
et al., 2018; Lubberstedt et al., 2011). However, Gerets et al. (2012) reported that CYP 3A4 activity 
was about 17.0-fold lower in the HepaRG cells than in freshly isolated human hepatocytes from three 
different donors. This conflicting result may result from inter-individual variability in CYP 3A4 
activity and/or from differences in the level of enzyme induction the DMSO treated HepaRG cells. 
However based on the limited difference in the cytotoxicity of riddelliine and lasiocarpine in primary 
hepatocytes and the HepaRG cells observed in the present study (Figure 3), we conclude that induction 
of the CYPs involved in bioactivation of these PAs in the HepRG cells was adequate. Gerets et al. 
(2012) also reported that cryopreserved primary human hepatocytes showed a 3-fold higher sensitivity 
for the detection of hepatotoxic compounds compared with HepaRG cells. In the present study, the 
IC50 value for lasiocarpine and riddelliine derived from HepaRG cells was 10- and 3-fold higher, 
respectively, than the IC50 derived from studies with human hepatocytes, probably reflecting the lower 
metabolic capacity of the HepaRG cells for bioactivation of the PAs. Given these differences, 
prediction of the acute liver toxicity of both PAs was based on the in vitro concentration-response 
curves obtained with human primary hepatocytes.   
Based on the sensitivity analysis, the predicted Cmax values of lasiocarpine and riddelliine in average 
Chinese and average Caucasians are highly affected by the absorption rate constant (Ka) for uptake 
from the GI tract and the kinetic constants for metabolic clearance of the parent compounds in the liver. 
Variability in the kinetic constants for metabolic clearance can result from the individual differences in 
the expression of CYP 3A4 which is the primary enzyme for metabolizing lasiocarpine and riddelliine 
in humans (Miranda et al., 1991). The literature reports that the abundance of CYP 3A4 in the liver 
varies significantly in individuals (Fu et al., 2004), and the inter-individual variation in the level of 
CYP 3A4 expression can vary up to 100-fold (Westlind-Johnsson et al., 2003). In addition to the 
kinetic constants, the Ka value also has a large influence on the model predictions. In the present study, 
the Ka values of lasiocarpine and riddelliine were 1.55/h and 0.72/h, respectively as reported by Chen 
et al. (2018). In the study of Chen et al. (2018), Ka values of both compounds were defined based on 
Papp values derived by two methods: Qikprop software (SchrÖdinger, trial version, Germany) and a 
QSAR method developed by Hou et al. (2004). The Papp values obtained from these two methods 
differ only 1.3-fold for lasiocarpine, but 4.5-fold for riddelliine (Chen et al., 2018). The large 
difference in Papp values for riddelliine may therefore largely affect PBK model-predicted internal 
concentrations and related predicted dose levels that cause acute toxicity. Previously, Chen et al. (2018) 
reported the predicted BMDL5-BMDU5 for riddelliine in rat amounting to 1.0-2.2 mg/kg bw/day when 
using the Ka  (0.27 /h) obtained by Qikprop software and to 3.3-14.6 mg/kg bw/day when using the
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Ka (1.17/h) obtained by the QSAR method of Hou et al. (2004). The PoDs for riddelliine obtained in 
rats when using the average Ka amount to 4.9-8.4 mg/kg bw/day (Chen et al., 2018). This outcome 
supports the outcome of the sensitivity analysis indicating that the Ka value has a large influence on 
the model predictions. This leads to the conclusions that further refinement of especially the Papp and 
resulting Ka value may improve the models and their predictions. However, given that the predicted 
BMD5 values for riddelliine in Chinese and Caucasian subjects amounting to 2.6 and 0.5 mg/kg 
bw/day, respectively are comparable to the literature reported in vivo data for human subjects 
amounting to 0.7-3 mg/kg bw/day  (Culvenor, 1983) when using the average Ka values, the use of the 
average Ka value for riddelliine seems a reasonable strategy. A recent study reported that the 
pyrrolizidine alkaloid monocrotaline (retronecine-type PA) is a high affinity substrate of the organic 
cation transporter 1 (OCT1), a transporter mainly expressed in liver and involved in uptake of 
chemicals from blood into the hepatocytes. This study suggested that active transport mechanisms may 
be involved in the cellular uptake of pyrrolizidine alkaloids into the liver tissue (Tu et al., 2013). In the 
present study, we used log Kow to estimate the liver tissue:blood partition coefficients of lasiocarpine 
and riddelliine. In perfusion-limited PBK models, such as used in our study, an immediate partitioning 
between plasma and tissue is assumed, which is not dependent on chemical diffusion across cell 
membranes and/or active uptake processes. Therefore we do not expect to underestimate hepatic 
concentrations in our models. Given that the sensitivity analysis revealed that the Cmax of lasiocarpine 
and riddelliine in liver blood were not highly affected by the liver tissue:blood partition coefficients 
(see supplementary materials 6), estimation of this kinetic parameter for uptake of lasiocarpine and 
riddelliine into liver tissue based on partitioning between plasma and tissue is unlikely to affect the 
outcomes to a significant extent. 
Given that the methods used in the present study and in the previous study (Chen et al., 2018) for 
predicting the in vivo liver toxicity of lasiocarpine and riddelliine in rat were similar, using species 
specific primary hepatocytes and species specific subcellular tissue fractions in similar in vitro 
incubations to define the species specific metabolic clearance, using a similar PBK model structure, 
the model predictions also provide insight in species differences in acute liver toxicity of lasiocarpine 
and riddelliine. This inter-species comparison, revealed that the predicted BMDL5 for liver toxicity of 
lasiocarpine and riddelliine in humans (average PoDs of Chinese and Caucasians) is up to 2.0-fold 
and8.2-fold lower, respectively, than that for rat, indicating that humans are somewhat more sensitive 
towards acute liver toxicity of lasiocarpine and riddelliine than rats. It is of interest to note that the in 
vitro cytotoxicity of these two compounds in human Caucasian hepatocytes was lower than in rat 
hepatocytes, and that the predicted higher toxicity in vivo thus results from inter-species differences in 
the kinetics. The kinetics showed a 1.9- and 5.0-fold slower clearance of lasiocarpine and riddelliine in 
humans (Caucasian) compared to rats. According to literature, the metabolism of PAs in rodents is 
mainly catalyzed by CYP 2B and CYP 3A subfamilies, while in humans, metabolism is mainly
175
C
ha
pt
er
 5
 
 
174 
 
as determined by measuring the clearance of the CYP 3A4 probe substrate midazolam (Kanebratt and 
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et al., 2018; Lubberstedt et al., 2011). However, Gerets et al. (2012) reported that CYP 3A4 activity 
was about 17.0-fold lower in the HepaRG cells than in freshly isolated human hepatocytes from three 
different donors. This conflicting result may result from inter-individual variability in CYP 3A4 
activity and/or from differences in the level of enzyme induction the DMSO treated HepaRG cells. 
However based on the limited difference in the cytotoxicity of riddelliine and lasiocarpine in primary 
hepatocytes and the HepaRG cells observed in the present study (Figure 3), we conclude that induction 
of the CYPs involved in bioactivation of these PAs in the HepRG cells was adequate. Gerets et al. 
(2012) also reported that cryopreserved primary human hepatocytes showed a 3-fold higher sensitivity 
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Ka (1.17/h) obtained by the QSAR method of Hou et al. (2004). The PoDs for riddelliine obtained in 
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chemicals from blood into the hepatocytes. This study suggested that active transport mechanisms may 
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present study, we used log Kow to estimate the liver tissue:blood partition coefficients of lasiocarpine 
and riddelliine. In perfusion-limited PBK models, such as used in our study, an immediate partitioning 
between plasma and tissue is assumed, which is not dependent on chemical diffusion across cell 
membranes and/or active uptake processes. Therefore we do not expect to underestimate hepatic 
concentrations in our models. Given that the sensitivity analysis revealed that the Cmax of lasiocarpine 
and riddelliine in liver blood were not highly affected by the liver tissue:blood partition coefficients 
(see supplementary materials 6), estimation of this kinetic parameter for uptake of lasiocarpine and 
riddelliine into liver tissue based on partitioning between plasma and tissue is unlikely to affect the 
outcomes to a significant extent. 
Given that the methods used in the present study and in the previous study (Chen et al., 2018) for 
predicting the in vivo liver toxicity of lasiocarpine and riddelliine in rat were similar, using species 
specific primary hepatocytes and species specific subcellular tissue fractions in similar in vitro 
incubations to define the species specific metabolic clearance, using a similar PBK model structure, 
the model predictions also provide insight in species differences in acute liver toxicity of lasiocarpine 
and riddelliine. This inter-species comparison, revealed that the predicted BMDL5 for liver toxicity of 
lasiocarpine and riddelliine in humans (average PoDs of Chinese and Caucasians) is up to 2.0-fold 
and8.2-fold lower, respectively, than that for rat, indicating that humans are somewhat more sensitive 
towards acute liver toxicity of lasiocarpine and riddelliine than rats. It is of interest to note that the in 
vitro cytotoxicity of these two compounds in human Caucasian hepatocytes was lower than in rat 
hepatocytes, and that the predicted higher toxicity in vivo thus results from inter-species differences in 
the kinetics. The kinetics showed a 1.9- and 5.0-fold slower clearance of lasiocarpine and riddelliine in 
humans (Caucasian) compared to rats. According to literature, the metabolism of PAs in rodents is 
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176
 
 
176 
 
catalysed by CYP 3A4 (Li et al., 2011; Miranda et al., 1991). This observation is of interest when 
considering rat toxicity data for human risk assessment. Extrapolating rodent toxicity data to the 
human situation usually includes the use of a default uncertainty factor of 10 to account for species 
differences, consisting of a factor of 4.0 for kinetic and a factor of 2.5 for dynamic differences (WHO, 
1999). In the present study, the inter-species differences in acute liver toxicity of lasiocarpine and 
riddelliine fall well within the default factor of 10. Such a compound specific uncertainty factor that 
could be smaller than the default value of 10 was also reported for aristolochic acid I for which in 
vitro-PBK model facilitated reverse dosimetry-based predicted PoDs differed about 1.8-fold between 
rat and human and about 1.9-fold between mouse and human (Abdullah et al., 2016). Also for the 
bioactivation of estragole the compound specific uncertainty factor for differences in kinetics between 
humans and rats was predicted to be 2-fold and thus smaller than the default factor of 4 for kinetic 
differences (Punt et al., 2009). Altogether, these results reveal that the in vitro-PBK modelling-based 
reverse dosimetry may provide a way forward to define compound specific uncertainty factors, also 
called compound specific adjustment factors (CSAFs), in risk assessment.  
Comparison of the predicted BMDL5 for lasiocarpine and riddelliine between Chinese and Caucasian 
subjects showed that for Chinese subjects, the predicted BMDL5 for lasiocarpine was 2.0-fold higher 
and for riddelliine 5.0-fold higher than for Caucasians, suggesting that Chinese subjects might be less 
sensitive towards acute hepatotoxicity of lasiocarpine and riddelliine. This is mainly due to the 
differences in bioactivation of the parent compound, resulting in less bioactivation for both 
compounds at similar dose levels in average Chinese compared to average Caucasian subjects, and 
occurs in spite of less efficient clearance in Chinese as compared to Caucasians. In the present study, 
human hepatocytes used to study the in vitro cytotoxicity of lasiocarpine and riddelliine were derived 
from Caucasian subjects. Since human hepatocytes derived from Chinese subjects are not available, in 
vitro cytotoxicity for Chinese hepatocytes was defined by read-across from the Caucasian liver 
hepatocytes taking into account the difference in bioactivation between Chinese and Caucasian liver 
microsomes, as reflected by 7-GS-DHP formation in in vitro incubations. In the present study, we used 
GSH as a trapping agent to estimate the amount of reactive metabolites formed in liver microsomal 
incubations which is in line with the method described previously (Tamta et al., 2012). It has been 
reported that dehydro-PAs react with GSH forming three metabolites, 7-GS-DHP, 9-GS-DHP and 7,9-
di-GSH-DHP, of which 7-GS-DHP is the major metabolite formed in vivo and in vitro (Chen et al., 
2016; Lame et al., 1990; Lin et al., 1998; Reed et al., 1992; Tamta et al., 2012), whereas 7,9-di-GS-
DHP is only formed in vitro (Lin et al., 1998; Reed et al., 1992; Tamta et al., 2012). Other factors 
influencing the dynamics of liver toxicity caused by PAs, for example the relative potential for repair, 
cannot be taken into account in this way. Nevertheless the approach now taken provides an adequate 
first approach to study the potential ethnic differences in the toxicokinetic process of PA-induced liver
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liver toxicity caused by PAs, for example the relative potential for repair, cannot be taken into account 
in this way. Nevertheless the approach now taken provides an adequate first approach to study the 
potential ethnic differences in the toxicokinetic process of PA-induced liver toxicity. 
The ethnic differences in metabolic clearance of lasiocarpine and riddelliine determined by substrate 
depletion using liver microsomess for both populations was 2- to 4-fold, with clearance by the average 
Caucasian being more efficient. The difference in efficiency for formation of bioactive metabolites for 
both compounds by the Chinese and Caucasian incubations amounted to 7- to 8-fold, the value for the 
average Caucasian being highest. It has been reported that besides CYP 450 enzymes, flavin-
containing monooxygenases (FMO) and carboxylesterases are considered to be involved in 
detoxification pathways as shown in Figure 1 (Fu et al., 2004). FMO was found to be partly involved 
in the N-oxide formation and carboxylesterases are involved in hydrolysis of the ester groups of PAs 
leading to the formation of necine base and necic acid moieties, which is considered to be the major 
detoxification pathway (Fu et al., 2004). Currently, two predominant carboxylesterases (CES) 
enzymes have been identified in human, i.e. CES 1 and CES 2 (Wang et al., 2018). A recent review 
reported that ethnic differences in carboxylesterases enzymes activity may be present due to single 
nucleotide polymorphisms (SNPs). For instance, CES 1 variants G1420E and D260fs, which are two 
important functional SNPs in Caucasian populations, showed reduced esterase activity in vitro, while 
these two variants were not found in the Asian populations (Cha et al., 2014; Wang et al., 2018). 
However, detailed studies of assessing ethnic differences in carboxylesterases activity are still lacking.  
It is also of interest to note that in toxicological risk assessment, a default uncertainty factor of 10 is 
used to account for inter-individual variation, which can be divided into a factor 3.16 for kinetics and 
3.16 for dynamic differences (WHO, 1999). The ethnic human difference in predicted PoDs of 
lasiocarpine and riddelliine between Chinese and Caucasian subjects, were estimated to be 1.7-and 
5.0-fold respectively, and are thus in line with the default value of 3.16 for inter-individual kinetic 
differences. However, various studies report much higher than 2 to 4-fold inter-individual variability 
in the expression of the major hepatic CYP enzyme (CYP 3A4) involved in PA metabolism, ranging 
up to 100-fold (Westlind-Johnsson et al., 2003), or even up to 400-fold when taking illness, inhibition, 
and induction-related interactions into account (Galetin et al., 2004; Wilkinson, 2005). Another study 
reported that inter-individual variation in the expression of CYP 3A4 varies 40- to 50-fold (Ingelman-
Sundberg, 2004). Therefore, the human inter-individual variation in kinetics is likely to be larger than 
the default value of 3.16. In a next step, to actually quantify inter-individual human variation in 
sensitivity to acute liver toxicity of lasiocarpine and riddelliine, the PBK model of the present study 
should be developed for individual subjects and combined with Monte Carlo modelling to predict 
hepatotoxicity within the human population. This Monte Carlo modelling should especially consider 
the variability in the PBK model parameters shown in the sensitivity analysis to influence the model
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catalysed by CYP 3A4 (Li et al., 2011; Miranda et al., 1991). This observation is of interest when 
considering rat toxicity data for human risk assessment. Extrapolating rodent toxicity data to the 
human situation usually includes the use of a default uncertainty factor of 10 to account for species 
differences, consisting of a factor of 4.0 for kinetic and a factor of 2.5 for dynamic differences (WHO, 
1999). In the present study, the inter-species differences in acute liver toxicity of lasiocarpine and 
riddelliine fall well within the default factor of 10. Such a compound specific uncertainty factor that 
could be smaller than the default value of 10 was also reported for aristolochic acid I for which in 
vitro-PBK model facilitated reverse dosimetry-based predicted PoDs differed about 1.8-fold between 
rat and human and about 1.9-fold between mouse and human (Abdullah et al., 2016). Also for the 
bioactivation of estragole the compound specific uncertainty factor for differences in kinetics between 
humans and rats was predicted to be 2-fold and thus smaller than the default factor of 4 for kinetic 
differences (Punt et al., 2009). Altogether, these results reveal that the in vitro-PBK modelling-based 
reverse dosimetry may provide a way forward to define compound specific uncertainty factors, also 
called compound specific adjustment factors (CSAFs), in risk assessment.  
Comparison of the predicted BMDL5 for lasiocarpine and riddelliine between Chinese and Caucasian 
subjects showed that for Chinese subjects, the predicted BMDL5 for lasiocarpine was 2.0-fold higher 
and for riddelliine 5.0-fold higher than for Caucasians, suggesting that Chinese subjects might be less 
sensitive towards acute hepatotoxicity of lasiocarpine and riddelliine. This is mainly due to the 
differences in bioactivation of the parent compound, resulting in less bioactivation for both 
compounds at similar dose levels in average Chinese compared to average Caucasian subjects, and 
occurs in spite of less efficient clearance in Chinese as compared to Caucasians. In the present study, 
human hepatocytes used to study the in vitro cytotoxicity of lasiocarpine and riddelliine were derived 
from Caucasian subjects. Since human hepatocytes derived from Chinese subjects are not available, in 
vitro cytotoxicity for Chinese hepatocytes was defined by read-across from the Caucasian liver 
hepatocytes taking into account the difference in bioactivation between Chinese and Caucasian liver 
microsomes, as reflected by 7-GS-DHP formation in in vitro incubations. In the present study, we used 
GSH as a trapping agent to estimate the amount of reactive metabolites formed in liver microsomal 
incubations which is in line with the method described previously (Tamta et al., 2012). It has been 
reported that dehydro-PAs react with GSH forming three metabolites, 7-GS-DHP, 9-GS-DHP and 7,9-
di-GSH-DHP, of which 7-GS-DHP is the major metabolite formed in vivo and in vitro (Chen et al., 
2016; Lame et al., 1990; Lin et al., 1998; Reed et al., 1992; Tamta et al., 2012), whereas 7,9-di-GS-
DHP is only formed in vitro (Lin et al., 1998; Reed et al., 1992; Tamta et al., 2012). Other factors 
influencing the dynamics of liver toxicity caused by PAs, for example the relative potential for repair, 
cannot be taken into account in this way. Nevertheless the approach now taken provides an adequate 
first approach to study the potential ethnic differences in the toxicokinetic process of PA-induced liver
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liver toxicity caused by PAs, for example the relative potential for repair, cannot be taken into account 
in this way. Nevertheless the approach now taken provides an adequate first approach to study the 
potential ethnic differences in the toxicokinetic process of PA-induced liver toxicity. 
The ethnic differences in metabolic clearance of lasiocarpine and riddelliine determined by substrate 
depletion using liver microsomess for both populations was 2- to 4-fold, with clearance by the average 
Caucasian being more efficient. The difference in efficiency for formation of bioactive metabolites for 
both compounds by the Chinese and Caucasian incubations amounted to 7- to 8-fold, the value for the 
average Caucasian being highest. It has been reported that besides CYP 450 enzymes, flavin-
containing monooxygenases (FMO) and carboxylesterases are considered to be involved in 
detoxification pathways as shown in Figure 1 (Fu et al., 2004). FMO was found to be partly involved 
in the N-oxide formation and carboxylesterases are involved in hydrolysis of the ester groups of PAs 
leading to the formation of necine base and necic acid moieties, which is considered to be the major 
detoxification pathway (Fu et al., 2004). Currently, two predominant carboxylesterases (CES) 
enzymes have been identified in human, i.e. CES 1 and CES 2 (Wang et al., 2018). A recent review 
reported that ethnic differences in carboxylesterases enzymes activity may be present due to single 
nucleotide polymorphisms (SNPs). For instance, CES 1 variants G1420E and D260fs, which are two 
important functional SNPs in Caucasian populations, showed reduced esterase activity in vitro, while 
these two variants were not found in the Asian populations (Cha et al., 2014; Wang et al., 2018). 
However, detailed studies of assessing ethnic differences in carboxylesterases activity are still lacking.  
It is also of interest to note that in toxicological risk assessment, a default uncertainty factor of 10 is 
used to account for inter-individual variation, which can be divided into a factor 3.16 for kinetics and 
3.16 for dynamic differences (WHO, 1999). The ethnic human difference in predicted PoDs of 
lasiocarpine and riddelliine between Chinese and Caucasian subjects, were estimated to be 1.7-and 
5.0-fold respectively, and are thus in line with the default value of 3.16 for inter-individual kinetic 
differences. However, various studies report much higher than 2 to 4-fold inter-individual variability 
in the expression of the major hepatic CYP enzyme (CYP 3A4) involved in PA metabolism, ranging 
up to 100-fold (Westlind-Johnsson et al., 2003), or even up to 400-fold when taking illness, inhibition, 
and induction-related interactions into account (Galetin et al., 2004; Wilkinson, 2005). Another study 
reported that inter-individual variation in the expression of CYP 3A4 varies 40- to 50-fold (Ingelman-
Sundberg, 2004). Therefore, the human inter-individual variation in kinetics is likely to be larger than 
the default value of 3.16. In a next step, to actually quantify inter-individual human variation in 
sensitivity to acute liver toxicity of lasiocarpine and riddelliine, the PBK model of the present study 
should be developed for individual subjects and combined with Monte Carlo modelling to predict 
hepatotoxicity within the human population. This Monte Carlo modelling should especially consider 
the variability in the PBK model parameters shown in the sensitivity analysis to influence the model
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predictions to the largest extent including the Ka and the kinetic parameters for metabolic clearance in 
the liver. 
Given that the ultimate critical effect of lasiocarpine and riddelliine is not only acute hepatotoxicity 
but also genotoxicity and subsequently, carcinogenic transformation, it may also be of interest to 
extent the current PBK model to a physiologically based dynamic (PBD) model able to predict in vivo 
DNA binding as previously done for estragole (Paini et al., 2010). This would require definition of an 
in vitro concentration response curve for DNA adduct formation in the primary hepatocytes, which can 
subsequently be translated to an in vivo dose-response curve for DNA adduct formation. According to 
the study of Xia et al. (2013), DNA adduct formation is a common biological biomarker of PA-
induced tumorigenicity in rats. Previous studies reported that the metabolism of riddelliine by human 
liver microsomes resulted in a similar metabolic pattern and DNA adduct profile to those formed in 
the rat liver, suggesting that the mode of action of PAs studied in experimental rodents is highly 
relevant to humans (Xia et al., 2003; Zhao et al., 2012). The current PBK model could also translate in 
vitro concentration-response curves for DNA adduct formation in human liver cells to in vivo dose-
response curves for DNA adduct formation in the liver of human.  
In conclusion, the present study shows that PBK modelling-based reverse dosimetry can identify the 
differences in inter-species and inter-ethnic human differences in liver toxicity of lasiocarpine and 
riddelliine. The species dependent variation in hepatotoxicity defined by the BMDL5 (average PoDs of 
Caucasians and Chinese)  is up to 2.0-fold for lasiocarpine and 8.2-fold for riddelliine, with humans 
being more susceptible to lasiocarpine and riddelliine-induced liver toxicity than rat. The inter-ethnic 
human difference between average Chinese and average Caucasian subjects was estimated to be 2.0-
fold for lasiocarpine and 5.0-fold for riddelliine, with the average Caucasian being more sensitive 
towards the acute liver toxicity of lasiocarpine and riddelliine, mainly due to more efficient reactive 
metabolite formation. Altogether, the present study shows proof-of-principle for a method to predict 
inter-species and inter-ethnic differences in in vivo liver toxicity for PAs by an alternative testing 
strategy integrating in vitro cytotoxicity assays with PBK modelling-based reverse dosimetry. 
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response curves for DNA adduct formation in the liver of human.  
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towards the acute liver toxicity of lasiocarpine and riddelliine, mainly due to more efficient reactive 
metabolite formation. Altogether, the present study shows proof-of-principle for a method to predict 
inter-species and inter-ethnic differences in in vivo liver toxicity for PAs by an alternative testing 
strategy integrating in vitro cytotoxicity assays with PBK modelling-based reverse dosimetry. 
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Supplementary materials 1  
 
 
Fig. S1 LC-MS chromatogram of 7-GSH-DHP formed in the incubation of 200 µM lasiocarpine with Caucasian 
liver microsomes in the presence of 2 mM NADPH and 20 mM GSH for 30 min
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Supplementary materials 2  
Table S2 Parameters used in the PBK model for lasiocarpine and riddelliine in Chinese and Caucasian subjects 
as obtained from literature. 
Model parameters Chinese a,c Caucasian b,c 
Physiological parameters   
Bodyweight (kg) 60 70 
Tissue volumes (% of body weight)   
Fat 18.7 21.4 
Liver 2.3 2.6 
Small intestine 0.5 0.9 
Richly perfused 4.8 4.1 
Slowly perfused 62.3 59.6 
Arterial blood 2.0 2.0 
Venous blood 5.9 5.9 
Cardiac output (L/hr/kg bw 0.74) 15 15 
Percentage of cardiac output   
Fat 6.75 5.2 
Liver 26.3 22.7 
Small intestine 10.5 18.1 
Richly perfused 33.2 43.7 
Slowly perfused 23.3 23.3 
   
Tissue: blood partition coefficients   
Lasiocarpine   
Fat/blood 3.46 3.46 
Liver/blood 0.78 0.78 
Small intestine/blood 0.78 0.78 
Richly perfused/blood 0.78 0.78 
Slowly perfused/blood 0.86 0.86 
   
183
C
ha
pt
er
 5
 
 
182 
 
Supplementary materials 1  
 
 
Fig. S1 LC-MS chromatogram of 7-GSH-DHP formed in the incubation of 200 µM lasiocarpine with Caucasian 
liver microsomes in the presence of 2 mM NADPH and 20 mM GSH for 30 min
2.5 5.0 7.5 10.0 12.5 min
0
500
1000
1500
2000
2500
3000
3500
4000
4500
5000
5500
6000
4:7-GSH-DHP 443.20>247.20(+) CE: -15.0
4:7-GSH-DHP 443.20>118.10(+) CE: -24.0
4:7-GSH-DHP 443.20>425.15(+) CE: -7.0
4:7-GSH-DHP TIC(+)
 
 
183 
 
Supplementary materials 2  
Table S2 Parameters used in the PBK model for lasiocarpine and riddelliine in Chinese and Caucasian subjects 
as obtained from literature. 
Model parameters Chinese a,c Caucasian b,c 
Physiological parameters   
Bodyweight (kg) 60 70 
Tissue volumes (% of body weight)   
Fat 18.7 21.4 
Liver 2.3 2.6 
Small intestine 0.5 0.9 
Richly perfused 4.8 4.1 
Slowly perfused 62.3 59.6 
Arterial blood 2.0 2.0 
Venous blood 5.9 5.9 
Cardiac output (L/hr/kg bw 0.74) 15 15 
Percentage of cardiac output   
Fat 6.75 5.2 
Liver 26.3 22.7 
Small intestine 10.5 18.1 
Richly perfused 33.2 43.7 
Slowly perfused 23.3 23.3 
   
Tissue: blood partition coefficients   
Lasiocarpine   
Fat/blood 3.46 3.46 
Liver/blood 0.78 0.78 
Small intestine/blood 0.78 0.78 
Richly perfused/blood 0.78 0.78 
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Riddelliine   
Fat/blood 0.25 0.25 
Liver/blood 0.63 0.63 
Small intestine/blood 0.63 0.63 
Richly perfused/blood 0.63 0.63 
Slowly perfused/blood 0.77 0.77 
a NHFPC (2007); NHFPC (2014) 
b Brown et al. (1997) 
c DeJongh et al. (1997) 
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;===============================================================================
=========== 
;Physiological parameters 
;===============================================================================
=========== 
 
;Tissue volumes 
BW = 70 {Kg}                ; body weight   
 VFc = 0.214   ; fraction of fat tissue 
 VLc = 0.026   ; fraction of liver 
 VSic = 0.009   ; fraction of small intestine 
 ;VAc = 0.02   ; fraction of arterial blood: 0.074*1/4  
 ;VVc = 0.059   ; fraction of venous blood: 0.074*3/4 
 VBc = 0.079 
 VRc = 0.076-VLc-VSic  ; fraction of richly perfused tissue 
 VSc = 0.81-VFc                ; fraction of blood flow to slowly perfused tissue 
    ; total of fractions = 88.6 
 
VF = VFc*BW  {L or Kg} 
VL = VLc*BW    
VSi = VSic*BW  
VR = VRc*BW     
VS = VSc*BW  
;VA = VAc*BW 
;VV = VVc*BW 
VB = VBc*BW 
;----------------------------------------------------------------------------------------------------------------------------- ----------
---------------------------------------------  
;Blood flow rates 
QC = 15*BW^0.74 {L/hr} ; Info: QC=15*BW^0.74  
  QFc = 0.052   ; Fraction of blood flow to fat 
  QLc = 0.227 -QSic  ; Fraction of blood flow to liver  
  QSic = 0.181                        ; Fraction of blood flow to small intestine 
  QRc = 0.7-QLc-QSic  ; Fraction of blood flow to richly perfused tissue  
  QSc = 0.3-QFc                 ; Fraction of blood flow to slowly perfused tissue 
      ; total of fractions = 1 
 
QF = QFc*QC {L/hr} 
QL = QLc*QC 
QSi = QSic*QC 
QR = QRc*QC    
QS = QSc*QC  
 
; ;===============================================================================
=========== 
;Partition Coefficients 
;===============================================================================
=========== 
;lasiocarpine 
PLL = 0.78   ; liver/blood partition coefficient  
PFL = 3.46   ; fat/blood partition coefficient 
PRL = 0.78   ; richly perfused tissues/blood partition coefficient 
PSL = 0.86   ; slowly perfused tissues/blood partition coefficient 
PIL = 0.78                                         ; intestine/blood partition coefficient
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Riddelliine   
Fat/blood 0.25 0.25 
Liver/blood 0.63 0.63 
Small intestine/blood 0.63 0.63 
Richly perfused/blood 0.63 0.63 
Slowly perfused/blood 0.77 0.77 
a NHFPC (2007); NHFPC (2014) 
b Brown et al. (1997) 
c DeJongh et al. (1997) 
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;===============================================================================
=========== 
;Physiological parameters 
;===============================================================================
=========== 
 
;Tissue volumes 
BW = 70 {Kg}                ; body weight   
 VFc = 0.214   ; fraction of fat tissue 
 VLc = 0.026   ; fraction of liver 
 VSic = 0.009   ; fraction of small intestine 
 ;VAc = 0.02   ; fraction of arterial blood: 0.074*1/4  
 ;VVc = 0.059   ; fraction of venous blood: 0.074*3/4 
 VBc = 0.079 
 VRc = 0.076-VLc-VSic  ; fraction of richly perfused tissue 
 VSc = 0.81-VFc                ; fraction of blood flow to slowly perfused tissue 
    ; total of fractions = 88.6 
 
VF = VFc*BW  {L or Kg} 
VL = VLc*BW    
VSi = VSic*BW  
VR = VRc*BW     
VS = VSc*BW  
;VA = VAc*BW 
;VV = VVc*BW 
VB = VBc*BW 
;----------------------------------------------------------------------------------------------------------------------------- ----------
---------------------------------------------  
;Blood flow rates 
QC = 15*BW^0.74 {L/hr} ; Info: QC=15*BW^0.74  
  QFc = 0.052   ; Fraction of blood flow to fat 
  QLc = 0.227 -QSic  ; Fraction of blood flow to liver  
  QSic = 0.181                        ; Fraction of blood flow to small intestine 
  QRc = 0.7-QLc-QSic  ; Fraction of blood flow to richly perfused tissue  
  QSc = 0.3-QFc                 ; Fraction of blood flow to slowly perfused tissue 
      ; total of fractions = 1 
 
QF = QFc*QC {L/hr} 
QL = QLc*QC 
QSi = QSic*QC 
QR = QRc*QC    
QS = QSc*QC  
 
; ;===============================================================================
=========== 
;Partition Coefficients 
;===============================================================================
=========== 
;lasiocarpine 
PLL = 0.78   ; liver/blood partition coefficient  
PFL = 3.46   ; fat/blood partition coefficient 
PRL = 0.78   ; richly perfused tissues/blood partition coefficient 
PSL = 0.86   ; slowly perfused tissues/blood partition coefficient 
PIL = 0.78                                         ; intestine/blood partition coefficient
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;===============================================================================
=========== 
;Biochemical parameters  
;===============================================================================
=========== 
 
;Linear uptake rate (hr-1) 
Ka = 1.55   ;The averaged Ka values reported by Chen et al., 2018. The Ka value was 
based on 1. Papp predicted by Schrodinger  and 2. Papp derived from equation log Papp = -5.469 + 0.236 log P 
(Hou et al., 2004)  
;----------------------------------------------------------------------------------------------------------------------------- ----------
---------------------------------------------  
  ;Metabolism liver 
  ;Scaling factors 
MPL=35 ;Liver microsomal protein yield (mg/gram liver)  
 
L=VLC*1000 ;Liver = 34 (gram/kg BW)   
;metabolites of lasiocarpine, unscaled maximum rate of metabolism (nmol min-1 (mg protein)-1) 
VmaxLM1c = 5.107   ; based on substrate depletion in Caucasian liver microsome  
 
 
;metabolites of  lasiocarpine, scaled maximum rate of metabolism (umol hr-1) 
VMaxLM1 = VMaxLM1c/1000*60*MPL*L*BW 
 
 
;metabolites of  lasiocarpine, affinity constants (umol/L) 
KmLM1 = 25.81     ; based on substrate depletion in Caucasian liver microsome  
 
 
 
 
;------------------------------------------------------------------------------------------------------------------------------ ---------
---------------------------------------------  
  ;Metabolism small intestine 
  ;Scaling factor 
MPSi=20.6    ;Small intestine microsome fraction yield (mg/g small intestine)  
Si =VSiC*1000   
 
;metabolites of  lasiocarpine, unscaled maximum rate of metabolism (nmol min-1 (mg)-1) 
VmaxSiM2c = 0.8840  ; based on the substrate depletion in Caucasian intestine microsome 
 
 
;metabolites of  lasiocarpine, scaled maximum rate of metabolism (umol hr-1) 
VMaxSiM2 = VMaxSiM2c/1000*60*MPSi*SI*BW 
 
 
;metabolites of  lasiocarpine, affinity constants (umol/L) 
KmSiM2 = 72.12  ;  based on the substrate depletion in Caucasian intestine microsome    
  
 
;===============================================================================
=========== 
;Run settings 
;===============================================================================
=========== 
 
;Molecular weight
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MWL =411.2;   Molecular weight lasiocarpine  
  
;Given dose (mg/ kg bw) and oral dose umol/ kg bw}  
 GDOSE = 10 {mg/ kg bw}    ; GDOSE = given dose 
 ODOSE = GDOSE*1E-3/MWL*1E6  {umol/ kg bw} ; ODOSE = given dose recalculated to umol/kg 
bw 
 DOSE=ODOSE*BW;     ; DOSE = umol 
 
;Time 
 Starttime = 0;   in hrs 
 Stoptime = 24;   in hrs 
 
;===============================================================================
=========== 
;Dynamics 
;===============================================================================
=========== 
;slowly perfused tissue compartment 
 
;AS = Amount lasiocarpine in slowly perfused tissue, umol 
       AS' = QS*(CB-CVS)  
       Init AS = 0 
       CS = AS/VS 
       CVS = CS/PSL 
;----------------------------------------------------------------------------------------------------- ----------------------------------
---------------------------------------------  
;richly perfused tissue compartment 
 
;AR = Amount lasiocarpine in richly perfused tissue, umol 
       AR' = QR*(CB-CVR)  
       Init AR = 0 
       CR = AR/VR 
       CVR = CR/PRL 
;----------------------------------------------------------------------------------------------------------------------------- ----------
---------------------------------------------  
;fat compartment 
 
;AF = Amount lasiocarpine in fat tissue, umol 
       AF' = QF*(CB-CVF)  
       Init AF = 0 
       CF = AF/VF 
       CVF = CF/PFL 
;----------------------------------------------------------------------------------------------------------------------------- ----------
---------------------------------------------  
;uptake lasiocarpine from GI tract 
 
;AGI = Amount  lasiocarpine remaining in GI tract (umol) 
      AGI' =-ka*AGI 
      Init AGI = dose 
;-------------------------------------------------------------------------------------------------------------------- -------------------
---------------------------------------------  
;liver compartment 
 
;AL = Amount  lasiocarpine in liver tissue, umol 
      AL' = QL*CB +QSi*CVSi - (QL+QSi) *CVL - AMLM1'  
       Init AL = 0 
       CL = AL/VL 
       CVL = CL/PLL
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;===============================================================================
=========== 
;Biochemical parameters  
;===============================================================================
=========== 
 
;Linear uptake rate (hr-1) 
Ka = 1.55   ;The averaged Ka values reported by Chen et al., 2018. The Ka value was 
based on 1. Papp predicted by Schrodinger  and 2. Papp derived from equation log Papp = -5.469 + 0.236 log P 
(Hou et al., 2004)  
;----------------------------------------------------------------------------------------------------------------------------- ----------
---------------------------------------------  
  ;Metabolism liver 
  ;Scaling factors 
MPL=35 ;Liver microsomal protein yield (mg/gram liver)  
 
L=VLC*1000 ;Liver = 34 (gram/kg BW)   
;metabolites of lasiocarpine, unscaled maximum rate of metabolism (nmol min-1 (mg protein)-1) 
VmaxLM1c = 5.107   ; based on substrate depletion in Caucasian liver microsome  
 
 
;metabolites of  lasiocarpine, scaled maximum rate of metabolism (umol hr-1) 
VMaxLM1 = VMaxLM1c/1000*60*MPL*L*BW 
 
 
;metabolites of  lasiocarpine, affinity constants (umol/L) 
KmLM1 = 25.81     ; based on substrate depletion in Caucasian liver microsome  
 
 
 
 
;------------------------------------------------------------------------------------------------------------------------------ ---------
---------------------------------------------  
  ;Metabolism small intestine 
  ;Scaling factor 
MPSi=20.6    ;Small intestine microsome fraction yield (mg/g small intestine)  
Si =VSiC*1000   
 
;metabolites of  lasiocarpine, unscaled maximum rate of metabolism (nmol min-1 (mg)-1) 
VmaxSiM2c = 0.8840  ; based on the substrate depletion in Caucasian intestine microsome 
 
 
;metabolites of  lasiocarpine, scaled maximum rate of metabolism (umol hr-1) 
VMaxSiM2 = VMaxSiM2c/1000*60*MPSi*SI*BW 
 
 
;metabolites of  lasiocarpine, affinity constants (umol/L) 
KmSiM2 = 72.12  ;  based on the substrate depletion in Caucasian intestine microsome    
  
 
;===============================================================================
=========== 
;Run settings 
;===============================================================================
=========== 
 
;Molecular weight
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MWL =411.2;   Molecular weight lasiocarpine  
  
;Given dose (mg/ kg bw) and oral dose umol/ kg bw}  
 GDOSE = 10 {mg/ kg bw}    ; GDOSE = given dose 
 ODOSE = GDOSE*1E-3/MWL*1E6  {umol/ kg bw} ; ODOSE = given dose recalculated to umol/kg 
bw 
 DOSE=ODOSE*BW;     ; DOSE = umol 
 
;Time 
 Starttime = 0;   in hrs 
 Stoptime = 24;   in hrs 
 
;===============================================================================
=========== 
;Dynamics 
;===============================================================================
=========== 
;slowly perfused tissue compartment 
 
;AS = Amount lasiocarpine in slowly perfused tissue, umol 
       AS' = QS*(CB-CVS)  
       Init AS = 0 
       CS = AS/VS 
       CVS = CS/PSL 
;----------------------------------------------------------------------------------------------------- ----------------------------------
---------------------------------------------  
;richly perfused tissue compartment 
 
;AR = Amount lasiocarpine in richly perfused tissue, umol 
       AR' = QR*(CB-CVR)  
       Init AR = 0 
       CR = AR/VR 
       CVR = CR/PRL 
;----------------------------------------------------------------------------------------------------------------------------- ----------
---------------------------------------------  
;fat compartment 
 
;AF = Amount lasiocarpine in fat tissue, umol 
       AF' = QF*(CB-CVF)  
       Init AF = 0 
       CF = AF/VF 
       CVF = CF/PFL 
;----------------------------------------------------------------------------------------------------------------------------- ----------
---------------------------------------------  
;uptake lasiocarpine from GI tract 
 
;AGI = Amount  lasiocarpine remaining in GI tract (umol) 
      AGI' =-ka*AGI 
      Init AGI = dose 
;-------------------------------------------------------------------------------------------------------------------- -------------------
---------------------------------------------  
;liver compartment 
 
;AL = Amount  lasiocarpine in liver tissue, umol 
      AL' = QL*CB +QSi*CVSi - (QL+QSi) *CVL - AMLM1'  
       Init AL = 0 
       CL = AL/VL 
       CVL = CL/PLL
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;AMLM1=Amount lasiocarpine metabolized in liver to metabolite 1, umol 
       AMLM1' = VmaxLM1*CVL/(KmLM1 + CVL)  
       Init AMLM1 = 0 
   
 
 
;----------------------------------------------------------------------------------------------------------------------------- ----------
---------------------------------------------  
;small intestine compartment 
 
;ASi = Amount  lasiocarpine in small intestine tissue, umol 
      ASi' = QSi*(CB -CVSi) + ka*AGI - AMSiM2'  
       Init ASi = 0 
       CSi = ASi/VSi 
       CVSi = CSi/PIL 
 
;AMSiM2=Amount lasiocarpine metabolized in small intestine to metabolites2, umol 
      AMSiM2'= VmaxSiM2*CVSi/(KmSiM2 + CVSi)  
      Init AMSiM2 = 0 
                  
 
;---------------------------------------------------------------------------------------------------------------------------------------
---------------------------------------------  
; arterial blood compartment       
 
;CA = Concentration arterial blood  lasiocarpine 
;CA =  CV 
 
;---------------------------------------------------------------------------------------------------------------------------------------
---------------------------------------------  
; venous blood compartment      
 
;CB = Concentration venous blood  lasiocarpine (umol/L) 
      AB' = (QF*CVF + (QL+QSi)*CVL + QR*CVR + QS*CVS - QC*CB) 
      Init AB = 0             
      CB = AB/VB 
     AUC' = CB 
      init AUC = 0 
 
;===============================================================================
=========== 
;Mass balance calculations 
{Mass Balance} 
Total = DOSE 
Calculated = AF + AS + AR + AL +  AB  + AGI + ASI + AMLM1+AMSiM2 
ERROR= ((Total-Calculated)/Total+1E-30)*100 
MASSBBAL=Total-Calculated + 1  
PercAMLM1 = (AMLM1)*100/DOSE 
PercAMSiM2 = (AMSiM2)*100/DOSE 
PercAL = AL*100/DOSE 
;===============================================================================
=========== 
; blood concentration in ng/ml 
CBngmL = CB*MWL 
;===============================================================================
===========
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Table S4 In vitro cytotoxicity data of lasiocarpine and riddelliine based on the experiments of the present study 
Compound Cell model 
Compound 
concentration (µM) 
Mean of cell 
viability % 
The effect 
concentration in 
human liver blood 
(µM) 
Dose reconstructed 
using PBK model 
(mg/kg bw) 
Lasiocarpine 
HepaRG 
0, 4.7, 9.4, 18.8, 
37.5, 75, 150, 300 
100, 108, 
108, 89, 93, 
75, 52, 40 
0, 10.9, 21.8, 43.6, 
87.2, 174.4, 348.8, 
697.7 
0, 27.7, 43.5, 63.2, 
86.4, 116.8, 164.3, 
248.4 
Human 
(Caucasian) 
hepatocyte 
0, 4.7, 9.4, 18.8, 
37.5, 75, 150, 300 
100, 82, 62, 
52, 33, 26, 
20, 17 
0, 10.9, 21.8, 43.6, 
87.2, 174.4, 348.8, 
697.7 
0, 27.7, 43.5, 63.2, 
86.4, 116.8, 164.3, 
248.4 
Corrected 
human 
(Chinese) 
hepatocyte 
0, 34, 70, 104, 230, 
351, 707, 1414 
100, 82, 62, 
52, 33, 26, 
20, 17 
0, 79.3, 160.8, 
242.5, 535.9, 
817.6, 1645.2, 
3290.5 
0, 62.0, 93.7, 120.4, 
202.2, 276.5, 489.6, 
904.1 
Riddelliine 
HepaRG 
0, 4.7, 9.4, 18.8, 
37.5, 75, 150, 300 
100, 90, 81, 
80, 70, 67, 
49, 37 
0, 10.9, 21.8, 43.6, 
87.2, 174.4, 348.8, 
697.7 
0, 6.0, 11.5, 22.9, 
43.9, 80.8, 144.6, 
253.7 
Human 
(Caucasian) 
hepatocyte 
0, 4.7, 9.4, 18.8, 
37.5, 75, 150, 300 
100, 80, 71, 
63, 54, 40, 
32, 29 
0, 10.9, 21.8, 43.6, 
87.2, 174.4, 348.8, 
697.7 
0, 6.0, 11.5, 22.9, 
43.9, 80.8, 144.6, 
253.7 
Corrected 
Human 
(Chinese) 
hepatocyte 
0, 39.3, 85.5, 192.8, 
307.4, 618.3, 
1236.7, 2236.1 
100, 80, 71, 
63, 54, 40, 
32, 29 
0, 91.4, 198.7, 
448.4, 714.9, 
1438.0, 2875.9, 
5200.2 
0, 28.3, 58.0, 122.4, 
187.3, 359.8, 694.1, 
1230.1 
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;AMLM1=Amount lasiocarpine metabolized in liver to metabolite 1, umol 
       AMLM1' = VmaxLM1*CVL/(KmLM1 + CVL)  
       Init AMLM1 = 0 
   
 
 
;----------------------------------------------------------------------------------------------------------------------------- ----------
---------------------------------------------  
;small intestine compartment 
 
;ASi = Amount  lasiocarpine in small intestine tissue, umol 
      ASi' = QSi*(CB -CVSi) + ka*AGI - AMSiM2'  
       Init ASi = 0 
       CSi = ASi/VSi 
       CVSi = CSi/PIL 
 
;AMSiM2=Amount lasiocarpine metabolized in small intestine to metabolites2, umol 
      AMSiM2'= VmaxSiM2*CVSi/(KmSiM2 + CVSi)  
      Init AMSiM2 = 0 
                  
 
;---------------------------------------------------------------------------------------------------------------------------------------
---------------------------------------------  
; arterial blood compartment       
 
;CA = Concentration arterial blood  lasiocarpine 
;CA =  CV 
 
;---------------------------------------------------------------------------------------------------------------------------------------
---------------------------------------------  
; venous blood compartment      
 
;CB = Concentration venous blood  lasiocarpine (umol/L) 
      AB' = (QF*CVF + (QL+QSi)*CVL + QR*CVR + QS*CVS - QC*CB) 
      Init AB = 0             
      CB = AB/VB 
     AUC' = CB 
      init AUC = 0 
 
;===============================================================================
=========== 
;Mass balance calculations 
{Mass Balance} 
Total = DOSE 
Calculated = AF + AS + AR + AL +  AB  + AGI + ASI + AMLM1+AMSiM2 
ERROR= ((Total-Calculated)/Total+1E-30)*100 
MASSBBAL=Total-Calculated + 1  
PercAMLM1 = (AMLM1)*100/DOSE 
PercAMSiM2 = (AMSiM2)*100/DOSE 
PercAL = AL*100/DOSE 
;===============================================================================
=========== 
; blood concentration in ng/ml 
CBngmL = CB*MWL 
;===============================================================================
===========
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Table S4 In vitro cytotoxicity data of lasiocarpine and riddelliine based on the experiments of the present study 
Compound Cell model 
Compound 
concentration (µM) 
Mean of cell 
viability % 
The effect 
concentration in 
human liver blood 
(µM) 
Dose reconstructed 
using PBK model 
(mg/kg bw) 
Lasiocarpine 
HepaRG 
0, 4.7, 9.4, 18.8, 
37.5, 75, 150, 300 
100, 108, 
108, 89, 93, 
75, 52, 40 
0, 10.9, 21.8, 43.6, 
87.2, 174.4, 348.8, 
697.7 
0, 27.7, 43.5, 63.2, 
86.4, 116.8, 164.3, 
248.4 
Human 
(Caucasian) 
hepatocyte 
0, 4.7, 9.4, 18.8, 
37.5, 75, 150, 300 
100, 82, 62, 
52, 33, 26, 
20, 17 
0, 10.9, 21.8, 43.6, 
87.2, 174.4, 348.8, 
697.7 
0, 27.7, 43.5, 63.2, 
86.4, 116.8, 164.3, 
248.4 
Corrected 
human 
(Chinese) 
hepatocyte 
0, 34, 70, 104, 230, 
351, 707, 1414 
100, 82, 62, 
52, 33, 26, 
20, 17 
0, 79.3, 160.8, 
242.5, 535.9, 
817.6, 1645.2, 
3290.5 
0, 62.0, 93.7, 120.4, 
202.2, 276.5, 489.6, 
904.1 
Riddelliine 
HepaRG 
0, 4.7, 9.4, 18.8, 
37.5, 75, 150, 300 
100, 90, 81, 
80, 70, 67, 
49, 37 
0, 10.9, 21.8, 43.6, 
87.2, 174.4, 348.8, 
697.7 
0, 6.0, 11.5, 22.9, 
43.9, 80.8, 144.6, 
253.7 
Human 
(Caucasian) 
hepatocyte 
0, 4.7, 9.4, 18.8, 
37.5, 75, 150, 300 
100, 80, 71, 
63, 54, 40, 
32, 29 
0, 10.9, 21.8, 43.6, 
87.2, 174.4, 348.8, 
697.7 
0, 6.0, 11.5, 22.9, 
43.9, 80.8, 144.6, 
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Human 
(Chinese) 
hepatocyte 
0, 39.3, 85.5, 192.8, 
307.4, 618.3, 
1236.7, 2236.1 
100, 80, 71, 
63, 54, 40, 
32, 29 
0, 91.4, 198.7, 
448.4, 714.9, 
1438.0, 2875.9, 
5200.2 
0, 28.3, 58.0, 122.4, 
187.3, 359.8, 694.1, 
1230.1 
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Fig. S5 lasiocarpine and riddelliine concentration-dependent rate of formation of 7-GSH-DHP by liver in 
incubations with Chinese (dotted line) and Caucasian (solid line) liver microsomes in the presence of the 
cofactor NADPH. Data points represent mean values ± SD of three individual experiments 
Table S5 Fold-differences in 7-GSH-DHP formation in incubation with Chinese and Caucasian liver 
microsomes  at each substrate concentration.   
Substrate concentration 
(µM) 
Fold-difference ± SD 3 
Lasiocarpine Riddelliine 
3.1 4.5 ± 0.4 5.1 ± 0.6 
6.2 6.4 ± 0.6 10.2 ± 2.9 
12.5 7.2 ± 1.0 8.4 ± 0.9 
25 7.3 ± 1.5 9.1 ± 2.6 
50 5.5 ± 1.7 10.3 ± 0.8 
100 6.2 ± 1.8 8.2 ± 0.8 
150 a/200 b 4.7 ± 1.1 8.2 ± 1.1 
200 a/400 b 4.7 ± 0.2 7.5 ± 0.6 
a Lasiocarpine concentration  
b Riddelliine concentration  
c Calculated as peak areas of 7-GSH-DHP in incubation with Caucasian liver microsomes divided by those in 
incubation with Chinese liver microsomes 
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Fig. S6 Normalized sensitivity coefficients of model parameters for the prediction of Cmax of lasiocarpine and 
riddelliine in Chinese (black bar) and Caucasian (white bar) liver after oral administration to 8 ng/kg bw (a) and 
3 mg/kg bw (b) of both compounds. VLc=fraction of liver tissue, VSic=fraction of small intestine tissue, 
QSic=fraction of blood flow to small intestine, Ka= absorption rate constant, MPL=microsomal protein yield in 
liver, MPSi=microsomal protein yield in small intestine. The VmaxLM1/SiM2 and Km LM1/SiM2 represent the 
maximum rate of formation and Michaelis-Menten constant for the substrate depletion in the liver/small intestine
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Fig. S5 lasiocarpine and riddelliine concentration-dependent rate of formation of 7-GSH-DHP by liver in 
incubations with Chinese (dotted line) and Caucasian (solid line) liver microsomes in the presence of the 
cofactor NADPH. Data points represent mean values ± SD of three individual experiments 
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Fig. S6 Normalized sensitivity coefficients of model parameters for the prediction of Cmax of lasiocarpine and 
riddelliine in Chinese (black bar) and Caucasian (white bar) liver after oral administration to 8 ng/kg bw (a) and 
3 mg/kg bw (b) of both compounds. VLc=fraction of liver tissue, VSic=fraction of small intestine tissue, 
QSic=fraction of blood flow to small intestine, Ka= absorption rate constant, MPL=microsomal protein yield in 
liver, MPSi=microsomal protein yield in small intestine. The VmaxLM1/SiM2 and Km LM1/SiM2 represent the 
maximum rate of formation and Michaelis-Menten constant for the substrate depletion in the liver/small intestine
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PROAST analysis  
 BMD analysis was performed using the PROAST software from The National Institute for Public Health 
and the Environment of the Netherlands (RIVM) version 38.9 (Slob, 2002) using Exponential and Hill models for 
continuous data. The model was selected if the fitted model passes the goodness-of-fit test at P = 0.05 and the 
ratio of BMD and BMDL should not be more than 3-fold (EPA, 2017). 
We performed BMD modelling for both ethnic populations on the predicted dose-response data for 
lasiocarpine and riddelliine based on PBK modelling-based reverse dosimetry of cytotoxicity data using human 
hepatocytes. 
Table S7.1 Results from the BMD analysis using PROAST software of the predicted dose-response data of 
lasiocarpine for the average Chinese using PBK modelling-based reverse dosimetry of cytotoxicity data derived 
from human hepatocytes. The table presents the BMD5, BMDL5 and BMDU5 for a BMR (Benchmark response) of 
5% compared to the control group, with characteristics of the model fit for Hill 5. 
 
Fig. S7.1 Predicted in vivo dose-response curve for liver toxicity induced by lasiocaprine in average Chinese
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 a-    1.05 
 CED-    26 
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 d-    2.11 
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 CES    -0.05 
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 scaling f actor on x :  1 
 dty pe :  1 
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 CEDL    14.67 
 CEDU    41.23
Model BMR  Log-likelihood BMD5  
(mg/kg bw) 
BMDL5  
(mg/kg bw) 
BMDU5  
(mg/kg bw) 
Full  5% -5.7 NA NA NA 
Hill 5-CED 
a*(1+(c-1)x^d/(b^d+x^d)) 
5% -6.09 26.0 14.7 41.2 
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Table S7.2 Results from the BMD analysis using PROAST software of the predicted dose-response data of 
lasiocarpine for the average Caucasian using PBK modelling-based reverse dosimetry of cytotoxicity data derived 
from human hepatocytes. The table presents BMD5, BMDL5 and BMDU5 for a BMR of 5% compared to the 
control group, with characteristics of the model fit for Hill 5.  
 
Fig. S7.2 Predicted in vivo dose-response curve for liver toxicity induced by lasiocaprine in average Caucasian
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Hill 5-CED 
a*(1+(c-1)x^d/(b^d+x^d)) 
5% -7.37 14.1 7.4 23.7 
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PROAST analysis  
 BMD analysis was performed using the PROAST software from The National Institute for Public Health 
and the Environment of the Netherlands (RIVM) version 38.9 (Slob, 2002) using Exponential and Hill models for 
continuous data. The model was selected if the fitted model passes the goodness-of-fit test at P = 0.05 and the 
ratio of BMD and BMDL should not be more than 3-fold (EPA, 2017). 
We performed BMD modelling for both ethnic populations on the predicted dose-response data for 
lasiocarpine and riddelliine based on PBK modelling-based reverse dosimetry of cytotoxicity data using human 
hepatocytes. 
Table S7.1 Results from the BMD analysis using PROAST software of the predicted dose-response data of 
lasiocarpine for the average Chinese using PBK modelling-based reverse dosimetry of cytotoxicity data derived 
from human hepatocytes. The table presents the BMD5, BMDL5 and BMDU5 for a BMR (Benchmark response) of 
5% compared to the control group, with characteristics of the model fit for Hill 5. 
 
Fig. S7.1 Predicted in vivo dose-response curve for liver toxicity induced by lasiocaprine in average Chinese
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Table S7.2 Results from the BMD analysis using PROAST software of the predicted dose-response data of 
lasiocarpine for the average Caucasian using PBK modelling-based reverse dosimetry of cytotoxicity data derived 
from human hepatocytes. The table presents BMD5, BMDL5 and BMDU5 for a BMR of 5% compared to the 
control group, with characteristics of the model fit for Hill 5.  
 
Fig. S7.2 Predicted in vivo dose-response curve for liver toxicity induced by lasiocaprine in average Caucasian
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Table S7.3 Results from the BMD analysis using PROAST software of the predicted dose-response data of 
riddelliine for the average Chinese using PBK modelling-based reverse dosimetry of cytotoxicity data derived from 
human hepatocytes. The table presents the BMD5, BMDL5 and BMDU5 for a BMR of 5% compared to the control 
group, with characteristics of the model fit for Hill 5. 
 
Fig. S7.3  Predicted in vivo dose-response curve for liver toxicity induced by riddelliine in average Chinese
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Table S7.4 Results from the BMD analysis using PROAST software of the predicted dose-response data of 
riddelliine for the average Caucasian using PBK modelling-based reverse dosimetry of cytotoxicity data derived 
from human hepatocytes. The table presents the BMD5, BMDL5 and BMDU5 for a BMR of 5% compared to the 
control group, with characteristics of the model fit for Hill 5.  
 
Fig. S7.4  Predicted in vivo dose-response curve for liver toxicity induced by riddelliine in average Caucasian
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Abstract 
Pyrrolizidine alkaloids (PAs) are naturally occuring genotoxic compounds, and PA-contaning plants 
can pose a risk to humans through contaminated food sources and herbal products. Upon metabolic 
activation, PAs can form DNA adducts, DNA and protein cross-links, chromosomal aberrations, 
micronuclei and DNA double-strand breaks. These genotoxic effects may induce gene mutations and 
play a role in the carcinogenesis of PAs. This study aims to predict in vivo genotoxicity for two well-
studied PAs, lasiocarpine and riddelliine, in rat using in vitro genotoxicity data and physiologically 
based kinetic (PBK) modelling-based reverse dosimetry. The γH2AX assay was used to determine the 
in vitro genotoxicity for lasiocarpine and riddelliine in primary rat hepatocytes and human HepaRG 
cells. The in vitro concentration-response curves obtained from primary rat hepatocytes were 
subsequently converted to in vivo dose-response curves from which points of depature (PoDs) were 
derived that were compared to available in vivo genotoxicity data. The results showed that the 
predicted PoDs for lasiocarpine and riddelliine were comparable to in vivo genotoxicity data. It is 
concluded that this quantitative in vitro-in silico approach provides a method to predict in vivo 
genotoxicity for the large number of PAs for which in vivo genotoxicity data are lacking by 
integrating in vitro genotoxicity assays with PBK modelling-facilitated reverse dosimetry. 
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Introduction 
Pyrrolizidine alkaloids (PAs) are secondary metabolites that plants produce against insects (Fu et al., 
2004). To date, more than 660 PAs and their N-oxides have been identified from more than 6000 
plants, and half of them are hepatotoxic (Fu et al., 2010; Wiedenfeld, 2011). PA containing plants are 
widely distributed around the world, and a number of human and livestock poisoning incidents with 
high mortality due to (unintentional) contamination by PAs have been reported in different countries 
(Creeper et al., 1999; Edgar et al., 2014; Hill et al., 1997; Molyneux et al., 2011). Human exposure to 
PAs mainly results from PA containing foods, such as herbal teas, herbal medicines, milk and honey 
(Bodi et al., 2014; EFSA, 2016, EFSA 2017; Kempf et al., 2010; Mathon et al., 2014; Roeder, 2000). 
PAs can induce acute hepatotoxicity in both rat and human, resulting in liver necrosis, hepatomegaly, 
and veno-occlusive disease (VOD) (Fu et al., 2007; Fu et al., 2004; Lin et al., 2011; Mattocks, 1986; 
Wiedenfeld, 2011). Chronic exposure to PAs is of concern because of their genotoxicity and 
carcinogenicity (EFSA, 2011). Especially 1,2-unsaturated PAs are hepatotoxic and considered to be 
genotoxic carcinogens, thus posing a potential risk to human health (Mori et al., 1985). 
Upon metabolic activation PAs can lead to a variety of genotoxic effects, including formation of DNA 
adducts, DNA and protein cross-links, chromosomal aberrations, micronuclei and DNA double-strand 
breaks (DSB) (Allemang et al., 2018; Chou et al., 2003; Chou et al., 2004; Fu et al., 2001; Fu et al., 
2010; Fu et al., 2004; Prakash et al., 1999; Uhl et al., 2000; Wang et al., 2005a; Xia et al., 2006; Xia et 
al., 2013). These genotoxic effects may result in gene mutations and tumour formation (Chen et al., 
2010; Hoeijmakers, 2009). Recently, the European Food Safety Authority (EFSA) has drawn attention 
to the fact that more data on the toxicokinetics and genotoxicity of individual PAs would greatly refine 
their risk assessment (EFSA, 2017). State-of-the-art genotoxicity and carcinogenicity data on PAs are 
limited, and among the 1,2-unsaturated PAs, lasiocarpine and riddelliine are the PAs most studied in in 
vivo genotoxicity and carcinogenicity studies. For instance, both PAs have been shown to induce 
genotoxicity in rat liver upon oral exposure (Chan et al., 1994; Xia et al., 2013; Yan et al., 2002). In 
addition, they were both tested in oral 2-year carcinogenicity studies and shown to induce liver 
haemangiosarcomas in rats upon chronic oral exposure (NTP, 1978, 2003). In addition, limited in vivo 
genotoxicity data are available for seneciphylline, senkirkine, monocrotaline and retrorsine (Candrian 
et al., 1984; Wang et al., 2005a; Wang et al., 2005b), and results from carcinogenicity bioassays have 
been reported for monocrotaline, clivorine, petasitenine, senkirkine and symphytine with only in some 
of these studies rats being dosed via the oral route (Hirono et al., 1979; Hirono et al., 1976; Kuhara et 
al., 1980; Shumaker et al., 1976). Studies to assess whether exposure to PAs results in genotoxicity 
and carcinogenicity in humans are not available. Lack of genotoxicity studies for most 1,2-unsaturated 
PAs, hampers PA risk assessment, while economic and ethical constraints limit the possibilities to 
perform in vivo genotoxicity and carcinogenicity studies for all relevant PAs, including
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Pyrrolizidine alkaloids (PAs) are naturally occuring genotoxic compounds, and PA-contaning plants 
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Introduction 
Pyrrolizidine alkaloids (PAs) are secondary metabolites that plants produce against insects (Fu et al., 
2004). To date, more than 660 PAs and their N-oxides have been identified from more than 6000 
plants, and half of them are hepatotoxic (Fu et al., 2010; Wiedenfeld, 2011). PA containing plants are 
widely distributed around the world, and a number of human and livestock poisoning incidents with 
high mortality due to (unintentional) contamination by PAs have been reported in different countries 
(Creeper et al., 1999; Edgar et al., 2014; Hill et al., 1997; Molyneux et al., 2011). Human exposure to 
PAs mainly results from PA containing foods, such as herbal teas, herbal medicines, milk and honey 
(Bodi et al., 2014; EFSA, 2016, EFSA 2017; Kempf et al., 2010; Mathon et al., 2014; Roeder, 2000). 
PAs can induce acute hepatotoxicity in both rat and human, resulting in liver necrosis, hepatomegaly, 
and veno-occlusive disease (VOD) (Fu et al., 2007; Fu et al., 2004; Lin et al., 2011; Mattocks, 1986; 
Wiedenfeld, 2011). Chronic exposure to PAs is of concern because of their genotoxicity and 
carcinogenicity (EFSA, 2011). Especially 1,2-unsaturated PAs are hepatotoxic and considered to be 
genotoxic carcinogens, thus posing a potential risk to human health (Mori et al., 1985). 
Upon metabolic activation PAs can lead to a variety of genotoxic effects, including formation of DNA 
adducts, DNA and protein cross-links, chromosomal aberrations, micronuclei and DNA double-strand 
breaks (DSB) (Allemang et al., 2018; Chou et al., 2003; Chou et al., 2004; Fu et al., 2001; Fu et al., 
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al., 2013). These genotoxic effects may result in gene mutations and tumour formation (Chen et al., 
2010; Hoeijmakers, 2009). Recently, the European Food Safety Authority (EFSA) has drawn attention 
to the fact that more data on the toxicokinetics and genotoxicity of individual PAs would greatly refine 
their risk assessment (EFSA, 2017). State-of-the-art genotoxicity and carcinogenicity data on PAs are 
limited, and among the 1,2-unsaturated PAs, lasiocarpine and riddelliine are the PAs most studied in in 
vivo genotoxicity and carcinogenicity studies. For instance, both PAs have been shown to induce 
genotoxicity in rat liver upon oral exposure (Chan et al., 1994; Xia et al., 2013; Yan et al., 2002). In 
addition, they were both tested in oral 2-year carcinogenicity studies and shown to induce liver 
haemangiosarcomas in rats upon chronic oral exposure (NTP, 1978, 2003). In addition, limited in vivo 
genotoxicity data are available for seneciphylline, senkirkine, monocrotaline and retrorsine (Candrian 
et al., 1984; Wang et al., 2005a; Wang et al., 2005b), and results from carcinogenicity bioassays have 
been reported for monocrotaline, clivorine, petasitenine, senkirkine and symphytine with only in some 
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al., 1980; Shumaker et al., 1976). Studies to assess whether exposure to PAs results in genotoxicity 
and carcinogenicity in humans are not available. Lack of genotoxicity studies for most 1,2-unsaturated 
PAs, hampers PA risk assessment, while economic and ethical constraints limit the possibilities to 
perform in vivo genotoxicity and carcinogenicity studies for all relevant PAs, including
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the 17 PAs identified by EFSA to be relevant for exposure via feed and food (EFSA, 2017). Thus, 
alternative testing strategies for estimating the genotoxicity and carcinogencity of different PAs are 
required. 
In our previous studies, we have successfully predicted in vivo acute liver toxicity for lasiocarpine and 
riddelliine in rat using physiologically based kinetic (PBK) modelling-facilitated reverse dosimetry 
(Chen et al., 2018). In this approach, in vitro concentration-response curves for cytotoxicity of 
lasiocarpine and riddelline in primary rat hepatocytes were translated to in vivo dose-response curves 
for acute liver toxicity in rat using PBK modelling (Chen et al., 2018). The aim of the present study 
was to investigate whether the developed PBK modelling-facilitated reverse dosimetry approach can 
also adequately translate in vitro concentration-response curves for genotoxicity of lasiocarpine and 
riddelliine, to in vivo dose-response curves for genotoxicity of these PAs. To this end, the in vitro 
concentration-responses curves obtained from in vitro genotoxicity studies with primary rat 
hepatocytes using the H2AX in-cell Western (ICW) assay were translated into in vivo dose-response 
curves by using PBK modelling-facilitated reverse dosimetry. The γH2AX ICW assay allows to 
quantify the amount of phosphorylated histone H2AX (γH2AX), which is known to be associated with 
DNA damage (Audebert et al., 2010; Khoury et al., 2013). Recently, this assay has been successfully 
applied to determine the in vitro genotoxic potencies of a large number of PAs, belonging to different 
chemical classes, in the human liver cell line HepaRG (Louisse et al., Submitted).  In the present study, 
the predicted in vivo dose-response curves were used to determine the points of departure (PoDs) 
which were compared to available in vivo data for genotoxicity induced by lasiocarpine and riddelliine 
in rats. 
Materials and methods 
Chemicals 
Lasiocarpine (> 97%) was purchased from PhytoLab (PhytoLab GmbH & Co. KG, Germany) 
(primary rat hepatocyte studies and HepaRG studies), riddelliine (95.4%) was kindly provided by the 
National Toxicology Program (NTP) (U.S. Department of Health and Human Service) (primary rat 
hepatocyte studies) and from Dr. Tao Chen (U.S. FDA) as a generous gift (HepaRG studies). Corning 
96 Well cellbind black microplates were obtained from Sigma-Aldrich (St. Louis, MO, USA). The 
cryopreserved rat (Sprague-Dawley) hepatocytes, thawing/plating supplement pack, cell maintenance 
supplement pack, fetal bovine serum (FBS) and Williams E Medium (A1217601) were purchased 
from ThermoFisher (Naarden, The Netherlands). HepaRG cells were obtained from Biopredic 
International (Saint-Grégoire, France). William's E medium and glutamax were obtained from Life 
Technologies (Paisley, UK). Primary antibody ‘anti-Phospho Histone H2AX’ (ser 139) (20E3) rabbit 
mAb, and secondary antibody CF770 goat anti rabbit IgG (H+L) were purchased from Cell Signaling 
Technology (Danvers, MA, USA) and Biotium (Fremont, CA, USA), respectively. Fetal bovine serum 
(FBS) and human insulin were purchased from PanBiotech (Aidenbach, Germany). 
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Penicillin/Streptomycin was from Capricorn Scientific (Ebsdorfergrund, Germany). Phosphate 
buffered saline (PBS) was obtained from Lonza BioWhittaker (Walkersville, MD, USA). Dimethyl 
sulfoxide (DMSO) was obtained from Acros Organics (Geel, Belgium). Acetonitrile (UPLC/MS grade) 
was obtained from Biosolve (Valkenswaard, The Netherlands). Triton X-100, bovine pancrease RNase 
A was purchased from Sigma-Aldrich (St Louis). PhosStop tablet was purchased from Roche 
Diagnostics (Mannheim, Germany). 16% Paraformaldehyde (PFA) was purchased from Electron 
microscopy sciences (Hatfield, USA). Reddot was obtained from Biotium (Fremont) and MaxBlock 
was purchased from Active Motif (Carlsbad, CA, USA).  
Cell culture 
Two types of cells were used for determing in vitro concentration-response curves for genotoxicity, i.e. 
primary rat hepatocytes and HepaRG cells. Briefly, cryopreserved primary rat hepatocytes were 
seeded at concentration of 5x105 cells/well in black 96 well cellbind plates, and incubated in Williams’ 
Medium E (no phenol red) consisting of hepatocyte plating supplement pack (CM3000, serum-
contaning) for 4-6 hours before exposure. Only batches with a cell viability > 90% were used for 
experiments. HepaRG cells were grown in growth medium consisting of Williams’ medium E, 
supplemented with 10% FBS, 100 IU/ml penicillin, 100 μg/ml streptomycin, 1% (v/v) L-glutamine, 5 
μg/ml human insulin and 50 μM hydrocortisone-21-hemisuccinate. The growth medium was renewed 
every two to three days. After two weeks, the HepaRG cells were trypsinized and seeded at a 
concentration of 9x103 cells/well in black 96 well cellbind plates, and kept on growth medium for two 
weeks and subsequently for another two weeks on differentiation medium consisting of growth 
medium supplemented with 1.7% (v/v) DMSO (Aninat et al. 2006). The medium was refreshed every 
two to three days. After two weeks culturing in differentiation medium, HepaRG cells were fully 
differentiated and used for experiments within four weeks with refreshing the medium every two to 
three days according to the protocol provided by Biopredic International. Primary rat hepatocytes and 
HepaRG cell were incubated in a 5% CO2: 95% air-humidified incubator. 
γH2AX assay 
The γH2AX ICW assay allows to simultaneously determine genotoxicity and cytotoxicity (Audebert et 
al., 2010; Khoury et al., 2013) and was used in the present study to assess the in vitro genotoxicity of 
non-cytotoxic concentrations of lasiocarpine and riddelliine in both primary rat hepatocytess and 
HepaRG cells. 4-6 hours after seeding the rat hepatocytes, the medium was replaced by exposure 
medium (Williams’ Medium E no phenol red supplemented with hepatocyte plating supplement pack 
(CM4000, serum-free)), containing lasiocarpine (final concentrations: 0 (solvent control), 0.006, 0.012, 
0.024, 0.048, 0.09, 0.195, 0.39, 0.78, 1.56, 3.125 and 6.25 µM) or riddelliine (final concentrations: 0 
(solvent control), 0.065, 0.13, 0.26, 0.52, 1.04, 2.08, 4.16, 8.32, 10 and 15 µM). Each concentration 
was tested in three replicates, and two independent experiments with different batches of primary rat 
hepatocytes were carried out. The HepaRG cells were placed on growth medium supplemented with 
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cryopreserved rat (Sprague-Dawley) hepatocytes, thawing/plating supplement pack, cell maintenance 
supplement pack, fetal bovine serum (FBS) and Williams E Medium (A1217601) were purchased 
from ThermoFisher (Naarden, The Netherlands). HepaRG cells were obtained from Biopredic 
International (Saint-Grégoire, France). William's E medium and glutamax were obtained from Life 
Technologies (Paisley, UK). Primary antibody ‘anti-Phospho Histone H2AX’ (ser 139) (20E3) rabbit 
mAb, and secondary antibody CF770 goat anti rabbit IgG (H+L) were purchased from Cell Signaling 
Technology (Danvers, MA, USA) and Biotium (Fremont, CA, USA), respectively. Fetal bovine serum 
(FBS) and human insulin were purchased from PanBiotech (Aidenbach, Germany). 
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Penicillin/Streptomycin was from Capricorn Scientific (Ebsdorfergrund, Germany). Phosphate 
buffered saline (PBS) was obtained from Lonza BioWhittaker (Walkersville, MD, USA). Dimethyl 
sulfoxide (DMSO) was obtained from Acros Organics (Geel, Belgium). Acetonitrile (UPLC/MS grade) 
was obtained from Biosolve (Valkenswaard, The Netherlands). Triton X-100, bovine pancrease RNase 
A was purchased from Sigma-Aldrich (St Louis). PhosStop tablet was purchased from Roche 
Diagnostics (Mannheim, Germany). 16% Paraformaldehyde (PFA) was purchased from Electron 
microscopy sciences (Hatfield, USA). Reddot was obtained from Biotium (Fremont) and MaxBlock 
was purchased from Active Motif (Carlsbad, CA, USA).  
Cell culture 
Two types of cells were used for determing in vitro concentration-response curves for genotoxicity, i.e. 
primary rat hepatocytes and HepaRG cells. Briefly, cryopreserved primary rat hepatocytes were 
seeded at concentration of 5x105 cells/well in black 96 well cellbind plates, and incubated in Williams’ 
Medium E (no phenol red) consisting of hepatocyte plating supplement pack (CM3000, serum-
contaning) for 4-6 hours before exposure. Only batches with a cell viability > 90% were used for 
experiments. HepaRG cells were grown in growth medium consisting of Williams’ medium E, 
supplemented with 10% FBS, 100 IU/ml penicillin, 100 μg/ml streptomycin, 1% (v/v) L-glutamine, 5 
μg/ml human insulin and 50 μM hydrocortisone-21-hemisuccinate. The growth medium was renewed 
every two to three days. After two weeks, the HepaRG cells were trypsinized and seeded at a 
concentration of 9x103 cells/well in black 96 well cellbind plates, and kept on growth medium for two 
weeks and subsequently for another two weeks on differentiation medium consisting of growth 
medium supplemented with 1.7% (v/v) DMSO (Aninat et al. 2006). The medium was refreshed every 
two to three days. After two weeks culturing in differentiation medium, HepaRG cells were fully 
differentiated and used for experiments within four weeks with refreshing the medium every two to 
three days according to the protocol provided by Biopredic International. Primary rat hepatocytes and 
HepaRG cell were incubated in a 5% CO2: 95% air-humidified incubator. 
γH2AX assay 
The γH2AX ICW assay allows to simultaneously determine genotoxicity and cytotoxicity (Audebert et 
al., 2010; Khoury et al., 2013) and was used in the present study to assess the in vitro genotoxicity of 
non-cytotoxic concentrations of lasiocarpine and riddelliine in both primary rat hepatocytess and 
HepaRG cells. 4-6 hours after seeding the rat hepatocytes, the medium was replaced by exposure 
medium (Williams’ Medium E no phenol red supplemented with hepatocyte plating supplement pack 
(CM4000, serum-free)), containing lasiocarpine (final concentrations: 0 (solvent control), 0.006, 0.012, 
0.024, 0.048, 0.09, 0.195, 0.39, 0.78, 1.56, 3.125 and 6.25 µM) or riddelliine (final concentrations: 0 
(solvent control), 0.065, 0.13, 0.26, 0.52, 1.04, 2.08, 4.16, 8.32, 10 and 15 µM). Each concentration 
was tested in three replicates, and two independent experiments with different batches of primary rat 
hepatocytes were carried out. The HepaRG cells were placed on growth medium supplemented with 
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0.5% DMSO for 24 hours before exposure to the compounds. After 24 hours treatment, the HepaRG 
cells were treated with exposure medium (growth medium without FBS) contaning lasiocarpine (final 
concentrations: 0 (solvent control), 0.78, 1.56, 3.13, 6.25, 12.5, 25 and 50 µM) or riddelliine (final 
concentrations: 0 (solvent control), 1.56, 3.13, 6.25, 12.5, 25 and 50 µM) in duplicates with three 
independent experiments. Lasiocarpine and riddelliine used in the γH2AX assay were added as 200 
times concentrated stock solutions in DMSO, solvent controls were treated with DMSO (final 
concentration: 0.5%). 
The γH2AX in-cell western (ICW) technique was performed essentially as previously described 
(Audebert et al., 2010; Khoury et al., 2013). Briefly, primary rat hepatocytes and HepaRG cells were 
treated with lasiocarpine and riddelliine for 24 hours, after 24 hours treatment the medium was 
removed and the cells were washed with PBS. After washing, the cells were fixed with 4% PFA in 
PBS at room temperature, and subsequently washed with PBS. PFA was neutralized with 20 mM 
NH4Cl and the wells were washed with PBS. Cells were permeabilized with 0.2% Triton X-100 in 
PBS and washed with PST buffer (PBS containg 2% FBS and 0.2% Triton X-100). Cells were blocked 
with MAXblock Blocking medium supplemented with phosphatase inhibitor PHOSTOP and RNase A, 
followed by 2h incubation with rabbit monoclonal anti γH2AX in PST buffer. After three washes with 
PST, secondary detection was carried out using an infrared fluorescent dye conjugated to goat 
antibody with an absorption peak at 770 nm in PST buffer. For DNA labelling, RedDot in PST was 
used together with the secondary antibody. The RedDot signal is used as a measure for cell number, 
allowing normalization of the γH2AX-response to cell number. Only concentrations resulting in 
cytotoxicity lower than 20% (i.e cell viability of at least 80%) were used for further data evaluation. 
After 1h of incubation and subsequent three washes with PST, RedDot and γH2AX signals were 
simultaneously visualized using an Odyssey Infrared Imaging Scanner (LiCor ScienceTec, Les Ulis, 
France). The quantification of phosphorylated histone H2AX (γH2AX) is expressed relative to the 
amount of γH2AX detected in cells exposed to the vehicle control. Error bars represent SD (standard 
deviation) of the mean. Statistically significant increases in H2AX phosphorylation after treatment 
were compared with controls using t-test with Graphpad software. 
PBK modelling-based reverse dosimetry  
The PBK modelling-facilated reverse dosimetry approach to predict in vivo genotoxicity based on in 
vitro genotoxicity data consisted of the following steps: (1) determination of in vitro concentration-
response curves for genotoxicity of lasiocarpine and riddelliine in primary rat hepatocytes and 
HepaRG cells, (2) translation of the in vitro concentration-response curves to in vivo dose-response 
curves for rat using previously developed PBK models (Chen et al., 2018),  (3) BMD analysis on the 
predicted in vivo dose-response curves to derive the points of depature (PoDs), (4) evaluation of the 
predicted PoD values with the values obtained from in vivo genotoxicity studies. 
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In the step 2, the possible differences in protein binding due to different protein levels in the medium 
of the in vitro assay and the in vivo situation should be considered. We previously used RED (rapid 
equilibrium dialysis) to detect the fraction unbound (fub) of lasiocarpine and riddelliine in rat serum, 
resulting in fub values amounting to 0.64 for lasiocarpine and 0.66 for riddelliine (Chen et al., 2018). 
Thus, the effect concentrations of lasiocarpine and riddelliine in rat blood (CLc/Rd, rat blood) applied for 
reverse dosimetry were corrected by the following equation: CLc/Rd, rat blood = Cub, in vitro / fub, rat blood. 
Where Cub, in vitro is the unbound concentration of lasiocarpine and riddelliine in the in vitro medium. 
Since the exposure medium used in the present study for the in vitro genotoxicity asssay was serum 
free, the concentration of lasiocarpine and riddelliine in the in vitro γH2AX assay was considered to be 
equal to the unbound concentration in rat serum.  
When considering an endpoint like genotoxicity the total dose over time and thus the area under the 
curve (AUC) presents the most relevant parameter for reverse dosimetry (Groothuis et al., 2015). To 
this end, the in vitro concentration-response data were translated to in vitro AUC-response data, by 
multiplying the effect concentration with the assay time (24 hours) (Daston et al. 2010). The AUC-
response curves thus obtained were translated to the in vivo situation setting them equal to the 
unbound AUC values in the plasma. 
BMD analysis of in vitro concentration-response curves and of predicted in vivo dose-
response data 
In order to support the validity and use of the in vitro-in silico approach the predicted BMD10 (the 
benchmark dose responsible for a 10% response) values for lasiocarpine and riddelliine were 
compared with PoDs derived from in vivo genotoxicity data from the literature (Chan et al., 1994; Xia 
et al., 2013; Yan et al., 2002). The continuous model using summary data from the PROAST software 
(version 66.42, the Dutch National Insitude for Public Health and the Environment, The Netherlands) 
was applied to analyse the predicted in vivo dose-response data for lasiocarpine and riddelliine and to 
derive the BMD10 values. The goodness of fit was used to judge if the model could be accepted. Only 
a model fit with P > 0.05 was considered acceptable for the determination of BMD10 values.  
Results 
In vitro genotoxicity 
Figure 1a and b present the in vitro concentration-response curves for genotoxicity of lasiocarpine and 
riddelliine in the γH2AX assay in primary rat hepatocytes and metabolic competent HepaRG cells, 
respectively. The PROAST program was applied to analyse the concentration-response data and to 
determine the critical effect concentration, i.e. BMC10 (the benchmark concentration responsible for a 
10% response). Histone H2AX phosphorylation in these two types of cells increased upon exposure to 
lasiocarpine and riddelliine in a dose-dependent manner (Figure 1). Table 1 shows the BMC10 values 
of lasiocarpine and riddelliine derived from these concentration-response curves. The primary rat 
203
C
ha
pt
er
 6
 
 
201 
 
0.5% DMSO for 24 hours before exposure to the compounds. After 24 hours treatment, the HepaRG 
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times concentrated stock solutions in DMSO, solvent controls were treated with DMSO (final 
concentration: 0.5%). 
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treated with lasiocarpine and riddelliine for 24 hours, after 24 hours treatment the medium was 
removed and the cells were washed with PBS. After washing, the cells were fixed with 4% PFA in 
PBS at room temperature, and subsequently washed with PBS. PFA was neutralized with 20 mM 
NH4Cl and the wells were washed with PBS. Cells were permeabilized with 0.2% Triton X-100 in 
PBS and washed with PST buffer (PBS containg 2% FBS and 0.2% Triton X-100). Cells were blocked 
with MAXblock Blocking medium supplemented with phosphatase inhibitor PHOSTOP and RNase A, 
followed by 2h incubation with rabbit monoclonal anti γH2AX in PST buffer. After three washes with 
PST, secondary detection was carried out using an infrared fluorescent dye conjugated to goat 
antibody with an absorption peak at 770 nm in PST buffer. For DNA labelling, RedDot in PST was 
used together with the secondary antibody. The RedDot signal is used as a measure for cell number, 
allowing normalization of the γH2AX-response to cell number. Only concentrations resulting in 
cytotoxicity lower than 20% (i.e cell viability of at least 80%) were used for further data evaluation. 
After 1h of incubation and subsequent three washes with PST, RedDot and γH2AX signals were 
simultaneously visualized using an Odyssey Infrared Imaging Scanner (LiCor ScienceTec, Les Ulis, 
France). The quantification of phosphorylated histone H2AX (γH2AX) is expressed relative to the 
amount of γH2AX detected in cells exposed to the vehicle control. Error bars represent SD (standard 
deviation) of the mean. Statistically significant increases in H2AX phosphorylation after treatment 
were compared with controls using t-test with Graphpad software. 
PBK modelling-based reverse dosimetry  
The PBK modelling-facilated reverse dosimetry approach to predict in vivo genotoxicity based on in 
vitro genotoxicity data consisted of the following steps: (1) determination of in vitro concentration-
response curves for genotoxicity of lasiocarpine and riddelliine in primary rat hepatocytes and 
HepaRG cells, (2) translation of the in vitro concentration-response curves to in vivo dose-response 
curves for rat using previously developed PBK models (Chen et al., 2018),  (3) BMD analysis on the 
predicted in vivo dose-response curves to derive the points of depature (PoDs), (4) evaluation of the 
predicted PoD values with the values obtained from in vivo genotoxicity studies. 
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In the step 2, the possible differences in protein binding due to different protein levels in the medium 
of the in vitro assay and the in vivo situation should be considered. We previously used RED (rapid 
equilibrium dialysis) to detect the fraction unbound (fub) of lasiocarpine and riddelliine in rat serum, 
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Since the exposure medium used in the present study for the in vitro genotoxicity asssay was serum 
free, the concentration of lasiocarpine and riddelliine in the in vitro γH2AX assay was considered to be 
equal to the unbound concentration in rat serum.  
When considering an endpoint like genotoxicity the total dose over time and thus the area under the 
curve (AUC) presents the most relevant parameter for reverse dosimetry (Groothuis et al., 2015). To 
this end, the in vitro concentration-response data were translated to in vitro AUC-response data, by 
multiplying the effect concentration with the assay time (24 hours) (Daston et al. 2010). The AUC-
response curves thus obtained were translated to the in vivo situation setting them equal to the 
unbound AUC values in the plasma. 
BMD analysis of in vitro concentration-response curves and of predicted in vivo dose-
response data 
In order to support the validity and use of the in vitro-in silico approach the predicted BMD10 (the 
benchmark dose responsible for a 10% response) values for lasiocarpine and riddelliine were 
compared with PoDs derived from in vivo genotoxicity data from the literature (Chan et al., 1994; Xia 
et al., 2013; Yan et al., 2002). The continuous model using summary data from the PROAST software 
(version 66.42, the Dutch National Insitude for Public Health and the Environment, The Netherlands) 
was applied to analyse the predicted in vivo dose-response data for lasiocarpine and riddelliine and to 
derive the BMD10 values. The goodness of fit was used to judge if the model could be accepted. Only 
a model fit with P > 0.05 was considered acceptable for the determination of BMD10 values.  
Results 
In vitro genotoxicity 
Figure 1a and b present the in vitro concentration-response curves for genotoxicity of lasiocarpine and 
riddelliine in the γH2AX assay in primary rat hepatocytes and metabolic competent HepaRG cells, 
respectively. The PROAST program was applied to analyse the concentration-response data and to 
determine the critical effect concentration, i.e. BMC10 (the benchmark concentration responsible for a 
10% response). Histone H2AX phosphorylation in these two types of cells increased upon exposure to 
lasiocarpine and riddelliine in a dose-dependent manner (Figure 1). Table 1 shows the BMC10 values 
of lasiocarpine and riddelliine derived from these concentration-response curves. The primary rat 
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hepatocytes appear more sensitive towards the genotoxicity of lasiocarpine and riddellliine than the 
HepaRG cells, since the BMC10 values for genotoxicity in the γH2AX assay for lasiocarpine and 
riddelliine derived from primary rat hepatocytes were respectively 105- and 31-fold lower than those 
obtained in the HepaRG cells. 
Table 1 BMC10 values for lasiocarpine and riddelliine derived from the concentration-response curves presented 
in Figure 1 
 
 
 
 
 
 
 
Fig. 1 Concentration-response curves for γH2AX induction in primary rat hepatocytes (a) and HepaRG cells (b) 
treated with increasing concentration of lasiocarpine (red triangle) and riddelliine (black circle) for 24 hours 
(mean ± SD) 
Translation of the in vitro concentration-response curves to the in vivo dose-response 
curves and prediction of in vivo BMD10 values 
The in vitro concentration-response curves obtained for primary rat hepatocytes were first corrected 
for differences in binding to proteins in medium (in vitro) and serum (in vivo), resulting in effect 
concentrations, which were then converted to AUC-response curves by multiplying the effect 
concentration with 24 hours, the duration of the in vitro incubations. Figure 2a presents the AUC-
response curves thus obtained. These in vitro AUC-response curves were subsequently translated into 
predicted dose-response curves using the respective PBK models (Figure 2b). The dose levels thus 
Cell model BMC10 (µM) 
Primary rat hepatocytes  
    Lasiocarpine 0.02 
    Riddelliine 0.07 
HepaRG cells  
    Lasiocarpine 2.09 
    Riddelliine 2.17 
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obtained for the dose-response curves are shown in the Supplementary data (Table 1).  From these 
predicted dose-response curves, the BMD10 values for lasiocarpine and riddelliine were derived 
amounting to 8.82 and 3.41 mg/kg bw/day, respectively (Table 2). Compared to the in vitro 
genotoxicity data in primary rat hepatocytes where lasiocarpine was 3.5-fold more active than 
riddelliine (Figure 1a and 2a), the predicted in vivo genotoxicity of riddelliine appeared to be 2.6-fold 
higher than that of lasiocarpine (Figure 2b). This can be ascribed to the differences in kinetics with a 
slower clearance of riddelliine compared to lasiocarpine, with the total scaled in vivo catalytic 
efficiency in rat for depletion of riddelliine previously shown to be 11-fold lower than that for 
lasiocarpine (Chen et al., 2018). 
Table 2 Predicted BMD10 values for lasiocarpine and riddelliine obtained using PBK modelling-facilitated 
reverse dosimetry, which allowed translation of the in vitro AUC-genotoxicity curves (Figure 2a) to the in vivo 
dose-response curves (Figure 2b) 
   
 
 
 
 
 
 
 
 
 
Fig. 2 The in vitro AUC-response curves for lasiocarpine and riddelliine obtained with primary rat hepatocytes 
using the γH2AX assay (a) and in vivo dose-response curves for genotoxicity in rat liver predicted from in vitro 
AUC-response curves using PBK modelling (b). Lasiocarpine (red triangle); riddelliine (black circle). Data 
expressed as (mean ± SD) 
Compound Predicted BMD10 (mg/kg bw/day) 
Lasiocarpine 8.82 
Riddelliine 3.41 
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Evaluation of the predicted PoDs for in vivo genotoxicity  
To evaluate the outcomes of the in vitro-PBK model based predictions for dose-dependent 
genotoxicity of lasicoarpine and riddelliine in rat liver, the predicted BMD10 values for lasiocarpine 
and riddelliine were compared to the in vivo genotoxicity data in rat liver that have been published 
previously (Chan et al., 1994; Xia et al., 2013; Yan et al., 2002). Table 3 presents an overview of 
literature data in rat hepatocytes in vivo, measuring endpoints including DNA adduct formation and 
unscheduled DNA synthesis. The data from these in vivo animal studies were not suitable for BMD 
analysis due to the limited number of data points and insufficient distribution of the data points over 
the dose-response curves. Therefore, the lowest observed adverse effect level (LOAEL) of 
lasiocarpine and riddelliine that induced in vivo genotoxicity were used for the validation (Table 3). 
Figure 3a and b shows a comparison of the predicted BMD10 values for in vivo genotoxicity of 
lasiocarpine and riddelliine and these LOAEL values derived from in vivo literature rat data for 
genotoxicity of lasiocarpine and riddelliine. For lasiocarpine, the predicted BMD10 was only 1.1-fold 
different (lower) compared to the LOAEL derived from the in vivo study detecting DNA adduct 
formation (Xia et al., 2013) (Figure 3a), while it was higher than the dose level of 1.85 mg/kg bw at 
which lasiocarpine derived DNA adducts were not yet detectable. At this dose level riddelliine DNA 
adducts could already be detected in the in vivo study, which is in line with the predicted BMD10 
values which indicated riddelliine to have a lower BMD10 value than lasiocarpine. For riddelliine, the 
predicted BMD10 was only 1.8-fold different (higher) compared to the LOAEL derived from in vivo 
experimental data measuring DNA-adduct formation (Xia et al., 2013). Comparison to the dose level 
inducing detectable DNA adduct formation by riddeliine of 10 mg/kg bw/day in the study reported by 
Yan et al. (Yan et al., 2002), showed that the prediction is 2.9-fold lower, but this may in part be due 
to the fact that the effective dose level reported in this study was the only dose level tested, and dose 
levels lower than 10 mg/kg bw/day were not included in the study. Compared to the lowest dose level 
that causes a statistically significant increase in unscheduled DNA synthesis the predicted BMD10 for 
riddelliine was 3.4-fold higher (Chan et al., 1994). 
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Evaluation of the predicted PoDs for in vivo genotoxicity  
To evaluate the outcomes of the in vitro-PBK model based predictions for dose-dependent 
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and riddelliine were compared to the in vivo genotoxicity data in rat liver that have been published 
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literature data in rat hepatocytes in vivo, measuring endpoints including DNA adduct formation and 
unscheduled DNA synthesis. The data from these in vivo animal studies were not suitable for BMD 
analysis due to the limited number of data points and insufficient distribution of the data points over 
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Discussion  
The aim of present study was to assess whether the developed PBK modelling-facilitated reverse 
dosimetry could adequately predict in vivo dose-response curves for genotoxicity of lasiocarpine and 
riddelliine in rats. The γH2AX ICW assay was used to quantify the genotoxicity of these PAs in 
primary rat hepatocytes. So far, the γH2AX ICW assay has been successfully applied to evaluate the 
genotoxiciy of several food contaminants, including aflatoxins (Theumer et al., 2018), heavy metals 
(Kopp et al. 2018), polycyclic aromatic hydrocarbons (Audebert et al., 2010; Audebert et al., 2012) 
and PAs (Louisse et al., Submitted), for possible genotoxicity. 
To date, lasiocarpine and riddelliine have been reported to induce genotoxic effects in in vitro assays 
for different endpoints including formation of micronuclei (Allemang et al., 2018), DNA-adducts (Xia 
et al., 2006), chromosomal aberrations (Takanashi et al., 1980), DNA-cross links (Kim et al., 1995) 
and sister chromatid exchange (Chan et al., 1994). Comparison of the results obtained in the present 
study using the γH2AX assay to these published genotoxic data, reveals that also the phosphorylation 
of histone H2AX (γH2AX) provides a relevant readout for determining in vitro genotoxicity of PAs. 
γH2AX has been reported to correlate strongly with DNA damage and is a well-recognized pre-
cancerous biomarker in vivo, and this biomarker is present in all cell types (Bonner et al., 2008; Singh 
et al., 2011). One of the main advantages of the γH2AX assay is that it allows the simultaneous 
determination of genotoxicity and cytotoxicity (Graillot et al., 2012). In the present study, the cut-off 
value for cytotoxicity was set to 80% viable cells to exclude any false-positive genotoxic results, since 
H2AX phosphorylation could be linked to apoptosis or necrosis rather than to true genotoxicity (Imreh 
et al., 2011). The cut of value of 80% selected in the present study was in line with previous studies 
(Clarke et al., 2012; O’donovan, 2012). Regarding metabolic activation, the primary rat hepatocytes 
and HepaRG cells used in the present study are considered to be relevant, because they are expect to 
present relevant biotransformation. As for genotoxicity, the γH2AX is considered to be a relevant 
read-out for PAs, since PAs have been shown to induce genotoxicity by different modes of actions 
(Chen et al., 2010), and γH2AX occurs after a DNA double strand break in a cell can reflect and 
reflects a global genotoxic insult that may originate from different types of DNA damage: DNA 
adduct formation, DNA single-strand breaks, DNA replication or transcription blocking lesions 
(Sedelnikova et al., 2010). The γH2AX ICW assay has been reported to detect genotoxins with such a 
variety of DNA damaging characteristics (Khoury et al., 2013). 
In the present study both primary rat hepatocytes and HepaRG cells were used to perform the γH2AX 
assay, since these two types of cells contain the CYP450 enzymes required for biotransformation of 
lasiocarpine and riddelliine into DNA reactive intermediates (Fu et al., 2004). HepaRG cells are 
derived from a human hepatocellular carcinoma, and express most of the CYP450 enzymes, especially 
the CYP 3A and 2B isoforms, that are key enzymes for PAs bioactivation (Fu et al., 2004; Guillouz
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et al., 2007; Lin et al., 2003; Prakash et al., 1999; Turpeinen et al., 2009). Although the levels of these 
two enzymes in primary rat hepatocytes and HepaRG cells have not been quantified, our previous 
study, in which we assessed cytotoxicity of lasiocarpine and riddelline in both cell models, already 
confirmed that both cell lines contain the CYPs required for bioactivation of these PAs. The IC50 for 
cytotoxicity of lasiocarpine and riddelliine in primary rat hepatocytes was 20- and 22-fold lower than 
the IC50 in HepaRG cells, respectively (Ning et al., 2019). This indicated that HepaRG cells are 
capable of bioactivating PAs but likely to an about 20-fold lower level than primary rat hepatocytes. 
This is why also in the present genotoxicity study we included both cell models. Quantifying γH2AX 
formation as the endpoint for genotoxicity, the primary rat hepatocytes appeared to be about one to 
two orders of magnitude more sensitive to lasiocarpine and riddelliine induced genotoxicity than the 
HepaRG cells. Allemang et al. (2018) investigated genotoxicity of lasiocarpine and riddelliine in 
HepaRG cells using the micronucleus assay, showing dose-dependent increases in micronucleus 
induction. The BMC10 values for lasiocarpine and riddelliine derived from these concentration-
response curves amounted to 0.13 and 0.63 µM, respectively (Allemang et al., 2018). Comparison of 
these values to the BMC10 values derived from the HepRG cells in the γH2AX assay in the present 
study (Table 1) reveals that the micronucleus endpoint is 16.1- and 3.4-fold more sensitive for 
lasiocarpine and riddelliine, respectively. Compared to the results obtained in the present study using 
the primary hepatocytes in the γH2AX assay, the HepaRG cells in the micronucleus assay were still 
6.5- and 9.0-fold less senitive for lasiocarpine and riddelliine, respectively. It is concluded that for 
quantitative in vitro to in vivo extrapolation (QIVIVE) use of primary hepatocytes is favoured over 
use of HepaRG cells. For this reason, and also because of the availability of rat in vivo data, in the 
present study the results obtained in the primary rat hepatocytes were used for the reverse dosimetry. 
For this reverse dosimetry we used the AUC instead of the the maximum concentration (Cmax) as the 
selected metric. When predicting toxicity for which a threshold exists and thus a concentration below 
which there will be no effect, the Cmax may be the selected parameter for the reverse dosimetry, while 
the use of the AUC would be relevant for endpoints like genotoxicity or tumour formation that depend 
more on the total dose than on peak concentrations (Groothuis et al., 2015). In the present study, the 
predicted PoDs based on the AUC approach were comparable with available in vivo data on 
genotoxicity of lasiocarpine and riddelliine in rat liver (Figure 3). When making the prediction based 
on the Cmax approach, the predicted BMD10 of lasiocarpine and riddelliine were up to 17.4- and 42.2-
fold lower compared to in vivo animal data. This corroborates that prediction of genotoxicity for the 
target compound based on the AUC approach is an adequate choice (Groothuis et al., 2015).  
It is also of interest to compare the values obtained for in vivo genotoxicity of lasicarpine and 
riddelliine to PoDs derived from available tumour data. From data on the incidence of liver 
haemangiosarcoma obtained in 2-year carcinogenicity studies in rats upon chronic oral exposure to
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lasiocarpine and riddelliine (NTP, 1978, 2003). EFSA derived a BMD10 of 0.131 mg/kg bw/day for 
lasiocarpine and of 0.292 mg/kg bw/day for riddelliine (EFSA, 2017). These BMD10 values obtained 
from the 2-year carcinogenicity studies are one to two orders of magnitude lower than the BMD10 
levels predicted in the present study and the dose levels used in other studies to detect genotoxicity 
(Chan et al., 1994; Xia et al., 2013; Yan et al., 2002) (Figure 3). This may be related to the fact that the 
exposure duration in the genotoxicity studies is far shorter (1-5 days) than the 2-year exposure applied 
in carcinogenicity studes.  
It is also of interest to consider that in risk assessment for PAs, the estimate daily intake (EDI) values 
were calculated based on total PA levels in food, taking into consideration combined exposure to 
different PAs (BfR, 2013; EFSA, 2016, 2017). When considering combined exposure, different 
potency of the various PAs could be considered. This implies that combined exposure could take their 
relative potency (REP) into account to ‘adjust’ the individual PA concentrations. The concept of REP 
factors describes the relative toxic potency of each congener in comparison to a selected reference 
congener. The most well established example in toxicology for this approach is the equivalency 
concept for polychlorinated dioxins, furans and PCBs (Van den Berg et al., 2006). Similar approaches 
were suggested for phototoxic furocoumarins (Raquet and Schrenk, 2014), or are applied in 
pharmacology to synthetic glucocorticoids (Suzuki et al., 2015). Recently, Allemang et al. (2018) 
determined the concentration-dependent PA-induced formation of micronuclei in HepaRG cells by 
exposing the cells to 15 PAs and calculated the REP values based on these concentration-response 
curves, lasiocarpine was found to be 6 times more potent than riddellliine (Allemang et al., 2018). In 
the present study, we used the γH2AX assay to detect the genotoxicity of lasiocarpine and riddelliine 
in primary rat hepatocytes and found that lasiocarpine was 3.5-fold more potent than riddelliine. These 
REP values, however, are based on in vitro data and do not take the differences in toxicokinetics into 
account. The results of the present study, in which the concentration-response curves were translated 
to in vivo dose-response curves using PBK modelling, reveal that the differences in toxicokinetics 
between different PAs may be substantial and may influence their ultimate in vivo REP values. On the 
basis of the predicted in vivo rat genotoxicity, riddelliine was found to be more potent (2.6-fold) than 
lasiocarpine, which is in agreement with in vivo genotoxicity findings. 
In conclusion, we demonstrated that the PBK modelling-facilitated reverse dosimetry can adequately 
translate in vitro concentration-response curves for lasiocarpine and riddelliine, obtained using the 
γH2AX assay in primary hepatocytes, to in vivo dose-response curves for genotoxicity. The present 
study provides an alternative approach for the assessment of other types of PAs for which in vivo 
genotoxic data are not available, and definition of in vivo REP values, thereby contributing to the 
reduction, refinement and replacement of animal testing. 
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Major findings 
One of the aims of this thesis was to perform a risk assessment for PAs derived from botanical 
products following daily life-time exposure and more realistic exposure scenarios. Another aim was to 
develop a novel animal-free approach to predict in vivo liver toxicity and genotoxicity of PAs using 
lasiocarpine and riddelliine as two model PAs. The botanical products used in this thesis were herbal 
teas, herbal medicines and plant food supplements (PFS), because consumption of these botanical 
products is thought to represent major routes for human exposure to PAs (Bodi et al., 2014; Roeder, 
2000). Given that 1,2-unsaturated PAs are genotoxic and carcinogenic, their risk assessment is 
currently based on the Margin of Exposure (MOE) approach (EFSA, 2005). In this approach daily life-
time exposure is the default assumption, but such an assumption may not be fully adequate as people 
might rather consume herbal products occasionally or only during certain periods, for example illness. 
Application of the MOE approach combined with Haber’s rule was used to take shorter than life-time, 
i.e.  more realistic, exposure scenarios into account. Another consideration was that consumption of 
herbal teas usually occurs by hot water extraction of partially intact or coarsely ground leaves, so that 
extraction of comminuted leaves for exposure and subsequent risk assessment may represent a worst 
case situation. Another bottle neck encountered in the risk assessment of PAs is that exposure is often 
to a mixture of different PAs of different potency while data to define their in vivo relative potency 
(REP) factors are lacking. Lack of data is a general problem in the field of PA toxicity since only for a 
limited number of PAs data on liver toxicity, genotoxicity and/or carcinogenicity are available. This is 
why the present thesis also investigated whether alternative testing strategies could be of use in 
predicting in vivo toxicity of different PAs and whether proofs-of-principle for using such alternative 
testing strategies could be provided for two selected PA model compounds, riddelliine and 
lasiocarpine. These PAs were selected because for these PAs in vivo data enabling evaluation of the in 
vivo predictions are available at least to some extent. The alternative method used to predict in vivo 
liver toxicity and genotoxicity of lasiocarpine and riddelliine, is based on extrapolation of 
concentration-response curves obtained from in vitro cytotoxicity and genotoxicity assays to in vivo 
dose-response curves using physiologically based kinetic (PBK) modelling-based reverse dosimetry. 
From the predicted in vivo dose-response curves points of departure (PoD) for risk assessment can be 
derived and compared to PoDs derived from data obtained in in vivo studies reported in the literature. 
In Chapter 2, a risk assessment based on the MOE approach was performed using the BMDL10 
(benchmark dose lower confidence limit for 10% extra risk on tumour formation above background 
levels) of 0.07 mg/kg bw/day for lasiocarpine derived by EFSA (EFSA, 2011) from data established in 
a 2-year carcinogenicity study on induction of liver haemangiosarcomas in male rats, and mean PA 
levels reported in literature for herbal teas and PFS. The results indicated that consumption of one cup 
of tea a day during a whole lifetime would result in MOE values lower than 10000 for several types of 
herbal teas, indicating a priority for risk management for these products. A refined risk assessment 
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using interim REP factors for different PAs was also performed and showed that based on the mean 
PA levels, 7 (54%) of 13 types of herbal teas and 1 (14%) of 7 types of PFS resulted in MOE values 
lower than 10000. The herbal preparations that raised a concern included preparations containing PA-
producing plants but also preparations containing non-PA-producing plants. In addition, a literature 
review on tumour data for PAs was provided summarizing tumour data available on lasiocarpine, 
riddelliine, monocrotaline, clivorine, senkirkine and symphytine. Except for the data on lasiocarpine 
and riddelliine, these data were not suitable for BMD analysis but enabled definition of T10 values 
(dose levels causing 10% extra tumour incidence above background levels upon life time exposure). 
The T10 values of monocrotaline, clivorine, senkirkine and symphytine were 21-, 4-, 34- and 60- fold 
higher, respectively, than the BMDL10 value of 0.07 mg/kg bw/day for lasiocarpine. These values 
support that the BMDL10 for lasiocarpine of 0.07 mg/kg bw/day is the lowest PoD and thus seems a 
(too) conservative estimate when applied for other PAs without correcting for differences in relative 
potencies. The data resulted in REP values for lasiocarpine, riddelliine, monocrotaline, clivorine, 
senkirkine and symphytine that amounted to 1.00, 0.39, 0.05, 0.23, 0.03, 0.02. In a later opinion EFSA 
referred to our study as well as to the paper on interim REP values reported by Merz and Schrenk 
(Merz and Schrenk, 2016) stating that although the REP values presented were not robust enough to 
be taken into account in risk assessment of combined exposure, they did reveal that using the BMDL10 
for lasiocarpine of 0.07 mg/kg bw/day may be too worst case (EFSA, 2017). Moreover, EFSA 
suggested the use of the newly derived BMDL10 of 0.24 mg/kg bw/day for riddelliine instead. It is of 
interest to note that the interim REP values proposed by Merz and Schrenk were based on in vitro 
cytotoxicity, genotoxicity in Drosophila, and acute toxicity in rodents (LD50) so they did not reflect 
the expected in vivo differences in carcinogenicity between the different PAs, the critical effect 
evaluated when performing a risk assessment for chronic toxicity using the MOE. This lack of data to 
characterise the in vivo relative potencies of PAs provides another reason to work towards methods 
that can predict relative differences in in vivo potency as aimed for in the present thesis. 
Given that the use of botanical products during every day of a whole life-time may not be realistic, we 
also investigated methods to correct for shorter-than-lifetime exposure (Chapter 3). Use of the MOE 
approach with the BMDL10 of 0.24 mg/kg bw/day for riddelliine and total PA levels, combined with 
Haber’s rule was employed to analyse the risks of shorter-than-lifetime exposure for 5 herbal teas, 8 
herbal medicines, 34 previously analysed herbal teas and 19 PFS (Bodi et al., 2014; EFSA, 2016; 
Mulder et al., 2015). This analysis revealed that shorter-than-lifetime use would result in MOE values 
lower than 10000 upon use for 40 up to 3450 weeks during a lifetime (depending on the preparation). 
Only for a limited number of herbal teas and medicines, use of two weeks a year (150 weeks during a 
75 year lifetime) would still raise a concern. When considering the fact that consumption of teas 
usually occurs by hot water extraction of partially intact or coarsely ground leaves, it is conceivable 
that use of PAs from comminuted leaves may facilitate their extraction from the teas. This may 
influence the actual exposure and corresponding risk assessment. Five types of herbal teas were used 
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approach with the BMDL10 of 0.24 mg/kg bw/day for riddelliine and total PA levels, combined with 
Haber’s rule was employed to analyse the risks of shorter-than-lifetime exposure for 5 herbal teas, 8 
herbal medicines, 34 previously analysed herbal teas and 19 PFS (Bodi et al., 2014; EFSA, 2016; 
Mulder et al., 2015). This analysis revealed that shorter-than-lifetime use would result in MOE values 
lower than 10000 upon use for 40 up to 3450 weeks during a lifetime (depending on the preparation). 
Only for a limited number of herbal teas and medicines, use of two weeks a year (150 weeks during a 
75 year lifetime) would still raise a concern. When considering the fact that consumption of teas 
usually occurs by hot water extraction of partially intact or coarsely ground leaves, it is conceivable 
that use of PAs from comminuted leaves may facilitate their extraction from the teas. This may 
influence the actual exposure and corresponding risk assessment. Five types of herbal teas were used 
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to compare the total amount of PAs that were extracted either from the intact or the comminuted 
leaves. The results showed that the PA levels extracted from intact leaves were 1.1- to 4.1-fold lower 
than from the corresponding comminuted leaves, so that it was concluded that the size of the leaves 
may have an impact on the relative extraction efficiency of PAs present in the leaves, and thus on the 
resulting exposure and risk assessment.  
To develop and validate methods for quantitative in vitro to in vivo extrapolation (QIVIVE), further 
studies of the present thesis focussed on prediction of in vivo liver toxicity for lasiocarpine and 
riddelliine in rat (Chapter 4). To this end, the in vitro cytotoxicity of lasiocarpine and riddelliine was 
determined in primary rat hepatocytes. Then, PBK models were developed that described the clearance 
of lasiocarpine and riddelline in rat. The kinetic parameters were collected from in vitro incubations 
using rat liver microsomes. The developed PBK models were used for translation of in vitro 
concentration-response curves to in vivo dose-response curves. From these in vivo dose-response 
curves, the predicted BMDL5-BMDU5 (lower/upper limit of the 90% confidence interval of the 
benchmark dose that gives a 5% response) of lasiocarpine and riddelline were obtained which were 
23.0-34.4 and 4.9-8.4 mg/kg bw/day, respectively. Due to the absence of in vivo acute liver toxicity 
data reported in the literature for riddelliine, the predicted PoDs for in vivo liver toxicity could only be 
evaluated for lasiocarpine. To this end, the predicted BMDL5-BMDU5 of lasiocarpine were compared 
with in vivo reported data for acute liver toxicity of lasiocarpine as available in the literature 
(Dalefield et al., 2016; Jago, 1970; Nolan et al., 1966). The predicted BMDL5 of lasiocarpine was 1.9- 
to 2.9-fold higher than the NOAELs (no observed adverse effect level) derived as corresponding PoD 
from the available experimental in vivo data. Overall, the predicted BMDL5-BMDU5 of lasiocarpine 
falls well within the range of the PoDs derived from available in vivo toxicity data. The results 
indicate that the data and range of PoD values derived using our combined in vitro-PBK modelling 
approach are a good approximation for the in vivo acute liver toxicity of lasiocarpine. In addition, the 
BMDL5-BMDU5 values predicted for riddelliine were 2.7 to 7.0 times lower than those values 
predicted for lasiocarpine. This indicates that in vivo riddelliine is predicted to induce liver toxicity at 
lower dose levels than lasiocarpine. In line with this, the in vitro cytotoxicity of riddelliine was also 
higher than that of lasiocarpine. The higher in vivo toxicity of riddelliine may in part be due to the fact 
that there are differences in kinetics which revealed a slower clearance of riddelliine compared to 
lasiocarpine. This observation indicates that when defining relative potencies for differences in in vivo 
toxicity, such differences in toxicokinetics should be taken into account. It is reasonable to expect that 
the approach, now validated for lasiocarpine, can also provide adequate data for the in vivo toxicity of 
other related PAs. 
The same QIVIVE method was subsequently used to predict the inter-species and inter-ethnic
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human differences in liver toxicity of lasiocarpine and riddelliine using a human PBK model for 
reverse dosimetry of in vitro toxicity data obtained in human primary hepatocytes (Chapter 5). The 
concentration-response curves for in vitro cytotoxicity of lasiocarpine and riddelliine defined in pooled 
primary human hepatocytes were translated to in vivo dose-response curves by PBK models 
developed using kinetic data obtained from incubations with pooled tissue fractions from Chinese and 
Caucasian individuals, providing PBK models for the average Chinese and average Caucasian, 
respectively. From the predicted in vivo dose-response curves, the BMDL5-BMDU5 of lasiocarpine 
were found to amount to 14.7-41.2 mg/kg bw/day for Chinese and 7.4-23.7 mg/kg bw/day for 
Caucasian, indicating the Chinese to be less sensitive. The predicted BMDL5-BMDU5 of riddelliine 
were 1.0-5.9 mg/kg bw/day for Chinese and 0.2-1.2 mg/kg bw/day for Caucasian. These values were 
subsequently compared to those previously obtained in rat to evaluate inter-species differences. The 
inter-species differences amounted to 2.0-fold for lasiocarpine and 8.2-fold for riddelliine with humans 
being more sensitive than rats. The inter-ethnic human differences varied 2.0-fold for lasiocarpine and 
5.0-fold for riddelliine with the average Caucasian being more sensitive than the average Chinese. 
These results provide a proof-of-principle for predicting inter-species and inter-ethnic differences in in 
vivo liver toxicity for PAs by an alternative testing strategy integrating in vitro cytotoxicity data with 
PBK modelling-based reverse dosimetry. 
In a subsequent study of the present thesis the same approach was used for prediction of genotoxicity, 
another endpoint relevant for PA toxicity (Chapter 6). State-of-the-art genotoxicity data on PAs are 
limited, and lack of genotoxicity studies for most 1,2-unsaturated PAs, hampers PA risk assessment, 
while economic and ethical constraints limit the possibilities to perform in vivo genotoxicity studies 
for all relevant PAs, including the 17 PAs identified by EFSA to be relevant for exposure via feed and 
food (EFSA, 2017). Thus, alternative testing strategies for estimating the genotoxicity of different PAs 
are required. It is obvious to investigate whether the developed PBK modelling-facilitated reverse 
dosimetry approach developed in Chapter 4 can quantitatively translate in vitro concentration-response 
curves for genotoxicity of lasiocarpine and riddelliine, to in vivo dose-response curves for 
genotoxicity of these PAs in rat liver. To this end, the in vitro concentration-responses curves obtained 
from in vitro genotoxicity studies with primary rat hepatocytes using the H2AX assay were translated 
into in vivo dose-response curves using PBK modelling-facilitated reverse dosimetry. The predicted 
BMD10 for lasiocarpine and riddelliine amounted to 8.82 and 3.41 mg/kg bw/day, respectively, and 
were in line with the experimental data on in vivo genotoxicity available in the literature for these two 
PAs (Chan et al.,1994; Xia et al., 2013; Yan et al., 2002). Lasiocarpine was found to be 6 times more 
potent than riddelliine based on results from an in vitro micronuclei assay (Allemang et al., 2018). 
However, when taking the differences in toxickinetics into account, the predicted in vivo genotoxicity 
of riddelliine was found to be 2.6-fold higher than that of lasiocarpine. These results reveal that the 
differences in toxicokinetics between different PAs may be substantial and may influence their 
ultimate in vivo REP values. It is concluded that integrating in vitro genotoxicity assays with PBK
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to compare the total amount of PAs that were extracted either from the intact or the comminuted 
leaves. The results showed that the PA levels extracted from intact leaves were 1.1- to 4.1-fold lower 
than from the corresponding comminuted leaves, so that it was concluded that the size of the leaves 
may have an impact on the relative extraction efficiency of PAs present in the leaves, and thus on the 
resulting exposure and risk assessment.  
To develop and validate methods for quantitative in vitro to in vivo extrapolation (QIVIVE), further 
studies of the present thesis focussed on prediction of in vivo liver toxicity for lasiocarpine and 
riddelliine in rat (Chapter 4). To this end, the in vitro cytotoxicity of lasiocarpine and riddelliine was 
determined in primary rat hepatocytes. Then, PBK models were developed that described the clearance 
of lasiocarpine and riddelline in rat. The kinetic parameters were collected from in vitro incubations 
using rat liver microsomes. The developed PBK models were used for translation of in vitro 
concentration-response curves to in vivo dose-response curves. From these in vivo dose-response 
curves, the predicted BMDL5-BMDU5 (lower/upper limit of the 90% confidence interval of the 
benchmark dose that gives a 5% response) of lasiocarpine and riddelline were obtained which were 
23.0-34.4 and 4.9-8.4 mg/kg bw/day, respectively. Due to the absence of in vivo acute liver toxicity 
data reported in the literature for riddelliine, the predicted PoDs for in vivo liver toxicity could only be 
evaluated for lasiocarpine. To this end, the predicted BMDL5-BMDU5 of lasiocarpine were compared 
with in vivo reported data for acute liver toxicity of lasiocarpine as available in the literature 
(Dalefield et al., 2016; Jago, 1970; Nolan et al., 1966). The predicted BMDL5 of lasiocarpine was 1.9- 
to 2.9-fold higher than the NOAELs (no observed adverse effect level) derived as corresponding PoD 
from the available experimental in vivo data. Overall, the predicted BMDL5-BMDU5 of lasiocarpine 
falls well within the range of the PoDs derived from available in vivo toxicity data. The results 
indicate that the data and range of PoD values derived using our combined in vitro-PBK modelling 
approach are a good approximation for the in vivo acute liver toxicity of lasiocarpine. In addition, the 
BMDL5-BMDU5 values predicted for riddelliine were 2.7 to 7.0 times lower than those values 
predicted for lasiocarpine. This indicates that in vivo riddelliine is predicted to induce liver toxicity at 
lower dose levels than lasiocarpine. In line with this, the in vitro cytotoxicity of riddelliine was also 
higher than that of lasiocarpine. The higher in vivo toxicity of riddelliine may in part be due to the fact 
that there are differences in kinetics which revealed a slower clearance of riddelliine compared to 
lasiocarpine. This observation indicates that when defining relative potencies for differences in in vivo 
toxicity, such differences in toxicokinetics should be taken into account. It is reasonable to expect that 
the approach, now validated for lasiocarpine, can also provide adequate data for the in vivo toxicity of 
other related PAs. 
The same QIVIVE method was subsequently used to predict the inter-species and inter-ethnic
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human differences in liver toxicity of lasiocarpine and riddelliine using a human PBK model for 
reverse dosimetry of in vitro toxicity data obtained in human primary hepatocytes (Chapter 5). The 
concentration-response curves for in vitro cytotoxicity of lasiocarpine and riddelliine defined in pooled 
primary human hepatocytes were translated to in vivo dose-response curves by PBK models 
developed using kinetic data obtained from incubations with pooled tissue fractions from Chinese and 
Caucasian individuals, providing PBK models for the average Chinese and average Caucasian, 
respectively. From the predicted in vivo dose-response curves, the BMDL5-BMDU5 of lasiocarpine 
were found to amount to 14.7-41.2 mg/kg bw/day for Chinese and 7.4-23.7 mg/kg bw/day for 
Caucasian, indicating the Chinese to be less sensitive. The predicted BMDL5-BMDU5 of riddelliine 
were 1.0-5.9 mg/kg bw/day for Chinese and 0.2-1.2 mg/kg bw/day for Caucasian. These values were 
subsequently compared to those previously obtained in rat to evaluate inter-species differences. The 
inter-species differences amounted to 2.0-fold for lasiocarpine and 8.2-fold for riddelliine with humans 
being more sensitive than rats. The inter-ethnic human differences varied 2.0-fold for lasiocarpine and 
5.0-fold for riddelliine with the average Caucasian being more sensitive than the average Chinese. 
These results provide a proof-of-principle for predicting inter-species and inter-ethnic differences in in 
vivo liver toxicity for PAs by an alternative testing strategy integrating in vitro cytotoxicity data with 
PBK modelling-based reverse dosimetry. 
In a subsequent study of the present thesis the same approach was used for prediction of genotoxicity, 
another endpoint relevant for PA toxicity (Chapter 6). State-of-the-art genotoxicity data on PAs are 
limited, and lack of genotoxicity studies for most 1,2-unsaturated PAs, hampers PA risk assessment, 
while economic and ethical constraints limit the possibilities to perform in vivo genotoxicity studies 
for all relevant PAs, including the 17 PAs identified by EFSA to be relevant for exposure via feed and 
food (EFSA, 2017). Thus, alternative testing strategies for estimating the genotoxicity of different PAs 
are required. It is obvious to investigate whether the developed PBK modelling-facilitated reverse 
dosimetry approach developed in Chapter 4 can quantitatively translate in vitro concentration-response 
curves for genotoxicity of lasiocarpine and riddelliine, to in vivo dose-response curves for 
genotoxicity of these PAs in rat liver. To this end, the in vitro concentration-responses curves obtained 
from in vitro genotoxicity studies with primary rat hepatocytes using the H2AX assay were translated 
into in vivo dose-response curves using PBK modelling-facilitated reverse dosimetry. The predicted 
BMD10 for lasiocarpine and riddelliine amounted to 8.82 and 3.41 mg/kg bw/day, respectively, and 
were in line with the experimental data on in vivo genotoxicity available in the literature for these two 
PAs (Chan et al.,1994; Xia et al., 2013; Yan et al., 2002). Lasiocarpine was found to be 6 times more 
potent than riddelliine based on results from an in vitro micronuclei assay (Allemang et al., 2018). 
However, when taking the differences in toxickinetics into account, the predicted in vivo genotoxicity 
of riddelliine was found to be 2.6-fold higher than that of lasiocarpine. These results reveal that the 
differences in toxicokinetics between different PAs may be substantial and may influence their 
ultimate in vivo REP values. It is concluded that integrating in vitro genotoxicity assays with PBK
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modelling-facilitated reverse dosimetry provides a method to predict in vivo genotoxicity for the large 
number of PAs for which in vivo genotoxicity data are lacking. 
Major discussion points  
The results obtained in the present study show some important steps forward in the risk assessment of 
PAs but at the same time also raise issues for further consideration and future research. The next 
sections provide an overview of these future challenges and their perspectives. 
Cut off value in the MOE approach based risk assessment 
To assess the risk to human health of compounds that are both genotoxic and carcinogenic based on 
data derived from animal experiments, the MOE approach was developed (EFSA, 2005). The MOE is 
defined as the ratio between the BMDL10 and the estimated daily intake (EDI). An MOE value higher 
than 10000 is considered as a low priority for risk management actions and would be of low concern 
from a public health point of view (EFSA, 2005). The cut-off value of 10000 was defined taking 
several factors into account, including a factor 100 for species differences and human variability in 
toxicokinetics and toxicodynamics, a factor 10 for inter-individual human variability in cell cycle 
control and DNA repair, and a factor 10 because the BMDL10 when used as a reference point is not 
identical to a no effect level (EFSA, 2005; O’Brien et al., 2006). The proposed default value of 10 for 
interspecies differences consists of a factor of 4 for differences between species in toxicokinetics and 
2.5 for interspecies differences in toxicodynamic (IPCS, 2005). However, whether this factor of 10 is 
suitable for all the genotoxic carcinogens may need further investigations defining compound specific 
assessment factors (CSAFs). In Chapter 4 and 5, an in vitro-PBK model based approach was 
developed to predict in vivo liver toxicity for lasiocarpine and riddelliine in rat and human, showing 
that lasiocarpine and riddelliine induced liver toxicity was predicted to be 2-fold and 8-fold higher in 
human than in rat, indicating humans to be somewhat more sensitive towards acute liver toxicity of 
lasiocarpine and riddelliine than rats. The higher toxicity of humans may be due to the kinetics that 
resulted in a 1.9- and 5.0-fold slower clearance of lasiocarpine and riddelliine in humans compared to 
rats. The major species-specific differences in susceptibility to PA toxicity may be attributed to several 
toxicokinetic factors such as CYP-mediated capacity of bioactivation, efficiency of N-oxidation, and 
carboxylesterase-mediated hydrolysis as well as the level of cellular GSH (Fu et al., 2004; Huan et 
al.,1998; Stegelmeier et al., 1999; Duringer et al., 2004; Winter et al., 1998). Fashe et al. (2015) 
examined the species-dependent variations in the metabolic detoxification and bioactivation of 
lasiocarpine. The results showed that the relative amount of the main demethylation metabolite (M9) 
as the major detoxification product of lasiocarpine was lower with human liver microsomes than with 
the liver microsomes of other species including rats, and more GSH reactive metabolites were formed 
with human liver microsomes (Fashe et al., 2015). The results obtained reveal that when extrapolating 
rodent toxicity data for lasiocarpine and riddelliine to the human situation, the proposed default value 
of 10 for interspecies differences is adequately or perhaps even somewhat overprotective because
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humans were shown to be 2- and 8-fold more sensitive than rats. A CSAF that could be smaller than 
the default value of 10 could thus be defined, especially for lasiocarpine. Then the default MOE value 
of 10000 may decrease accordingly which would result in less botanical product samples to result in 
MOE values that might raise a concern upon lifetime use. One could argue that when the uncertainty 
factor for interspecies differences of 10 could be reduced to 2 or 8 an MOE of 2000 or 8000 could be 
used as a cut off value. As outlined by EFSA when introducing the MOE approach selection of the cut 
off value is ultimately a matter for the risk managers (EFSA, 2005). The results of the present thesis 
indicate that use of QIVIVE based on PBK modelling may prove a way forward in defining CSAFs 
and thus also, compound specific MOE cut off values in risk assessment.   
Combined exposure to PAs 
Exposure to PAs generally includes exposure to a mixture of different congeners. EFSA identified 17 
PAs to be especially relevant for exposure via food and feed including also lasiocarpine as one of the 
two model compounds of the present thesis (EFSA, 2017). Close analysis of the type of PAs present in 
the different herbal products revealed that in the majority of samples lasiocarpine and riddelliine did 
not represent a major PA or were even absent (Bodi et al., 2014; EFSA, 2016; Mulder et al., 2015, 
2018) (Chapter 3). However, for the majority of the 17 PAs identified by EFSA to be important in 
food and feed, tumour data and related PoDs are absent hampering their risk assessment. So far, 
amongst all PAs only for lasiocarpine and riddelliine 2-year animal bioassays have been performed 
and provided data that are suitable to derive BMDL10 values for induction of liver tumours (NTP, 1978, 
2003). Whether the BMDL10 for lasiocarpine or riddelliine is the most appropriate or rather a too 
conservative PoD for risk assessment remains to be established. As already outlined above, EFSA 
reconsidered the use of the BMDL10 of 0.07 mg/kg bw/day for lasiocarpine and proposed to use of the 
BMDL10 of 0.24 mg/kg bw/day for riddelliine for the combined risk assessment of PAs by dose 
addition. Determining REP factors for the different PAs and using these to adjust exposure values in a 
dose-addition concept would be a way forward in the risk assessment of PA-containing botanicals. 
The interim REP factors for PAs defined by Merz and Schrenk, (2016) were based on data from in 
vitro cytotoxicity, genotoxicity in Drosophila, and acute toxicity in rodents (LD50). From these data, 
REPs were derived for structurally related subgroups of PAs, amounting to 1.0 for cyclic diesters and 
heliotridine-type (7S) open diesters (based on data for monocrotaline, retrorsine, riddelliine, 
senecionine, seneciphylliine, senkirkine, heliosupine and lasiocarpine). 0.3 for heliotridine-type (7S) 
monoesters (based on data for echinatine and heliotrine), 0.1 for retronecine-type (7R) open diesters 
(based on data for echimidine and symphytine), and 0.01 for retronecine-type (7R) monoesters (based 
on data for indicine, intermedine and lycopsamine) (Merz and Schrenk, 2016). Recently, Allemang et 
al. (2018) determined the concentration-dependent PA-induced formation of micronuclei in HepaRG 
cells by exposing the cells to 15 PAs and calculated the REP values based on these concentration-
response curves (Allemang et al., 2018). In both studies lasiocarpine and riddelliine have a relatively
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modelling-facilitated reverse dosimetry provides a method to predict in vivo genotoxicity for the large 
number of PAs for which in vivo genotoxicity data are lacking. 
Major discussion points  
The results obtained in the present study show some important steps forward in the risk assessment of 
PAs but at the same time also raise issues for further consideration and future research. The next 
sections provide an overview of these future challenges and their perspectives. 
Cut off value in the MOE approach based risk assessment 
To assess the risk to human health of compounds that are both genotoxic and carcinogenic based on 
data derived from animal experiments, the MOE approach was developed (EFSA, 2005). The MOE is 
defined as the ratio between the BMDL10 and the estimated daily intake (EDI). An MOE value higher 
than 10000 is considered as a low priority for risk management actions and would be of low concern 
from a public health point of view (EFSA, 2005). The cut-off value of 10000 was defined taking 
several factors into account, including a factor 100 for species differences and human variability in 
toxicokinetics and toxicodynamics, a factor 10 for inter-individual human variability in cell cycle 
control and DNA repair, and a factor 10 because the BMDL10 when used as a reference point is not 
identical to a no effect level (EFSA, 2005; O’Brien et al., 2006). The proposed default value of 10 for 
interspecies differences consists of a factor of 4 for differences between species in toxicokinetics and 
2.5 for interspecies differences in toxicodynamic (IPCS, 2005). However, whether this factor of 10 is 
suitable for all the genotoxic carcinogens may need further investigations defining compound specific 
assessment factors (CSAFs). In Chapter 4 and 5, an in vitro-PBK model based approach was 
developed to predict in vivo liver toxicity for lasiocarpine and riddelliine in rat and human, showing 
that lasiocarpine and riddelliine induced liver toxicity was predicted to be 2-fold and 8-fold higher in 
human than in rat, indicating humans to be somewhat more sensitive towards acute liver toxicity of 
lasiocarpine and riddelliine than rats. The higher toxicity of humans may be due to the kinetics that 
resulted in a 1.9- and 5.0-fold slower clearance of lasiocarpine and riddelliine in humans compared to 
rats. The major species-specific differences in susceptibility to PA toxicity may be attributed to several 
toxicokinetic factors such as CYP-mediated capacity of bioactivation, efficiency of N-oxidation, and 
carboxylesterase-mediated hydrolysis as well as the level of cellular GSH (Fu et al., 2004; Huan et 
al.,1998; Stegelmeier et al., 1999; Duringer et al., 2004; Winter et al., 1998). Fashe et al. (2015) 
examined the species-dependent variations in the metabolic detoxification and bioactivation of 
lasiocarpine. The results showed that the relative amount of the main demethylation metabolite (M9) 
as the major detoxification product of lasiocarpine was lower with human liver microsomes than with 
the liver microsomes of other species including rats, and more GSH reactive metabolites were formed 
with human liver microsomes (Fashe et al., 2015). The results obtained reveal that when extrapolating 
rodent toxicity data for lasiocarpine and riddelliine to the human situation, the proposed default value 
of 10 for interspecies differences is adequately or perhaps even somewhat overprotective because
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humans were shown to be 2- and 8-fold more sensitive than rats. A CSAF that could be smaller than 
the default value of 10 could thus be defined, especially for lasiocarpine. Then the default MOE value 
of 10000 may decrease accordingly which would result in less botanical product samples to result in 
MOE values that might raise a concern upon lifetime use. One could argue that when the uncertainty 
factor for interspecies differences of 10 could be reduced to 2 or 8 an MOE of 2000 or 8000 could be 
used as a cut off value. As outlined by EFSA when introducing the MOE approach selection of the cut 
off value is ultimately a matter for the risk managers (EFSA, 2005). The results of the present thesis 
indicate that use of QIVIVE based on PBK modelling may prove a way forward in defining CSAFs 
and thus also, compound specific MOE cut off values in risk assessment.   
Combined exposure to PAs 
Exposure to PAs generally includes exposure to a mixture of different congeners. EFSA identified 17 
PAs to be especially relevant for exposure via food and feed including also lasiocarpine as one of the 
two model compounds of the present thesis (EFSA, 2017). Close analysis of the type of PAs present in 
the different herbal products revealed that in the majority of samples lasiocarpine and riddelliine did 
not represent a major PA or were even absent (Bodi et al., 2014; EFSA, 2016; Mulder et al., 2015, 
2018) (Chapter 3). However, for the majority of the 17 PAs identified by EFSA to be important in 
food and feed, tumour data and related PoDs are absent hampering their risk assessment. So far, 
amongst all PAs only for lasiocarpine and riddelliine 2-year animal bioassays have been performed 
and provided data that are suitable to derive BMDL10 values for induction of liver tumours (NTP, 1978, 
2003). Whether the BMDL10 for lasiocarpine or riddelliine is the most appropriate or rather a too 
conservative PoD for risk assessment remains to be established. As already outlined above, EFSA 
reconsidered the use of the BMDL10 of 0.07 mg/kg bw/day for lasiocarpine and proposed to use of the 
BMDL10 of 0.24 mg/kg bw/day for riddelliine for the combined risk assessment of PAs by dose 
addition. Determining REP factors for the different PAs and using these to adjust exposure values in a 
dose-addition concept would be a way forward in the risk assessment of PA-containing botanicals. 
The interim REP factors for PAs defined by Merz and Schrenk, (2016) were based on data from in 
vitro cytotoxicity, genotoxicity in Drosophila, and acute toxicity in rodents (LD50). From these data, 
REPs were derived for structurally related subgroups of PAs, amounting to 1.0 for cyclic diesters and 
heliotridine-type (7S) open diesters (based on data for monocrotaline, retrorsine, riddelliine, 
senecionine, seneciphylliine, senkirkine, heliosupine and lasiocarpine). 0.3 for heliotridine-type (7S) 
monoesters (based on data for echinatine and heliotrine), 0.1 for retronecine-type (7R) open diesters 
(based on data for echimidine and symphytine), and 0.01 for retronecine-type (7R) monoesters (based 
on data for indicine, intermedine and lycopsamine) (Merz and Schrenk, 2016). Recently, Allemang et 
al. (2018) determined the concentration-dependent PA-induced formation of micronuclei in HepaRG 
cells by exposing the cells to 15 PAs and calculated the REP values based on these concentration-
response curves (Allemang et al., 2018). In both studies lasiocarpine and riddelliine have a relatively
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high potency, but lasiocarpine was found to be 6 times more potent than riddelliine in the 
micronucleus study. In the present thesis, the γH2AX assay was used to detect genotoxicity of 
lasiocarpine and riddelliine in primary rat hepatocytes, and translation of the concentration-response 
curves to in vivo dose-response curves was based on PBK model facilitated reverse dosimetry. Based 
on the in vitro genotoxicity data thus obtained lasiocarpine was 3.5-fold more potent than riddelliine. 
However when differences in kinetics were taken into account and the in vitro data were translated to 
the in vivo situation the predicted dose-response curves, riddelliine was found to be 2.6-fold more 
potent than lasiocarpine (Chapter 6). This difference could be ascribed to a far more efficient clearance 
of lasiocarpine as compared to riddelliine with the catalytic efficiency for clearance being 11-fold 
higher for lasiocarpine. This indicates that definition of REP values based on in vitro data without 
taking possible differences in toxicokinetics into account may result in inaccurate values. Preferably 
REP values used in the MOE based risk assessment of combined exposure to PAs should be derived 
from in vivo carcinogenicity potencies. However, this seems unrealistic given the large number of PAs 
for which actual carcinogenicity data are lacking. More recently, EFSA re-calculated the BMDL10 
values for lasiocarpine and riddelliine based on the 2-year carcinogenicity data, indicating that the 
previously obtained BMDL10 of lasiocarpine was affected by a high degree of uncertainty (EFSA, 
2017). Despite the large difference between the BMDL10 for lasiocarpine and riddelliine, a partial 
overlap of the BMDL10-BMDU10 confidence intervals calculated using model averaging was observed, 
suggesting that the carcinogenic potency of these two PAs could be quite similar. This was more 
evident when the BMD analysis of the available tumour data was performed using a BMR falling 
within the tested dose ranges for both substance, such as a BMD30 the dose level resulting in 30% 
extra tumour incidence above background values. In this analysis BMD30 values of 0.491 and 0.435 
mg/kg bw/day were calculated for lasiocarpine and riddelliine, respectively (EFSA, 2017). This 
additional modelling supported the assumption that the two PAs can be considered of similar 
carcinogenic potency (EFSA, 2017). One possible explanation for this similarity could be that the 
same 4 types of DHP-derived DNA adducts were produced in rats exposed to lasiocarpine and 
riddelliine, which might result in similar chances on gene mutations and tumour formation (Xia et al., 
2013; Chen et al., 2010). Together these results show that REP values should not be based on in vitro 
concentration-response curves without taking differences in kinetics into account. For better 
refinement, the REP factors could be based on data for genotoxicity of PAs, combined with PBK 
modelling. Such an in vitro-in silico approach could be applied for different PAs, especially the 17 
PAs identified by EFSA to be relevant for exposure via feed and food (EFSA, 2017). Using PBK 
model based reverse dosimetry for QIVIVE, the toxicokinetics of PAs can be taken into account and 
the estimated REP for PAs could be closer to the values representing differences in their in vivo 
potencies.
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Banding of the MOE values for risk management 
MOE values obtained for herbal products in the present thesis showed wide variation, for example, the 
MOE values for herbal teas varied from 100 to 550000 (Chapter 3). At the current state-of-the-art 
there is no clear definition of interpretation of MOE values that differentiate from 10000 to a different 
degree. This implies that an MOE far below 10000 of for example 10, or close to 10000 of for 
example 9990, are both judged to be of concern, while an MOE of 10005 or 100000 are both of no 
concern, while these values obviously may represent different risk levels for human health. A banding 
system has been proposed by the Committee on Carcinogenicity of Chemicals in Food, Consumer 
Products and the Environment (COC) to assist risk management. The proposed MOE banding is as 
follow: MOE lower than 10000: may be a concern, MOE value in the range of 10000-1000000: 
unlikely to be a concern, MOE value higher than 1000000: very unlikely to be a concern (COC, 2012). 
This system helps the discrimination of the different risk levels above 10000, but it does not consider 
the situation of MOE values below 10000. One could consider further banding of MOE cut-off values 
that are lower than 10000 as follows: MOE lower than 1000: a very high concern; MOE values in the 
range of 1000-5000: a high concern; MOE values in the range of 5000-10000: a concern. When 
applying this MOE banding, in total 3 (7%) of 39 types of herbal teas, 3 (38%) of 8 types of herbal 
medicines and 1 (5%) of 19 types of PFS resulted in MOE values lower than 1000 based on daily 
consumption during a whole lifetime, indicating a very high concern for human health (Chapter 3). 
These examples show how this banding may help the discrimination of the risks of MOE values below 
10000. 
Shorter-than-lifetime exposure 
Another item that appeared relevant to consider is the fact that exposure to herbal products may not 
always be relevant during every day of a whole life time. This implies that methods to consider 
shorter-than-lifetime exposure need to be considered and developed. Since MOE values represent a 
risk assessment of human health considering daily exposure during a whole life span, this assumption 
can cause overestimation of the risk for exposure to certain toxic compounds when realistic 
consumption patterns would imply a period shorter-than-lifetime. This holds especially for adverse 
effects that are dependent on the total exposure, such as genotoxicity and carcinogenicity,  rather than 
on maximum plasma levels. In Chapter 3, Haber’s rule was applied to assess the potential risk for 
human exposure to PAs derived from consumption of herbal products for periods shorter-than-lifetime. 
The application of Haber’s rule is based on the assumption that the tumour incidence and carcinogenic 
processes induced by genotoxic carcinogens have a linear relationship with the cumulative dose 
(Crump et al., 1976). When assuming lifelong daily consumption, 10 out of 39 herbal teas, 3 out of 8 
herbal medicines and 2 out of 19 PFS had MOE values below 10000, indicating that these herbal 
products may pose a potential risk for human health. Considering shorter-than-lifetime exposure for 2 
weeks/year and after applying Haber’s rule for correction of the exposure values, only 4 types of
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high potency, but lasiocarpine was found to be 6 times more potent than riddelliine in the 
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on the in vitro genotoxicity data thus obtained lasiocarpine was 3.5-fold more potent than riddelliine. 
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extra tumour incidence above background values. In this analysis BMD30 values of 0.491 and 0.435 
mg/kg bw/day were calculated for lasiocarpine and riddelliine, respectively (EFSA, 2017). This 
additional modelling supported the assumption that the two PAs can be considered of similar 
carcinogenic potency (EFSA, 2017). One possible explanation for this similarity could be that the 
same 4 types of DHP-derived DNA adducts were produced in rats exposed to lasiocarpine and 
riddelliine, which might result in similar chances on gene mutations and tumour formation (Xia et al., 
2013; Chen et al., 2010). Together these results show that REP values should not be based on in vitro 
concentration-response curves without taking differences in kinetics into account. For better 
refinement, the REP factors could be based on data for genotoxicity of PAs, combined with PBK 
modelling. Such an in vitro-in silico approach could be applied for different PAs, especially the 17 
PAs identified by EFSA to be relevant for exposure via feed and food (EFSA, 2017). Using PBK 
model based reverse dosimetry for QIVIVE, the toxicokinetics of PAs can be taken into account and 
the estimated REP for PAs could be closer to the values representing differences in their in vivo 
potencies.
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applying this MOE banding, in total 3 (7%) of 39 types of herbal teas, 3 (38%) of 8 types of herbal 
medicines and 1 (5%) of 19 types of PFS resulted in MOE values lower than 1000 based on daily 
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shorter-than-lifetime exposure need to be considered and developed. Since MOE values represent a 
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weeks/year and after applying Haber’s rule for correction of the exposure values, only 4 types of
228
 
 
226 
 
herbal teas and 1 type of herbal medicines resulted in MOE values lower than 10000, all the PFS had 
MOE values above 10000. Thus, the use of the MOE based on life-time exposure estimates might 
overestimate the actual risk for human health. Based on the considerations discussed above it is 
concluded that it would be encouraged to further refine the MOE approach, developing generally 
accepted methods that take shorter than life-time exposure into account. 
The in vitro system selected for quantitative in vitro to in vivo extrapolation (QIVIVE) 
In QIVIVE based on in vitro-PBK modelling-based reverse dosimetry, there are several issues that 
need to be considered. A first one is selection of a cell model that contains sufficient levels of enzymes 
involved in PA biotransformation, given that the expression of the relevant biotransformation enzymes 
may differ between the different cell models or may even be completely absent. The biotransformation 
capacity of a cell model is considered to be an important issue in in vitro testing (Coecke et al., 2013). 
A second issue to consider is that the critical effect quantified in the in vitro model and the underlying 
mode of action should be relevant for the in vivo response and can thus provide a basis for estimation 
of the in vivo PoD. For prediction of in vivo liver toxicity for lasiocarpine and riddelliine in human, 
we selected cell-based liver models including HepaRG cells and primary human hepatocytes to 
generate the in vitro data (Chapter 5). HepaRG cells are derived from a human hepatocellular 
carcinoma composed of a mixture of both hepatocytes-like and biliary-like cells. The HepaRG cell 
model contains most of the active CYP450 enzymes, especially the CYP 3A and 2B isoforms that are 
key enzymes for PAs bioactivation (Fu et al., 2004; Guillouzo et al., 2007; Lin et al., 2003; Prakash et 
al., 1999; Turpeinen et al., 2009). Primary human hepatocytes represent a unique in vitro system and 
serve as a ‘gold standard’ for studies of drug metabolism and toxicity, and are often used by default 
for hepatotoxicity studies (LeCluyse, 2001). It was demonstrated that the HepaRG cells were able to 
maintain hepatic functions comparable to primary human hepatocytes (Lübberstedt et al. 2010). 
Comparisons of the activity of CYP450s in HepaRG cells and primary human hepatocytes have been 
reported, but the results were inconsistent across different studies. Gerets et al. (2012) reported that 
CYP 3A4 activity was about 17.0-fold lower in the HepaRG cells than in primary human hepatocytes 
from three different donors (Gerets et al., 2012). However, Kvist et al. (2018), and Lubberstedt et al. 
(2011) investigating the CYP 1A2, CYP 2B6, CYP 2C8, CYP 2C9, CYP 2C19 and CYP 2D6 
activities in HepaRG cells and primary human hepatocytes, showed that these enzyme activities were 
generally lower in HepaRG cells than in human hepatocytes, except for CYP 3A4 showing a generally 
1.5-fold higher activity in HepaRG cells (Kvist et al., 2018, Lübberstedt et al., 2011). Comparison of 
the lasiocarpine and riddelliine induced cytotoxicity between HepaRG cells and primary human 
hepatocytes, revealed primary human hepatocytes to be 10- and 3-fold more sensitive to lasiocarpine 
and riddelliine induced cytotoxicity than the HepaRG cells. On the other hand, quantifying H2AX 
formation as the endpoint for genotoxicity, the primary rat hepatocytes appeared to be about one to
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two orders of magnitude more sensitive to lasiocarpine and riddelliine induced genotoxicity than the 
HepaRG cells (Chapter 6). Combining the results from these two Chapters, it is concluded that 
HepaRG cells have lower metabolic capacity for bioactivation of the PAs compared to primary 
hepatocytes. One could argue that a large inherent variation of primary human hepatocytes due to the 
inter-individual variability between different donors as well as the limited supply of high quality donor 
tissues may lead to a compromised experimental result (Shimada et al., 1994; Zuo et al., 2017). For 
better understanding of human liver function using in vitro models and to overcome the disadvantage 
of using primary human hepatocytes, new cell culture technologies such as induced pluripotent stem 
cells (iPSCs) (Wong et al., 2018), 3D cell culture systems (Bell et al., 2016), 3D-bioreactor technology 
(Knöspel et al., 2016) and organ-on-a-chip devices (Kimura et al., 2018) can be considered, although it 
remains to be established whether CYP levels in these models will adequately support PA 
bioactivation. 
Another challenge in the present thesis was to quantitatively define PoDs for the in vivo situation. In 
Chapter 6, the H2AX assay was applied to quantify the genotoxicity of the PAs lasiocarpine and 
riddelliine. Several studies reported in the literature have assessed the in vitro genotoxicity of PAs 
using diverse assays, showing that PAs may induce divergent DNA damage including DNA-adducts, 
DNA cross-linking and clastogenic effects (Chan et al., 1994; Xia et al., 2006; Kim et al., 1995; 
Takanashi et al., 1980). The phosphorylation of histone H2AX (H2AX) occurs after a DNA double 
strand break in a cell and reflects a global genotoxic insult that may originate from different types of 
DNA damage (Sedelnikova et al., 2010). These genotoxic effects may result in gene mutations and 
tumour formation (Chen et al., 2010; Hoeijmakers, 2009). When comparing the values obtained for in 
vivo genotoxicity of lasicarpine and riddelliine with PoDs derived from available tumour data. From 
data on the incidence of liver haemangiosarcoma obtained in 2-year carcinogenicity studies in rats 
upon chronic oral exposure to lasiocarpine and riddelliine (NTP, 1978, 2003). EFSA derived a BMD10 
of 0.131 mg/kg bw/day for lasiocarpine and of 0.292 mg/kg bw/day for riddelliine (EFSA, 2017). 
These BMD10 values obtained from the 2-year carcinogenicity studies are one to two orders of 
magnitude lower than the BMD10 levels predicted in the present study and the dose levels used in other 
studies to detect genotoxicity (Chan et al., 1994; Xia et al., 2013; Yan et al., 2002). This may be 
related to the fact that the exposure duration in the genotoxicity studies is far shorter (1-5 days) than 
the 2-year exposure applied in carcinogenicity studies. Although the developed PBK models can 
predict the genotoxicity in vivo, which takes the modelling approach one step beyond the kinetics for 
bioactivation and closer to the ultimate adverse effect of tumour formation, a real challenge is to build 
models for prediction of tumour formation. The Moolgavkar-Venzon-Knudson (MVK) multistage 
carcinogenesis model can describe the tumour formation via mathematic formulas (Luebeck and 
Moolgavkar, 2002). The principle of this model is based on tumour formation being a multistep 
process, in which the normal cells become tumour cells upon a series of transformations induced by
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herbal teas and 1 type of herbal medicines resulted in MOE values lower than 10000, all the PFS had 
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for hepatotoxicity studies (LeCluyse, 2001). It was demonstrated that the HepaRG cells were able to 
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remains to be established whether CYP levels in these models will adequately support PA 
bioactivation. 
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riddelliine. Several studies reported in the literature have assessed the in vitro genotoxicity of PAs 
using diverse assays, showing that PAs may induce divergent DNA damage including DNA-adducts, 
DNA cross-linking and clastogenic effects (Chan et al., 1994; Xia et al., 2006; Kim et al., 1995; 
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sequential mutations in different tumour suppressor genes and/or oncogenes. This has been 
investigated for colorectal cancer where mutations in the adenomatous polyposis coli (APC) tumour 
suppressor gene have been linked to early stages in the carcinogenic process, and where mutation in 
the K-ras oncogene and the P53 tumour suppressor gene are aligned with malignant transformations 
that occur later in the carcinogenic process (Frank, 2007). Such MVK model for tumour progression 
may be used to identify the adequate in vitro model(s) to provide the in vitro data for the PBK 
modelling based facilitated reverse dosimetry facilitated QIVIVE for prediction of in vivo 
carcinogenicity. However, so far, there are no in vitro experimental methods available for detection of 
cell death, cell division and mutation rates in different tumour stages and the effects of chemicals on 
these rates, while these parameters would be important for development of such QIVIVE approaches 
for carcinogenicity. Another step to be considered in these models for tumour formation would be 
repeated dose regimens. In Chapter 6, primary rat hepatocytes were used as the rat cell-based liver 
model to obtain in vitro data for prediction of acute liver toxicity in the rat in vivo. However, primary 
rat hepatocytes are difficult to maintain in culture for more than a few days, and this makes the cells 
inadequate for evaluating the chronic effects of chemicals at physiologically relevant (low) dose levels. 
To date, use of microfluidic platforms for the co-culture of primary rat hepatocytes and endothelial 
cells (Kang et al., 2015) and the HepatoPac culture technique (Ukairo et al., 2013) maybe an option for 
studying chronic exposure of PAs since primary rat hepatocytes can be cultured for at least 4 weeks 
with constant metabolic enzyme activities. Furthermore, the gene and protein expression could be 
included in in silico models. For example PAs have been shown to significant change Fez1 and Mgat5 
genes that are related to cancer induction (Guo et al., 2007) and these results may illustrate the cellular 
network response that should be considered to enable definition of a comprehensive simulation model 
of chemical carcinogenicity. 
Extrapolation of the in vitro dose metrics to the in vivo situation 
Another important issue when translating in vitro concentration-response curves to in vivo dose-
response curves is the choice of the dose metric for the extrapolation. The predictions can be done 
based on two approaches. In the first approach, each in vitro concentration is set equal to the 
maximum concentration (Cmax) of the compound as input in the PBK model to calculate the oral dose 
that results in this concentration. In the second approach, each concentration is translated to an area 
under the time-response curve (AUC), by multiplying the concentration with the assay time (Daston et 
al., 2010). The choice of the dose metric to be used for the reverse dosimetry, Cmax or AUC, depends 
on the mode of action of the test compound and the endpoint of interest. In Chapter 3, we translated 
the in vitro concentration-response curves for cytotoxicity to in vivo dose-response curves based on a 
Cmax approach, because for liver toxicity a threshold can be assigned and the effect size can be 
assumed to be dominated by the Cmax rather than by the AUC. The results obtained in this way for the 
predicted PoD of lasiocarpine were in line with the in vivo liver toxicity data. When making the
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the prediction based on the AUC approach, the predicted PoD for lasiocarpine was 111-173 mg/kg 
bw/day, more than one order of magnitude above the PoD derived from the in vivo liver toxicity data. 
This indicates that when predicting toxicity for which a threshold exists and thus a concentration 
below which there will be no effect, Cmax may be the selected parameter for the reverse dosimetry. In 
order to predict genotoxicity of lasiocarpine and riddelliine in rat, we translated the in vitro 
concentration-response curves of genotoxicity to in vivo dose-response curves based on the AUC 
approach (Chapter 6). When using Cmax for this conversion, the predicted BMD10 of lasiocarpine and 
riddelliine was up to 17.4- and 42.2-fold lower compared to in vivo animal data. However, when 
predicting BMD10 values for lasiocarpine and riddelliine using the AUC approach, for lasiocarpine the 
difference between predicted PoD values and the observed data derived from an in vivo study 
detecting DNA adduct formation was only 1.1-fold (Xia et al., 2013). For riddelliine, the predicted 
PoD was 1.8- to 2.9-fold different from the in vivo dose causing detectable DNA-adduct formation 
(Xia et al., 2013; Yan et al., 2002), and 3.4-fold different from the in vivo dose causing detectable 
unscheduled DNA synthesis in rat (Chan et al., 1994).  This thesis confirmed that when considering 
non-threshold effects that accumulate in time, including effects like genotoxicity and carcinogenicity, 
use of the AUC is preferred over use of the Cmax in reverse dosimetry (Groothuis et al., 2015). 
Future perspectives 
Development of generic PBK models for a group of compounds 
Due to the lack of available in vivo liver toxicity, genotoxicity and carcinogenicity data for PAs, 
Chapter 4, 5 and 6 investigated whether using PBK modelling-based reverse dosimetry can predict 
PoDs for lasiocarpine and riddelliine by translating in vitro cytotoxicity and genotoxicity 
concentration-response curves to in vivo dose-response curves. To this end, PBK models were 
developed for lasiocarpine and riddelliine, respectively. However, it is important to realise that the 
PBK models developed in the present thesis specifically for these two PAs required a large number of 
parameters. Therefore, development of such PBK models is time consuming although compared to 
performing an animal bioassay the amount of work may still be considered relatively small, cheaper 
and of less ethical concern. Future efforts could be focussed on developing more generic PBK models 
for the PAs. This will provide an even more efficient approach for future risk assessment of groups of 
genotoxic carcinogens for which rodent toxicity data are not available (Bessems et al., 2014). Some 
efforts in development of generic PBK models have been reported. Zhang et al. (2017) developed a 
generic PBK model that can predict in vivo uterotrophic responses induced by 17β-estradiol (E2) and 
bisphenol A (BPA) in rats, and this work could serve as a starting point of developing a generic PBK 
model to predict the estrogenicity for a large number of chemicals (Zhang et al., 2017). Brightman et 
al. (2007) applied a generic PBK model that can estimate the in vivo pharmacokinetics of a set of 18 
compounds for which plasma levels have been determined following an intravenous dose (Brightman 
et al., 2006). Depending on the group of chemicals under study only a few compound specific
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sequential mutations in different tumour suppressor genes and/or oncogenes. This has been 
investigated for colorectal cancer where mutations in the adenomatous polyposis coli (APC) tumour 
suppressor gene have been linked to early stages in the carcinogenic process, and where mutation in 
the K-ras oncogene and the P53 tumour suppressor gene are aligned with malignant transformations 
that occur later in the carcinogenic process (Frank, 2007). Such MVK model for tumour progression 
may be used to identify the adequate in vitro model(s) to provide the in vitro data for the PBK 
modelling based facilitated reverse dosimetry facilitated QIVIVE for prediction of in vivo 
carcinogenicity. However, so far, there are no in vitro experimental methods available for detection of 
cell death, cell division and mutation rates in different tumour stages and the effects of chemicals on 
these rates, while these parameters would be important for development of such QIVIVE approaches 
for carcinogenicity. Another step to be considered in these models for tumour formation would be 
repeated dose regimens. In Chapter 6, primary rat hepatocytes were used as the rat cell-based liver 
model to obtain in vitro data for prediction of acute liver toxicity in the rat in vivo. However, primary 
rat hepatocytes are difficult to maintain in culture for more than a few days, and this makes the cells 
inadequate for evaluating the chronic effects of chemicals at physiologically relevant (low) dose levels. 
To date, use of microfluidic platforms for the co-culture of primary rat hepatocytes and endothelial 
cells (Kang et al., 2015) and the HepatoPac culture technique (Ukairo et al., 2013) maybe an option for 
studying chronic exposure of PAs since primary rat hepatocytes can be cultured for at least 4 weeks 
with constant metabolic enzyme activities. Furthermore, the gene and protein expression could be 
included in in silico models. For example PAs have been shown to significant change Fez1 and Mgat5 
genes that are related to cancer induction (Guo et al., 2007) and these results may illustrate the cellular 
network response that should be considered to enable definition of a comprehensive simulation model 
of chemical carcinogenicity. 
Extrapolation of the in vitro dose metrics to the in vivo situation 
Another important issue when translating in vitro concentration-response curves to in vivo dose-
response curves is the choice of the dose metric for the extrapolation. The predictions can be done 
based on two approaches. In the first approach, each in vitro concentration is set equal to the 
maximum concentration (Cmax) of the compound as input in the PBK model to calculate the oral dose 
that results in this concentration. In the second approach, each concentration is translated to an area 
under the time-response curve (AUC), by multiplying the concentration with the assay time (Daston et 
al., 2010). The choice of the dose metric to be used for the reverse dosimetry, Cmax or AUC, depends 
on the mode of action of the test compound and the endpoint of interest. In Chapter 3, we translated 
the in vitro concentration-response curves for cytotoxicity to in vivo dose-response curves based on a 
Cmax approach, because for liver toxicity a threshold can be assigned and the effect size can be 
assumed to be dominated by the Cmax rather than by the AUC. The results obtained in this way for the 
predicted PoD of lasiocarpine were in line with the in vivo liver toxicity data. When making the
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the prediction based on the AUC approach, the predicted PoD for lasiocarpine was 111-173 mg/kg 
bw/day, more than one order of magnitude above the PoD derived from the in vivo liver toxicity data. 
This indicates that when predicting toxicity for which a threshold exists and thus a concentration 
below which there will be no effect, Cmax may be the selected parameter for the reverse dosimetry. In 
order to predict genotoxicity of lasiocarpine and riddelliine in rat, we translated the in vitro 
concentration-response curves of genotoxicity to in vivo dose-response curves based on the AUC 
approach (Chapter 6). When using Cmax for this conversion, the predicted BMD10 of lasiocarpine and 
riddelliine was up to 17.4- and 42.2-fold lower compared to in vivo animal data. However, when 
predicting BMD10 values for lasiocarpine and riddelliine using the AUC approach, for lasiocarpine the 
difference between predicted PoD values and the observed data derived from an in vivo study 
detecting DNA adduct formation was only 1.1-fold (Xia et al., 2013). For riddelliine, the predicted 
PoD was 1.8- to 2.9-fold different from the in vivo dose causing detectable DNA-adduct formation 
(Xia et al., 2013; Yan et al., 2002), and 3.4-fold different from the in vivo dose causing detectable 
unscheduled DNA synthesis in rat (Chan et al., 1994).  This thesis confirmed that when considering 
non-threshold effects that accumulate in time, including effects like genotoxicity and carcinogenicity, 
use of the AUC is preferred over use of the Cmax in reverse dosimetry (Groothuis et al., 2015). 
Future perspectives 
Development of generic PBK models for a group of compounds 
Due to the lack of available in vivo liver toxicity, genotoxicity and carcinogenicity data for PAs, 
Chapter 4, 5 and 6 investigated whether using PBK modelling-based reverse dosimetry can predict 
PoDs for lasiocarpine and riddelliine by translating in vitro cytotoxicity and genotoxicity 
concentration-response curves to in vivo dose-response curves. To this end, PBK models were 
developed for lasiocarpine and riddelliine, respectively. However, it is important to realise that the 
PBK models developed in the present thesis specifically for these two PAs required a large number of 
parameters. Therefore, development of such PBK models is time consuming although compared to 
performing an animal bioassay the amount of work may still be considered relatively small, cheaper 
and of less ethical concern. Future efforts could be focussed on developing more generic PBK models 
for the PAs. This will provide an even more efficient approach for future risk assessment of groups of 
genotoxic carcinogens for which rodent toxicity data are not available (Bessems et al., 2014). Some 
efforts in development of generic PBK models have been reported. Zhang et al. (2017) developed a 
generic PBK model that can predict in vivo uterotrophic responses induced by 17β-estradiol (E2) and 
bisphenol A (BPA) in rats, and this work could serve as a starting point of developing a generic PBK 
model to predict the estrogenicity for a large number of chemicals (Zhang et al., 2017). Brightman et 
al. (2007) applied a generic PBK model that can estimate the in vivo pharmacokinetics of a set of 18 
compounds for which plasma levels have been determined following an intravenous dose (Brightman 
et al., 2006). Depending on the group of chemicals under study only a few compound specific
232
 
 
230 
 
parameters may have to be added but the PBK model development could start from the generic basic 
model and its evaluation before adding additional parameters. In order to develop the model more 
efficient, some parameter may be obtained from in silico methods instead of experimental work. For 
example, the sensitivity analysis showed that permeability coefficients (Papp) had a large influence on 
model prediction (Chapter 3). Use of experimental Caco-2 transport studies to derive the Papp values in 
PBK models has been reported (Louisse et al., 2015; Li et al., 2017; Zhang et al., 2018). To build a 
generic PBK model for a large number of chemicals, such parameters could be obtained from in silico 
methods. Hou et al. (2004) described that Papp values for Caco-2 transport can be predicted using 
QSAR approaches requiring information on the polar surface area alone (Hou et al., 2004), indicating 
that no experimental work is needed to quantify this parameter. Consequently, development of a 
generic PBK models can assist in making the PBK model description more time and cost efficient.  
Quality control of botanicals 
Since high level of PAs have been detected in botanicals and botanical preparations (Bodi et al., 2014; 
IPCS, 1988; Mulder et al., 2015, 2018; EFSA, 2016), and these botanical products are still 
commercially available, this situation raises a concern for public health and represents a food safety 
issue. In spite of this, consumer demands for these products continue to grow. Meantime, the reported 
cases of adverse events upon consumption of botanicals and botanical preparations are also rising 
globally (Rocha et al., 2016). To adequately guarantee the safe use of botanical preparations, it is 
essential to internationally harmonize the approach and procedures for the regulatory safety 
assessment of those products. In reality, however, the legislation and the risk assessment criteria for 
botanical supplements vary among different countries (Low et al., 2017). While some countries 
classify PFS as a food or health food (CFDA, 2016; JETRO, 2011), others regulate PFS as medicines 
(Health Canada 2016; TGA, 2013). To date, EU, Australia and the US have established criteria for the 
safety evaluation of PFS ingredients (EFSA, 2009) whereas there appear to be no such criteria in other 
countries. Internet sales of herbal products has further complicated matters as consumers can easily 
purchase products from all over the world. To address these issues and ensure public health, increasing 
regulatory oversight for botanical preparations seems necessary. Harmonization of risk assessment 
criteria as well as the creation of internationally recognized compendia of botanicals should be 
emphasized as a way forward. The international regulatory community may create a list of botanicals 
with known safety concerns and update the list on a regular basis, such as is the case for the 
compendium developed by EFSA (EFSA, 2012). Also a better system for quality control and 
traceability seems indicated. The traceability system can be built for each botanical product, food 
business operator, including those trading in food supplements. The data and information to be 
collected include name, address and date of the supplier, business customer, delivery company and 
food business operator. The most important information about the batch should always follow the 
material by a batch documentation, and integrity of botanical material (EUROPAM 2006;
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FoodSupplementsEurope 2016). The findings of widespread contamination by PAs in herbal teas has 
confirmed that the situation with PA contamination is serious. Applying a good quality control can 
prevent the herbal tea contamination by PA-producing plants. A Code of Practice (CoP) has been 
developed that focuses on weed control and provides guidance on good management practices to 
prevent and reduce PA contamination by control measures for the management of PA-producing 
plants (CAC, 2014). In addition, an appropriate sampling plan should be developed depending on 
whether a herbal substance (spot contamination) or a herbal preparation/finished product (homogenous 
sample) is tested. Sampling should be in accordance with Commission Regulation 401/2006/EC (EC, 
2006). Manufacturers should be required to provide ingredient information and highly sensitive 
analytical methods are also needed to monitor the PA levels during the sampling and production 
process. These quality control measures will facilitate risk assessment and guarantee the safety of the 
herbal products.  
Conclusion 
This thesis assessed the risks of herbal teas, herbal medicines and PFS that contain PAs based on the 
MOE approach, and also developed new methods to tackle existing data gaps and to improve the 
scientific basis for PA risk and safety assessment. The overall conclusion of the risk assessment of 
herbal products revealed that daily life-time consumption of some of these products would be a 
priority for risk management. When considering realistic exposure scenarios, exposure to most of 
these herbal products would have MOE values higher than 10000 indicating a low priority for risk 
management. Moreover, this thesis demonstrated that the combined in vitro PBK modelling-based 
reverse dosimetry approach could adequately predict in vivo liver toxicity and genotoxicity for two 
model PAs, lasiocarpine and riddelliine. Such QIVIVE methods may prove to be of use in defining 
more realistic REP values for the different food/feed-related PAs, i.e. REP values that are not solely 
based on in vitro concentration-effect data but also taking differences in toxicokinetics into account. 
The results obtained reveal the feasibility of this combined quantitative in vitro-in silico approach to 
determine a PoD for a chemical without the use of experimental animals and to address the issue of 
how to use in vitro data for risk assessment. 
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Summary 
Botanicals and botanical preparations may contain natural constituents that are of concern for human 
health. One group of such natural toxic compounds that may raise a concern is the group of 
pyrrolizidine alkaloids (PAs). At the current state-of-the-art, risk assessment of botanicals and 
botanical preparations is generally not required before they can enter the market. The present thesis 
aimed to perform the risk assessment for PAs derived from botanical products following daily life-
time exposure and also more realistic exposure scenarios. Another aim of the present thesis was to 
investigate whether animal-free testing strategies could be of use in tackling data and knowledge gaps 
for PAs by predicting in vivo toxicity of different PAs and whether proofs-of-principle for applying 
such alternative testing approaches could be provided for two selected PA model compounds, 
riddelliine and lasiocarpine. 
Chapter 1 provided general background information on PAs, a description of the physico-chemical  
properties of lasiocarpine and riddelliine, as well as exposure, metabolism, genotoxicity, 
carcinogenicity and hepatotoxicity characteristics of PAs, a brief outline of the methodology used for 
risk assessment of PAs, a short introduction to PBK modelling-based reverse dosimetry and the 
objectives of the present thesis. In Chapter 2, a risk assessment was performed based on the margin of 
exposure (MOE) approach using the BMDL10 (benchmark dose lower confidence limit for 10% extra 
risk on tumour formation above background levels) of 0.07 mg/kg bw/day for lasiocarpine and mean 
levels of PAs reported in literature for herbal teas and plant food supplements (PFS). After using 
interim REP (relative potency) factors to ‘adjust’ PA levels and resulting exposure, 54% of the types 
of herbal teas and 14% of the PFS were estimated to result in daily intakes that would give rise to 
MOE values lower than 10000, indicating a possible health risk. The herbal preparations that raised a 
concern included preparations containing PA-producing plants but also preparations containing non-
PA-producing plants. In Chapter 3, the MOE approach, using the BMDL10 of 0.24 mg/kg bw/day for 
riddelliine and total PA levels, and Haber’s rule were employed to analyse the risks of shorter-than-
lifetime exposure for 5 herbal teas, 8 herbal medicines and previously analysed herbal products from 
Chapter 2. This revealed that shorter-than-lifetime use of these herbal products resulted in MOE 
values lower than 10000 when the preparations would be used for only 40 to up to 3450 weeks during 
a lifetime (depending on the preparation), with for only a limited number of herbal teas and medicines 
use of two weeks a year (150 weeks during a 75 year lifetime) still raising a concern. The results also 
revealed that the PA levels extracted from intact leaves were lower than the leaves extracted from 
comminuted leaves, and this may influence the actual exposure and corresponding risk assessment. In 
Chapter 4 and 5, PBK models were developed for prediction of liver toxicity of lasiocarpine and 
riddelliine in rats and humans on the basis of in vitro toxicity data. Using PBK model based reverse 
dosimetry the in vitro concentration-response curves for cytotoxicity in primary rat hepatocytes were 
translated to in vivo dose-response curves. From these in vivo dose-response curves, the predicted
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BMDL5-BMDU5 (lower/upper limit of the 90% confidence interval of the benchmark dose that gives a 
5% response) of lasiocarpine and riddelliine in both rats (Chapter 4) and humans (Chapter 5) were 
obtained. Due to the absence of in vivo acute liver toxicity data reported in the literature for riddelliine, 
the predicted PoDs (point of departures) for in vivo liver toxicity could only be evaluated for 
lasiocarpine. To this end, the predicted BMDL5-BMDU5 of lasiocarpine for rats was compared with in 
vivo reported data for acute liver toxicity of lasiocarpine, and the results showed that the predicted 
BMDL5-BMDU5 of lasiocarpine appeared to fall well within the range of PoDs obtained from the 
available in vivo studies. In Chapter 6, the same approach was used for prediction of genotoxicity for 
lasiocarpine and riddelliine in rats. The in vitro concentration-genotoxic response curves of the two 
PAs, as determined in primary rat hepatocytes using the H2AX assay, were translated into in vivo 
dose-response curves by applying the developed PBK models. The predicted BMD10 (benchmark dose 
that gives a 10% response) values for lasiocarpine and riddelliine were in line with the experimental in 
vivo genotoxicity data available in the literature. Chapter 7 presented a summary and overall 
discussion of the results obtained in the thesis, and concluded with the future perspectives regarding 
the development and application of generic PBK models and the safety assessment of botanical 
preparations.  
Altogether, the present thesis developed new methods to support and improve the risk assessment of 
PAs without the use of experimental animals, and demonstrated the feasibility and importance of 
combined in vitro PBK modelling-based reverse dosimetry to adequately predict in vivo acute liver 
toxicity and genotoxicity using lasiocarpine and riddelliine as two model PAs. 
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Summary 
Botanicals and botanical preparations may contain natural constituents that are of concern for human 
health. One group of such natural toxic compounds that may raise a concern is the group of 
pyrrolizidine alkaloids (PAs). At the current state-of-the-art, risk assessment of botanicals and 
botanical preparations is generally not required before they can enter the market. The present thesis 
aimed to perform the risk assessment for PAs derived from botanical products following daily life-
time exposure and also more realistic exposure scenarios. Another aim of the present thesis was to 
investigate whether animal-free testing strategies could be of use in tackling data and knowledge gaps 
for PAs by predicting in vivo toxicity of different PAs and whether proofs-of-principle for applying 
such alternative testing approaches could be provided for two selected PA model compounds, 
riddelliine and lasiocarpine. 
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risk on tumour formation above background levels) of 0.07 mg/kg bw/day for lasiocarpine and mean 
levels of PAs reported in literature for herbal teas and plant food supplements (PFS). After using 
interim REP (relative potency) factors to ‘adjust’ PA levels and resulting exposure, 54% of the types 
of herbal teas and 14% of the PFS were estimated to result in daily intakes that would give rise to 
MOE values lower than 10000, indicating a possible health risk. The herbal preparations that raised a 
concern included preparations containing PA-producing plants but also preparations containing non-
PA-producing plants. In Chapter 3, the MOE approach, using the BMDL10 of 0.24 mg/kg bw/day for 
riddelliine and total PA levels, and Haber’s rule were employed to analyse the risks of shorter-than-
lifetime exposure for 5 herbal teas, 8 herbal medicines and previously analysed herbal products from 
Chapter 2. This revealed that shorter-than-lifetime use of these herbal products resulted in MOE 
values lower than 10000 when the preparations would be used for only 40 to up to 3450 weeks during 
a lifetime (depending on the preparation), with for only a limited number of herbal teas and medicines 
use of two weeks a year (150 weeks during a 75 year lifetime) still raising a concern. The results also 
revealed that the PA levels extracted from intact leaves were lower than the leaves extracted from 
comminuted leaves, and this may influence the actual exposure and corresponding risk assessment. In 
Chapter 4 and 5, PBK models were developed for prediction of liver toxicity of lasiocarpine and 
riddelliine in rats and humans on the basis of in vitro toxicity data. Using PBK model based reverse 
dosimetry the in vitro concentration-response curves for cytotoxicity in primary rat hepatocytes were 
translated to in vivo dose-response curves. From these in vivo dose-response curves, the predicted
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BMDL5-BMDU5 (lower/upper limit of the 90% confidence interval of the benchmark dose that gives a 
5% response) of lasiocarpine and riddelliine in both rats (Chapter 4) and humans (Chapter 5) were 
obtained. Due to the absence of in vivo acute liver toxicity data reported in the literature for riddelliine, 
the predicted PoDs (point of departures) for in vivo liver toxicity could only be evaluated for 
lasiocarpine. To this end, the predicted BMDL5-BMDU5 of lasiocarpine for rats was compared with in 
vivo reported data for acute liver toxicity of lasiocarpine, and the results showed that the predicted 
BMDL5-BMDU5 of lasiocarpine appeared to fall well within the range of PoDs obtained from the 
available in vivo studies. In Chapter 6, the same approach was used for prediction of genotoxicity for 
lasiocarpine and riddelliine in rats. The in vitro concentration-genotoxic response curves of the two 
PAs, as determined in primary rat hepatocytes using the H2AX assay, were translated into in vivo 
dose-response curves by applying the developed PBK models. The predicted BMD10 (benchmark dose 
that gives a 10% response) values for lasiocarpine and riddelliine were in line with the experimental in 
vivo genotoxicity data available in the literature. Chapter 7 presented a summary and overall 
discussion of the results obtained in the thesis, and concluded with the future perspectives regarding 
the development and application of generic PBK models and the safety assessment of botanical 
preparations.  
Altogether, the present thesis developed new methods to support and improve the risk assessment of 
PAs without the use of experimental animals, and demonstrated the feasibility and importance of 
combined in vitro PBK modelling-based reverse dosimetry to adequately predict in vivo acute liver 
toxicity and genotoxicity using lasiocarpine and riddelliine as two model PAs. 
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